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Bacterial resistance to antibiotics is an emerging epidemic throughout the world and there is a 
desperate need for new antibiotics and new strategies to maintain the effectiveness of current agents. 
-Lactams, such as the penicillins and cephalosporins, have been the most important class of 
antibiotic for several decades and represent half of the global antibacterial market, but the continued 
use of -lactams is threatened by -lactamases, enzymes that efficiently inactivate -lactams through 
hydrolysis. Class A, C, and D -lactamases use an active-site serine residue for hydrolysis and 
achieve turnover through an acylenzyme intermediate while the class B metallo--lactamases (MBLs) 
use a zinc-bound hydroxide as the active-site nucleophile.  
Two successful approaches to combat -lactamase-mediated resistance have involved the 
development of -lactam antibiotics which bind poorly to -lactamases and the combination of -
lactams with -lactamase inhibitors. These strategies have been effective for overcoming resistance 
due to class A -lactamases, but the ever-increasing prevalence of extended-spectrum -lactamases 
(ESBLs), metallo--lactamases, and carbapenemases compromises the effectiveness of current 
penicillins, cephalosporins, carbapenems, and mechanism-based -lactamase inhibitors.  
Cyclobutanone analogues of -lactam antibiotics were explored in the early 1980s as potential 
inhibitors of -lactamases and D-Ala-D-Ala transpeptidases, but simple analogues showed only weak 
inhibitory activity and this approach was subsequently abandoned. The increasing threat of multidrug-
resistant -lactamase-producing organisms in recent years, however, has inspired a re-evaluation of 
these inhibitors since cyclobutanones have the potential to exhibit broad-spectrum inhibition of both 
serine- and metallo--lactamases through the formation of enzyme-bound hemiketals or hydrates.   
7,7-Dichloro-2-thia-bicyclo[3.2.0]heptan-6-one-4-carboxylic acid (65), a dichlorocyclobutanone 
that had shown modest inhibition of the class B and D -lactamases IMP-1 and OXA-10 in earlier 
work in this laboratory, was prepared in an efficient seven-step sequence from triethyl 
phosphonoacetate (103) with an overall yield of 28%. Initial efforts to improve upon the potency of 
the cyclobutanones involved functionalization at C3 and a highly stereoselective chlorination with 
sulfuryl chloride provided the 3-chloro derivative 117 in nearly quantitative yield. Elimination of 
HCl from 117 was achieved under a variety of conditions and 3-alkoxy derivatives were prepared 
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from 117 through diastereoselective substitution reactions with alcohols. Cyclobutanones with 3-
OR substituents were found to favour an endo envelope conformation while the 3-OR derivatives 
adopt the exo envelope conformation. Evidence from X-ray crystal structures and ab initio molecular 
orbital calculations suggests that an anomeric effect contributes to the large conformational 
preference of the tetrahydrothiophene ring that favours the 3-alkoxy substituent in an axial 
orientation. In addition, the conformation of the bicyclic system was found to have a dramatic effect 
on the tendency of the cyclobutanone to undergo hemiketal formation.   
Cyclobutanone analogues of penicillins, including 3-alkoxy derivatives, and cyclobutanone 
analogues of penems were evaluated against class A, B, C, and D -lactamases and found to be 
moderate inhibitors of KPC-2, IMP-1, GC1, and OXA-10. The cyclobutanones found to be most 
potent were those which are hydrated to a larger extent in aqueous solution. Dichlorocyclobutanones 
were found to be better inhibitors than dechlorinated cyclobutanones and a 3-methoxy derivative 
152, which favours the exo envelope conformation in which the C4 carboxylate is equatorial, was 
found to be a better inhibitor than cyclobutanones that favour the endo envelope conformation. A 3,4-
unsaturated penem analogue, 153, showed comparable potency to that of 152 and molecular models 
of enzyme–inhibitor complexes indicate that an equatorial carboxylate is required for binding to -
lactamases. An X-ray crystal structure of 152 bound to the class D -lactamase OXA-10 confirms 
that a serine hemiketal is formed in the active site and that the inhibitor adopts the exo envelope.  
The biochemical data described above demonstrate that cyclobutanones can indeed act as inhibitors 
of serine- and metallo--lactamases and these cyclobutanones represent the first class of reversible 
inhibitors to show moderate inhibition of all four classes of -lactamase. Although the inhibitory 
potency of these compounds is modest (low micromolar IC50 values), penem analogue 153 was able 
to enhance the potency of meropenem against carbapenem-resistant MBL-producing clinical isolates 
of Chryseobacterium meningosepticum and Stenotrophomonas maltophilia and the synergy 
demonstrated in these antimicrobial assays is encouraging.    
Synthetic studies toward other C3-alkyl and C3-thioalkyl-substituted inhibitors are described and 
the design and synthesis of C7-monochloro- and 7-hydroxymethyl-7-chloro cyclobutanone 
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bacterial strains tested  
min minute(s) 
mol % mole percent 
mp melting point 
MRSA methicillin-resistant 
Staphylococcus aureus 
Ms mesyl (methanesulfonyl) 
MS mass spectrometry, molecular 
sieves  
m/z mass-to-charge ratio 
na not available 
NAG N-acetyl glucosamine 




nd not determined 
NMR nuclear magnetic resonance 
NOE nuclear Overhauser effect 
NOESY nuclear Overhauser enhancement 
spectroscopy 
obsd observed 
PAS penicillanic acid sulfone 
PBP penicillin-binding protein 






Phth phthalyl  
PNB para-nitrobenzyl 
ppm parts per million (spectral) 
Pro proline 
p-Tol para-toluyl, 4-methylphenyl 
Py pyridine 
q quartet (spectral) 
QM/MM quantum mechanical/molecular 
mechanical 
RHF restricted Hartree–Fock 
RMSD root-mean-square deviation 
rt room temperature 
s singlet (spectral); second(s) 
SAR structure–activity relationship(s) 




SN1 unimolecular nucleophilic 
substitution 
SN2 bimolecular nucleophilic 
substitution 









TLC thin layer chromatography 
TMS trimethylsilyl; tetramethylsilane 
(spectral) 
Trp tryptophan 
Ts tosyl (toluenesulfonyl) 
TS transition state 
Tyr tyrosine 
Val valine 
Vmax  the maximum rate attainable for 
an enzymatic reaction 
VRE vancomycin-resistant enterococci 
VRSA vancomycin-resistant S. aureus  









1.1 Antibiotics and Bacterial Resistance 
The development of antibiotics is perhaps the most important medical advance of the twentieth 
century and, since their introduction into clinical use prior to World War II, antibiotics have been 
used to save countless human lives.  
The effectiveness of the sulfonamides and penicillin in the 1930s and 1940s for the treatment of 
once deadly infections triggered decades of extensive research toward other antibiotics. These efforts 
were rewarded with the discovery of a variety of different classes of antimicrobial agents such as the 
aminoglycosides, polyketides, cephalosporins, tetracyclines, macrolides, glycopeptides, 
streptogramins, carbapenems, quinolones, and oxazolidinones (Figure 1).1  
The widespread use of antibiotics, however, has proven to be a major driving force for the 
evolution of bacteria,2 and the enormous benefits of antibiotics to human health are necessarily 
coupled with the development of resistance.3 Without exception, resistance has developed to every 
major class of antibiotic, both natural and synthetic, within only a few years of its introduction and it 
is now widely recognized that bacterial resistance to antibiotics is an inevitable consequence of 
antibiotic use.4,5,6 
Unfortunately, the success of the pharmaceutical industry in the development of large numbers of 
antibiotics caused complacency toward antibiotic resistance and, with increasing costs for 
antimicrobial development, most major pharmaceutical companies withdrew from the area in the 
1980s and 1990s.7,8 As a result, the antibiotic pipeline is now ill-equipped to address the relentless 
increase in bacterial resistance and the current situation has been described as a “perfect storm”.9   
Antibiotic resistance was recognized as a crisis as early as 1992 with the emergence of methicillin-
resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), and vancomycin-resistant 
Enterococcus spp. (VRE).10 In recent years, the list of most threatening pathogens has grown to 






















































































































































































Figure 1. Representative structures of several classes of clinically used antibiotics.  
baumannii, Pseudomonas aeruginosa, and Enterobacter spp., and these have been collectively 
dubbed the ESKAPE pathogens.11,12 The increasing prevalence of multidrug-resistant and pan-
resistant strains is also extremely concerning and has elevated fears that the era of untreatable 
infections has arrived and the antibiotic era is about to end.13,14 It is clear that there is an urgent need 
for new antibiotics and new strategies to maintain the effectiveness of known antibiotics.15,16,17,18  
-Lactams are the most important antibiotics and penicillins and cephalosporins represent half of 
the $42 billion global antibiotic market.19,20 In addition to obvious economic motivations, continuing 
efforts to preserve the usefulness of the -lactams are justified by the unparalleled efficacy and safety 
of these agents.21 Furthermore, the -lactams are active against Gram-positive and Gram-negative 
bacteria and target bacterial cell wall biosynthesis, a process that is uniquely prokaryotic and more 
easily accessed than the intracellular targets of other antibiotics.22,23    




Figure 2. Comparison of Gram-positive and Gram-negative bacterial cell walls.1,19,21    
decreased permeability or efflux,24 and drug inactivation or modification. With respect to -lactams, 
the deletion of porin proteins in the membrane, the acquisition of efflux exporter proteins, and the 
expression of -lactam-sensing proteins are notable defensive measures, but penicillin-binding 
protein (PBP) alterations and the expression of -lactamases are the most important mechanisms of 
resistance (Figure 2).25,26  
-Lactamases, enzymes which hydrolytically inactivate -lactams, were first encountered by 
Abraham and Chain in 1940,27 even before the widespread use of penicillin. Though not apparent at 
the time, -lactamases would prove to be the largest driving force for the development of new 
generations of penicillins and cephalosporins in the decades to follow.28 Initially, the most successful 
strategy for overcoming -lactam resistance was to modify the sidechains of penicillins and 
cephalosporins in order to improve stability to -lactamases. Another approach involves the 
combination of the -lactam antibiotic with a -lactamase inhibitor which protects the -lactam from 
deactivation by -lactamases. Such combinations have been used clinically since the mid-1980s and 
mechanism-based inhibitors, such as clavulanic acid, have been very successful against serine -
lactamases. However, new -lactamases are emerging at an alarming rate (more than 850 are now 
known)29 and new enzymes, such as extended-spectrum -lactamases (ESBLs), carbapenemases, and 
metallo--lactamases (MBLs), compromise the effectiveness of current penicillins, cephalosporins, 
carbapenems, and mechanism-based inhibitors.  
The metallo--lactamases are among the most threatening of the new -lactamases since they have 
a spectrum of activity encompassing all -lactam classes (except monobactams) and there are no 
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MBL inhibitors available for clinical use at present. As a result, there has been a longstanding interest 
in the Dmitrienko laboratory in the development of MBL inhibitors and this thesis describes efforts 
by this author in the design and synthesis of cyclobutanone analogues of -lactams which have the 
potential to act as inhibitors of both serine- and metallo--lactamases.  
This introductory chapter provides a summary of the development of -lactam antibiotics, a brief 
description of penicillin-binding proteins, and a review of -lactamases and -lactamase inhibitors as 
essential context for the present study. While a comprehensive review of these topics is well beyond 
the scope of this thesis, efforts have been made to provide an accurate and appropriate summary of 
the 80 years of research in the field in the following sections of this chapter. This introduction has 
been written from an historical perspective with an intent to highlight the most important classical 
contributions to the field.   
It should be noted that the evolution of the penicillins, cephalosporins, carbapenems, and other -
lactams has always been intimately interconnected with the evolution of penicillin-binding proteins 
(PBPs), -lactamases, and -lactamase inhibitors and the remainder of this chapter represents an 
attempt to provide a chronological yet cohesive summary of each area. The discovery and 
development of -lactam antibiotics are presented in Section 1.2, followed by a discussion of 
penicillin-binding proteins and the -lactam mode of action in Section 1.3. -Lactamases and -
lactamase inhibitors are reviewed in Sections 1.4 and 1.5, respectively.   
1.2 -Lactam Antibiotics  
With the prominent role that the penicillins and cephalosporins have played in the history of modern 
medicine, and the advancement of other antibiotics, it seems appropriate to mention some of the most 
important events in their early development. The following sections describe the fascinating story of 
the discovery of penicillin and its curative effect in infectious diseases (for which Sir Alexander 
Fleming, Ernst Chain, and Sir Howard Florey were awarded the Nobel Prize in medicine in 1945), the 
monumental collaborative effort between American and British scientists to elucidate the structure of 
penicillin and complete its total synthesis, the discovery of the cephalosporins, and the development 




Figure 3. Families of -lactam antibiotics.   
discussion provided below of the early years of penicillin and cephalosporin research is based on 
several first-hand accounts from scientists directly involved in its development.30,31,32,33,34,35,36 The 
following sections also describe the discovery of the cephamycins, carbapenems, penems, 
monobactams, and other -lactam families (Figure 3). Structures of selected penicillins, 
cephalosporins, carbapenems, and monobactams are provided in Appendix A.  
1.2.1 Penicillins 
While Sir Alexander Fleming’s name is widely recognized for the discovery of penicillin, the 
scientific contributions of those at Oxford and elsewhere in England and the United States are much 
less appreciated.37,38 In reality, penicillin may have been forgotten if it were not for the efforts of 
Florey and Chain.  
Alexander Fleming worked as a bacteriologist in a basement laboratory at St. Mary’s hospital in 
London. On September 28, 1928 Fleming examined a Petri dish of Staphylococcus that had been left 
on the bench for several days and noticed that a contaminant mould, later identified as Penicillium 
notatum, had developed in a corner of it. In a fairly large circumference around the mould were 
‘ghosts’ of the colonies of Staphylococcus and it was obvious to Fleming, a trained and experienced 
observer, that the colonies had undergone lysis under the influence of the mould. This was a striking 
observation as staphylococci were known to be notoriously resistant to lysis and Fleming already had 
a special interest in lysis through his discovery of lysozyme in 1922, six years earlier.39  
Fleming was able to subculture the mould40 and found that a substance was produced that passed 
into the liquid. This solution, which he called ‘penicillin’,41 had potent antibacterial activities against 
many different microbes, including human pathogens,42 and was no more toxic to mice, rabbits, or 
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leukocytes than the broth itself. These results were published in 192943 with suggestions that it could 
be used as an antiseptic for application to, or injection into, areas infected with penicillin-sensitive 
microbes. Fleming knew that more serious clinical trials would demand a large amount of active 
penicillin and that purification of the unstable substance would require considerable effort.30a It is 
widely believed that Fleming had lost interest in penicillin because he did not publish additional 
research in this area, but Wainright has argued that Fleming did continue research with penicillin 
throughout the 1930s.44  
A group of natural product chemists from London reported their attempts to purify penicillin in 
1932 and they had found, just as Fleming did, that the active substance was most stable between pH 5 
and 6.45 Extraction of the broth at pH 2 was much more efficient than extraction at neutral or alkaline 
pH, but the extracted material was considered too labile upon removal of the ether and their efforts 
were discontinued.  
In 1935 a biochemist named Ernst Chain joined the staff of Professor Howard Florey, the newly 
appointed head of the Sir William Dunn School of Pathology at the University of Oxford. Chain 
began research into the mode of action of lysozyme and in 1938 found evidence that it acted on the 
bacterial cell wall with carbohydrase activity. In a search of the literature for other bacteriolytic 
substances, Chain came across Fleming’s penicillin paper and considered the possibility that 
penicillin was an enzyme that had a similar carbohydrase mode of action to that of lysozyme. Chain 
and Florey then began their work with the Penicillium mould with their new colleague Norman 
Heatley.31 They quickly found that penicillin was not an enzyme, but their disappointment was 
converted to optimism when they found that a concentrated form of the penicillin (solid but non-
homogeneous) was nontoxic to mice in “enormous” doses of 10 mg. They published these results and 
the effectiveness of this form of penicillin in vivo against various pathogenic organisms in 1940.46 
Later that year, Abraham and Chain reported that an enzyme from Escherichia coli, which they called 
penicillinase, inactivates penicillin and that the growth of the mould and isolation of penicillin 
therefore require strictly sterile conditions.27  
The group published a more refined method in 1941 for culturing the mould and for harvesting and 
purifying the penicillin with more precise antimicrobial activity results and the results of a small 
series of clinical trials with humans.47 The new method for purification, developed by Heatley,36 
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involved an extraction of the penicillin into amyl acetate, followed by a crude chromatographic 
purification with alumina and extraction of the penicillin back into aqueous solution at pH 6–7. In the 
first extraction, penicillin hydrolysis was minimized by passing the crude aqueous solution through a 
cooling coil and acidification to pH 2 with phosphoric acid just seconds before droplets of this 
solution were allowed to fall through a column of amyl acetate.  
A major source of difficulty for the group was the small amount of material to work with for the 
structural elucidation. Cultures of the mould produced only 0.5 mg/mL and most of the pure penicillin 
was reserved for clinical trials. Since it was obvious that the tremendous therapeutic potential of 
penicillin could only be realized if its production were to be expanded beyond the means of the 
Oxford laboratory, pharmaceutical companies in the U.K. and the U.S. were asked to help with large-
scale culture and production. Following the discovery of a deep fermentation technique in late 1941 
by the U.S. Department of Agriculture (Peoria, IL), other academic and industrial laboratories in both 
England and the U.S. entered the collaborative effort. These included the Imperial College of Science, 
Imperial Chemical Industries, Wellcome, and Glaxo in England and included Harvard, Cornell, and 
Michigan universities and Merck, Squibb, Pfizer, Abbott, Eli Lilly, Upjohn, and Shell in the United 
States.32  
The possibility that penicillin might be more easily obtained by chemical synthesis was considered 
and in 1942 Florey’s group began to collaborate with Sir Robert Robinson and Dr. Wilson Baker of 
the Dyson Perrins Laboratory at Oxford. In the early stages of the collaborative chemical work at 
Oxford little was known about the penicillin structure except that it was a carboxylic acid, it was 
inactivated in weak acid and alkali to liberate new ionizable groups, and it was soluble in alcohols but 
readily inactivated in methanol.48 It was most stable at pH 5–7 but was inactivated at neutral pH in the 
presence of heavy metal salts such as Zn2+, Cu2+, and Pb2+. It was later found that the barium salt of 
penicillin was stable when dry or in organic solvents and was also highly active in vivo.49    
The barium salt, one of the purest samples of penicillin available in 1942, was found to contain 
nitrogen, and the nitrogen content was correlated with antibiotic potency.50 Analysis of this sample 
suggested a formula of C24H32O10N2Ba and that sulfur was not present. This unfortunate analytical 
error caused confusion for several months and was not corrected until the structure of penicillamine 
was determined in 1943.   
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Degradation studies by Abraham in late 1942 showed that hot acid hydrolysis yielded a volatile 
acid and the crystalline salt of a base (called penicillamine) with the loss of CO2 (Scheme 1).
51 
Molecular weight determinations seemed to be consistent with a formula of C6H11O4NHClH2O but 
this formula was later found to be incorrect. The presence of sulfur was recognized after Abraham 
had found that penicillamine could be oxidized with bromine/water to a strongly acidic compound 
named penicillaminic acid, which had a molecular formula inconsistent with only C, H, N, and O. 
Finally, the puzzling results of earlier experiments involving penicillamine could be rationalized, and 
the molecular formula of penicillamine was revised to C5H11O2SNHCl. In October 1943 the structure 
of penicillamine was confirmed to be 3-mercapto-D-valine by John Cornforth through a synthesis 
from hippuric acid.52,53   
While these advances were being made, Chain had found that hydrolysates of penicillin contained 
an ether-soluble compound that yielded a 2,4-dinitrophenylhydrazone in addition to the water-soluble 
penicillamine. They named this compound 2-pentenylpenilloaldehyde and its structure was later 
confirmed through synthesis.32,36   
Meanwhile, early research in the United States had been mainly concerned with large-scale 
preparation of penicillin. Production had been developed to take advantage of deep-tank fermentation 
vessels and purification was optimized using silica gel chromatography. By 1942 Americans had also 
become actively involved in the chemical work and in August 1943 researchers at Squibb had 
successfully crystallized a sodium salt of their penicillin and found a molecular formula of 




Figure 4. Structures proposed for the penicillins, penicilloic acids, and penillic acids (R =  C5H9 or 
CH2Ph).  
purified barium salt into the sodium salt (which they had avoided using due to its hygroscopic nature) 
and found that it had the formula C14H19O4N2SNa. It had become clear that the American penicillin 
was different than the British penicillin and it was later found to be due to the addition of corn steep 
liquor, which contained phenylacetic acid, to stimulate the growth of the Penicillium mould in the 
American fermentations. Oxford’s 2-pentenyl penicillin was then named penicillin F and the 
American benzyl penicillin was called penicillin G.30b,32,36  
After the molecular formula for penicillin was determined and the structures of penicillamine and 
2-pentenylpenilloaldehyde were confirmed, it seemed clear that penicilloic acid was a thiazolidine 
and that the carbon dioxide liberated upon acid-catalyzed hydrolysis came from a carboxyl group in 
the -position to the formyl group of the penilloaldehyde. Structure 1 was correctly assigned to 
penicilloic acid, the hydrolysis product of penicillin, but it was unclear how a molecule of water had 
been added to the structure (Figure 4).  
Robinson proposed a thiazolidine–oxazolone structure 3 for penicillin because it offered an 
explanation for the isomerization of penicillin to penillic acid at pH 2 (as indicated by arrows in 
Figure 4). Penillic acid, isolated in early 1943 by researchers at Wellcome, was known to have two 
acid groups and one basic group, and was correctly assigned the structure 2.54 Robinson’s oxazolone 
structure appeared to have the support of the majority of those in the field until 1945.36  
In late 1943 Abraham and Chain proposed a -lactam structure 4 (which was independently put 
forward by Merck) but this ring system was not supported by Robinson and received little attention 
from other laboratories. The main difficulty in acceptance of the -lactam structure was that penicillin 
was much more labile than all known -lactams which, at that time, included only monocyclic - 
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Scheme 2. Summary of Degradation Studies Used for the Structural Elucidation of the Penicillins.  
 
lactams.36  
Other potential structures for penicillin were proposed by various groups, including the tricyclic 
structure 5 in 1944 independently by researchers at Eli Lilly and Glaxo, tri-cycle 6 by the Imperial 
College group, and azlactol 7 by Stodola of the U.S. Department of Agriculture. Each of these 
possessed a pre-formed core of penillic acid and seemed to give reasonable explanations for the 
formation of penillic acid at pH 2, but none of these structures was widely accepted.32a   
A major criticism of the non--lactam structures and support for the -lactam structure involved 
electrometric titrations done by Abraham in late 1943.36,55 Each of the non--lactam structures contain 
a weakly basic group that could not be detected in the titration experiments and provided evidence 
against 5, 6, 7, and Robinson’s oxazolone 3, and support for the -lactam 4. In addition, other 
evidence began to accumulate in favour of the -lactam structure, including infrared spectroscopic 
studies that suggested the presence of a mono-substituted amide in penicillin, and some reasoning 
from Woodward regarding the labile nature of the penicillins. Woodward suggested in late 1944 that 
the penicillins could be less stable than monocyclic -lactams because amide resonance would be 
suppressed by the non-planarity at the bridgehead nitrogen.56 More convincing synthetic evidence 
provided support for the -lactam structure when researchers at Merck treated penicillin with Raney 
nickel to provide desthiopenicillin, a -lactam that behaved like other known monocyclic -lactams 
(Scheme 2).57  
Debate about the structure of penicillin continued until May 1945 when the structure was 
conclusively determined by Crowfoot and Low at Oxford using X-ray crystallographic analysis.58 The 
-lactam ring was shown clearly in electron density projections from crystals of the sodium,  
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potassium, and rubidium salts of penicillin.59 For this and other structures of biochemical 
significance, Dorothy Crowfoot Hodgkin was awarded the Nobel Prize in chemistry in 1964.  
Although the large-scale production of penicillin for the war effort through total synthesis was 
unsuccessful, fermentation methods had been become so effective by early 1944 that sufficient 
amounts of penicillin could be supplied to the allied soldiers for the D-Day invasion in June 1944.  
At the height of the effort more than one thousand highly skilled chemists were involved in the 
collaborative project but research on the chemistry of penicillin had declined significantly after the 
war had ended.60 Many of these researchers had come to the conclusion that the synthesis of penicillin 
was “an impossible problem” and even Woodward had described the molecule was “a diabolical 
concatenation of reactive groups”.61 Sheehan’s view of the situation, however, was simply that the 
appropriate organic reactions for construction of the “enchanted ring” had not yet been discovered.62 
In 1957, more than a decade after Hodgkin’s structure determination by X-ray crystallographic 
analysis, Sheehan published the first rational total synthesis of a penicillin (Scheme 3).63,64,65  
Many unsuccessful attempts were made to generate the -lactam ring via a [2 + 2] Staudinger 
reaction between thiazolines and ketenes, including several studies by the Sheehan group, but the first 
successful synthesis involved a late-stage cyclization to form the -lactam ring from a penicilloic 
acid. This was accomplished only after the development of mild conditions involving carbodiimides 
that are now very well-known and widely used for the coupling of amines with carboxylic acids.  
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The condensation of D-penicillamine with malonaldehyde 8 afforded a mixture of only two 
diastereomeric thiazolidines 9, the D--isomer of which could be isomerized in high yield to the 
natural and desired D--isomer. Deprotection with hydrazine, followed by acidification and acylation, 
provided amino ester 10 and cleavage of the t-butyl ester provided the penicilloic acid that was 
cyclized with a DCC-mediated amide coupling to provide penicillin V in 10–12% yield. Subsequent 
studies in 1962 demonstrated that protection of the primary amine of 12 with a trityl group prevented 
the undesired azlactonization in the cyclization to follow and also improved the yield of the 
lactamization to 67%.66 Hydrogenolysis and acidification provided the hydrochloride salt of 6-
aminopenicillanic acid (6-APA), a versatile molecule that proved to be crucial in the development of 
new penicillins (vide infra, Section 1.2.3).  
1.2.2 Cephalosporins 
In July 1945, as the therapeutic properties of penicillin were becoming widely known, a Professor of 
Hygiene in Sardinia named Brotzu had been looking for antibiotic-producing organisms and collected 
a sample of Cephalosporium acremonium, a seawater fungus.60,67,68 He found that it produced 
antibiotic material that was active against Gram-positive and Gram-negative species and sent a 
culture of the organism to Oxford in 1948 with the hope that the work would be taken up by the 
Florey group.  
The antibiotic extracted by organic solvent, named cephalosporin P, was shown to be a steroid with 
activity against Gram-positive bacteria but this compound alone could not be responsible for the 
broad-spectrum antibacterial activity observed by Brotzu. Abraham then detected an unstable 
hydrophilic antibiotic in the aqueous phase which was named cephalosporin N because it showed 
activity against both Gram-negative and Gram-positive bacteria. Cephalosporin N was inactivated by 
penicillinase and, after purification69 and chemical degradation studies,70,71 was actually found to be a 




It was during chemical studies in 1953, to establish the molecular formula of penicillin N, that 
Newton and Abraham discovered a third antibiotic from the Cephalosporium species. Penicillin N 
was converted to its isomeric penillic acid at pH 3 because it was thought that purification of the 
penillic acid might be more straightforward than purification of the penicillin. Anion-exchange 
chromatography provided the desired penillic acid and an additional compound which had UV 
absorbance at 260 nm73 and crystallized as a sodium salt. This compound, named cephalosporin C, 
was similar to penicillin N as it was found to have the aminoadipoyl sidechain and a -lactam ring, as 
indicated by an IR band at 5.62  (1780 cm–1), but was stable to dilute acid and its -lactam was 
clearly fused to a ring that differed from the thiazolidine of the penicillins.74,75,76  
Preliminary antimicrobial assays revealed cephalosporin C to be a broad-spectrum antibiotic that 
was resistant to hydrolysis by a penicillinase from Bacillus cereus. While the Oxford group’s interests 
in this material were purely academic in nature, benzylpenicillin-resistant penicillinase-producing 
strains of staphylococci were becoming a serious clinical problem, and the clinical need for such a 
compound was obvious, even in the early-1950s.  
In 1957, a mutant strain of the Cephalosporium fungus was isolated which produced considerably 
more cephalosporin C than Brotzu’s wild strain. This development was crucial to provide enough 
material for the chemical studies that led to the structural elucidation. Abraham’s conclusion through 
chemical methods that cephalosporin C was a -lactam fused with a dihydrothiazine ring77 was 
confirmed by an X-ray crystallographic analysis by Hodgkin and Maslen and published in 1961.78  
 
Woodward, who had been actively involved in the structural assignment of cephalosporin C 
through discussions with Abraham and Hodgkin, described the completion of its total synthesis in his 
Nobel lecture in 196579 and published the work in 1966 (Scheme 4).80 While Sheehan’s route to 
penicillin V involved the formation of the -lactam ring at a late stage from a penicilloic acid 
(Scheme 3), an analogous route to cephalosporin C would not be viable since the cephalosporoic acid 
was known to be less stable than penicilloic acids and could therefore not be used as a synthetic  
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Scheme 4. Woodward’s Total Synthesis of Cephalosporin C.80  
 
intermediate.79 Instead, Woodward’s route began with L-(+)-cysteine as a readily available and chiral 
building block from which the -lactam ring could be constructed with the desired stereochemistry. 
Condensation of -lactam 13 with dialdehyde 14, followed by acid-catalyzed deprotection of 15 and 
cyclization provided the dihydrothiazine ring of the delicate but versatile aminoaldehyde 16 which 
was taken through to cephalosporin C.  
1.2.3 Semisynthetic Penicillins and Cephalosporins from 6-APA and 7-ACA 
In the course of optimizing fermentation conditions for the production of penicillins, it was shown 
that penicillins with differing 6-acylamido sidechains were produced in different fermentation 
conditions. Structure–activity relationships with the penicillins had made it clear that antimicrobial 
activity was dependent to a great extent on the nature of the sidechain.   
In 1959, Batchelor et al. reported that 6-aminopenicillanic acid (6-APA) was produced from 
Penicillium chrysogenum fermentations when no sidechain precursor was present.81 The significant 
impact of this development is evident in the many semisynthetic penicillins that have been prepared 




































































































































































from 6-APA and used clinically since many of them would not have been prepared without 6-APA 
readily available (Scheme 5).82 Around the same time, 6-APA was prepared by Sheehan via total 
synthesis63 and methods for the conversion of benzylpenicillin to 6-APA by various microorganisms 
and enzyme preparations (penicillin deaminase/penicillin (de)acylase) were being studied.60,83  
Some of the many semisynthetic penicillins that became clinically useful in the 60s and 70s include 
methicillin84 and oxacillin, which were stable to staphylococcal penicillinases,85,86 and ampicillin and 
carbenicillin, which showed an improved spectrum of activity including Gram-negative bacteria.87  
After the discovery in the mid-1950s that cephalosporin C possessed the same aminoadipoyl 
sidechain and penicillin N, which had only 1% the antimicrobial activity of penicillin G, the Oxford 
group considered the logical possibility that substitution of the aminoadipoyl sidechain of the 
cephalosporin for a phenylacetyl group may improve its antibiotic potency. In 1961, Loder, Newton, 
and Abraham reported that 7-aminocephalosporanic acid (7-ACA) could be obtained in low yield by 
mild acid hydrolysis, although this was accompanied by formation of lactone 17 (Scheme 6). 
Acylation of 7-ACA with phenylacetyl chloride generated an antibiotic (18) 100 times more potent 
than cephalosporin C against S. aureus.88 The group also discovered that substitution had occurred at 
the C3ʹ position when preparations of cephalosporin C were stored in aqueous pyridinium acetate and 
that the pyridinium salt 19 was more active than cephalosporin C.89 7-ACA also underwent 
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substitution with pyridine to give 20.  
In 1962 researchers at Eli Lilly reported more practical chemical conditions for the conversion of 
cephalosporin C to 7-ACA (nitrosyl chloride in anhydrous formic acid) which involved an 
intramolecular substitution to form iminolactone 21.90,91 The group also prepared several 7-
arylacetylamido cephalosporins from 7-ACA, including 18, 22, 23, and a 2-thienylacetyl derivative 
they called cephalothin, which all showed better antibiotic activity than the corresponding penicillins 
against several organisms.92  
Cephalothin, which became the prototype of the so-called first-generation cephalosporins, was 
found to be very resistant to staphylococcal penicillinase, showed activity against Gram-negative 
pathogens such as E. coli and Klebsiella pneumoniae, and was available for clinical use around 
1964.87 Other first-generation cephalosporins include cephaloridine and cefalexin.  
 
The demand for large amounts of 7-ACA in the early 1960s also prompted chemists to pursue 
methods for the synthesis of cephalosporins from penicillins. In 1963 Morin and coworkers at Eli 
Lilly discovered a process to achieve the ring-expansion through penicillin sulfoxides (Scheme 
7).93,94,95,96 This strategy may be considered to be biomimetic as the penicillins were later confirmed to 
be biosynthetic precursors to the cephalosporins.97  




1.2.4 Cephamycins and Expanded-Spectrum Penicillins and Cephalosporins 
By the mid-1960s, Gram-negative bacteria had replaced S. aureus as the most problematic hospital 
pathogens and biochemical studies in the early 1970s suggested that the major mechanism for 
resistance to the clinically available cephalosporins was inactivation by -lactamases.98,99 Major 
pharmaceutical companies therefore directed efforts toward the design and synthesis of -lactams 
with high stability to new -lactamases and broad-spectrum antibacterial activity. These efforts were 
restricted to chemical modification of existing -lactams until the discovery of the cephamycins in 
1971, when researchers at Eli Lilly isolated and identified three new -lactam antibiotics from 
streptomycetes.100 7-Methoxycephalosporin C (24) was produced by a strain of Streptomyces 
lipmanii and S. clavuligerus produced carbamates 25 and 26. Researchers at Merck simultaneously 
reported the isolation of the 7-methoxycephalosporins 27, 28, and 26 from other species of 
Streptomyces (actinomycetes from soil) and named these compounds cephamycins A, B, and C, 






























X = OMe   
 The discovery of a new family of cephalosporins among streptomycetes was considered a major 
breakthrough but the greatest significance of the discovery was the broad spectrum of Gram-negative 
activity and the high stability to hydrolysis by -lactamases.98 The concept of expanded-spectrum -
lactams was introduced with the discovery of the cephamycins and these new structures provided 
additional inspiration for the design and synthesis of new generations of cephalosporins.    
Cephalosporins have been classified as belonging to the first, second, or third generation on the 
basis of their biological characteristics. First generation cephalosporins, including cephalothin and 
cephaloridine, were very potent against staphylococci and streptococci but much less active against 
Gram-negative bacteria.86 The second generation cephalosporins such as cefamandole, cefoxitin, and 
cefuroxime, showed improved clinical utility because of their greater stability to -lactamases and, 
while these compounds were more active against Gram-negative bacilli than first generation agents, 




Modification of the acylamido sidechains of the penicillins was also explored extensively in the 
mid-1970s and led to the development of the ureidopenicillins (which are also called third-generation 
penicillins).104 Piperacillin, azlocillin, and mezlocillin, which are N-acylated derivatives of ampicillin, 
were shown to have similar activity to that of ampicillin against streptococci and better activity 
against P. aeruginosa than carbenicillin. The acylureido sidechain does not significantly increase -
lactamase stability but does improve affinity for PBPs and improves penetration of the outer 
membrane of P. aeruginosa and K. pneumoniae.86,87   
 
The third generation cephalosporins, which originated with cefotaxime in the early 1980s,105 have 
an even broader spectrum of activity, including all or most Enterobacteriaceae and improved activity 
against P. aeruginosa. They also have improved stability to plasmid-mediated and chromosomal -
lactamases.99 The 2-aminothiazoyloximino sidechain present in many third generation cephalosporins 
was found to be a major improvement. The aminothiazole heterocycle provides high affinity for PBPs 
and the syn-oximino106 group was found to improve stability to -lactamases.86 Third generation 
cephalosporins such as cefotaxime, ceftazidime, and ceftriaxone have very potent activity against a 
broad range of microorganisms, including Gram-negative aerobes, but tend to be less active than 
earlier generation agents against Gram-positives such as S. aureus.19 Moxalactam,107 an 
oxacephamycin108 with performance superior to many other third generation cephalosporins, has 
suffered restricted clinical use due to side effects.19  
In the 1990s, efforts to improve upon the spectrum and activity of the third generation 
cephalosporins against both Gram-negative and Gram positive organisms and the stability to -
lactamases led to the development of the fourth generation cephalosporins. The observation that 





activity against P. aeruginosa prompted further exploration of other C3ʹ quaternary ammonium 
cephems, including cefepime, cefpirome, cefclidin, and cefozopran.109 Cefipime and cefpirome, 
zwitterionic oximino cephalosporins,110 indeed demonstrated reduced affinity for -lactamases, 
increased outer membrane permeability, better activity than third generation agents against P. 
aeruginosa, and similar potency against S. aureus as first generation cephalosporins.111  
 
Ceftobiprole112 and ceftaroline113 are cephalosporins currently in development114 which have been 
categorized as fifth generation because of their high activity against MRSA.115 Ceftaroline has a 
spectrum of activity against Gram-negative bacteria similar to earlier broad-spectrum cephalosporins, 
but has poor activity against P. aeruginosa and is labile to hydrolysis by AmpC -lactamases and 
ESBLs. Ceftobiprole has an unusually broad antibiotic spectrum, with potent activity against a wide 
range of Gram-positive and Gram-negative bacteria including P. aeruginosa, but is susceptible to 
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hydrolysis by class A ESBLs and class B and D -lactamases.19 These agents are considered the first 
of the fifth generation, despite their instability to -lactamases, because of their high affinity for 
PBP2a,116 the penicillin-binding protein that is largely responsible for conferring resistance to -
lactams in MRSA (see Section 1.3).  
1.2.5 Carbapenems 
In the late 1960s and early 1970s, various pharmaceutical companies had programs to screen for 
inhibitors of cell wall biosynthesis and -lactamases and the carbapenems were discovered as a direct 
result of these efforts.117,118 Thienamycin was discovered at Merck in fermentation broths of the soil 
bacterium Streptomyces cattleya along with several epimeric compounds and some acetylated 
derivatives. Beecham independently isolated several related carbapenems from Streptomyces 
olivaceus, some of which were identical to Merck’s epithienamycins, and named them olivanic acids. 
Some Japanese groups isolated related derivatives from S. fulvoviridis and S. cremeus including the 
carpetamycins and so-called PS- compounds (Appendix A). Other important -lactams discovered in 
these screening programs include clavulanic acid,119 monocyclic -lactams called nocardicins,120 and 
discovered later were the pluracidomycins121,122 and asparenomycins.123,124  
 
Thienamycin showed very potent antibiotic activity against both Gram-positive and Gram-negative 
bacteria, including Pseudomonas spp, and equally impressive stability to -lactamases.125 Its high 
activity was surprising at first because of the lack of acylamino functionality at C6 and because of the 
 stereochemistry of the hydroxyethyl substituent. Comparison of the biological activities of 
carbapenem stereoisomers revealed that the so-called trans arrangement between C5 and C6 and the 
(R)-stereochemistry at C8 of thienamycin provided maximum -lactamase stability and antibacterial 
potency.117,126  
The first total synthesis of thienamycin,127 published in 1978 by researchers at Merck, was soon  
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followed by a more practical second-generation synthesis from the process group at Merck in 1980.128 
The first synthesis relied on a late-stage cyclization to form the C2–C3 bond while the second-
generation approach was based on a highly efficient rhodium-catalyzed N–H bond insertion to join 
C3 with N4 (Scheme 8).65   
In the early 1980s thienamycin was thought to be the “ultimate antibiotic,” both in broadness of its 
spectrum and in its potency against pathogenic bacteria,87 but thienamycin itself was too unstable to 
be pursued clinically because of its free amine and highly reactive -lactam.129 Derivatization of the 
amine, to improve chemical stability and maintain or improve its antibacterial activity, revealed that a 
basic sidechain was required for antipseudomonal activity since acetylation reduced activity. Of the 
many derivatives prepared, the N-formimido derivative, now called imipenem, was the first to be 
selected for clinical evaluation. Imipenem showed greatly improved stability in concentrated solution, 





















 While imipenem showed improved antibiotic potency relative to thienamycin, a similar antibiotic 
spectrum, and improved pharmacokinetics in humans, imipenem retained the instability to renal 
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dehydropeptidase I (DHP-I) and nephrotoxicity of its metabolites.132 The approach that was used 
successfully to overcome this problem has involved co-administration of imipenem with cilastatin, an 
inhibitor of DHP-I. This combination significantly reduces the associated nephrotoxicity and 
improves urinary recovery in animals. Imipenem-cilastatin (Primaxin, Merck) has been used for 
more than 26 million people since it was put on the market in 1986,133 generated $555 million in sales 
in 1997,1 and is still considered one of the most important carbapenems in clinical use.134   
In 1993, panipenem became the second carbapenem to be introduced and has been approved for 
use in Japan, China, and South Korea.134 Panipenem is also unstable to DHP-I and is therefore co-
administered with the DHP-1 inhibitor betamipron.  
 
Meropenem, which was introduced in 1995, has a spectrum of antibiotic activity broadly similar to 
that of imipenem, but is more active against Gram-negative aerobes, active against imipenem-
resistant P. aeruginosa, and is more stable to DHP-I.134,135,136 A study by the Sumitomo group in 1992 
revealed that the -methyl group at C1 of meropenem provides sufficient stability to human DHP that 
co-administration with a DHP inhibitor is not required.137 As a result, all carbapenems developed 
since the early 1990s have incorporated the 1-methyl group or a similar substituent.  
Biapenem, a zwitterionic carbapenem clinically used in Japan since 2002, is generally considered 
to have a spectrum of activity similar to imipenem and meropenem but is slightly more active than 
imipenem against Gram-positive bacteria and less active against some Gram-negative pathogens.19 
Ertapenem is an N-arylated analogue of meropenem which was approved in the U.S. in 2001.138 In 
contrast to the zwitterionic carbapenems imipenem and meropenem, which penetrate Gram-negative 
outer membranes efficiently,136 ertapenem has an overall negative charge at physiological pH and 
penetrates Gram-negative organisms much more slowly, but has a much longer serum half-life.19 
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Ertapenem has activity against Gram-positive and Gram-negative aerobes and anaerobes and is 
resistant to nearly all -lactamases, but shows much less activity than imipenem and meropenem 
against nosocomial pathogens P. aeruginosa, Acinetobacter, MRSA, and enterococci. Because of its 
unique spectrum of activity, ertapenem represents a separate class134 within the carbapenem group 
and is also unique from other carbapenems because it is considered suitable for community-acquired 
infections.   
Doripenem is structurally similar to meropenem and became the most recent carbapenem to be 
launched in 2005.19,134 Doripenem combines the best features of the carbapenem class as it boasts a 
broad antibiotic spectrum with better activity against Gram-positive organisms than meropenem and 
better activity against Gram-negative organisms than imipenem. It is also more potent than other -
lactams against P. aeruginosa and ESBL- and AmpC-producing pathogens139 and shows the lowest 
rate of spontaneous resistance in vitro.134,140  
 
Tebipenem (as its pivaloyloxymethyl ester prodrug, L-084), is an oral carbapenem in Phase III 
clinical studies with high bioavailability in humans and very potent activity against S. pneumoniae 
(MIC90 of 0.02–0.06 g/mL) and other bacteria that cause respiratory infections.19,141 Razupenem, 
which is currently in Phase II clinical trials for complicated skin infections, features a lipophilic 2-
thiazol-2-ylthio- sidechain that is thought to be important in its tight binding to PBPs. Razupenem 
shows activity against a wide range of Gram-positive and Gram-negative bacteria and is also very 
active against MRSA (MIC90 of 2 g/mL) and VRE (MIC90 of 8 g/mL).142 ME1036 is a carbapenem 
in Phase I evaluation for the treatment of respiratory infection. While it is inactive against P. 




pneumoniae, and Enterobacteriaceae, and resistant to hydrolysis by ESBLs and AmpC -
lactamases.19 Tricyclic -lactams (trinems) represent another set of carbapenems in development. 
Sanfetrinem has shown very potent antimicrobial activity against Gram-positive and Gram-negative 
bacteria.144,145,146  
1.2.6 Penems 
The notion that the biological activities of the -lactams were correlated with chemical reactivity of 
the -lactam ring had arisen because penicillins and cephalosporins were known to be far more 
reactive than monocyclic -lactams. Even before the structures of the carbapenems were published in 
the late 1970s, Woodward had postulated that penems, hybrid structures of penams and cephems, 
should be more reactive and more potent antibiotics.147  
The accepted rationale for the increased reactivity of the penicillins, in comparison to monocyclic 
-lactams, toward ring-opening by nucleophiles had been given by Woodward in 1944 and proposed 
that the pyramidal geometry of the -lactam nitrogen limits delocalization of its unshared electrons 
into the carbonyl and results in a weakened amide bond.56 The increased reactivity of the 
cephalosporins, however, in which the -lactam nitrogen is nearly planar, was thought to arise from a 
conjugative interaction with the adjacent double bond (3) which also results in a weakened -lactam 
amide bond.148  
Woodward first targeted penems with 6-acylamino substituents, as it was clear that these sidechains 
were important for the activity of the penicillins and cephalosporins, and reported the synthesis of 
penems 29 and 30 in 1978 (Scheme 9).149 The first penems of the series, 29 and 30, indeed showed 
antibiotic activity against strains of S. aureus but the potency of these compounds was disappointing.  
In order to study the new system in a more systematic way, a series of 6-unsubstituted penems were 
pursued. Even though 6-unsubstituted penams and cephems were known to have poor antibiotic 
activity, the appearance of clavulanic acid in the literature, which is 6-unsubstituted, encouraged the 
preparation of the simpler analogues.  
In 1979, the Woodward group published the synthesis of the racemic simplified analogues 31–
34.150,151,152 Not only did each of the new penems 31–33 show better stability153 and activity than 29 
and 30, but they were also more potent than cephalexin against most Gram-positive and Gram- 
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Scheme 9. Woodward’s Syntheses of Penems.149,150   
 
negative strains tested. These results indicate that the penems 29 and 30 were too reactive to interact 
specifically with their biological targets.  
The recent discovery of thienamycin and other carbapenems prompted the Woodward group to 
incorporate the hydroxyethyl sidechain at C6 and, in 1980, the Woodward group reported the 
synthesis of penems 35 and 36.147 Penem 35 proved to be 16–64 times more potent than 36 against 
Gram-positive and Gram-negative bacteria and 4–32 times more potent than ()-34 (except against P. 
aeruginosa).154   
 
After Woodward’s contributions to the field, many other penems were prepared and evaluated.148 
In general, the penems have good to excellent activity against Gram-positive bacteria but are inferior 
to their carbapenem analogues against Gram-negatives.19 Of the several that were selected for clinical 
evaluation, including Sch 29482155 and Sch 34343,156 only faropenem and sulopenem remain in 
development. Faropenem has a broad spectrum of antibiotic activity and is stable to class A, C, and D 
-lactamases. Faropenem has been available in Japan since 1997157 and has been in Phase III 
development elsewhere as an oral antibiotic for community-onset infections.158 The development of 
sulopenem began in the 1980s and clinical trials have recently been resumed by Pfizer. Sulopenem 
has potent activity against Gram-positive and Gram-negative bacteria, with MIC90s less than 1 g/mL 




6-Alkylidene penems represent another type of penem in development. These compounds have 
greater potential as broad-spectrum -lactamase inhibitors than as antimicrobial agents and are 
discussed in Section 1.5.2.    
1.2.7 Monobactams 
Many pharmaceutical companies had initiated large screening programs by the early 1970s to identify 
inhibitors of cell wall synthesis and -lactamase inhibitors. Screening at Beecham led to the isolation 
of the olivanic acids and clavulanic acid,119 screens at Merck generated thienamycin and 
epithienamycins,117 and a program in Japan led to the isolation of the nocardicins from Nocardia 
uniformis in 1976.120  
 
Nocardicin A shows moderate activity against some Gram-negative organisms such as P. 
aeruginosa but weak activity against E. coli and staphylococci. Initial efforts to improve potency 
focused on the synthesis of N-acyl derivatives of 3-amino nocardicinic acid (3-ANA) in the same way 
that 6-APA and 7-ACA were used for semi-synthetic penicillins and cephalosporins; however, 
nocardicin A proved to be the only useful antibiotic after extensive SAR with hundreds of 
compounds.19 The formadicins, structural relatives of the nocardicins which have a formamido 
substituent at C3, were isolated later from a species of Flexibacter.159,160 The formadicins have a 
spectrum of antibacterial activity similar to the nocardicins but the formamido substituent provides 
additional stability to -lactamases.161  
In 1981 groups at Takeda and Squibb discovered independently a new class of -lactam produced 




identification of sulfazecin and isosulfazecin and the Squibb group described their discovery of 
sulfazecin and several other monobactams including SQ 26180. In general, these monobactams 
showed weak activity against S. aureus and only modest activity against Gram-negative aerobes, but 
SQ 26180 showed good activity against P. aeruginosa (MIC of 3.1 g/mL). Early SAR studies 
showed that the N1-sulfonate served to increase the reactivity of the -lactam and that the -methoxy 
group was important for antibacterial activity and -lactamase stability. With 3-amino-3-methoxy 
monobactamic acid (3-AMA) and 37 in hand, Squibb was able to prepare a series of N-acyl analogues 
and discovered SQ 26776,164,165 an oximino-aminothaizole derivative which later became known as 
aztreonam.   
 
Aztreonam showed no activity against Gram-positive organisms or anaerobes but has very good 
activity against Gram-negative rods including Pseudomonas, Serratia, and Enterobacter, bacteria 
typically resistant to cephalosporins.166 Studies with PBPs indicated that it has very high affinity for 
PBP3 of Gram-negative organisms, moderate affinity for PBP1a, and poor interaction with all other 
PBPs of Gram-negatives and S. aureus.164 Although aztreonam lacks the 3-methoxy group and is 
slowly hydrolyzed by class A -lactamases, its affinity for these enzymes is low and it is active 
against class A-producing organisms.167,168 Aztreonam acts as a progressive inhibitor of class C 
enzymes and is one of the only -lactams that is stable to hydrolysis by metallo--lactamases. 
Aztreonam was approved for clinical use in 1986 and carumonam, which shows slightly improved 
activity over aztreonam against Enterobacteriaceae, is also clinically available.  
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The renewed interest in Gram-negative therapy, against drug-resistant A. baumannii and P. 
aeruginosa for example, has prompted new research with the monobactams and BAL30072 and 
BAL19764 are two siderophore monobactams in development by Basilea.19,169 BAL30376 is a three-
component combination of BAL19764, which is stable to MBLs, with clavulanate, a class A -
lactamase inhibitor, and a bridged monobactam (BAL29880) which inhibits class C -lactamases.170  
1.3 Penicillin-Binding Proteins 
After Florey and the Oxford group had demonstrated in the early 1940s that penicillin was effective 
as an antibiotic in humans, penicillin’s mode of action immediately became a subject of intense 
research interest. Early work in the 1940s, 50s, and 60s was concerned with the elucidation of the 
structure of the cell wall and, in combination with morphological studies, led to the conclusion that 
penicillin inhibited the transpeptidase reaction, the last stage in cell wall biosynthesis.171,172 Other 
research in the 1970s demonstrated that penicillin has many target enzymes, called penicillin-binding 
proteins (PBPs), and significant progress has been made since that time in understanding the roles 
that each enzyme plays in synthesis and maintenance of the cell wall.173,174,175 Current research in this 
area continues to build upon the understanding of these complex processes176 and also examines the 
role of PBPs in antibiotic resistance.177  
1.3.1 Peptidoglycan and D-Ala-D-Ala Transpeptidases 
Fleming noted that penicillin was not merely bacteriostatic but killed bacteria by lysis.31 Gardner 
observed in 1940 that organisms do not lyse in the presence of low concentrations of penicillin but are 
converted to elongated forms (filaments).178 In 1949, Park reported that uridine nucleotides 
accumulated in the cytoplasm of penicillin-inhibited S. aureus179 and this material was later identified 
as a uridine pyrophosphate (UDP) linked to an N-acetyl-aminosugar and a peptide containing D-
glutamate, L-lysine, and DL-alanine in a ratio of 1:1:3.180 In 1957 Park and Strominger concluded that 
this nucleotide was a cell wall precursor since its sugar and amino acid composition was found to be 
similar to that of the recently discovered cell wall.181 At the same time, Lederberg182 and Hanh and 




















































































Figure 5. Peptidoglycan structure and cross-linking by D-Ala-D-Ala transpeptidases in (A) S. aureus, 
and (B) E. coli (DAP = diaminopimelic acid; Glx = Gln or Glu; NAG = N-acetyl glucosamine; NAM 
= N-acetyl muramic acid).  
wall was already known to be a rigid macromolecule that determines cell shape and provides 
protection from osmotic rupture, each of these studies was recognized as support for the hypothesis 
that penicillin inhibited an essential step in synthesis of the cell wall.    
Over the next few years, the complex structure of peptidoglycan and steps leading to its synthesis 
became more clear. By the early 1960s, the cell wall glycopeptide in all species examined was known 
to contain alternating units of N-acetylglucosamine (NAG, or GlcNAc) and N-acetylmuramic acid 
(NAM, or MurNAc) with a peptide unit attached to the D-lactyl portion of NAM (Figure 5). In Gram-
negative bacteria, the pentapeptide unit is [L-Ala–-D-Glu–L,L-DAP–D-Ala–D-Ala]. In Gram-positive 
organisms, the pentapeptide unit also has a pentaglycine bridge bound to the -amino group of L-Lys 
and in S. aureus this peptide unit is [L-Ala–-D-Glx–L-Lys(-Gly5)–D-Ala–D-Ala].184  
In the early 1960s, it had become widely accepted that all reactions leading to the synthesis of the 
linear glycopeptide were insensitive to penicillin. Salton provided evidence that the bacterial cell wall 
was highly cross-linked185 and it seemed clear that cross-linking must be the last stage in 
peptidoglycan synthesis and the penicillin-sensitive step. In 1965 Wise and Park confirmed that this 
cross-linking reaction was a transpeptidation with a loss of D-alanine and proposed that penicillin 
inhibits this reaction by acting as an analogue of the L-Ala–-D-Glu portion of the substrate.186 Later 
that year, however, Tipper and Strominger proposed that penicillin was more likely to be an analogue 




Figure 6. Structural analogy of penicillin and the D-Ala-D-Ala fragment of peptidoglycan as proposed 
by Tipper and Strominger in 1965.187  
amide bond would correspond to the peptide bond cleaved during the transpeptidation process (Figure 
6).187,188 The Tipper–Strominger hypothesis is widely considered a major milestone in the 
understanding of the penicillin mode of action.189   
In accord with earlier evidence from Schepartz and Johnson that penicillin binds to its target 
covalently,190 Tipper and Strominger suggested that penicillin could react with the transpeptidase to 
form a stable penicilloyl enzyme intermediate (with the active-site serine nucleophile) which would 
prevent the enzyme from completing the transpeptidation (Figure 7).  
Several studies by Cooper and others in the 1940s and 50s demonstrated that radioactive [35S]- or 
[14C]-penicillin bound specifically to a target in bacterial membranes,191 but progress in this area was 
slow until the early 1970s. In 1972, the Strominger group used SDS-PAGE to study [14C]-penicillin 
G-binding components and discovered that multiple penicillin-binding proteins were present in B. 
subtilis, B. cereus, S. aureus, and E. coli.192,193  
Penicillin-binding proteins of each organism were originally numbered in order of decreasing 
apparent molecular weight and this historical numbering system persists to this day. The classical 
numbering scheme of PBPs can cause confusion, however, because PBPs from different organisms 
with the same number do not necessarily share any structural or functional similarities. It became 
apparent that PBPs did not only include D-Ala-D-Ala transpeptidases, which cross-link the glycan 
strands, when the Strominger group found that carboxypeptidases, which remove the terminal D-
alanine through hydrolysis, were also members of the PBP group (Figure 7).193,194 Other PBPs include 
endopeptidases, which hydrolyze the peptide bond connecting two strands, and transglycosylases, 
which catalyze the polymerization of the polysaccharide strand. PBPs vary greatly in their relative 
abundance, their sensitivity to different -lactams, and regulation. It should also be noted that the 














































































































Peptidoglycan cross-linking is sterically blocked,
leading to cell lysis due to osmotic pressure
Hydrolysis of this intermediate is slow in PBPs











L-Ala -D-Glu L,L-DAP D-Ala
D-Ala-D-Ala
transpeptidases
Shortened strand of peptidoglycan






Figure 7. Reactions of penicillin-binding proteins (D-Ala-D-Ala transpeptidases and D-Ala-D-Ala 
carboxypeptidases) in E. coli and inactivation of PBPs by penicillins via a stable acyl enzyme.  
cross-links) to allow for cell growth and division and that the degree of peptidoglycan cross-linking is 
different in each organism.175   
PBPs are distinguished by size and have been categorized into different classes (A, B, and C) 
according to function.195 High molecular weight (HMW, MW >55000) class A PBPs are 
multimodular proteins with a cytoplasmic tail, a transmembrane anchor, and two domains on the 
outer surface of the inner membrane (e.g. PBP1a and PBP1b of E. coli). In HMW class A PBPs, the 
C-terminal penicillin-binding domain has transpeptidase activity and the N-terminal domain has 
transglycosylase activity. HMW class B PBPs also have a C-terminal domain with transpeptidase 
activity but the N-terminal domain is believed to be involved with cell morphogenesis (e.g. PBP2 and 
PBP3 of E. coli). HMW class C PBPs include penicillin-sensing proteins such as BlaR and MecR 
which are involved in regulation of -lactamase and PBP2a, respectively.   
Low molecular weight (LMW) PBPs are also commonly divided into classes A, B, and C. LMW 




Figure 8. Peptidoglycan-mimetic peptides and penicillins prepared as substrates and inhibitors of the 
Streptomyces R61 DD-peptidase.  
endopeptidase activity, carboxypeptidase activity, transpeptidase activity, or both carboxypeptidase 
and transpeptidase activities.176,196  
While most physiologically important transpeptidases are membrane-bound, most of the early 
mechanistic information about PBPs was obtained from studies with soluble D-Ala-D-Ala 
carboxypeptidase–transpeptidases (often referred to as DD-peptidases) from Actinomadura strain R39 
and Streptomyces strain R61, which are PBPs secreted in the extracellular medium.175 Although these 
enzymes are not lethal targets in the bacteria that produce them, they have been very valuable as 
models.  
In the last few years, however, studies by the Pratt group have demonstrated that substrate 
specificities of the LMW soluble R61 DD-peptidase cannot be extended to HMW PBPs and that many 
mechanistic uncertainties still remain. Peptide 38, which was designed to incorporate an N-terminal 
glycine in order to best mimic the peptidoglycan of Streptomyces, was found to be the best (most 
specific) substrate ever found for the R61 enzyme and the corresponding peptidoglycan-mimetic 
penicillin 39 proved to be an excellent inhibitor of the R61 transpeptidase (Figure 8).197,198 X-ray 
structures of the DD-peptidase of Streptomyces strain R61 were solved with this so-called “perfect 
penicillin” bound as a non-covalent (Michaelis) complex (PDB: 1PW1) and with 39 bound as the 
acylenzyme (PDB: 1PWG).199,200 In a related study, a peptidoglycan-mimetic boronic acid was shown 
to be a potent inhibitor of the Actinomadura R39 DD-peptidase (Ki of 32 nM) and was co-crystallized 
with this enzyme (PDB: 2XDM).201 Rather surprisingly, however, peptidoglycan-mimetic peptides 
such as 38 are not good substrates for the physiologically more important high molecular weight 
PBPs and peptidoglycan-mimetic -lactams such as 40 are much poorer inhibitors of other PBPs in 
vitro and in vivo than generic -lactams such as penicillin G.202,203 It is possible that there is no 
specific recognition of the peptidoglycan chain by the HMW PBPs or that there is an unknown 
mechanism through which the active site is opened or closed.204 Nevertheless, these studies clearly 
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demonstrate that cell wall biosynthesis is a complex process and give an indication of the difficulties 
that challenge the rational design of inhibitors and -lactam antibiotics.205  
1.3.2 PBPs and Resistance to -Lactam Antibiotics 
Resistance to antibiotics is inevitable. The small proportion of mutant bacteria that escape the action 
of a given antibacterial agent will be selected for and amplified and various mechanisms of resistance 
to -lactams have been discovered since the introduction of the penicillins in the 1940s. Aside from 
the restriction of the permeability of the -lactams (porin deletion) and active export of the -lactams 
from the periplasm (efflux pumps), major resistance mechanisms involve the modification of 
penicillin-recognizing proteins (-lactamases, PBPs with low affinity for -lactams, and -lactam-
sensing proteins).177,206  
The most important mechanism of bacterial resistance to -lactams is the expression of -
lactamases. An evolutionary link between the PBPs and -lactamases was proposed as early as the 
1960s187 and modern gene sequence analysis has been used to describe this evolutionary relationship 
in detail.207 Transpeptidases and serine -lactamases are similar in the formation of acyl enzyme 
intermediates upon reaction with -lactams (the first half-reaction), but serine -lactamases have 
evolved the ability to hydrolyze the acyl enzyme intermediate much faster than transpeptidases in 
order to complete the second half-reaction. At the same time, however, -lactamases have lost the 
ability to recognize the peptidoglycan substrate of the transpeptidases in order to be effective as 
enzymes that protect -lactam-sensitive enzymes.26,208 -Lactamases represent the primary mode of 
resistance to -lactams in Gram-negative bacteria and are discussed in more detail below (Section 
1.4).  
A second strategy that bacteria have used to overcome the threat of -lactams involves PBPs which 
retain their main function as transpeptidases but have low-affinity for -lactams. Some important 
examples of low-affinity penicillin-binding proteins include PBP1a, PBP2b, and PBP2x of S. 
pneumoniae, and PBP5 of E. faecium,19,206 but the most clinically significant is PBP2a (also known as 
PBP2ʹ) of MRSA.209 S. aureus normally expresses four PBPs with transpeptidase activity, including 
three HMW PBPs (PBP1, PBP2, PBP3) and one LMW PBP (PBP4).26 These enzymes are all 
unchanged in MRSA but PBP2a (which is encoded by the mecA gene) is expressed in addition to the 
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others. Surprisingly, it is not an increase in the rate of the deacylation (second half-reaction) in 
PBP2a, but a decrease in the rate of acylation (2–3 orders of magnitude compared to PBP2) that gives 
this enzyme low affinity for -lactams.210,211 Crystal structures indicate that a conformational change 
is necessary in the -helix that contains the nucleophilic serine (Ser403) before acylation can 
occur.26,212 Extensive efforts have been made to develop -lactam antibiotics which are able to bind to 
PBP2a (without sacrificing activity against the other HMW PBPs) and therefore be effective against 
MRSA. Ceftobiprole, a new cephalosporin with impressive anti-MRSA activity,213 is under regulatory 
review in the U.S. and has been approved in Canada and Switzerland for the treatment of complicated 
skin and skin structure infections (cSSSIs).214 Another cephalosporin called ceftaroline and 
carbapenems ME1036 and razupenem are also in development as anti-MRSA -lactams.  
 
-Lactam-sensing proteins represent another set of modified PBPs that contribute to -lactam 
resistance. The induction of -lactamase production in B. cereus,215,216 B. licheniformis,217 and other 
organisms has been known since the mid-1940s.218 In the mid-1980s Salerno and Lampen reported 
that -lactamase production in B. licheniformis 749 increased 180-fold one hour after exposure to a -
lactam and decreased slowly over the 1–2 hours that follow.219 The induction of -lactamase 
production implied that a transduction mechanism was present and a membrane-spanning protein 
called BlaR, which is structurally very similar to class D -lactamases,220 was later detected. It is 
believed that the reaction with the -lactam (acylation) is accompanied by a conformational change in 
the protein which transmits a signal through the cell membrane to de-repress transcription of the bla 
operon and increase -lactamase production. The bla operon is also present in S. aureus and codes for 
the expression of the PC1 -lactamase.   
Methicillin-resistant S. aureus (MRSA), however, has acquired a second mechanism for resistance 
with a -lactam-sensing system coded by the mec operon. The sensor–transducer protein MecR1, 
coded by the mecR gene, undergoes a conformational change221 upon reaction with -lactams and 




-Lactamases are enzymes that efficiently hydrolyze -lactam antibiotics. Serine -lactamases form 
an acyl enzyme intermediate upon reaction with -lactams in the same way that penicillin-binding 
proteins do; however, -lactamases have evolved the ability to hydrolyze this acyl enzyme 
intermediate much more quickly than PBPs. -Lactamases were discovered by Abraham and Chain in 
194027 and currently represent the most important mechanism of bacterial resistance to -lactam 
antibiotics. The widespread use of penicillins and cephalosporins over the last six decades has been 
an enormous evolutionary driving force and, as with all types of antibiotics, has inadvertently selected 
for resistant bacterial strains. It should be noted, however, that -lactamases did not evolve from 
PBPs as a result of the selective pressure exerted by humans. Instead, -lactamases are ancient 
enzymes which evolved from DD-peptidases billions of years ago.223,224 Correlation of their amino 
acid sequences shows that the different classes of -lactamase are more closely related to different 
classes of PBPs than to each other.207  
1.4.1 -Lactamases and Resistance to -Lactams 
The introduction of benzylpenicillin into widespread use in the mid-1940s was quickly followed by 
-lactamase-producing penicillin-resistant staphylococci. By 1948 50% of hospital isolates of S. 
aureus had become penicillin-resistant and this number had risen to 80% by the mid-1950s.225 
Methicillin, which was introduced in 1960 as the first -lactamase-stable semisynthetic penicillin, 
reduced considerably the problem of penicillin-resistant staphylococci and, as a result, had also 
reduced the perceived clinical relevance of the -lactamases.226 However, these enzymes were 
recognized to be of crucial importance when it was realized in the mid-1960s that new broad-
spectrum penicillins and cephalosporins such as ampicillin and cephaloridine (which were stable to 
staphylococcal -lactamase) were not stable to -lactamases of Gram-negative bacteria. Significant 
advances were made in the fight against -lactamase-producing organisms in the 1970s and 80s with 
the second- and third generation cephalosporins, ureido penicillins, carbapenems, and clavulanate, but 
the clinical utility of these -lactams is currently threatened by the increasingly more common 
extended-spectrum -lactamases (ESBLs) and carbapenemases which are often plasmid-encoded and 
expressed in multidrug-resistant human pathogens.    
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1.4.2 -Lactamase Classifications 
Penicillinase was the original name that Abraham and Chain27 had given to the enzyme that destroyed 
the growth-inhibiting activity of penicillin and this name was based simply on biochemical function. 
It became apparent when additional substrates became available in the years to follow (e.g. 
semisynthetic penicillins, cephalosporins) that enzymes from different sources exhibited different 
properties and enzymes were described as penicillinases or cephalosporinases based on their preferred 
substrates.227 The term “-lactamase” entered common use in the 1960s to distinguish the enzymes 
that hydrolyze the -lactam amide bond from penicillin acylases or amidases, which hydrolyze the 6-
acylamino sidechain of the penicillins, and cephalosporin esterases, which hydrolyze the C3ʹ acetoxy 
group.218  
The first widely accepted classification scheme for -lactamases was proposed by Richmond and 
Sykes in 1973228 and enzymes were classified into five major groups on the basis of substrate profile 
and inhibition profile (cloxacillin, NaCl, and p-chloromercuribenzoate) and sub-grouped according to 
whether the enzyme was inducible or constitutive.229 Sykes and Matthew revised and updated this 
classification in 1976 and divided enzymes according to whether the -lactamase was chromosomally 
encoded or R-factor-mediated.218,230  
In 1980 Ambler proposed a different classification based on the amino acid sequences of four 
serine -lactamases that were available and a partial sequence for a zinc-dependent enzyme.231,232 The 
four very similar serine -lactamases (PC1, BcI, TEM-1, and B. licheniformis 749/C) were called 
class A -lactamases and the metallo--lactamase (BcII) designated class B. The first of the class C 
-lactamases were described in 1981 when an AmpC cephalosporinase from E. coli was sequenced233 
and it was suggested in 1987 that the oxacillinases OXA-1 and OXA-2 be classified as class D -
lactamases because of the lack of sequence homology with the class A and C enzymes.234   
The Bush classification, which was proposed in 1989 as a modification of the Richmond–Sykes 
scheme, was the first attempt to correlate -lactamase function (substrate and inhibitory profiles) with 
structure and sequence.235,236 The Bush scheme grouped cephalosporinases into group 1 (e.g. Gram-
negative AmpC enzymes), penicillinases into group 2 (e.g. Ambler class A and D enzymes), and 
metallo--lactamases into group 3. Updates to this classification were made in 1995237 and 2010238 to 
include new sub-groups for enzymes such as extended-spectrum -lactamases and carbapenemases.239  
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A table of important -lactamases, sorted according to the Ambler and Bush–Jacoby classifications 
is supplied in Appendix B. Several reviews of -lactamases were published in the 1980s225,226,240, 241 
and 1990s242,243 and other reviews have been written more recently.26,244,245  
1.4.3 Class A -Lactamases 
The first enzymes to be designated as class A -lactamases include the chromosomally-encoded 
penicillinases PC1 of S. aureus, B. cereus -lactamase I (BcI), and the -lactamase of B. licheniformis 
749/C, and the R-factor (plasmid)-encoded broad-spectrum -lactamase TEM-1 (R-TEM) of E. 
coli.231 The plasmid-encoded TEM-1 quickly spread worldwide within a few years of its first isolation 
and its genetic location has also facilitated its transfer to other species of bacteria.246 TEM-1 is an 
enzyme in Bush’s functional group 2b and is able to hydrolyze penicillins and early generation 
cephalosporins such as cephalothin and cephaloridine. TEM-1 is the most commonly encountered -
lactamase in Gram-negative bacteria and accounts for most ampicillin resistance in E. coli and 
contributes to the increasing resistance in H. influenzae, and N. gonorrhoeae.246 As of November 
2010, more than 180 unique TEMs have been identified.247  
Mutations to TEM-1 over the last three decades have given rise to TEM variants with the ability to 
hydrolyze oximino cephalosporins more efficiently. These enzymes were called extended spectrum -
lactamases (ESBLs) and have been classified by Bush as group 2be.248 Other mutations provide 
resistance to clavulanic acid and these TEM derivatives were called inhibitor-resistant TEMs (IRTs) 
(e.g. TEM-30 and -31, group 2br). However, the mutations that increase the spectrum of activity, 
which generally ‘open’ the active site, typically also enhance the susceptibility of the enzyme to 
clavulanate and are usually distinct from mutations that lead to inhibitor resistance.244 Complex 
mutant TEMs (CMTs) such as TEM-50 and TEM-158 represent exceptions to this trend since they 
both have ESBL activity and a modest increase in resistance to clavulanate (group 2ber).238   
The SHV -lactamases, which have high sequence homology and similar overall structures with 
the TEM enzymes, is the second largest among Ambler class A -lactamases with more than 130 
members.247 Most mutants of SHV-1 (a group 2b enzyme) have ESBL activity (Bush’s group 2be), a 
small number have an inhibitor-resistant phenotype (e.g. SHV-10, group 2br), but none of the SHV 
enzymes characterized to date display both phenotypes (functional group 2ber). SHV -lactamases 
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are most commonly found in K. pneumoniae but have also been found in E. coli and P. aeruginosa.246    
Over the last decade, the CTX-M family of ESBLs has emerged as the largest group of class A -
lactamases not related to the TEM or SHV enzymes.249 Most (but not all) CTX-Ms have greater 
activity against cefotaxime than ceftazidime, they hydrolyze cephaloridine and cephalothin better 
than benzylpenicillin and, in contrast to TEMs and SHVs, they are inhibited more effectively by 
tazobactam than clavulanate.238 Currently, more than 100 CTX-Ms are known and all belong to 
functional group 2be.247 TOHO-1 and TOHO-2 are ESBLs that were later found to be part of the 
CTX-M group and are now also called CTX-M-44 and -45, respectively. The PER and VEB families 
are other ESBLs in group 2be that are unrelated to the TEMs, SHVs, or CTX-Ms.  
-Lactamases with carbapenemase activity have also arisen from class A and these group 2f 
enzymes include the SME, IMI, NMC-A, KPC, and GES families. The SME, IMI, and NMC-A 
families are closely related as IMI-1 and NMC-A share 97% amino acid identity and SME has 
approximately 70%. The SME, IMI, and NMC-A -lactamases are all chromosomally located (except 
for IMI-2) and are isolated relatively rarely. These enzymes have a broad spectrum of activity which 
includes penicillins, early cephalosporins, aztreonam, and carbapenems.  
The KPC and GES families, however, are plasmid-encoded -lactamases which are able to 
hydrolyze oximino cephalosporins in addition to penicillins and carbapenems. While GES enzymes 
have been isolated from E. cloacae, K. pneumoniae, and P. aeruginosa from cities scattered 
throughout the world, they have not been associated with large outbreaks. KPCs, on the other hand, 
have the greatest potential to spread as they are most commonly found in K. pneumoniae, an 
organism known for its ability to transfer resistance determinants. Several reports of KPC-producing 
K. pneumoniae have come from New York and the east coast of the U.S. since the early 2000s and, 
more recently, from other countries worldwide.  
The TEM family of class A -lactamases were the most abundant and clinically significant group 
of -lactamase in the 1980s and the class A enzymes have been the best studied of the four Ambler 
classes since that time. The mechanisms of -lactam hydrolysis and -lactamase inactivation have 
been topics of interest since the -lactamases were discovered. Various chemical methods were used 
in the 1970s in an effort to define active site amino acids and sequencing of various -lactamases was 
also undertaken with the hope that conserved residues might be identified. Speculation that the active 
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site nucleophile in -lactamases was a serine was confirmed by studies in 1979 with the irreversible 
-lactamase inhibitor 6-bromopenicillanic acid (see section 1.5.2).250 Inactivation of BcI with [3H]-
6-bromopenicillanic acid followed by a tryptic digest demonstrated that the 3H label was bound to 
the Ser44-containing peptide251 and these results provided the first strong evidence that -lactamases 
act through a serine acylenzyme mechanism.225   
 
The conclusion that an acylenzyme intermediate is formed during catalysis was supported by 
subsequent well-known studies in the Knowles group of the mechanism of inactivation of RTEM by 
clavulanate252,253 and interaction with cefoxitin.254 (The mechanisms of inactivation by clavulanate are 
discussed in more detail in Section 1.5.2). By the early 1990s X-ray crystallography and site-directed 
mutagenesis had become important tools for the study of -lactamases and indicated that functional 
class A -lactamase active sites included Ser70, Glu166, Lys73, Lys234, and an oxyanion hole 
analogous to that of serine proteases.255 Protein crystallography continues to be very valuable for the 
study of -lactamases since an understanding of the three-dimensional relationship of these residues 
is crucial for understanding their evolution as resistance enzymes (Figure 9).  
When Glu166 was found to be near Ser70 it was naturally suspected to act as a general base both in 
the acylation process, by activating Ser70, and in the deacylation process, by activating the hydrolytic 
water molecule, but it was recognized that these conclusions were not unambiguous (Figure 10). 
Glu166 mutants (e.g. Glu166Asp, -Asn, -Ala, and -Arg), for example, were unable to undergo 
deacylation but retained the ability to undergo acylation (albeit more slowly) and these mutagenesis 
studies indicated that Lys73 was the general base for the acylation half-reaction.256 In 1992 Strynadka 
et al. reported the X-ray crystal structure of benzylpenicillin bound to the TEM-1 deacylation-
defective mutant Glu166Asn (PDB: 1FQG) as the acyl enzyme intermediate and the group supported 
the hypothesis that Lys73 activates Ser70.257    
While there has been consensus since the late 1980s that Glu166 acts as the general base in the 

































































































































Figure 9. Class A -lactamase active sites and the mechanism of penicillin turnover by TEM-1. The 
modeled Michaelis complex of TEM-1 with penicillanic acid was generated by docking the -lactam 
into an X-ray structure of the wild type enzyme (PDB: 1ZG4)258 and one of the two reasonable 
mechanisms266 for acylation is indicated with arrows (albeit in a simplified manner, wherein the 
formation and collapse of the tetrahedral intermediate are not shown). The mechanism of deacylation 
is shown with arrows in a model of an acylenzyme which was generated from an X-ray structure of a 
penicillin-acylated TEM-1 mutant (PDB: 1FQG).257 Figures of PC1 (3BLM), SHV-2 (1N9B), TOHO-
1 (1IYS), CTX-M-9 (1YLJ), BlaC (2GDN), GES-1 (2QPN), SME-1 (1DY6), NMC-A (1BUE), and 
KPC-2 (3DW0) were created from X-ray coordinates deposited in the PDB. Note that the Gly170Asn 
mutation of GES-1 (as in GES-2 and GES-4–6) is associated with carbapenemase activity (group 
2f).259 The Bush–Jacoby functional group designations (Appendix B) for each enzyme are shown in 
brackets (asterisks indicate where designations are unofficial and deduced by this author). For Figure 
9–Figure 14, small red spheres represent water molecules and hydrogen, nitrogen, oxygen, and sulfur 




Figure 10. Mechanisms for penicillin acylation in class A -lactamases in which Glu166 (A) or Lys73 
(B) acts as the general base to activate Ser70 for nucleophilic attack. See text and ref 266.     
since the early 1990s. In 2002, the Shoichet group solved an ultrahigh-resolution (0.85 Å) X-ray 
structure of a boronic acid transition state analogue bound to TEM-1.260 The structure, which 
represents a snapshot of the complex mid-way through the acylation, exhibited clear enough electron 
density to view a proton bound to Glu166 H-bonding with the water molecule that bridges Glu166 
and Ser70. This X-ray study of TEM-1 provides compelling evidence in favour of a mechanism in 
which Glu166 acts as the general base via the water molecule and Lys73 functions as a Lewis acid 
that increases the acidity of the Ser70 proton and facilitates its activation. The Glu166 pathway is also 
supported by other high-resolution X-ray studies with CTX-M enzymes261,262 and computational work 
by Díaz et al.263 and Hermann et al.264  
Recent work by the Mobashery group, however, indicating that the pKa of Lys73 in TEM-1 is 8.0–
8.5, has led the group to suggest that the acylation step involves deprotonation of Lys73 by Glu166, 
followed by activation of Ser70 by a neutral Lys73.265 Subsequent high-level ab initio QM/MM 
calculations from the same group indicate that both pathways exist in TEM-1 and Ser70 is activated 
by dual participation of Glu166 and Lys73.266 The energy barrier calculated for the pathway in which 
Glu166 activates Ser70 through a water molecule is 26 kcal/mol (Figure 10A) while the pathway 
involving Lys73 (neutral) activating Ser70 directly has a barrier of 22 kcal/mol (Figure 10B).267  
The formation of the tetrahedral intermediate (not shown in Figure 9 for clarity) is often called a 
“proton shuttle” mechanism in which the proton of Ser70 is shuttled to Glu166. The collapse of the 
tetrahedral intermediate is referred to in the same way as the proton of Lys73 is shuttled to the 
nitrogen of the substrate via Ser130 as the -lactam ring is opened.268 Lys234 serves to enhance the 
acidity of Ser130 in the breakdown of the tetrahedral intermediate. As for the second half-reaction, it 
is widely accepted that hydrolysis of the acylenzyme intermediate occurs through activation of the 
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hydrolytic water molecule by Glu166.  
The roles of important residues in the active sites of class A -lactamases have been studied in 
detail over the past few decades. Several common mutations in TEM- and SHV -lactamases are 
apparent upon inspection of the TEM and SHV tables provided by Bush and Jacoby 
(http://www.lahey.org/studies/). The effects of several mutations on substrate and inhibition profiles 
of class A ESBLs and IRTs have been reviewed by Fisher et al.26 and Drawz and Bonomo.29 While 
the study of class A carbapenemases is less advanced, it is clear that the introduction of a new 
disulfide bond (Cys69–Cys238) is important for the acquisition of carbapenemase activity. This 
cystine serves to enlarge the binding cavity for the hydroxyethyl sidechain of the carbapenems by 
causing a change in conformation of the S3 strand, which contains residues 237–240, and indirectly 
altering the orientation of Asn132.259   
1.4.4 Class C -Lactamases 
The penicillin-destroying “penicillinase” first reported by Abraham and Chain in 1940 was actually 
an E. coli cephalosporinase.269 In the 1960s and 1970s, many Gram-negative bacteria were found to 
produce chromosomal cephalosporinases (encoded by the ampC gene) and many of these were 
normally expressed at low levels but inducible in the presence of -lactams.218,270 The AmpC -
lactamase of E. coli strain K-12 was sequenced in 1981 and became the first enzyme of the class C -
lactamases because of its lack of sequence homology with known class A and B enzymes.233  
Plasmid-mediated AmpC enzymes have been known since the late 1980s and include the MIR, 
CMY, BIL, FOX, DHA, ACC, and LAT -lactamase families.271 These plasmid-encoded enzymes, 
and the very closely related chromosomal AmpC -lactamases of Bush functional group 1, generally 
provide resistance to penicillins, cephamycins, oximino cephalosporins, and monobactams, and are 
resistant to inhibition by clavulanate. Plasmid-mediated AmpCs have been found worldwide but are 
less often a cause of cefoxitin resistance than an increased production of chromosomal AmpCs. 
Hyperproduction of chromosomal AmpC -lactamases is often a result of mutations in the regulatory 
gene (ampR) and the development of resistance in enteric organisms upon therapy is a concern.269 
Production of group 1 -lactamases in large amounts can even provide resistance to carbapenems.238  
In 1995 Nukaga et al. described the isolation of the first extended-spectrum class C -lactamase 
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(functional group 1e) from a clinical isolate of E. cloacae (strain GC1) in Japan.272 The kinetic 
parameters of the new GC1 -lactamase differed significantly from the well-known class C -
lactamase P99 (the AmpC enzyme from E. cloacae strain P99) and its substrate profile included 
oximino cephalosporins normally considered unfavourable substrates. The expanded spectrum of 
GC1 is attributed to a duplication of three amino acid residues (Ala208–Val209–Arg210) after 
position 210, which increases the flexibility of the  loop and allows the enzyme to accommodate the 
bulky sidechains of oximino cephalosporins.273 Several other group 1e -lactamases are now known 
and all have amino acid insertions or alterations in the  loop, the R2 loop, or the H-9 helix which 
increase the accessibility for bulky substrates.270    
The class C -lactamases share with the class A -lactamases a similar acyl enzyme mechanism of 
-lactam hydrolysis, but there are several important points of difference. While the class A and C -
lactamases have both reached “catalytic perfection” for their favoured substrates (penicillins and 
cephalosporins, respectively), the rate-limiting step for class A enzymes is the acylation step and for 
class C enzymes is the deacylation.26 Another difference, which was revealed by an X-ray structure of 
P99 in 1993,274 is that the approach of the hydrolytic water molecule in the class C -lactamases 
occurs from the “” face while the approach in class A enzymes is from the “” face.  
The first X-ray crystal structure of a class C enzyme was that of the chromosomal -lactamase of 
Citrobacter freundii in 1990 (PDB: 1FR1).275 Comparison of the structure of this AmpC enzyme with 
the class A enzyme TEM-1 revealed that they shared similar folds and active site residues. The 
residues of the class C -lactamases Ser64, Lys67, Lys315, and Tyr150 occupy similar positions as 
the catalytically important residues Ser70, Lys73, Lys234, and Ser130 of the class A enzymes. Since 
the class C enzymes lack a residue equivalent to Glu166 of the class A -lactamases, Oefner et al. 
suggested that Tyr150 (as its anion) might act as a general base in both the acylation and deacylation 
steps of -lactam hydrolysis.275  
The anionic Tyr150 was proposed to activate Ser64 directly in the formation of the tetrahedral 
intermediate, to shuttle the proton of Ser64 to the nitrogen of the -lactam substrate in the breakdown 
of the tetrahedral intermediate, and to activate the hydrolytic water molecule for hydrolysis of the 
acyl enzyme intermediate. This hypothesis is inconsistent, however, with NMR experiments which 
indicate that the pKa of Tyr150 is >11 (in the apo enzyme)




Figure 11. Class C -lactamases and the mechanism of penicillin turnover by E. coli AmpC. The 
modeled Michaelis complex with penicillanic acid was generated by docking the -lactam into an X-
ray structure of AmpC (PDB: 3GSG)277 and a simplified mechanism of acylation (wherein the 
formation and collapse of the tetrahedral intermediate are not shown) is indicated with arrows. The 
mechanism of deacylation is shown with arrows in a modeled acylenzyme that was generated using 
X-ray structures of a penicillin-acylated AmpC (PDB: 1LL9)278 and a boronic acid-inhibited AmpC 
(2FFY). Figures of the P99 (1XX2), GC1 (1GCE), and CMY-10 (1ZKJ) active sites were created 
from X-ray structures downloaded from the PDB. Bush–Jacoby functional group designations are 
shown in brackets. 
Dubus et al.279 Mutation of Tyr150 to Phe, Ser, and Glu produced much smaller changes in kcat (200- 
to 2000-fold) than would be expected for substitution of a catalytically important residue. These 
results implicate Lys67 (as the free base) as the general base in the acylation process, either by 
activating Ser64 directly or via Tyr150 (Figure 11).  
The mechanism of deacylation in the class C -lactamases has also been debated. The original 
proposal that Tyr150 (as its anion) activates the hydrolytic water are clearly challenged by the NMR 
studies of the Ishiguro group which indicate that its pKa is >11.
276 A related model, supported by 
Gherman et al.,280 involves activation of the hydrolytic water molecule by the basic form of Lys67 
through Tyr150 (neutral). This hypothesis is disfavoured, however, by a recent high-resolution X-ray 
structure of AmpC (PDB:2FFY) from the Shoichet group which resolves a proton on Tyr150 (H-
bonding with an oxygen of the boronic acid transition state analogue) and shows that Lys67 is fully 
protonated.281     
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Given that the approach of the hydrolytic water occurs from the -face in class C enzymes, the 
Mobashery group proposed a mechanism for deacylation involving activation of the water molecule 
by the thiazolidine nitrogen of the substrate itself.282 The evaluation of a pyrrolidine-containing non-
-lactam substrate and a cyclopentane (amine-lacking) analogue supported this proposal as the 
amine-containing analogue was turned over (underwent acylation and deacylation) and the amine-
lacking substrate acted as an irreversible inhibitor (acylation only). This type of activation has been 
called substrate-assisted catalysis and this mechanism is consistent with available X-ray crystal 
structures of AmpC.281,283  
1.4.5 Class D -Lactamases 
Among the first types of -lactamases known to be encoded on Gram-negative plasmids were the 
TEM, OXA, SHV, and PSE families.284 The OXAs were originally set apart from the TEMs by their 
ability to hydrolyze isoxazoyl -lactams such as oxacillin and cloxacillin. In the late 1980s OXA-1, 
OXA-2, and PSE-2 (now known as OXA-10) became the first class D -lactamases when their 
sequences were found to be very similar to each other but very different from the class A and C serine 
-lactamases that had been sequenced.234,285  
Over the last few years, the number of enzymes in the OXA family has increased drastically. While 
only 20 class D enzymes were known in 2000286 and 50 in 2005,26 nearly 200 OXA variants have 
been described to date.247 The class D -lactamases have expanded from a series of narrow spectrum 
enzymes (functional group 2d) to become the most diverse of the four Ambler classes, with 
increasing numbers of OXAs with ESBL activity against third generation cephalosporins (group 2de) 
and carbapenemase activity (group 2df). The OXAs have also expanded from their historical host of 
P. aeruginosa to other Gram-negative organisms including E. coli, K. pneumoniae, and most 
importantly, A. baumannii.287    
The OXAs were originally defined as -lactamases that hydrolyze oxacillin faster than 
benzylpenicillin but many of the recently characterized OXAs hydrolyze oxacillin only poorly. Most 
class D -lactamases, however, can hydrolyze amino- and ureidopenicillins well, most are resistant to 
inhibition by clavulanate, tazobactam, and sulbactam, and most are inhibited by NaCl.288  
Several OXA subgroups have been identified within the Ambler class D enzymes and the most 
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important of the narrow spectrum families are the OXA-1, OXA-2, and OXA-10 subgroups. Whereas 
OXA-1 and OXA-2 variants mostly retain a narrow spectrum of activity, many OXA-10 variants, 
including OXA-11, OXA-13, OXA-16, OXA-28, OXA-35, and OXA-74, have increased activities 
toward expanded-spectrum cephalosporins. OXAs with ESBL activities which are not variants of 
narrow spectrum OXAs include OXA-18, OXA-45, and OXA-53.288  
The most clinically important OXAs are the carbapenem-hydrolyzing class D -lactamases 
(CHDLs), which include those of the OXA-23, OXA-40 (OXA-24 is now known as OXA-40), OXA-
48, OXA-51, and OXA-58 subgroups and others.289 The importance of the CHDLs to carbapenem 
resistance has been debated because of the relatively low level of hydrolysis of carbapenems by these 
enzymes, but knockout and complementation experiments demonstrate that OXA-23, OXA-40, and 
OXA-58 (to a lesser extent) contribute significantly to carbapenem resistance in A. baumannii.290 So 
far, none of the class D -lactamases have both ESBL and carbapenemase activity.    
Structural and mechanistic information about the class D -lactamases was extremely limited until 
2000, when two X-ray crystal structures of OXA-10 were published independently by the 
Strynadka291 and Mobashery286 groups. Both groups noted that the overall folds of the class D -
lactamase are more similar to class A enzymes than to class C enzymes and that several residues 
important for catalysis in TEM-1 aligned very well with residues in OXA-10. An important 
difference, however, was that OXA-10 appeared to lack an acidic residue equivalent to Glu166, the 
residue that functions as a general base in TEM-1. Lys70 was proposed as the best candidate for the 
general base in OXA-10 by both Strynadka and Mobashery, since it was thought that its pKa might be 
lowered significantly by its hydrophobic environment. This explanation was found to be incomplete 
later that year, when Mobashery and coworkers published an X-ray crystal structure of OXA-10 in 
which Lys70 was carboxylated (Figure 12).292 As an unusual functional group with some precedent, 
this carboxylated lysine was proposed to act as the general base in the hydrolysis of -lactams, 
through direct activation of Ser67 in the acylation process and through activation of the hydrolytic 
water molecule in the deacylation half-reaction (Figure 13).    
The discovery of lysine carboxylation in OXA-10, which is reversible, pH dependent, and critical 
for enzymatic activity,293 was a major breakthrough in the study of class D -lactamases because 




Figure 12. The discovery of Lys70 carboxylation in class D -lactamases. The first X-ray structures of 
OXA-10 by Strynadka (PDB: 1FOF) and Mobashery (1EWZ) are shown in black and blue, 
respectively. A subsequent structure (1E4D) showed that Lys70 is N-carboxylated (Kcx70).  
 
Figure 13. Class D -lactamase active sites and the mechanism of penicillin turnover by OXA-10. The 
Michaelis complex shown was generated by docking penicillanic acid into an X-ray structure of 
OXA-10 (3LCE) and arrows indicate a simplified version (without formation and collapse of the 
tetrahedral intermediate) of one possible mechanism of acylation.298 The acylenzyme structure shown 
is a model created from the PDB files 2WG1 and 1K54 and a possible mechanism for deacylation 
indicated with arrows. Images of OXA-1 (1M6K), OXA-2 (1K38), OXA-40 (3G4P), and OXA-48 
(3HBR) were created from X-ray structures retrieved from the PDB. The X-ray structure of OXA-45 
was kindly provided by Prof. J. Spencer (U. Bristol, U.K.) prior to publication. Bush–Jacoby 
functional group designations are shown in brackets.   
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type progress curves).26 Supplementation of the medium with bicarbonate to mimic the in vivo 
concentration of CO2 (ca. 1.3 mM)
294 restores the kinetic profile for most enzymes, but some OXAs 
retain biphasic profiles with some substrates. Evidence that OXA-10 exists predominantly as a dimer 
and that the dimer is the more active form,295,296,297 led to the proposal that a monomer–dimer 
equilibrium might be responsible for the complex biphasic kinetics (of OXA-10 and other OXAs); 
however, this rationale is not applicable to in vitro biochemical assays conducted with nanomolar 
concentrations of enzyme since dissociation constants for these enzymes are typically in the 
micromolar range.293  
It is widely accepted that the carboxylated lysine functions as the general base in the acylation and 
deacylation half-reactions, but the exact mechanisms of these processes have not yet been elucidated. 
Some of the most detailed mechanistic information currently available on the OXAs includes the 
results of advanced computational work done in 2005.298 Li et al. used QM/MM methods to 
investigate the mechanism of lysine carboxylation in OXA-10 and found that carboxylation is 
exothermic in the enzyme and that carboxylation of Lys70 (neutral) by CO2 (and not bicarbonate) is 
mediated by a water molecule. It is possible that this water molecule, which is the hydrolytic water 
involved in deacylation, is also involved in the acylation process as a bridge between Kcx70 and 
Ser67. In addition, the authors suggest the possibility that a decarboxylation event partway through -
lactam turnover may be the main source of the biphasic kinetics observed with various OXAs since it 
is known that Lys70 must be carboxylated for catalysis to resume.   
Additional mechanistic insights have been gained from a number of X-ray structures of OXAs with 
and without inhibitors but a recent focus of research in this area has involved structural studies with 
OXA carbapenemases. The Romero group, which reported the crystal structure of OXA-24 (now 
OXA-40) in 2007, postulated that the specificity of OXA-40 for carbapenems is a result of the 
hydrophobic barrier formed by residues Met223 and Tyr112 (Figure 13).299 The importance of these 
residues was demonstrated by site-directed mutagenesis but an explanation for the improved activity 
toward carbapenems, compared to other OXAs, was not provided. In 2009 Docquier et al. published 
the structure of OXA-48, a carbapenemase which is more similar in sequence and 3D structure to the 
narrow-spectrum enzyme OXA-10 than to the carbapenemase OXA-40.300 With support from 
molecular dynamics simulations, the authors proposed that the orientation and flexibility of the 5/6 
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loop of OXA-40 and OXA-48 better accommodates the hydroxyethyl sidechain of carbapenems than 
the corresponding loop of the narrow-spectrum enzymes OXA-10 and OXA-13.  
1.4.6 Class B -Lactamases 
The first metallo--lactamase, BcII of Bacillus cereus, was discovered indirectly by Newton and 
Abraham during the structural elucidations of penicillin N and cephalosporin C in the mid-1950s.75,216 
Crude preparations of -lactamase from B. cereus showed a selective loss of cephalosporinase 
activity upon purification, and a loss of penicillinase activity in aqueous solution at 60 C, indicating 
that the preparations were mixtures of two enzymes. The metal dependence of the cephalosporinase 
was confirmed with experiments in the mid-1960s which showed that activity was lost upon treatment 
with EDTA but restored with the addition of ZnSO4.
301 After purification of the penicillinase (called 
BcI) and cephalosporinase (called BcII) by fractional precipitation with a ammonium sulfate, BcII 
was shown to hydrolyze semisynthetic penicillins and cephalosporins at a rate comparable to 
benzylpenicillin.302  
BcII was the only known Ambler class B231 (Bush group 3) metallo--lactamase (MBL) for many 
years until the identification of L1 from Pseudomonas (now Stenotrophomonas) maltophilia in 
1982303 and the imipenem-hydrolyzing MBLs CphA and CcrA (also called CfiA) from Aeromonas 
hydrophila and Bacteroides fragilis, respectively, in 1986.304,305 Despite the ability of these enzymes 
to hydrolyze carbapenems and their resistance to inhibitors, the MBLs were not widely considered an 
immediate threat in the 1980s because these enzymes were chromosomally encoded. A plasmid-
encoded metallo--lactamase was discovered in 1991, however, when imipenem resistance due to the 
production of the MBL was found to be transferable in a Japanese isolate of P. aeruginosa.306 This 
enzyme, which was later identified as IMP-1, has a broad spectrum activity that includes penicillins, 
cephalosporins, and carbapenems (but not aztreonam).307 IMP-1 was subsequently isolated from 
Serratia marcescens308 and members of the IMP family, now known to be mobilized by integrons, 
were found in other strains of Pseudomonas spp., Acinetobacter spp., and Enterobacteriaceae in 
Japan.309 Since the mid-1990s the IMPs have spread worldwide259,310,311 and 24 IMP variants have 
been reported to date.247   
The VIM family of metallo--lactamases was first discovered in Verona from a strain of P. 
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aeruginosa isolated in 1997,312 and VIM-1, like IMP-1, hydrolyzes efficiently most -lactams except 
the monobactam aztreonam. The VIMs, which are mostly integron-borne, are the dominant MBLs in 
Europe and have quickly spread across the globe, with VIM-2 being the MBL most reported in the 
world.309 The VIMs have become the second largest family of MBLs with 21 variants.247  
The third type of acquired metallo--lactamase discovered was SPM-1, an enzyme first isolated 
from a highly resistant strain of P. aeruginosa in 2001 from São Paulo, Brazil.313 GIM-1, which has 
some similarity to IMPs and VIMs, was identified from an isolate of P. aeruginosa in Germany in 
2002314 but GIM-1 has not spread as quickly as the other MBLs.310 Other MBLs identified recently 
include SIM-1 from a strain of A. baumannii isolated in Seoul, Korea,315 KHM-1 from a C. freundii 
strain isolated in Tokyo,316 DIM-1 from a Dutch strain of Pseudomonas stutzeri,317 and AIM-1 from 
P. aeruginosa in Australia.318 
The recent discovery of a new MBL called NDM-1, which originated from New Delhi, India, 
represents a very concerning development. NDM-1 was found on a class 1 integron in a strain of K. 
pneumoniae which also expressed the ESBL CMY-4 and an erythromycin esterase and was resistant 
to all antibiotics tested (MICs > 32 g/mL) except colistin.319 Transferability of the MBL gene in vivo 
was inferred as NDM-1 was found in a strain of E. coli that was later isolated from the same patient. 
Since its first isolation in 2006, NDM-1 has spread rapidly and has been detected in India, Pakistan, 
the U.K.,320 the Netherlands, Australia,321 the U.S., Canada,322 Kenya,323 Norway,324 and Germany325 
in isolates of K. pneumoniae, E. coli, C. freundii, M. morganii, Providencia spp., and E. clocae. 
NDM-1 is most similar to VIM-2 (32% amino acid identity) and has an activity profile similar to the 
IMPs and VIMs, hydrolyzing most -lactams well except aztreonam.   
As a result of the increasing number and diversity of the metallo--lactamases in the late 1990s, 
Bush proposed326,327 that the MBLs could be subclassified according to structure (molecular 
subclasses B1, B2, and B3) or subgrouped according to substrate specificities (functional groups 3a, 
3b, and 3c). With additional biochemical characterization, however, the functional groupings were 
updated in 2010238 to include only two functional groups (groups 3a and 3b). Subgroup 3a is 
comprised of enzymes which hydrolyze penicillins and cephalosporins at rates of at least 60% of the 
rate of imipenem hydrolysis while group 3b enzymes hydrolyze carbapenems preferentially. With 
respect to the molecular/structural classification scheme, most known MBLs, including BcII, CcrA 
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(CfiA), BlaB, and the IMP, VIM, SPM, GIM families, belong to subclass B1. Subclass B2 includes 
CphA, ImiS, and Sfh-I, and subclass B3 contains L1, FEZ-1, THIN-B, BJP-1, and the GOB family. 
Structural subclasses B1 and B3 are part of Bush’s functional group 3a and subclass B2 aligns with 
functional group 3b.328,329,330 In 2002 Galleni et al. proposed a standardized numbering scheme for 
metallo--lactamases based on sequence homology and structural information.331,332   
Although MBLs have now been characterized extensively by X-ray crystallography, with nearly 
100 entries for MBLs in the PDB, the mechanisms of -lactam hydrolysis have not been completely 
resolved. Elucidation of these mechanisms has been complicated by the fact that ZnII is silent in most 
spectroscopic techniques333 and, with the exception of two structures (PDB: 1X8I, 2AIO), the lack of 
enzyme–substrate complexes. Furthermore, the metal content of the MBLs in vivo (mono- vs di-zinc) 
and the site of the zinc atom (in mono-zinc enzymes), which are issues of central importance to 
inhibitor design, remain controversial despite extensive study.   
The earliest data regarding the metal content of the MBLs and mechanism of action was obtained 
by chemical methods in the mid-1970s in the study of the metal-dependent -lactamase II of B. 
cereus (BcII). A cysteine residue became the first amino acid to be implicated in zinc binding as the 
presence of a thiol group in the enzyme was only detected (by derivatization with iodo-[2-14C]-
acetate, for example) in the presence of EDTA.216,334 Replacement of Zn2+ with Co2+, Cd2+, Mn2+, and 
Hg2+ gave enzymes with significant activity (albeit much lower) and, with respect to metal content, 
equilibrium dialysis revealed that at least two zinc binding sites were present.335 The enzyme bound 
one zinc with high affinity and the other with much lower affinity and, although BcII was active 
against benzylpenicillin with only one zinc (80% Vmax at 10 M ZnSO4), the rate of hydrolysis 
increased with increasing occupation of the second zinc site (full activity at 1 mM ZnSO4). NMR 
studies by Baldwin et al. implicated three histidines as ligands for one zinc and a fourth histidine 
ligand as a ligand in the other zinc-binding site.336  
In the 1980s and 90s it became apparent that the metallo--lactamases were quite diverse in their 
metal requirements for activity. The class B2 MBL of Aeromonas hydrophila (CphA), for example, 
binds one zinc tightly (nM) and the binding of a second zinc is inhibitory to enzymatic activity (Ki = 
46 M).337 The class B1 and B3 MBLs BcII, CcrA, BlaB, IMP-1, VIM-4, and L1 are known to 
require two zincs for maximal activity but each of these enzymes has also been shown to be active (at 
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a reduced level) in its mono-zinc form.335,338,339,340,341,342,343 The metal requirements for the activity of 
SPM-1 are uncertain, however, since the native form of the enzyme was found to contain 1.5 mol Zn 
per mol protein344 and the X-ray crystal structure of SPM-1 (PDB: 2FHX) shows only one zinc bound 
in the active site.345    
With the free zinc ion concentration in the cell estimated to be in the picomolar range and the low 
affinity of the MBLs for a second zinc atom, Wommer et al. suggested in 2002 that the 
physiologically relevant form of an MBL is the mono-zinc state and that the di-zinc form is 
unattainable under physiological conditions.341 The group also proposed that the apo (metal-free) 
form of the enzyme exists under normal conditions as they had found experimentally that the 
presence of a -lactam substrate activated (increased affinity) apo MBLs for binding zinc. In this 
model, the use of a second zinc atom is not necessary for catalysis but is regarded as catalytic 
augmentation since an incremental improvement in activity is achieved. Despite the possibility that 
the mono-zinc form of the MBLs may be the physiologically relevant one, kinetic assays with MBLs 
in vitro require the addition of Zn2+ in order to improve enzyme stability and reproducibility.  
As stated above, the metallo--lactamases have now been studied extensively by X-ray 
crystallography (Figure 14) and the first of these structures were reported in the mid-1990s. The 
structure of a mono-zinc form of BcII was published in 1995 by Carfi et al. (PDB: 1BMC),346,347 
followed by the structure of the dinuclear MBL CcrA by Concha et al. in 1996348 and a di-zinc form 
of BcII by Fabiane et al. in 1998.349 The common topology of these (and subsequent) metallo--
lactamases is an / sandwich fold and MLBs appear to be members of a large and ancient 
superfamily of metalloenzymes.350 In the structure of the mono-Zn BcII, the zinc atom was 
coordinated in a tetrahedral geometry to three histidines and a water molecule. In the di-zinc 
structures of CcrA and BcII (and all other di-zinc B1 MBLs), one zinc binds to the same site (called 
the Zn1 site or 3H site) and the other is coordinated by an aspartate, a histidine, a cysteine, and a 
water molecule (called the Zn2 or DHC site) in a trigonal bipyramidal geometry. The remaining 
ligand for both zincs, which are 3.5 Å apart in the CcrA structure, is a bridging water molecule or 
hydroxide molecule that was proposed to act as the nucleophile in the hydrolysis. The structure of 
SPM-1 indicates that the unusual orientation of Asp120 may be responsible for the low affinity for 















































































































































Figure 14. Class B metallo--lactamase active sites. Figures were generated from X-ray structures of 
BcII (1BC2), BlaB (1M2X), CcrA (1ZNB), IMP-1 (1DDK), VIM-2 (1KO3), SPM-1 (2FHX), CphA 
(1X8G), L1 (1SML), and FEZ-1 (1K07) retrieved from the PDB. All structures shown were 
crystallized without inhibitors except BlaB which was co-crystallized with the thiol D-captopril (not 
shown for clarity, except for a small yellow sphere which represents the sulfur atom that displaced the 
zinc-bridging hydroxide). Bush–Jacoby functional group designations are shown in brackets and 
molecular subclasses also indicated. It should be noted that amino acid residues have been numbered 
as in each PDB file and not according to the standardized (BBL) numbering schemes of Galleni331 
and Garau.332  
The structure of L1, a di-zinc class B3 MBL from S. maltophilia,351 shows that the Zn1 site is 
comprised of three histidines as with the class B1 enzymes but, in contrast to class B1 MBLs, the 
cysteine of the Zn2 site is replaced by a histidine in the class B3 enzymes and the site is therefore 
called the DHH site. This substitution is also present in FEZ-1,352 indicating that the DHH site for Zn2 
is a common feature of subclass B3 MBLs. The narrow-spectrum carbapenemases of subclass B2, 
such as CphA of Aeromonas hydrophila, possess the same Zn2 (DCH) site of the B1 enzymes, but the 
Zn1 site is comprised of two histidines and an asparagine.353 The His-to-Asn substitution causes a 
substantial decrease in the affinity for zinc at the Zn1 site and class B2 MBLs function as mono-zinc 
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enzymes.     
One of the first proposals for the mechanism of the metallo--lactamases was suggested by Carfi et 
al. in 1995 with the publication of the X-ray structure of a mono-zinc form of BcII.346 Based on 
molecular models and mechanistic studies with other zinc peptidases, the zinc atom was proposed to 
serve as a Lewis acid toward the substrate, to polarize and activate the -lactam carbonyl for attack, 
and as a Lewis acid toward the hydrolytic water, to increase its acidity. Asp90(120) was implicated as 
the general base that would be able to deprotonate the hydrolytic water and shuttle a proton to the 
nitrogen of the -lactam. Some aspects of this early proposal are supported by recent computational 
work by Dal Peraro et al.354,355 (Figure 15D) but it is thought that the pKa of the zinc-bound water in 
the mono-zinc form of BcII is less than 4.9 so that it exists as a hydroxide in vivo.356     
In one of the first proposals for the mechanism of -lactam hydrolysis by di-zinc (class B1 and B3) 
MBLs, Concha et al. suggested in 1996 that nucleophilic attack at the -lactam carbonyl is carried out 
by the bridging hydroxide, which is oriented appropriately through a hydrogen bond with 
Asp103(120), and that Zn1 and Asn193 together serve as an oxyanion hole to stabilize the tetrahedral 
intermediate.348 The pKa of the bridging hydroxide has been estimated to be between 4.9 and 5.6.
356,357 
A large amount of research has been focused on the di-zinc MBLs since Concha’s X-ray structure and 
mechanistic studies remains ongoing. A detailed summary of this research is beyond the scope of this 
review but several classical mechanistic studies should be mentioned. Early work in the late 1990s 
with BcII by Paul-Soto et al.339,340 and Bounaga et al.,357 for example, provided a basis for the 
understanding of the pH dependence of enzymatic activity, zinc binding, and inhibition by thiols. The 
Benkovic group proposed a minimum kinetic mechanism for the B. fragilis MBL (CcrA) based on the 
direct observation of an enzyme-bound intermediate in nitrocefin hydrolysis and was also able to rule 
out a mechanism involving nucleophilic catalysis by Asp103(120).358,359,360,361 Since these reports 
from Benkovic, the role of Asp120 in catalysis has been studied in detail362,363,364,365,366 and other 
enzyme-bound intermediates have also been detected.333,367,368 Other recent experimental research 
with MBLs, which includes several publications from the Crowder and Vila groups, has been focused 
on elucidating the relationships of metal content, localization, and movement with enzymatic 
activity356,369,370,371,372,373 and the roles of each metal in -lactam hydrolysis.333,372,374,375 Recent 
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Figure 15. Proposed mechanisms of -lactam hydrolysis by metallo--lactamases. Hydrolysis of 
cephalosporins by dinuclear class B1 and B3 enzymes (A) as adapted from Garrity et al.,362 Crowder 
et al.,350 Hu et al.375 and (B,C) as calculated by Dal Peraro et al.376 (D) The “water-assisted” 
mechanism of cephalosporin hydrolysis catalyzed by mono-zinc class B1 and B3 MBLs as studied 
computationally by Dal Peraro et al.355 (E) Mechanisms of carbapenem hydrolysis by class B2 MBLs 




Figure 16. The flexible loop region (red) of class B1 metallo--lactamases. Figures were generated 
from X-ray structures of CcrA (2BMI), CcrAMES (1A7T), IMP-1 (1DDK), and IMP-1thiol (1DD6) 
retrieved from the PDB. (MES = 2-(N-morpholino)ethanesulfonic acid).  
understanding of di-zinc MBL mechanisms (Figure 15B,C).376   
An interesting characteristic of many B1 MBLs is the presence of a flexible loop near the active 
site. NMR characterization by Dyson and coworkers,377,378,379 mutagenesis studies,379,380 molecular 
dynamics (MD) simulations,354,381,382,383 and X-ray crystal structures348,384 have shown that this loop is 
flexible in the absence of substrate but closes down on the active site in the presence of a substrate or 
inhibitor (Figure 16). The tryptophan residue present in the loops of CcrA and IMP-1 interacts non-
specifically with a variety of substrates and is thought to have a role in promoting catalysis. 
Substitution of Trp for other residues or deletion of the loop resulted in increased Km values and 
reduced kcat and kcat/Km values.
379,380    
While the mechanisms of the B1 and B3 MBLs have been investigated heavily since the mid-
1990s, the mechanisms of the class B2 MBLs had remained poorly understood until the mid-2000s. 
Class B2 MBLs, which have a narrow spectrum of activity including only carbapenems, were known 
to bind only one zinc tightly and be inhibited by binding a second zinc,337 but the three dimensional 
structure of the class B2 enzymes was unknown until the X-ray crystal structure of CphA was 
reported by Garau et al. in 2005.353 In contrast to mono-zinc B1 enzymes, in which the zinc binds to 
the Zn1 site, the zinc of CphA was observed in the Zn2 (DCH) site as a result of the substitution of a 
histidine for an asparagine in the Zn1 site of the class B2 enzyme that causes a significant decrease in 
the affinity for a zinc atom. Although spectroscopic studies with ImiS indicate that, even in the 
presence of added Zn2+, a second zinc atom does not binds in the active site,385,386 recent X-ray crystal 
structures (PDB: 3F9O, 3FAI) of di-zinc CphA show that the second zinc binds in the Zn1 site with a 
distorted geometry.387 Mutagenesis studies by Bebrone et al. demonstrate that the 
Asn116His/Asn220Gly double mutation significantly increases the affinity for a second zinc and also 
 
57 
broadens the substrate profile of CphA to include penicillins and cephalosporins.388    
With the X-ray crystal structure of CphA alone (PDB: 1X8G) and a complex of CphA with 
biapenem (PDB: 1X8I), Garau and coworkers proposed a mechanism for -lactam hydrolysis that 
involves activation of the hydrolytic water molecule by His118 and not by coordination to the zinc 
(Figure 15E).353 Xu et al. later examined this proposal computationally and found that a similar 
mechanism (for the first part of the reaction), which involves activation of the hydrolytic water by 
Asp120 (rather than His118), has an estimated activation energy of 14 kcal/mol;389 however, the 
second step of this reaction may have an energy barrier larger than experimental data.390 Simona et. 
al. have advanced a mechanism in which an additional water molecule in the active site allows the 
nucleophilic addition and nitrogen protonation to occur in a concerted manner with a calculated 
activation energy of 15 kcal/mol (Figure 15F).390 Very recently, however, Wu et al.391 have pointed 
out that the Simona mechanism is inconsistent with experiments that suggest direct substrate–metal 
contact and refinement of mechanistic proposals for the class B2 MBLs (which should also account 
for recent experimental data)392,393 appears to be an ongoing process.   
1.5 -Lactamase Inhibitors 
Two approaches have been used to overcome bacterial resistance to -lactam antibiotics due to the 
production of -lactamases. The first involves alteration of the structure of the antibiotic to reduce its 
susceptibility to -lactamases while its antibiotic potency is maintained. The second strategy uses a -
lactamase inhibitor in combination with a -lactam antibiotic. While the first approach avoids the -
lactamase, the second neutralizes it.394     
Although the concept that -lactamase inhibitors might be used to extend the action of -lactams 
against -lactam-resistant organisms was proposed as early as 1950,395 the first strategy that was 
employed clinically for circumventing bacterial resistance involved the use of semisynthetic -
lactams, such as methicillin, which retained potent antibiotic activity but were poorly recognized as 
substrates by -lactamases. Early screening programs for the discovery of -lactamase inhibitors in 
the 1940s and 50s, which involved miscellaneous organic, inorganic, and serine-reactive compounds, 
showed limited success396 and subsequent screens of semisynthetic penicillins showed moderate 
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success,397 but the screening of natural products in the late 1960s and early 1970s proved to be much 
more rewarding and led to the discovery of potent -lactamase inhibitors the olivanic acids and 
clavulanic acid.398 -Lactam–-lactamase inhibitor combinations (e.g. Augmentin, Timentin, Unasyn, 
Zosyn) have been used clinically for three decades and have been very successful since their 
introduction, with combined revenues of ca. $2.5 billion, for example, in 1997.1     
Several excellent reviews of -lactamase inhibition have been published, including the reviews of 
Cole,396,399 Sykes and Bush,400 and Cartwright and Waley,401 which describe the earliest -lactamase 
inhibition studies, and the reviews of Bush and Sykes,402 Knowles,394 Bush,403 Pratt,255 Rolinson,404 
and Mobashery,405 which summarize the development of the mechanism-based inhibitors. Since 2000, 
several updates of these reviews have been published406,407,408,409,410,411 and other more in-depth 
reviews have become available more recently.29,412,413,414 It should be noted, however, that each of 
these reviews offers a different perspective on a vast subject of research that has been active for more 
than 70 years and, since no single article claims to be completely comprehensive, a thorough review 
of the work in the field requires the combination of all of the articles cited above. While a thorough 
review of -lactamase inhibitors is also beyond the scope of this thesis, the summary provided herein 
discusses several aspects of inhibition that are often overlooked in other reviews of this topic. In 
addition, this summary is presented from an historical perspective in order to highlight the earliest 
studies that have played major roles in the development of this field of research. Some important 
classes of -lactamase inhibitors are discussed only briefly but a more detailed list of known -
lactamase inhibitors is supplied in Appendix C.    
1.5.1 -Lactams as -Lactamase Inhibitors 
Screening for -lactamase inhibitors began in the 1940s, as noted above, but the first breakthrough 
came with the discovery of inhibition of penicillinase by cephalosporin C in 1956.415 Cephalosporin 
C, which was insensitive to hydrolysis by the S. aureus penicillinase, was found to competitively 
inhibit the hydrolysis of penicillin G and penicillin N.  
While the observation that a -lactamase can be inhibited by a -lactam may initially seem 
counterintuitive, it should be noted that each -lactamase has a unique substrate profile and 
hydrolyzes one class of -lactam more rapidly than another. -Lactams which act as inhibitors of -
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lactamases can be considered to be substrate analogues (analogues of the enzyme’s preferred 
substrate) and are often called poor substrates or slow substrates to emphasize this point.   
In 1960 researchers from Beecham showed that methicillin was slowly inactivated by the 
penicillinase of B. cereus (BcI) but also acted as a competitive inhibitor of benzylpenicillin 
hydrolysis.84 Methicillin did not inhibit the activity of staphylococcal penicillinase (PC1) but was not 
hydrolyzed by this enzyme either and showed antibiotic activity against -lactamase-producing 
strains of S. aureus. -Lactamase inhibition gained further interest in 1964 with the demonstration of 
synergistic activity of methicillin and cloxacillin with benzylpenicillin and ampicillin against -
lactamase-producing Gram negative organisms.416 Other semisynthetic penicillins and cephalosporins 
were evaluated for -lactamase inhibition,396 but synergy was found to be significant in only a small 
proportion of clinical isolates and levels of cloxacillin required were too high be reached in vivo.404 
Although such combinations failed to find clinical utility, these studies did encourage the continued 
pursuit for other -lactamase inhibitors. While the bulky nature of the 6-acylamino sidechains 
decreases the affinity of -lactamases for the aforementioned penicillins, these agents form inert acyl 
enzyme adducts upon reaction with the enzyme. Studies in the 1970s and 80s indicate that the 
substrate-induced deactivation observed is a result of conformational changes in the enzyme caused 
by steric interactions with the bulky aromatic sidechains.417,418,419  
 
With cephalosporins, carbapenems, and penems the formation of inert acyl enzyme species with 
serine -lactamases is a result of a rearrangement of the position or conformation of the inhibitor 
itself within the active site. For example, the acyl enzyme complex (ES) formed with a cephalosporin 
may undergo deacylation or, if X is a sufficiently good leaving group, may undergo elimination to 
form ESʹ which is hydrolyzed much less readily (Scheme 10). The exact reasons for the slower 
hydrolysis of ESʹ are unclear but cephems which lack a C3ʹ leaving group are generally hydrolyzed 
much more rapidly and the ESʹ species has been observed as an accumulating species in class A420 
and C -lactamases and R61 transpeptidase.255 A similar (non-covalent) ESʹ complex is observed in 
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the X-ray crystal structure of a complex of the metallo--lactamase L1 with moxalactam (PDB: 
2AIO368); however, to the knowledge of this author, the kinetics of elimination and importance of the 
C3ʹ leaving group with MBLs have not been studied.  
The effect of the C3ʹ leaving group and the effect of the 7-methoxy group of the cephamycins can 
reinforce each other to improve inhibition.421 The 7-methoxy substitution not only serves to slow the 
acylation process, through steric interactions which decreases the affinity of -lactamases for 
cephamycins, but also slows the deacylation reaction. In acylenzyme complexes with class A -
lactamases, the methoxy group displaces the hydrolytic water molecule422 and perturbs the 
conformation of Asn132 and the loop that contains Glu166.423 In contrast, an X-ray crystal structure 
of a complex of the class C -lactamase AmpC with moxalactam shows that the -methoxy group 
does not displace the hydrolytic water molecule directly, but steric interactions force the oxacephem 
ring into a position which disfavours formation of the tetrahedral intermediate.283   
A similar situation applies to the carbapenems which generally bind poorly to -lactamases but also 
act as potent inhibitors of a broad range of -lactamases.255,424,425 Mechanistic studies by the Knowles 
group in the early 1980s indicated that the biphasic profile for carbapenem hydrolysis by TEM-1, 
which involved an initial fast phase for turnover followed by a slower phase, was a consequence of an 
isomerization of the acylenzyme to a 1-pyrroline (Scheme 10).426,427,428 While the conformations of 
the 2- and 1-acylenzyme species were found to be similar in computational work by the Mobashery 
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group, the studies suggested that the 6-1R-hydroxyethyl substituent slowed the hydrolysis of the 
acylenzyme through the formation of a hydrogen bond between the hydroxyl group and Asn132 and 
through displacement of the hydrolytic water by the methyl group.429 However, in 1998 an X-ray 
crystal structure of imipenem-acylated TEM-1 (PDB: 1BT5) showed a hydrogen bonding interaction 
between the hydroxyl group of the hydroxyethyl moiety and the hydrolytic water, an interaction 
which is thought to decrease the nucleophilicity of the water molecule.430 In addition, the structure 
revealed that the carbonyl of the acylenzyme was flipped out of the oxyanion hole, as a result of a 
steric interaction with the adjacent methyl group, and other conformational changes in the enzyme. 
Rotation of the ester carbonyl out of the oxyanion hole has been observed in crystal structures of 
other carbapenem-acylated class A -lactamases (e.g. SHV-1)431 and class C -lactamases as well.432  
 
In some of the earliest studies of -lactamase inhibition by carbapenems, the Knowles group found 
that the olivanic acid MM22382 behaved simply as a good substrate for TEM-2 while the sulfate ester 
analogue MM13902 was a poor substrate and potent inhibitor.426 Olivanic acids, pluracidomycins, 
and asparenomycins were found to be potent inhibitors of a wide range of -lactamases406 but were 
not suitable for clinical use as a result of poor penetration through bacterial cell walls and rapid 
metabolism in humans.404 Tricyclic carbapenems (trinems) represent another class of carbapenems 
which act as potent inhibitors and LK-157, one of the most potent in the series, exhibits nanomolar 
IC50 values against TEM-1, SHV-1, and AmpC, and synergy with penicillins and cephalosporins 
against -lactamase-producing organisms.433,434,435,436     
With the discovery that the hydroxyethyl group of imipenem contributes to -lactamase inhibition, 
by either sterically displacing or hydrogen bonding to the hydrolytic water molecule, the Mobashery 
group considered the possibility that 6-(hydroxymethyl)penam could acylate a -lactamase but resist 
deacylation.437 The molecule inhibited TEM-1 rapidly with a long-lived acylenzyme species and a 
partition ratio (kcat/kinact = 28) that is lower than those of clinically used mechanism-based inhibitors. 
An X-ray crystal structure of the 6-hydroxymethylated penicillin bound to TEM-1 (PDB: 1TEM) was 
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reported the following year and showed the hydroxymethyl substituent hydrogen bonded with the 
hydrolytic water molecule and Asn132.438     
 
The strategy of incorporating 6-hydroxyalkyl substituents into penicillins for inhibition was later 
applied to -lactamases such as the class A carbapenemase NMC-A439 and the class D enzyme OXA-
10286,293,440 and X-ray crystal structures of enzyme–inhibitor complexes were solved (PDB: 1BUL, 
1K54). In addition, a 6,6-bis-hydroxymethyl penicillin proved to be a moderate inhibitor of class A 
and C enzymes, with Ki values of 480 M and 700 M against TEM-1 and P99, respectively.441   
1.5.2 Mechanism-Based Inhibitors 
Each of the three clinically used -lactamase inhibitors, clavulanate, sulbactam, and tazobactam, are 
called “mechanism-based” inhibitors or “suicide” inhibitors since they are recognized by the enzyme 
as potential substrates but, in a diversion from the normal hydrolytic process, lead to irreversible 
inactivation of the -lactamase.394,442 
 
Clavulanic acid was discovered in a program begun by Beecham in the late 1960s in which 
microorganisms were screened for naturally occurring -lactamase inhibitors.398,443 Clavulanate was 
isolated from a strain of Streptomyces clavuligerus and, although it was found have only weak 
antibacterial activity (MICs: 31–125 g/mL),119 it showed synergy with ampicillin and cephaloridine 
against Gram-positive and Gram-negative organisms.398 Clavulanate was found to be a potent 
inhibitor of penicillinases (IC50 values <0.1 g/mL) but much less effective against chromosomal 
cephalosporinases. According to the Ambler classification of -lactamases, clavulanic acid has potent 
activity against class A enzymes and some class D enzymes, but shows poorer activity against most 
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class C -lactamases, and does not inhibit class B metallo--lactamases. Beecham’s formulation of 
clavulanate with amoxicillin, called Augmentin, was released in the U.K. in 1981444 and was soon 
followed by a combination of clavulanate with ticarcillin called Timentin.404 Augmentin has been 
used in more than 819 million patient courses worldwide since its introduction445 and generated a 
revenue of $1.4 billion in 1997.5     
In 1978, shortly after the disclosure of clavulanic acid, researchers at Pfizer reported the discovery 
of potent -lactamase inhibition by a semisynthetic derivative, penicillanic acid sulfone (PAS).446 
This compound showed weak antibacterial activity on its own but inhibited penicillinases with 
comparable potency to clavulanic acid. Penicillanic acid sulfone was also able to expand the spectrum 
of activity of ampicillin, penicillin G, carbenicillin, and cefazolin against Gram-positive and Gram-
negative organisms, although PAS was slightly less effective than clavulanate in a head-to-head 
comparison. The combination of PAS (later called sulbactam) with ampicillin447 was introduced as 
Unasyn in the U.S. by Pfizer in 1987448 and its revenue of $619 million in 19971 indicates its clinical 
success. Tazobactam, a triazole-substituted analogue of sulbactam, was found to have improved 
activity against class C -lactamases449 and its combination with piperacillin is marketed by Wyeth as 
Zosyn.    
The complex mechanisms by which clavulanate and penicillanic acid sulfones inhibit serine -
lactamases have been studied extensively. Initial efforts to elucidate these mechanisms in the late 
1970s, when structural information on -lactamases was not yet available and the serine acylenzyme 
mechanism had not yet been confirmed, indicated that clavulanate was a substrate for RTEM and 
inhibited the enzyme by forming two catalytically inactive forms.252 A transiently stable form, which 
could decompose to free enzyme and was the major component of enzyme after short time periods, 
was formed three-fold faster than the irreversibly inactivated form. The Knowles group found that 
both species showed an increase in absorbance at 281 nm, typical of ,-unsaturated esters, and 
treatment of inactivated enzyme with hydroxylamine partially restored enzymatic activity, consistent 
with cleavage of an acylenzyme species.253,450 Other studies by Durkin and Viswanatha,451 Reading 
and Hepburn,452 and the Knowles group453 were followed by spectroscopic studies with PC1 by Rizwi 
et al. which indicated that a slow isomerization of the initially formed cis-enamine B to the trans-
enamine C was responsible for the progression of transient inhibition to inactivation.454 Two forms of 
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the inhibitor were observed in the X-ray crystal structure of clavulanate-inhibited PC1 (PDB: 1BLC) 
published by Chen and Herzberg in 1992 and these forms were thought to be the cis- and trans-
enamines B and D.455 Potential mechanisms for the inhibition of class A -lactamases by clavulanate 
were evaluated by the Mobashery group in a detailed molecular modeling study and a refined 
mechanistic scheme was proposed (Scheme 11).456 Enamines B–D are thought to give rise to transient 
inhibition and irreversible inhibition a result of cross-linking with Ser130 (F) (and not Lys73 or 
Lys234). Other studies of the mechanism of inhibition of class A -lactamases by clavulanate have 
also been published.457,458,459     
The discovery of potent -lactamase inhibition by penicillanic acid sulfone in 1978446 stimulated 
several studies of its interactions with class A enzymes.460,461,462,463,464,465,466,467,468 Early indications that 
penicillanic acid sulfone shared a similar mechanism of inhibition with clavulanate inspired the 
synthesis of a number of other penam sulfones. Among the earliest PAS derivatives to show potent 
inhibition were 6-chloropenicillanic acid sulfone, reported by Cartwright and Coulson,469 and 6-
(trifluoromethanesulfonyl)amidopenicillanic acid sulfone, from the laboratories of Viswanatha and 
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Dmitrienko.470,471,472,473,474 Tazobactam was discovered in 1984475 and has found widespread clinical 
utility, possibly as a result of its improved activity against class C -lactamases.449 The sulfones of 
other -lactams were also evaluated461 and more recent developments include the 2-alkenyl PAS 
derivatives of Hoffman–La Roche476 and 2-imino penam sulfones of Phillips et al.477 A 2-
substituted penam sulfone, SA2-13, was designed to form a stabilized trans-enamine intermediate in 
the active site of SHV-1 (PDB: 2H5S) and was found to be 10-fold more stable to hydrolysis than 
tazobactam.466,478     
 
The 6-halopenicillinates represent another class of potent -lactamase inhibitors discovered in the 
late 1970s. In 1978 Loosemore and Pratt discovered that 6-bromopenicillanic acid (-BPA) was an 
irreversible inhibitor of -lactamases from B. cereus, B. licheniformis, S. aureus, and E. coli. 
Although 6-BPA showed weak antibacterial activity, its inhibitory potency against -lactamases was 
comparable to that of clavulanate and a study of its interactions with BcI were reported.250,479,480,481 A 
3H-labelled version of this compound was used by Knott-Hunziker et al. in 1979 to covalently modify 
the -lactamase of B. cereus and this work provided some of the first firm evidence that the active site 
nucleophile of -lactamases was a serine.251 In a detailed study of the mechanism of irreversible 
inhibition induced by 6-halopenicillinates, Pratt demonstrated that a rearrangement occurs upon 
acylation of the -lactamase to give an enzyme-bound dihydrothiazine and concluded that the 
rearrangement is more likely to proceed through an episulfonium intermediate than through 
thiazolidine ring-opening (Scheme 12).255,482 The serine-bound dihydrothiazine is also observed in 
recently solved X-ray crystal structures of the 6-iodopenicillinate-modified class A -lactamase 
from Bacillus licheniformis BS3 and the 6-iodopenicillinate-modified DD-transpeptidase from 
Actinomadura strain R39.483  
Other potent inhibitors were discovered in the early 1980s, including 6-alkylidene penams such as 
6-(methoxymethylidene)penicillanic acid 41, which was conceived by Knowles,484 and Hoffman–La 
Roche’s 6-(acetylmethylidene)penicillanic acid (Ro15-1903).485  
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Scheme 12. Inhibition of Serine -Lactamases by 6-Halopenicillins.  
 
Sulfone derivatives of alkylidene penams were also found to be potent mechanism-based inhibitors 
and the discovery of heteroarylmethylidene PAS 42 was disclosed by researchers at Pfizer in 
1986.486,487 In 1993 6-vinylidene derivatives, including 43, were reported by the Buynak group488 and 
other alkylidenepenam sulfones (e.g. 44) and -cephem sulfones have also been developed (Appendix 
C).489,490,491,492,493 With the lack of a proton at C6, which is important in the mechanism of inhibition 
for clavulanate and sulbactam, inhibition by the alkylidene PASs involves an intramolecular attack of 
the alkylidene substituent on the imine(iminium) intermediate and subsequent tautomerization 
(Scheme 13). Many of the alkylidene penam sulfone inhibitors have not only shown greater potency 
than clavulanate and sulbactam against class A -lactamases, but also inhibit class C and, more 
recently, class D -lactamases.494,495 Spirocyclopropylpenam sulfones 45 have been prepared by 
investigators at Wyeth and were shown to be potent inhibitors of TEM-1 and AmpC enzymes.496  
 
Structural modifications of penems in the late 1980s by Beecham led to the discovery of the BRL-
42715, an alkylidene penem which lacked clinically useful antibiotic activity but exhibited much 
more potent -lactamase inhibitory activity than clavulanate and sulbactam.497,498,499 BRL 42715 has 
been shown to be a progressive inhibitor of class A, C, and D -lactamases with nanomolar IC50 
values against TEM-1, SHV-1, P99, GC1, OXA-1, and other enzymes. Several studies concerned 
with the interactions of BRL 42715 with -lactamases500,501,502,503,504 and transpeptidases505 determined 
that the mechanism of inhibition involves the opening of the dihydrothiazole intermediate and 
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subsequent cyclization to form a dihydrothiazepine (Scheme 14). Despite the attractive inhibition 
profile of BRL 42715, its development has been discontinued as a result of its low serum half-life in 
humans and other factors.409  
Researchers at Wyeth reported in 2004 the evaluation of new bicyclic heterocycle-bearing 
alkylidene penems which show improved potency against TEM-1 and AmpC enzymes and 
impressive synergy with piperacillin against resistant strains.506,507,508,509 BLI-489, for example, 
showed IC50 values of 0.4 nM and 2 nM against TEM-1 and AmpC, respectively. Penems with 
tricyclic heterocycles, such as 46–48, offer additional lipophilicity (desirable in this case for in vivo 
evaluation) and display potent activity against class A and C enzymes (e.g. IC50 for 47 vs TEM-1 = 
1.9 nM; AmpC = 0.62 nM).510 X-ray crystal structures of BRL 42715 with 908R (PDB: 1Y54)504 and 
46 with SHV-1 and GC1 have been solved (PDB: 1Q2P, 1Q2Q).509 In addition, while BRL-42715 
was found to be a substrate for the metallo--lactamase CcrA, many of the Wyeth penems are potent 
(nanomolar) inhibitors of CcrA.507,511 More recently, potent inhibition of the class D OXA -
lactamases has also been observed.512 Detailed reviews of the 6-alkylidene penems have been 




The discovery of the nocardicins and monobactams as natural products in the early 1980s (Section 
1.2.7) led to the development of semisynthetic derivatives such as aztreonam.164,165 While certain 
monocyclic -lactams, such as nocardicin A and desthiobenzylpenicillin, are substrates for class A 
and class C -lactamases,513 aztreonam was found to have poor affinity for broad spectrum class A -
lactamases such as TEM-2 and exhibited potent inhibition of the class C enzyme P99 (Ki = 1.9 
nM).514 Bush et al. found that the trans relationship between the C3-acylamino substituent and the 4-
methyl substituent of aztreonam accounted for its significantly decreased affinity for TEM-2 and 
slower turnover relative to its 4-unsubstituted (SQ 82,402) or 4-epi (SQ 26,917) analogues. An X-ray 
crystal structure of an aztreonam-acylated AmpC enzyme (PDB: 1FR1)515 indicates that a steric 
interaction between the 4-methyl group and Tyr150 causes a bond rotation to occur such that the N-
sulfonyl group obstructs attack of the hydrolytic water. This observation prompted investigators at 
Hoffman–La Roche to investigate bridged monobactams which could form acylenzyme intermediates 
with more rigid conformations that might block hydrolysis more effectively.516 This strategy proved 
effective as a series of monobactams showed low nanomolar IC50s against class C enzymes, exhibited 
very long deacylation half-lives, and Ro-48-1256 was shown to potentiate -lactams against P. 
aeruginosa.517  
 
Merck researchers have recently prepared and evaluated analogues of Ro 48-1256 as inhibitors of 
class C -lactamases and potential partners for combination with imipenem and the (S)-azepine 
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analogue 49 was selected for preclinical development.518 BAL29880 is a bridged monobactam which 
is currently in development at Basilea as part of BAL30376, which is a three-component combination 
of clavulanate (for the inhibition of class A -lactamases and ESBLs), BAL29880 (class C -
lactamase inhibitor) and BAL19764 (a siderophore monobactam with activity against Gram-negative 
organisms and stability to MBLs).170   
1.5.3 Non--Lactam Inhibitors: -Lactam Mimics and Transition State Analogues 
The concept that analogues of -lactams might also have biological activity was explored as early as 
the 1940s as researchers at Lilly prepared -lactam and -lactam analogues of penicillin.519 The lack 
of antibiotic activity suggested that the amide bond of such compounds was insufficiently reactive to 
acylate the target enzymes or that the molecules were unable to fit appropriately into the active site 
and the failure of such attempts led to the belief that the -lactam moiety was essential for antibiotic 
activity. With the growing threat of -lactamases in the 1970s, researchers began to question this 
belief and the desire to prepare -lactam analogues with antibiotic activity and resistance to -
lactamases was renewed. Early studies, which were mainly directed toward screening for antibacterial 
activity, have been reviewed519,520 and the discussion below is limited to work related to -lactamase 
inhibition.      
 
One example of a natural non--lactam antibiotic which inhibits PBPs and -lactamases is 
lactivicin. Lactivicin was first reported in 1986 as a new antibiotic isolated from strains of 
Empedobacter lactamgenus and Lysobacter albus from soil samples in Japan.521 Lactivicin shares a 
similar mechanism of inhibition with clavulanate and X-ray crystal structures of lactivicin bound to 
PBP1b (PDB: 2JE5)522 and the class A -lactamase BS3 has recently been solved (PDB: 2X71).523  
Boronic acids have been known to be reversible -lactamase inhibitors since the late 1970s.524 Even 
very simple phenylboronic acids showed Ki values in the low micromolar range against class C 
enzymes (AmpCs) from P. aeruginosa and E. coli.525 Since these early investigations more than 20 
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studies with boronic acids have been reported and investigators have achieved potent inhibition (low 
nanomolar IC50 values) of class A and C -lactamases with these compounds (e.g. 50–53, see 
Appendix C). Another series of transition state analogues that have been evaluated as -lactamase 
inhibitors are the phosphonates. The phosphonate monoester 54 was first reported by Pratt in 1989 as 
a rapid inactivator of the P99 class C enzyme526 and many other phosphonates (e.g. 55) have been 
reported as inhibitors of class A, C, and D -lactamases. As some of the most potent serine -
lactamase inhibitors yet discovered, boronic acids and phosphonates have proven to be extremely 
valuable as tools in the study of -lactamase mechanisms and much of our knowledge in this area is 
derived from X-ray co-crystal structures of enzyme adducts with transition state analogues.  
-Sultams, the sulfonyl analogues of -lactams, have been found by Page to inactivate P99 -
lactamase and ESI MS experiments indicate that the mechanism of inactivation by 56 is through 
sulfonation of the active-site serine rather than acylation.527     
 
In the early 1980s several research groups proposed independently that analogues of -lactams in 
which the -lactam ring is replaced by a cyclobutanone system might inhibit serine -lactamases and 
DD-transpeptidases by virtue of their ability to form an enzyme-bound hemiketal with an active-site 
serine residue. Gordon et al. reported the synthesis of cyclobutanones 57–59 for this purpose, but 
found no significant inhibition of either R-TEM -lactamase or R61 transpeptidase.528 Meth-Cohn et 
al. synthesized cyclobutanone 60 but did not disclose any biochemical or biological data.529  
The 2-oxabicyclo[3.2.0]heptanones 61 and 62 prepared by Lowe and Swain, however, showed 
time-dependent inhibition of the class A -lactamases R-TEM-2 and BcI and 62 demonstrated 




the synthesis of several cyclobutanone derivatives, including the N-acetyl thienamycin analogue 63 
and simpler analogues 64.532 While none of the free acids showed significant activity, several of the 
esters 64b showed synergy with benzylpenicillin against penicillin-resistant S. aureus.533 The 
Dmitrienko laboratory described the preparation of dichlorocyclobutanone 65534 and Kelly et al. 
reported that 65 was a weak competitive inhibitor of R61 transpeptidase (Ki  1 mM).535,536,537  
Trifluoromethyl ketones were prepared by the Schofield group in 1996 as potential inhibitors of 
metallo--lactamases.538 Trifluoromethyl ketones 66, for example, inhibited the MBL from X. 
maltophilia with Ki values of 1.5 and 15 M and inhibited the MBL from A. hydrophila with Ki 
values of 44 and 6 M. However, inhibition of the metallo-enzymes of B. cereus and P. aeruginosa 
was more modest with Ki values >300 M.  
 
A small series of -ketoheterocycles was evaluated as inhibitors of serine -lactamases by the Pratt 
group in 2001.539 Moderate inhibition of the class C enzyme P99 was observed by tetrazole 67 (Ki = 
110 M) and thiazole 68 (Ki = 550 M) but these compounds were not inhibitors of TEM-1.  
In 2004 researchers at Aventis in France reported that a bicyclic urea derivative AVE1330A (or 
NXL104) was a potent inhibitor of serine -lactamases, with IC50s of 8 nM against TEM-1 (class A) 
and 80 nM vs P99 (class C).540 Although AVE1330A showed weak antibacterial activity of its own, 
the combination of this -lactamase inhibitor with ceftazidime showed impressive activity against a 
broad range of -lactamase-producing organisms, including CTX-M-, ESBL-, and carbapenemase 




Figure 17. Reaction of a serine -lactamase with NXL104. 
-lactamase KPC-2 (IC50 = 38 nM) and its combination with ceftazidime is effective against KPC-
producing isolates of K. pneumoniae,542,543,544 against P. aeruginosa,545 and carbapenemase-producing 
Enterobacteriaceae.546 An X-ray crystal structure of NXL104-treated CTX-M-15 confirms that the 
compound acylates the active-site serine (Figure 17)547 and recent mechanistic studies indicate that 
the serine carbamate intermediate is more stable than the corresponding acyl enzyme intermediates of 
clavulanate, sulbactam, and tazobactam.548 The combination of NXL104 with ceftazidime is currently 
in Phase II clinical trials and a combination of NXL104 with ceftaroline may also enter clinical trials 
for the treatment of MRSA infections.549,550 Novexel, a spin-off company created by Sanofi–Aventis, 
was sold to AstraZeneca in March, 2010 for more than $350 million.551    
1.5.4 Metallo--Lactamase Inhibitors  
Metallo--lactamases have a broad spectrum of substrate specificity that encompasses all -lactam 
classes with the exception of monobactams. The clinically available -lactamase inhibitors, 
clavulanate, sulbactam, and tazobactam, are ineffective against MBL-producing organisms. A large 
number of MBL inhibitors has been published since the mid-1990s but none of these have been 
developed for clinical use. The most common strategy for MBL inhibition has involved metal-binding 
or -chelating functional groups. Aside from EDTA, a metal chelator used for characterization and 
identification of MBLs, inhibitors often contain thiol- and carboxylic acid functional groups.  
Thiols have been reported as metallo--lactamase inhibitors by a number of research groups 
(Figure 18, Appendix C), including the Dmitrienko group,552 and several thiols have been co-
crystallized with MBLs. Thioesters have been investigated as thiol-releasing substrates and have also 
shown inhibitory activity. Mercaptophosphonates have recently been investigated as inhibitors of 













































































































































Figure 18. Inhibitors of metallo--lactamases.  
Other than thiols, pyridine carboxylates, succinic acids, maleic acids, and phthalates have been 
explored as metal-binding compounds, and other non-covalent inhibitors include biphenyl tetrazoles, 
triazoles, and tricyclic natural products (Figure 18). In this laboratory, N-arylsulfonyl hydrazones 
were found to act as competitive inhibitors of IMP-1554 and N-acyl hydrazone analogues were found 
to be inhibitors of a more broad spectrum of enzymes, including IMP-1, VIM-2, and OXA-10, and 
OXA-45.555  
 
A strategy employed by the Buynak group to simultaneously target serine- and metallo--
lactamases involved derivatization of penicillins with a thiol functionality at C6.556 Among the series 
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of penams and penam sulfones prepared, the mercaptomethyl PASs 69 and 69 showed the most 
potent and broad-spectrum activity with low micromolar IC50 values against class A (TEM-1), class C 
(P99), and class B (BcII) -lactamases and sub-micromolar IC50s against the metallo-enzyme L1.     
Although clinically used carbapenems can be hydrolyzed by metallo--lactamases, certain 
carbapenems have been shown to act as potent inhibitors of MBLs as a series with various sidechains 
at C2 was investigated by Banyu Tsukuba in the late 1990s.557 Carbapenems J-110,441 and J-
111,225, for example, inhibited IMP-1-catalyzed imipenem hydrolysis with IC50 values of <0.1 M 
and 0.7 M, respectively. The latter compound, which was later shown to have a Ki of 0.18 M vs 
IMP-1, demonstrated better antibacterial activity than imipenem when used alone against IMP-1-
producing organisms and synergy with imipenem when used in combination.558 In addition, the 
enzymes IMP-1, CcrA, BcII, and L1 hydrolyzed J-111,225 more slowly than imipenem.  
  
Cefotetan, a synthetic cephamycin that is considered a second generation cephalosporin, has been 
reported to be a poor substrate for the metallo--lactamases of Aeromonas spp. but gives rise to 
transient inactivation of the enzymes.559 Inhibition was maximal after a 15 minute incubation of the 
inhibitor and Ki values of 12 and 40 M against the MBLs of A. hydrophila and A. schubertii.   
1.6 Clinical Significance of -Lactamases and the Need for -Lactamase Inhibitors 
One of the most important criteria for the development of the third generation cephalosporins in the 
late 1970s was the requirement for stability to the class A TEM and SHV -lactamases since TEM-1, 
TEM-2, and SHV-1 had emerged as the most commonly encountered plasmid-encoded -lactamases 
worldwide. However, shortly after the introduction of cefotaxime and ceftazidime in the early 1980s, 
resistance to the third generation cephalosporins was observed as a result of mutant TEMs and 
SHVs.560 These enzymes were named extended-spectrum -lactamases (ESBLs) because of their 
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ability to hydrolyze extended-spectrum cephalosporins and monobactams. Class A ESBLs (Bush 
functional group 2be) now include the VEB and GES -lactamases, but the most widespread ESBLs 
are the CTX-Ms.249 Third generation cephalosporins, which have a broad spectrum of activity and are 
prescribed for a wide variety of infections,561 are among the most widely used of all antibiotics, with 
revenues of $11.9 billion in 2009,20 and ESBL-mediated resistance is deeply concerning.    
Resistance also quickly emerged to -lactamase inhibitor combinations, such as amoxicillin–
clavulanate and piperacillin–tazobactam, which were also developed in the mid-1980s in order to 
overcome resistance to broad-spectrum, plasmid-encoded class A -lactamases. While mutant TEMs 
and SHVs rarely possess both the extended-spectrum and inhibitor-resistant phenotypes (Bush group 
2ber), the increased prevalence of ESBLs and inhibitor-resistant -lactamases over the last decade has 
caused an increase in the use of carbapenems. Carbapenems, which have been historically considered 
the -lactams of last resort, are now being used as the first line of defense against Gram-negative 
infections in which ESBL-mediated resistance is suspected.562         
This increased dependence upon carbapenems adds to the concern that has already been caused by 
the emergence of carbapenemases in the last decade.134,259,326,563 Among the most threatening 
carbapenemases are metallo--lactamases such as VIM-2, which has replaced IMP-1 as the dominant 
MBL in P. aeruginosa, and serine carbapenemases such as the class A KPC-2, which is increasingly 
encountered in Enterobacteriaceae.564 Therapeutic options are becoming increasingly limited for 
carbapenem-resistant infections.    
With very few new -lactams in the antibiotic pipeline and increasing numbers of -lactamases, 
there is a growing movement toward the development of combination antibiotics.549 It is thought that 
single -lactam-containing agents will be difficult to sustain in the clinical setting and that 
combinations of established -lactam antibiotics with potent, broad-spectrum -lactamase inhibitors 
may be better suited to contend with multi--lactamase-producing multidrug-resistant Gram-negative 
pathogens.410,565 The ideal -lactamase inhibitor would show potent inhibition of both serine- and 




Cyclobutanone Analogues of -Lactam Antibiotics: Synthesis and           
.    Conformational Properties*,568   
2.1 Previous Work with Cyclobutanones  
By the early 1960s Gram-negative bacteria had replaced S. aureus as the most problematic hospital 
pathogens and biochemical studies in the early 1970s suggested that the major mechanism for 
resistance to the clinically available cephalosporins was inactivation by -lactamases.98,99 For the 
most part, pharmaceutical companies directed efforts toward the discovery of new cephalosporins that 
showed higher stability to -lactamases, but -lactamase inhibitors were also pursued as potential 
solutions to the -lactamase problem. Clavulanic acid, for example, which was discovered in the early 
1970s in a screening program by Beecham,119 showed very potent inhibitory activity and encouraged 
the development of other types of inhibitors.  
As noted in the previous chapter, the concept that the -lactam ring was essential for biological 
activity was a widely held belief but researchers began to question this notion in the 1970s with the 
synthesis and evaluation of -lactam mimics.519 With the increasing success of aldehydes and ketones 
in the late 1970s as transition state analogues569,570 for the inhibition of serine proteases,571 the 
synthesis of ketone analogues of -lactams for the inhibition of -lactamases and/or DD-
transpeptidases seemed to be a logical progression. Such compounds would be hydrolytically stable 
analogues of -lactams that might inhibit these enzymes through formation of a stable hemiketal 
linkage in the active site. In the early 1980s it became clear that other groups had also pursued this 
strategy for -lactamase inhibition.  
In 1981 Gordon, Pluščec, and Ondetti reported the synthesis of simple carbocyclic cyclobutanones 
57–59 as potential -lactamase inhibitors through a [2 + 2] cycloaddition of dichloroketene with 6,6- 
                                                     
 * Reproduced in part, with permission, from ref 568: Johnson, J. W.; Evanoff, D. P.; Savard, M. E.; 
Lange, G.; Ramadhar, T. R.; Assoud, A.; Taylor, N. J.; Dmitrienko, G. I. J. Org. Chem. 2008, 73, 
6970–6982. Copyright 2008 American Chemical Society. 
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bis(methylmercapto)fulvene, followed by a low-yielding hydrolysis of dithioketeneacetal 70 with 
mercuric chloride (Scheme 15). These compounds did not show significant inhibition of either R-
TEM -lactamase or R61 transpeptidase.528  
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Meth-Cohn, Reason, and Roberts synthesized oxime 60, by way of a tricyclic intermediate 71, 
through interesting rearrangement chemistry developed previously by that group.529,572 It was thought 
that the oxime moiety might improve the ability of cyclobutanone 60 to acylate the active-site serine 
but no biochemical or biological data was reported. 
Lowe and Swain pursued the synthesis of 2-oxabicyclo[3.2.0]heptanone analogues of penicillins 
and the cycloaddition of dichloroketene with dihydrofuran 72, prepared by Birch reduction of the 
parent furan, provided dichlorocyclobutanone 73.530,531 Catalytic hydrogenolysis of 73 gave the 
monochloro acid 61, which was regarded as an analogue of 6-bromopenicillanic acid. Attempts to 
introduce the 6-acylamino sidechain directly through a cycloaddition of phthalimidoketene with 
dihydrofuran 72 were unsuccessful but a route involving an intramolecular nitrene insertion from 74 
was devised and provided cyclobutanone 62 in low yield. Biochemical assays with the 2-
oxacyclobutanones indicated that 61 and 62 showed time-dependent inhibition of the class A -
lactamases R-TEM-2 and BcI and 62 demonstrated activity against R61 transpeptidase.530,531   
Cyclobutanone 63,  an analogue of N-acetyl thienamycin, was prepared by Cocuzza and Boswell in 
a 14-step synthesis from 6-silyloxyfulvene 75.532 Addition of the 7-hydroxyethyl sidechain was 
accomplished through treatment of a zirconium enolate of 76 with acetaldehyde and installation of the 
2-aminoethylthio group at C3 was done through an addition–elimination displacement of the 
phenylsulfonyl group of 77 with the corresponding thiolate nucleophile. Other cyclobutanone 
analogues such as 64a, which possess electron-withdrawing groups at C3 (e.g. SO2R, COPh, CN), 
were prepared from 78 using a similar addition–elimination strategy. While none of the free acids 63 
or 64a showed significant anti--lactamase activity, several benzhydryl esters 64b exhibited 
antibacterial activity against S. aureus (MICs: 25–50 g/mL) and synergy with benzylpenicillin 
against -lactamase-producing penicillin-resistant S. aureus.533   
 
Initial attempts in this laboratory to prepare simple cyclobutanone analogues of -lactams 79, 
through a [2 + 2] cycloaddition of dichloroketene with 5,5-dicyanocyclopentadiene, were 
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unsuccessful since a homo-Diels–Alder reaction of the diene to give 80 was favoured.573,574,575 As an 
alternative, sulfur-containing cyclobutanone derivatives were targeted and the 2-thiabicyclo-
[3.2.0]heptanone 65534 was prepared in four steps from the known dihydrothiophene 81.576,577 A novel 
and efficient deconjugation procedure was used for the conversion of conjugated acid 82 to the 
deconjugated ester 83 that was required for the [2 + 2] cycloaddition to afford cyclobutanone 84 
(discussed in more detail in Section 2.2). While dichlorocyclobutanone 65534 showed no significant 
inhibition of the serine -lactamase BcI from B. cereus (Dr. Marc Savard, unpublished results), Kelly 
et al. reported that 65 was a weak competitive inhibitor (Ki = 1 mM) of R61 transpeptidase.
535 In 
addition, X-ray crystallographic data by Kelly et al. was consistent with the binding of 65 to the 
active site of the transpeptidase but the resolution of the structure was low and the data was 
insufficient to define a detailed structure of the enzyme-bound inhibitor.536,537  
Other studies toward the synthesis of cyclobutanones were reported by the Page group but no 
biological data was reported.578,579 It should also be noted that the Baldwin group later prepared 
cyclobutanones 85 and 86 as hydrolytically stable analogues of penicillins that could be used for the 
study of penicillin biosynthetic enzymes. Martyres et al. reported the synthesis of the model system 
85 by combining the synthesis of 84, developed in this laboratory, with the nitrene insertion 
methodology developed by Lowe and Swain for the installation of the 7-acylamino sidechain.580 
Ferguson et al. extended this strategy to incorporate a gem-dimethyl group at C3 and the 
aminoadipoyl sidechain at C7 and generate a cyclobutanone analogue of penicillin N (86) for 
crystallographic studies.581 In 2007 the group published an X-ray crystal structure (PDB: 2JB4) of 
cyclobutanone 87 bound to isopenicillin N synthase (IPNS).582   
 
Although the preliminary biochemical data for 61, 62, 64b, and 65 served as a proof of principle 
for the concept that cyclobutanones can act as -lactamase and transpeptidase inhibitors, other more 
impressive advances in the inhibition of -lactamases were being made in the early 1980s which 




Figure 19. Cyclobutanones as potential broad-spectrum inhibitors of -lactamases and penicillin-
binding proteins (PBPs).  
In the 1980s the clinically most significant -lactamases were Ambler class A enzymes such as the 
plasmid-encoded TEMs of Gram-negative organisms and the introduction of the mechanism-based 
inhibitors clavulanic acid, sulbactam, and tazobactam, was very successful for combating such 
organisms. The current situation, however, is much different. Inhibitor-resistant TEMs, ESBLs, class 
A carbapenemases, hyper-produced AmpCs, OXA carbapenemases, and metallo--lactamases 
represent a very real threat to the continued use of penicillins and cephalosporins, the most heavily 
used classes of antibiotics, and carbapenems, the -lactam antibiotics of last resort. Renewed efforts 
are therefore required to establish strategies with potential for overcoming this emerging epidemic.  
Cyclobutanone analogues of -lactams have the potential to form an enzyme-bound hemiketal in 
the active site of a serine -lactamase and an enzyme-bound hydrate in the active site of a metallo--
lactamases (Figure 19) and therefore represent a core structure that might form the basis for the 
design of broad-spectrum inhibitors. The previous work with cyclobutanones mentioned above 
yielded only a superficial understanding of the inhibitory properties toward class A -lactamases and 
DD-transpeptidases and the interactions of such compounds with class B metallo--lactamases and 
class C and class D serine -lactamases, which were not of clinical interest in the 1980s, were not 
studied. At the outset of this project, encouraging preliminary studies in the Dmitrienko group had 
already indicated that the dichlorocyclobutanone 65 was a moderate inhibitor of the serine -
lactamase OXA-10 and the metallo--lactamase IMP-1.583 Therefore, a systematic investigation was 
undertaken to gain insight into the properties of the cyclobutanones and the nature of the inhibition of 
-lactamases with the ultimate goal of discovering broad-spectrum -lactamase inhibitors that might 
be developed for clinical use.  
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2.2 Synthesis of 2-Thiabicyclo[3.2.0]heptan-6-one-4-carboxylates 
2.2.1 Early Synthetic Studies 
Cyclobutanones are versatile intermediates in organic synthesis and can undergo a wide variety of 
transformations. Ring expansions of cyclobutanones with diazomethane, Baeyer–Villiger ring 
expansions with m-CPBA, and Favorskii584 ring contractions are well-documented and 
reviewed.585,586,587 More specifically, the bicyclo[3.2.0]heptanone system of interest to this laboratory, 
has been especially useful as precursors for the stereoselective synthesis of prostaglandins.588 The 
most widely used method for the synthesis of cyclobutanones involves a [2 + 2] cycloaddition of an 
alkene with a ketene and, since such reactions are stereospecific and are often highly regioselective,589 
this strategy has been used for the synthesis of the -lactam analogues 57–65 and 85–87 mentioned 
above.  
In the early 1980s the Dmitrienko group targeted cyclobutanones such as 79 and 88 as simple 
analogues of penicillins. The failure of 5,5-dicyanocyclopentadiene to undergo the desired [2 + 2] 
cycloaddition with dichloroketene to provide 79574 encouraged the group to pursue the synthesis of 
sulfur-containing analogues which might be synthetically more accessible and also act as better 
mimics of penicillins (Scheme 16). Early synthetic efforts in this laboratory toward 88 by Gerald 
Lange (M.Sc. 1984)590 involved unsuccessful attempts to cyclize malonates such as 89 and 
cyclobutanone analogues such as 90, which lack the gem-dimethyl group at C3, were then pursued. 
Dihydrothiophene 91, which could be generated from the Birch reduction of thiophene 92 and 
esterification with diazomethane, indeed reacted with dichloroketene to provide cyclobutanone 84 
with the desired regiochemistry, but the overall yield of 4% over three steps was considered 
impractical. A survey of the literature revealed that dihydrothiophene 81 was readily available from 
phosphonate 93 by the method of McIntosh and Sieler576,577 and this prompted Lange to explore the 
possibility that 91 might be prepared by isomerization of 95.  
Initial attempts to effect the deconjugation of 95 using potassium tert-butoxide at –78 C and 
quenching with acetic acid were unsuccessful and only the dimer 96, the result of a Michael-type 
addition, was isolated (Scheme 17). It was thought that the deconjugation could be more successful 
with a bulkier ester that might sterically hinder the dimerization. Thus a transesterification from  
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Scheme 16. Retrosynthetic Analysis of 2-Thiabicyclo[3.2.0]heptan-6-one-4-carboxylates.  
 
Scheme 17. Discovery of a Deconjugation Procedure Involving Chloroformates.590   
 
methyl ester 95 to benzyl ester 97 was attempted using a well-known method involving ethyl 
chloroformate. The saponification of 95, followed by treatment of the conjugated acid 82 with ethyl 
chloroformate and benzyl alcohol generated a mixture of the conjugated benzyl ester 97 and what was 
thought to be the deconjugated mixed anhydride 98. Further characterization of the undesired by-
product with 13C NMR and elemental analysis, however, indicated that the major product was not the 
mixed anhydride 98 but rather the deconjugated ethyl ester 83.590 The rationale for this outcome was 
based on the assumption that the enhanced acidity of the -proton of the mixed anhydride 
intermediate 99 would permit triethylamine to induce the elimination of carbon dioxide and ethoxide. 
Attack of the resulting ketene intermediate 100 by ethoxide would generate anion 101 which could 
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undergo kinetic protonation to provide the observed product 83. With Lange’s subsequent 
demonstration that the deconjugated ethyl ester 83 could be converted to the targeted cyclobutanone 
84, it became clear that the serendipitously discovered deconjugation process provided efficient 
access to the targeted cyclobutanones.  
With the decision to revisit the cyclobutanones in the early 2000s, Darryl Evanoff (M.Sc. 2004) 
prepared cyclobutanone 65 according to the route developed by Lange and Savard so that the 
cyclobutanones could be screened for inhibitory activity against two -lactamases that had been 
recently acquired. Preliminary biochemical results in this laboratory indicated that 65 was a moderate 
time-dependent inhibitor of the class D -lactamase OXA-10 and, more interestingly, the class B 
metallo--lactamase IMP-1. In order to prepare additional material for more detailed biochemical 
studies and to synthesize other potentially more potent analogues, it seemed reasonable to continue to 
use the fairly efficient route developed by Lange and Savard and attempt to make improvements to 
the procedures where possible.        
2.2.2 Synthetic Route for 2-Thiabicyclo[3.2.0]heptan-6-one-4-carboxylates 
As noted above, the methodology developed by McIntosh and Sieler576,577 provided efficient access to 
dihydrothiophene 81 and literature procedures were used for the preparation of the substrate required 
for this reaction, phosphonoacrylate 93 (Scheme 18).591 The Michaelis–Arbuzov reaction592 of ethyl 
bromoacetate (102) with triethyl phosphite has been conducted on scales of up to 300 mmol and was 
found to be a very convenient and high-yielding reaction. The two reagents were combined, warmed 
slowly593 without solvent to 85–95C, and heated overnight to afford the crude phosphonoacetate 103 
which could be distilled in 98% yield or used without purification in the next reaction. Triethyl 
phosphonoacetate (103), which is also available from commercial sources, was then treated with 
paraformaldehyde and piperidine and refluxed overnight in methanol to generate a primary alcohol 
that was concentrated but not purified.594 Dehydration of the intermediate with 10 mol% p-
toluenesulfonic acid (TsOH) in refluxing toluene under a Dean–Stark trap,595 followed by distillation 
under high vacuum, provided the desired phosphonoacrylate 93 in 91% yield over two steps. As 
indicated in Scheme 18, the methyl ester 94 was obtained in 76% yield from methyl bromoacetate 
(104).        
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The method developed by McIntosh and Sieler576,577 for the synthesis of dihydrothiophenes is a 
one-pot procedure involving the conjugate addition of a mercaptoaldehyde to a phosphonoacrylate 
and an intramolecular Horner–Wadsworth–Emmons cyclization (Scheme 19).596 For the synthesis of 
dihydrothiophene 81, phosphonate 93 was added to a suspension of triethylamine and 2,5-
dihydroxydithiane (106), which is a dimer of mercaptoacetaldehyde, in CH2Cl2 and refluxed 
overnight. Aqueous washes of the crude product and flash chromatography provided the conjugated 
ethyl ester 81 in 75% yield. The methyl ester 94 was converted to dihydrothiophene 95 with a yield of 
73%.  
Scheme 19. Synthesis of Dihydrothiophenes by the Method of McIntosh and Sieler.   
 
Hydrolysis of ester 81 with 25% aqueous NaOH at 70 C for 6–16 hours, followed by acidification 
gave the conjugated acid 82 as dull yellow powder which could be recrystallized to furnish the 
conjugated acid 82 as a storable crystalline solid (mp: 169–170 C (EtOAc/hexane)). Prolonged 
reaction times for the hydrolysis generated small amounts of the deconjugated acid 107 but isomeric 
mixtures of 82 and 107 could be used together in the following deconjugation reaction without issue. 
The acid 82 was obtained in 93% yield through hydrolysis of the methyl ester 95 under the same 
conditions.  
As described above, the conjugated acid 82 was converted to the deconjugated ester 83 through 
treatment with ethyl chloroformate and triethylamine in CH2Cl2 at room temperature (Scheme 20). 
The yield of this reaction was consistently above 90% on reaction scales as large as 100 mmol and, 
despite a noticeable warming of the reaction vessel during the slow addition of ethyl chloroformate on 
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large scales, only a small proportion (typically 3–7% by 1H NMR) of the undesired isomer 81 was 
generated. The deconjugated dihydrothiophene 83 was found to be more sensitive to oxidation than 
its conjugated isomer 81 and the oxidation product, thiophene 108, was observed as a minor by-
product of the reaction. The oxidation of 83 to the thiophene 108, which occurs even at 4 C, prevents 
long-term storage of the compound and the dihydrothiophene was therefore used immediately in the 
next step following its purification by flash chromatography.      





























(1 4%)  
Additional experiments in this laboratory in the mid-1980s suggest that the mixed anhydride 
method has some generality as straight-chain and carbocyclic ,-unsaturated acids can also undergo 
deconjugation (Dr. Marc Savard, unpublished results). Related deconjugations involving ,-
unsaturated acid chlorides have also been studied.597  
Lange’s early attempts at the [2 + 2] cycloaddition of 83 with dichloroketene (generated in situ by 
the combination of dichloroacetyl chloride and triethylamine) revealed that the ethyl ester substituent 
of 83 significantly deactivates the dihydrothiophene, presumably through inductive and steric effects, 
relative to 2,3-dihydrothiophene itself.590 A similar decrease in reactivity was noted by Lowe and 
Swain with the dihydrofuran 72.530,531 A slower addition of the ketene precursor dichloroacetyl 
chloride over 3.5 hours to a solution of triethylamine and 83 in CCl4, in order to decrease the known 
polymerization of the ketene,589 was successful for improving the yield of the dichlorocyclobutanone 
84 to 33% (Scheme 21). In an effort to further improve upon the yield of the cycloaddition, Evanoff 
studied the effects of even slower addition times (up to 24 hours) and extended stirring times 
following the slow addition (up to 24 hours).583 While the Baldwin group reported a yield of 80% for 
the same reaction,580 conducted in CCl4 with a slow addition over a 48 hour period, experiments in 
this laboratory indicated that an addition period of longer than 2 hours was not beneficial. The highest 
yield obtained from Evanoff’s six experiments was 40% and was the result of a slow drop-wise 
addition of dichloroacetyl chloride (2.5 equiv) over 2 hours to a solution of Et3N (2.5 equiv) and 83 in  
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(5 10%)  
CCl4, followed by an additional 22 hours of stirring.  
With the considerable increase in the price of carbon tetrachloride, more recent attempts to improve 
the yield of the [2 + 2] reaction have explored the use of other solvents. Hexane and cyclohexane 
were found to be reasonable alternatives to CCl4 as yields as high as 65% have been obtained. In the 
highest-yielding reaction, dichloroacetyl chloride (2.5 equiv) was added to a solution of Et3N (2.5 
equiv) and 83 (37 mmol) in hexane (0.1 M) at room temperature over a period of 3 hours with a 
motor-driven syringe pump and the solution was stirred for an additional 21 hours before workup. 
Attempts to improve the yield of the reaction, through slower addition times or by maintaining strictly 
anhydrous conditions, were unsuccessful. In addition, efforts to de-gas solvents and reagents prior to 
use failed to decrease the formation of the major by-product of the reaction, thiophene 108. Other 
unproductive attempts to improve the yield involved a reversal of the order of addition such that Et3N 
was added slowly to a solution of dihydrothiophene 83 and dichloroacetyl chloride in hexane. While 
only very small proportions of the C4-epimer 109 were observed in previous reactions, 109 was 
isolated in more significant amounts (3–5%) when Et3N was added to the dihydrothiophene and 
dichloroacetyl chloride. These observations may indicate that this [2 + 2] cycloaddition is not as 
stereoselective as once thought to be.  
As dichlorocyclobutanones are known to be sensitive to base-induced ring cleavage,528,598 
conversion of 84 to carboxylic acid 65 was accomplished with acid catalysis (Scheme 22). Ethyl ester 
84 was heated to 70–80 C in a 1:1 mixture of dioxane and 6 M HCl for 6–8 hours and extracted with 
CH2Cl2. The resulting yellow solid was recrystallized from toluene to give 65 in 79% yield.  
Ester 84 was readily dechlorinated with excess zinc dust (added in portions) in hot acetic acid for 
6–12 hours and purification by flash chromatography provided cyclobutanone 110 in good yield. The 
acid 65 could be dechlorinated with a similar procedure; however, longer reaction times were often 
required and chromatography was ineffective for purification. Upon completion of the reaction, 
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Scheme 22. Acid-Catalyzed Hydrolysis of Ethyl Ester 84 and Dechlorinations of 84 and 65.    
 
zinc salts were removed by filtration, the acetic acid removed under reduced pressure, and the crude 
product was diluted with aqueous HCl and extracted with EtOAc. In some cases, the dechlorinated 
acid 111 was purified by crystallization but simple trituration of the crude product was also found to 
be effective. The dechlorinated acid 111 could also be prepared through the acid-catalyzed hydrolysis 
of 110; however, an impurity produced by these reaction conditions prevented the purification of acid 
111. This by-product, which was not purified, was identified as the methyl ketone 112 by 1H NMR 
and is thought to be generated through the acid-catalyzed ring-opening of the cyclobutanone (Scheme 
22). Cyclobutanone ring openings of this type have precedent. 599,600  
Overall, the route developed in this laboratory for the synthesis of 2-thiabicyclo[3.2.0]heptan-6-
one-4-carboxylates is very efficient as the dichlorocyclobutanone 65 was prepared in seven steps 
from commercially available triethyl phosphonoacetate (103) with an overall yield of 28% (Scheme 
23). In practice, the four- or five-step synthesis of dihydrothiophene 82, a storable solid, by this 
method is high-yielding, operationally simple, and these reactions have been done on scales of up to 
250 mmol. The deconjugation is also high-yielding on large scale but the deconjugated 
dihydrothiophene 83 is unstable and must be used quickly in the next reaction. The key reaction in the 
sequence, the [2 + 2] cycloaddition, is low-yielding, requires careful setup and operation, and the 
maximum scale of this reaction (determined by practical limitations) is 75 mmol. Careful 
chromatography is required for purification of the [2 + 2] adduct 84 but the cyclobutanone can be 
stored for years at 4 C without decomposition. The acid-catalyzed hydrolysis of 84 can be done on 
large scales in reasonable yield and recrystallization provides the acid 65 as a crystalline solid.   
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2.2.3 Conformations of 2-Thiabicyclo[3.2.0]heptan-6-ones 
With the synthesis of cyclobutanone 84 in this laboratory in the early 1980s, Lange was able to 
correctly assign the stereochemistry at C4 through an examination of molecular models and 1H NMR 
analysis.534,590 An X-ray crystal structure of the 4-unsubstituted cyclobutanone 113 revealed that this 
simple analogue adopted an endo envelope conformation in the solid state, a preference that differed 
from the exo envelope conformation assigned to cyclobutanone 114 by Thandi (Figure 20).574 The 
feature of 84 which allowed Lange to assign the stereochemistry at C4 was that H5 appeared as a 
doublet in the 1H NMR spectrum and coupled only to H1. The lack of coupling between H4 and H5 
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Figure 20. Conformational analysis of cyclobutanones 113, 114, 84, and 109. (A) X-ray structure of 
Lange’s cyclobutanone 113.590 (B) The conformational preference of the carbocyclic cyclobutanone 
114 prepared by Thandi.574 (C) Lange’s conformational analysis of cyclobutanones 84 and 109 used 




Figure 21. X-ray crystal structures of cyclobutanones 84, 109, 65, and 111. Colour scheme: white, 
grey, red, yellow, and green represent H, C, O, S, and Cl, respectively. See Appendix G for tables of 
crystallographic data.   
relationship,601 and molecular models indicated that 84 possessed a 4-CO2Et group and favoured the 
endo envelope conformation. In the present study, X-ray crystallographic analysis (Figure 21) and ab 
initio molecular orbital calculations (RHF, Section 2.6) confirmed this conformational preference for 
ester 84 and acids 63 and 111 in the solid state and gas phase, respectively. NMR analysis of 
cyclobutanones 61 and 62 led Lowe and Swain to recognize that an endo envelope is also preferred 
by the 2-oxa- ring system.530,531 The 1H NMR spectrum of the recently isolated cyclobutanone 109 
shows a coupling of J4,5 = 7.6 Hz and an X-ray crystal structure confirms that this compound also 
favours the endo envelope.     
2.3 -Lactamase Inhibition with Simple Analogues 65 and 111  
The first cyclobutanone analogues to be tested for inhibitory activity against the metallo--lactamase 
IMP-1 were the dichlorocyclobutanone 65 and the dechlorinated derivative 111 prepared by 
Evanoff.583 These biochemical assays, which were conducted by Ms. Miriam Heynen in this 
laboratory in the early 2000s, indicated that the dichlorocyclobutanone 65 inhibited nitrocefin 
hydrolysis by IMP-1 with an IC50 of 526 M but the dechlorinated cyclobutanone 111 was a very 
poor inhibitor with an IC50 of approximately 180 mM (Table 1, Figure 22).  
It was thought that the dichlorocyclobutanone 65 displayed better inhibition than 111 because the 
electron-withdrawing chlorines could enhance the stability of an enzyme-bound hydrate. The extent 
to which these cyclobutanones undergo hydrate- and hemiketal formation in solution was then 
evaluated by NMR experiments in D2O (with acetone-d6 as a cosolvent to facilitate solubilization) 
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Table 1. Hydrate and Hemiketal Formation with Cyclobutanones 65 and 111 and Initial Inhibition 
















X = H  
ketone 












65 74 88 526 M 444 M 
111 0 24 180 mM 14 mM 
a Cyclobutanone hydrate and hemiketal formation data were determined by 1H NMR in 
the present study. b -Lactamase inhibition, as reported by Evanoff,583 was assessed by 
monitoring nitrocefin hydrolysis (Figure 22). The enzyme and inhibitor were allowed to 
preincubate prior to the addition of nitrocefin for 1 min in IMP-1 assays and for 10 min in 
OXA-10 assays. More recent inhibition results are reported in Chapter 3.  
 
Figure 22. Enzymatic hydrolysis of nitrocefin, a chromogenic cephalosporin substrate of serine- and 
metallo--lactamases.602     
and methanol-d4 (Table 1). Indeed the tendencies for 65 and 111 to form tetrahedral adducts in 
solution were found to parallel the inhibition results described above and these data were also 
consistent with other studies in which di- and trifluoromethyl ketones are more potent inhibitors of 
serine proteases than mono- and non-fluorinated ketones.603,604,605   
Further study of the interaction of IMP-1 with the cyclobutanones revealed that the inhibition by 65 
was progressive and was related to the time allowed for preincubation of the enzyme with the 
inhibitor prior to the addition of nitrocefin.583 At an inhibitor concentration of 500 M, for example, 
IMP-1 activity was inhibited by 40% after 1 minute and 80% inhibited after 40 minutes. The 
dechlorinated cyclobutanone 111, however, showed no significant improvement in inhibition of IMP-
1 with increased preincubation time.   
With the acquisition of the expression system for OXA-10 in the early 2000s, as a generous gift  
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from Prof. Mobashery (Notre Dame), cyclobutanones 65 and 111 could be evaluated as potential 
inhibitors of a class D serine -lactamase. While dichlorocyclobutanone 65 showed no inhibition after 
a 1 minute preincubation with the enzyme, an IC50 value of 444 M was obtained with a 10 minute 
preincubation. In a separate time course study, 500 M of cyclobutanone 65 inhibited OXA-10 
activity by 80% after 20 minutes and by 95% after 40 minutes.583   
In addition to the possibility that the progressive inhibition of IMP-1 and OXA-10 was a result of 
slow binding, alternate explanations for the time dependence were also considered. As mentioned 
above, dichlorocyclobutanones are well-known to be susceptible to ring-opening by alkoxides but 
Evanoff had demonstrated that acid 65 is especially sensitive as it is fully converted to the diacid 115 
in aqueous sodium carbonate in only 5 minutes and further hydrolyzed to aldehyde 116 with longer 
reaction times (Scheme 24). Hydrolysis to the diacid 115 was also found to occur under the assay 
conditions of IMP-1 (50 mM HEPES buffer, pH 7.3) and OXA-10 (100 mM NaxPO4, pH 7.0), with a 
half-life for the dichlorocyclobutanone 65 of approximately 2 hours in each case, but the aldehyde 
116 was not observed.583   
The progressive inhibition observed led to the speculation that the ring-opened diacid 115 and 
aldehyde 116 might be more potent inhibitors of IMP-1 and OXA-10 than the parent cyclobutanone 
65. In revisiting Evanoff’s chemistry for the preparation of the ring-opened products, cyclobutanone 
65 was treated with cold, dilute Na2CO3 to generate the diacid 115 as a mixture of diastereomers and 
an X-ray crystal structure of isomer 115a was obtained (Scheme 24). Exposure of 65 to Na2CO3 for 
30 minutes produced aldehyde 116 as a mixture of diastereomers. Biochemical evaluation of each of 
these diacids, however, revealed that 115 and 116 were poor inhibitors of IMP-1 and OXA-10 and 
ended speculation that the ring-openend products were the active inhibitory species.  
Extensive efforts have been made in this laboratory by Valerie Goodfellow and, more recently, Dr. 
Laura Marrone to elucidate the nature of the erratic behaviour of cyclobutanones 65 and 111 with 
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these enzymes. For example, one source of concern in the earliest experiments with IMP-1 was the 
significant loss of enzyme activity over the course of the assay. While enzyme stability was improved 
with higher concentrations of salt in the assays (100–500 M NaCl) inhibition of IMP-1 by the 
cyclobutanones decreased. Enzyme stability was also found to be sensitive to the concentration of 
DMSO and assays are now conducted with 1% DMSO for serine -lactamases and 0.1% with 
MBLs. It should also be noted that attempts were made to detect complexes of 65 with OXA-10, as 
an acyl-enzyme or serine hemiketal, and IMP-1, as a non-covalent zinc-bound hydrate or zinc-bound 
diacid, by mass spectrometry but these studies were unsuccessful. Other variables in the assays were 
investigated to improve the reproducibility and reliability of the IC50 values but the good behaviour of 
other inhibitors, such as the N-sulfonyl hydrazones552 and N-acyl hydrazones,555 with these enzymes 
discouraged further study of these cyclobutanones.    
2.4 Derivatization at C3: Chlorination and Substitutions 
While the irregular behaviour of the cyclobutanones in biochemical assays had prevented the 
determination of reliable IC50 or Ki values for the inhibition of IMP-1 and OXA-10, it seemed clear 
even from the earliest assays that the dichlorocyclobutanone 65 was a much better inhibitor than the 
dechlorinated analogue 111. Since the chlorines were beneficial for inhibition, synthetic efforts to 
improve upon the inhibitory potency focused on the functionalization of the tetrahydrothiophene ring. 
A sidechain at C3, for example, could increase the affinity of such inhibitors for -lactamase active 
sites through favourable hydrogen bonds or other non-covalent contacts. More specifically, sidechains 
similar to those of carbapenem antibiotics might improve the affinity of such cyclobutanones for 
carbapenemases.  
 
It was thought that carbapenem mimics might be accessed through a route involving chlorination at 




Figure 23. Initial strategy for the synthesis of carbapenem analogues.   

















































(Figure 23). Chlorination was first considered as a possible strategy for introducing functionality at 
C3 because Lange had successfully chlorinated the simpler analogue 113 with sulfuryl chloride.590   
The chlorination of 84 with SO2Cl2 in CH2Cl2 was fully regioselective and was also very 
stereoselective to produce 117 in nearly quantitative yield (Scheme 25). The stereoselectivity of the 
process may be a consequence of the initial chlorination of 84 occurring on the exo face to generate 
the S-chlorosulfonium ion A. Elimination of HCl might then lead to the sulfur-stabilized carbocation 
B with the chloride leaving group poised for subsequent attack from the exo face of the ring system, 
which would provide the 3-chloride 117.  
It was clear from the 1H NMR spectrum of 117 that the conformation was different from that of 
65 and 111 since the coupling constant between H4 and H5 was found to be 6 Hz (J4,5  0 Hz for 65 
and 111). The stereochemistry and exo envelope conformation for 117 were confirmed by a single-
crystal X-ray diffraction study (Scheme 25).  
Initial attempts to effect elimination with pyridine, Et3N, or DBU in CH2Cl2, THF, or MeCN were 
unsuccessful, however, and the use of Ag2CO3 resulted in a complex mixture with only a low yield of 
the elimination product 118. Heating of 117 in MeCN achieved partial elimination but the 3- 




2.5 Substitutions and Eliminations at C3 
As the preliminary efforts to prepare the unsaturated ester 118 indicated that 117 was unreactive in 
mildly basic conditions, the potential for elimination under acidic conditions was investigated. 
Heating of the -chloro derivative 117 in AcOH, for example, generated a mixture of products with 
small amounts of 118 and 117 and, more interestingly, larger proportions of substitution product. 
While the search for an efficient method for elimination continued, attention was also given to the 
exploration of substitution reactions. Hydrolysis of 117 to generate 119, for example, could provide 
another potential route toward carbapenem analogues (Figure 24).  
 
Figure 24. Revised strategy for the synthesis of carbapenem analogues.   
Hydrolysis of 117 in water and acetonitrile (1:1) generated the thiolactols 119 and 119, in a 
1:14 ratio, which could not be separated by flash chromatography. Interestingly, 1H and 13C NMR 
spectra of the chromatographed thiolactol mixture showed a third material (~6%) which was 
identified as a tricyclic hemiketal 119c (C6 105.9) (Figure 25). A similar oxatricyclo[3.2.1.03,6]octane 
120b (C3 103.90) has been observed by Grudzinski and Roberts (Figure 26).606,607,608 Since the 
119:119:119c ratio was consistently close to 6:88:6 in several different preparations, it is thought 
that the mixture may be part of an equilibrium that allows the interconversion of 119 and 119. In 
order to gain insight into the mechanism of interconversion, an NMR experiment was conducted in 
which the thiolactol mixture 119 was subjected to AcCl (to generate HCl in situ) in methanol-
d4/acetonitrile-d3 (1:1). The lack of any cross-over products from reaction with the solvent (to 
generate the 3-methoxy derivatives 121 or 121) suggests that equilibration via ring-opened 
aldehyde C is more likely than equilibration through a sulfur-stabilized carbocation D.  
With the 3-hydroxy derivatives 119 in hand, several attempts were made to oxidize the thiolactol to 
the corresponding thiolactone. Pyridinium chlorochromate (PCC),609 pyridinium dichromate 
(PDC),610 Dess–Martin periodinane (DMP),611,612 and (COCl)2/DMSO/Et3N (Swern oxidation)
613 had 




Figure 25. An equilibrium involving 119, 119, and 119c.  
 
Figure 26. Tricyclic hemiketals prepared by Grudzinski and Roberts.606  
SO2Cl2, N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS), and N-methylmorpholine-N-oxide 
(NMO) at room temperature and gave complex mixtures when treated with Br2 or I2/K2CO3. Other 
conditions that involved aqueous alkaline conditions were not attempted due to the sensitivity of the 
dichlorocyclobutanone ring. While there is some literature precedent for the oxidation of simpler 
thiolactols,614 Grudzinski and Roberts have reported that acetylation of a related cyclic hemiketal 
(120b) takes place at the reactive hemiketal site (Figure 26).606    
The lack of success with the attempted oxidation of 119, together with the relative ease with which 
117 was hydrolyzed, encouraged further exploration of substitution reactions since C3-alkoxy 
derivatives were thought of as penicillin analogues that would certainly be worthy of investigation.     
As with the hydrolysis of 117 in H2O/MeCN, the solvolysis of 117 in ROH/MeCN provided the 
3-alkoxy (S,O-acetal) derivatives 121–125 (Figure 27).  
Similar to the hydrolysis, the methanolysis of 117 in MeOH/MeCN was complete within 48 hours 
and cleanly generated the substitution products 121 and 121 (Table 2). However, the reactions with 




Figure 27. Solvolysis of 117 and X-ray crystal structures of 123 and 124.   
Table 2. Substitutions at C3 with Alcohols and AcOH.a   
 
solvent(s) time (h) product OR b  117 118 
MeCN/H2O 1:1 48 119 OH
c 6 88 0 0 
MeCN/MeOH 1:1 48 121 OMe 75 24 0 1 
MeCN/i-PrOH 1:1 40 122 Oi-Prd 46 20 16 18 
MeCN/t-BuOH 1:1 48 123 Ot-Bue 34f 7 44 15 
AcOH 48 124 OAc 3 52 43 2 
AcOH, 80 C 1 124 OAc 4 79 6 11 
CF3CH2OH 48 125 OTFE 5 76 0 19 
a Reactions were performed at room temperature unless otherwise stated. b Product distributions were 
determined by 1H NMR of the crude product. c Remaining 6% is attributed to 119c. d 85% conversion. e 
42% conversion. f An improved yield of 123 was obtained by heating 117 in t-BuOH at 80 C. See 
Chapter 5 for a detailed procedure. 
generated considerably more of the epimerization and elimination by-products, 117 and 118. The 
3-chloro isomer could not be prepared in useful quantities for further studies since it was found to be 
unstable during flash chromatography. However, 117 was found to prefer an endo envelope 
conformation in solution, as indicated by the multiplicity of H3 and H4 in the 1H NMR spectrum. As 
with 124, H3 and H4 in 117 appear as singlets and J3,4 = 0 Hz.  
In contrast to the hydrolysis, the substitutions in MeOH, i-PrOH, and t-BuOH selectively produced 




Figure 28. Control experiments which demonstrate that conjugate addition to the unsaturated ester 118 
does not occur under the conditions of the substitution reactions and that equilibration of substitution 













































































Figure 29. Possible intermediates in substitutions involving 117 with ROH (E = CO2Et).  
experiments which involved the exposure of 118 to AcCl (1 equiv) in methanol-d4/acetonitrile-d3 
(1:1), in order to mimic the conditions of the substitution reactions, discount the possibility that the -
OR products are the result of the conjugate addition of ROH to 118 since no reaction was observed by 
NMR in 48 hours (Figure 28). Similarly, the 3-OMe derivatives 121 and 121 were separately 
exposed to AcCl in isopropanol-d8/acetonitrile-d3 (1:1) and the lack of reaction over a period of 4 
days demonstrates that equilibration of the substitution products -OR and -OR does not occur. 
Together, these experiments imply that the / ratios are the consequences of kinetic and not 
thermodynamic control.  
The high -selectivity in the substitution with methanol led to the speculation that a cyclobutanone 
hemiketal could be generated that would block the endo face of C3 from subsequent inversion 
(structures E–F, Figure 29). In this way, attack from the exo () face of F would lead to the major 
isomer 121 whereas the minor isomer 121 would be a result of attack from the endo () face of D. 




Figure 30. Solvolysis of 117 with AcOH and TFEOH and a rationale for high  selectivity.  
inversion resulting from neighbouring group participation (structures G–H). Work reported by 
Grudzinski and Roberts involving the bromination of similar bicyclic substrates indicates that this 
pathway is plausible (Figure 26). The fact that a tricyclic methyl ketal (neutral form of H) was not 
observed may indicate that either this is a minor pathway, or that H is very reactive since one full 
equivalent of HCl is generated in this solvolysis reaction while the brominations by Grudzinski and 
Roberts using N-bromoacetamide were non-acidic. 
While the hypothesis involving intermediates E–H is reasonable for methanol, it was suspected that 
hemiketal formation with a bulkier alcohols is less significant. In order to determine the extent of 
hemiketal formation in alcohols other than methanol, cyclobutanone 118 was dissolved in deuterated 
alcohols such that hemiketal formation could be observed by NMR. In methanol-d4, 96% hemiketal 
was observed after 2 hours and 96% after 4 days. In t-butanol-d10, less than 1% hemiketal was 
observed after 24 hours and 5% after 18 days. In isopropanol-d8, 7% hemiketal was observed after 5 
hours and 36% after 8 days. In trifluoroethanol-d3, less than 1% hemiketal was observed after 4 hours 
and 3% after 8 days. 
With the confirmation that hemiketal formation in t-butanol occurs to a much lesser extent than in 
methanol, it is likely that the substitution products 123 and 123 are the result of attack by t-butanol 
on intermediate D. The five-membered ring of structure D is essentially flat, as indicated by a gas 
phase structural optimization (RHF/6-31G(d)), and the fact that the retention product 123 is 
generated in preference to 123 indicates that the exo face is more accessible than endo face as a 
consequence of steric shielding by the 7-chlorine atom. The rationale that steric hindrance drives the 
5:1 : selectivity would be consistent with the lower conversion observed with t-butanol.  
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The 2:1 : selectivity shown by 2-propanol could be rationalized by a combination of its 
capability to slowly form the hemiketal, which would lead to 122 from F or H, and its ability to 
attack from the endo () face of C or D, which would yield 122. The high selectivity in favour of 
inversion demonstrated by acetic acid (124:124  1:17) and trifluoroethanol (125:125  1:15) 
was unexpected as it clearly contrasts with that of the aforementioned alcohols. This selectivity 
suggests that attack from the endo face must be favoured electronically since the enhanced acidity and 
weaker nucleophilicity of AcOH and TFEOH increase the SN1 character of the substitution relative to 
reactions with ordinary alcohols (Figure 30). 
Attack on the carbocation from the  (exo) face may be disfavoured as a result of two destabilizing 
eclipsing interactions in TS that are not present in TS. The high -selectivity demonstrated by t-
BuOH, however, indicates that the 7-Cl imposes such a large destabilizing steric interaction in TS 
that TS is preferred. 
While the solvolysis reactions using ROH/MeCN were useful for the synthesis of 119 and 121–
123 and interesting from a mechanistic point of view, they generally required relatively long 
reaction times, difficult chromatographic separations, and generated large proportions of the 
epimerization and elimination by-products 117 and 118. Efforts were then made to develop a 
complementary method that would be more selective for inversion and improve upon the reaction 
times and the amount of by-products formed. The use of silver triflate was explored (Table 3) as it has 
been used as a promoter in substitutions at the anomeric position of chlorocarbohydrates. 
Since the / selectivity of the hydrolysis was not a concern (based on the proposed 
interconversion of the products 119 and 119), acetonitrile was chosen as a water-miscible solvent. 
However, the use of MeCN with 117 was otherwise considered problematic due to the spontaneous 
epimerization to 117 observed previously and CH2Cl2 was chosen for reactions with alcohols. 
Typically, 117 was slowly added as a solution in CH2Cl2 to a suspension of AgOTf, ROH, and 
molecular sieves in CH2Cl2 at 0 C.  
Indeed, the AgOTf-promoted reactions displayed improved reaction times and an increased 
selectivity for inversion with ROH. Interestingly, ten equivalents of methanol showed less selectivity 
for inversion than ten equivalents of t-butanol. Since a decrease to five equivalents of MeOH 
improved the  selectivity, it is possible that hemiketal formation remains significant at low 
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Table 3. Substitutions at C3 Promoted by Silver Triflate.a   
 
ROH equiv ROH time (h) product OR b  117 118 
H2O 
c excess 4 119 OHd 6 85 0 3 
MeOH 5 6 121 OMe 22 72 2 4 
MeOH 10 6 121 OMe 26 61 0 2 
i-PrOH  5 12 122 Oi-Pr 16 71 2 11 
t-BuOH  10 8 123 Ot-Bue 5 42 30 22 
a Reaction conditions: AgOTf (1.2 equiv) in CH2Cl2 was used with 4 Å MS (3 Å MS for R = Me). 
Reactions were begun at 0 C and allowed to warm to room temperature. b Product distributions were 
determined by 1H NMR of the crude product. c Hydrolysis was performed at room temperature in 
MeCN/H2O 1:1 without the use of molecular sieves. 
d Remaining 6% is attributed to 119c. e 92% 
conversion. 
concentrations of MeOH and that leakage to 121 could be through structures F–H (and to a lesser 
extent D).  
The proportion of the elimination by-product 118 remained a concern in the AgOTf-catalyzed 
reactions with the hindered nucleophiles i-PrOH and t-BuOH. This observation inspired an 
investigation into whether the elimination could be effected exclusively in the absence of a 
nucleophile. Gratifyingly, the addition of 117 to AgOTf in refluxing CH2Cl2 furnished 118 cleanly 
in 81% isolated yield (Scheme 26).    
It was also found that the unsaturated ester 118 could be prepared in high yield through dehydration 
of the thiolactols 119 with TsOH in refluxing toluene under a Dean–Stark trap,595 although it should 
be noted that high yields for this reaction were achieved only when the water from TsOHH2O was 
azeotropically removed prior to the addition of 120. A more convenient and expedient procedure for 
the synthesis of 118 was discovered more recently. Although one very early attempt to eliminate  


































HCl from the 117 involved methanesulfonic acid (MsOH), its use in only catalytic quantities was 
insufficient to promote the desired reaction. With a higher concentration of MsOH (10% in CH2Cl2), 
however, the unsaturated ester 118 was isolated in 72% yield. Cyclobutanone 118 could also be 
dechlorinated readily with zinc in acetic acid to give 126. 
2.6 Conformational Properties of C3 Derivatives and Anomeric Effects 
During the development of the solvolysis reactions and silver-triflate promoted substitutions it 
became clear that cyclobutanones with 3 substituents (Z = Cl, O-alkyl) conformed to an exo 
envelope while those with 3 substituents (Z = H, Cl, OAc, O-alkyl) showed preference for the endo 
envelope. This was apparent from 1H NMR spectroscopy (Figure 31) as the spectrum of each 
derivative displayed a pattern similar to either 117 and 123 or 124, the structures of which were 
































J4,5 = 0 Hz
J3 ,4 = 0 Hz
Z = Cl, OAc, OR
Z = Cl, OR
J4,5 = 5-6 Hz
J3 ,4 = 4-5 Hz
H3 H5 H1 H4OCH2
H3 H5 H1 H4OCH2
 
Figure 31. Conformations of C3-substituted cyclobutanones. Coupling patterns in the 1H NMR spectra 
shown (123 and 123, Z = Ot-Bu), are representative of derivatives 117, 119, and 121–125. 
The possibility was considered that the conformational preferences could be a result of an anomeric 
effect involving the sulfur and the electron-withdrawing substituents at C3.615 Although the 
conformational properties of sulfur-containing six-membered rings are well known,616 the anomeric 
effect has been studied relatively little in five-membered rings since the conformational consequences 































































































































Figure 32. Comparison of bond lengths (Å) obtained from X-ray crystal structures in the present study 
with related compounds. The X-ray structure of 111 contains two crystallographically different 
molecules in the unit cell (E = CO2Et). 
in pseudo-axial or pseudo-equatorial orientations. While this is evident in the crystal structures of 
numerous 4′-thionucleoside derivatives (-aza substituents),617 anomeric effects and gauche effects 
have been argued previously to rationalize the conformations of 4′-thionucleosides.617,618 In addition, 
it is possible that anomeric effects are responsible for the axial arrangements that have been 
recognized by 1H NMR analysis in known -halo and -alkoxy tetrahydrothiophenes such as trans-
2,3-dichlorotetrahydrothiophene,619 2-alkoxy-3-chlorotetrahydrothiophenes,620 trans-2,3-dibromo-
tetrahydrothiophene, and 2-alkoxy-3-bromotetrahydrothiophenes.621     
Since the anomeric effect is often characterized by a shortening of the O–C bond and lengthening 
of the C–X bond in the O–C–X segment of carbohydrate derivatives, the bond lengths obtained in the 
X-ray crystal structures of 117, 123, and 124 were examined closely (Figure 32). The anomeric 
effect is generally thought to be strongest with electron-withdrawing substituents (halogen > OR > SR 
> OH > NR2)
615c and structural evidence for the anomeric effect was indeed discovered in 2-
thiabicyclo[3.2.0]heptan-6-ones which possess electron-withdrawing substituents at C3.   
The X-ray crystal structure of 3-Cl derivative 117 clearly reveals a shortened S–C3 bond (1.782 
Å) and a lengthened C3–Cl bond (1.800 Å) in comparison to structurally related 
tetrahydrothiophenes, dithianes and dioxanes, chlorocarbohydrates, and the unsubstituted 
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cyclobutanones 65 and 111 (Figure 32). Similarly, the solid-state structure of 124 exhibits a shorter 
S–C3 bond (1.801 Å) relative to 65 and 111 and C3–O bond (1.441 Å) of intermediate length relative 
to acetoxythiopyranosides. 
Interestingly, in contrast to 117 and 124, the X-ray crystal structure of the 3-Ot-Bu derivative 
123 shows a long S–C3 bond (1.844 Å) and a short C3–O bond (1.395 Å). This is consistent with 
the general consensus that anomeric effects are stronger with oxygen than sulfur.615,616,622 
In order to probe these phenomena further, ab initio (RHF/6-31G(d)) molecular orbital (MO) 
calculations623 were carried out with several of the cyclobutanone derivatives that had been prepared 
synthetically (Table 4). The conformational preferences observed by NMR (solution phase) and by X-
ray (solid state) were also found in the gas phase and the preferred conformations are those in which 
C3- substituents are oriented axially.  
In order to gain additional insight into the origin of the conformational preferences and putative 
stereoelectronic stabilizations of axial arrangements, additional calculations were performed with a 
series of simplified cyclobutanone derivatives that lack the C4-carboxylate moiety. 
These calculations show that the C4-carboxylate has a minor effect on the conformations of 
unsubstituted (Z = H) cyclobutanones, as each of the cyclobutanones 65, 84, 110, and 111 (1.4–1.9 
kcal/mol) and 112 and 130 (2 kcal/mol) have a similar preference for the endo envelope, and suggest 
that the eclipsing interactions between substituents at C4 and C5 in the exo envelope are significant 
(Figure 33). The 2-oxa and 2-carba analogues 139–142 also favour the endo envelope conformation.  
Computational evidence for the anomeric effect is noted in the comparison of cyclobutanones 112 
and 130 to compounds with  substituents at C3. The small preference for the exo envelope (0.05 
kcal/mol) shown by cyclobutanone 131, for example, indicates that the energy gained by 
stereoelectronic stabilization in the exo envelope is enough to overcome the natural endo preference 
(1.89 kcal/mol) of the fused bicycle. Thus, comparison of 130 with 131–135 suggests that 
anomeric effects could be worth up to 1.9, 3.3, 3.1, 1.5, and 1.1 kcal/mol for Z = -Cl, -OAc, -
OMe, -Ot-Bu, and -SMe, respectively. Similar trends were found with the dichlorocyclobutanones 
136, 137, and 138, which gave values of 1.9, 3.2, and 1.0 kcal/mol for Z = -Cl, -OMe, and -




Table 4. Calculated Conformational Preferences for Cyclobutanone Derivatives (kcal/mol).a   
 
Cyclobutanone or -Lactam 
Relative Energy  
Cyclobutanone or -Lactam 
Relative Energy 
endo exo  endo exo 
 
     
 
    
65: R = H 0 + 1.93  136: Z = Cl 0 + 0.47 
84: R = Et 0 + 1.92  137: Z = OMe + 0.77 0 
127: R = – 0 + 2.28  138: Z = SMe 0 + 1.42 
 







    
111: R = H 0 + 1.43  136: Z = Cl 0 + 1.59 
110: R = Et 0 + 1.44  137: Z = OMe 0 + 4.84 
128: R = – 0 + 1.73  138: Z = SMe 0 + 0.51 
      
 
    
 
117: Z = Cl + 2.44 0  139: Y = O 0 + 0.78 
119: Z = OH + 3.84 0  140: Y = CH2 0 + 2.27 
121: Z = OMe + 3.75 0     






   
124: Z = OAc + 3.41 0  141: Y = O 0 + 1.40 
129: Z = SMe + 0.55 0  142: Y = CH2 0 + 2.02 
          
 






    
119: Z = OH 0 + 5.18  143: Z = OMe + 2.10 0 
121: Z = OMe 0 + 4.85  144: Z = SMe + 0.62 0 
123: Z = Ot-Bu 0 + 3.55      
124: Z = OAc 0 + 4.78  
 
    






     144: Z = SMe 0 + 0.38 
130: X = H 0 + 1.89      





    






131: Z = Cl + 0.05 0  146: Z = SMe 0 + 2.69 
132: Z = OAc + 1.40 0      
133: Z = OMe + 1.17 0  
 
    
134: Z = Ot-Bu 0 + 0.35  145: Z = OMe 0 + 2.41 
135: Z = SMe 0 + 0.75  146: Z = SMe +0.74 0 
          
 









    
132: Z = OAc 0 + 4.64  147: R = Me 0 + 2.05 
133: Z = OMe 0 + 4.46  148: R = CH2Ph 0 + 2.18 
134: Z = Ot-Bu 0 + 3.33     
 135: Z = SMe 0 + 0.92       




































































Figure 33. Favoured conformations and relevant steric interactions. 
 Calculations involving -substituents at C3 also indicate that an anomeric effect is present as the 
-alkoxy derivatives 132–134 show increased preferences for the endo envelope (2.8, 2.6, and 1.4 
kcal/mol for Z = -OAc, -OMe, and -Ot-Bu) relative to 130 (Z = H). However, the -Cl derivative 
131, which contains a sterically larger substituent, shows only a modest increase in endo preference 
(0.2 kcal/mol) and the -SMe analogue 135 shows a decrease in endo preference (1.0 kcal/mol). 
Since this pattern is magnified in the 7,7-dichloro series 136–138 (–0.8, +2.4, and –1.9 kcal/mol 
for -Cl, -OMe, and -SMe compared to 112), it seems reasonable to conclude that large 3-
substituents experience a significant steric interaction with the 7-H or 7-Cl (Figure 33).624,625   
Given the large magnitudes of the calculated conformational preferences (2–5 kcal/mol) for 
cyclobutanones 117, 119, 121, 123, 124, and 129, and the relatively small preferences with 
derivatives 131–135, and 136–138, it is clear that the C4-carboxylate moiety significantly 
enhances the preference for the exo conformation with -substituents. It is likely that a disfavoured 
steric interaction between the 3-Z function and the carboxylate in the endo envelope accounts for 
much of this energy since a significant rotation of the C4–CO2Et bond is observed in the optimized 
endo envelope conformations of 121, 123, 124, and 129, and not in the exo envelope 
conformations. A torsional scan about the C4–CO2Et bond of 84 revealed that the dihedral angle 
between the C4–C5 bond and the C=O bond of the ester was close to 0 in the lowest energy 
conformations, in both the endo envelope and exo envelope, and that rotation of the bond is 
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Figure 34. Rotation of the C4–CO2Et bond in cyclobutanone 84. Calculated (RHF/6-31G(d)) potential 
energies in the (A) endo envelope and (B) exo envelope conformations are superimposed and offset 
by 1.92 kcal/mol in (C) to reflect relative energies.  represents the dihedral angle between the C4–C5 
bond and the C=O bond (as coloured in blue). Determination of the potential energy at each angle 
involved the manual rotation of the C4-CO2Et bond (10 increments) from the RHF/6-31G(d)-
optimized geometry of 84, followed by calculation of the RHF/6-31G(d) energy at each angle.    
 
107 
conformational preferences of cyclobutanones with -substituents, however, indicates that the C4-
carboxylate has a minor energetic effect as 117, 121, and 129, have nearly identical preferences 
as the de-carboxy analogues 136–138. 
In addition to the computational results described thus far, the conformational preferences of 
several 2-oxa and 2-carba (CH2) analogues 139–146 have been calculated for the purpose of 
comparison. It is worth noting that the calculated conformational preferences for the 2-thia series are 
generally larger in magnitude than the preferences of the 2-oxa counterparts, and that this is likely a 
consequence of increased steric interactions in the tetrahydrofuran system due to the shorter 
endocyclic carbon-oxygen bond lengths.  
2.7 Conformational Properties of Penicillins 
The importance of the penicillins to antibiotic therapy has led to numerous studies of their three-
dimensional structures by experimental and theoretical methods and particular attention has been paid 
to the conformational properties of the thiazolidine ring. X-ray crystal structures, which have been 
obtained for a variety of penicillins, show that the bicycle can adopt an endo envelope conformation I 
or an exo envelope conformation J (Figure 35).626 The endo and exo envelopes are also referred to as 
the C3-puckered and S-puckered conformations, based on the atom that is most out of the plane of the 
ring, or the axial and equatorial conformations, respectively, based on the orientation of the 3-
carboxylate.  
Attempts have been made to correlate the solid-state conformational preferences with biological 
activity,627,628 but NMR studies by Dobson et al. demonstrate that these differences in conformational 
preference are not present in solution. The use of lanthanide ions as probes629 and 13C cross 
polarization magic angle spinning (CP-MAS) NMR experiments630,631 indicate that several penicillins 
(with different solid-state preferences) all favour the exo envelope conformation J in aqueous solution 
with ratios of endo:exo conformers ranging from 45:55 to 21:79, respectively.632   
While penicillin G has been found to favour the endo envelope conformation I in the gas phase by 
several computational studies633,634 including our own (2.2 kcal/mol, Table 4), molecular dynamics 




Figure 35. Two conformations of penicillin G. Figures of the endo envelope (C3-puckered, axial) 
conformation I and the exo envelope (S-puckered, equatorial) conformation J were adapted from X-
ray crystal structures of the potassium salt (CCDC: BPENK01) and the procaine salt (CCDC: 
PRPENG), respectively.  
 
Figure 36. Non-covalent complexes of penicillins with penicillin-recognizing proteins. (A) X-ray 
crystal structure (PDB: 1PW1) of a peptidoglycan-mimetic penicillin bound to an acylation-deficient 
form of R61 DD-transpeptidase.199 (B) X-ray crystal structure of benzylpenicillin bound to the 
Ser70Gly mutant of the class A -lactamase CTX-M-9 (PDB: 3HUO).637  
stabilizing the exo envelope conformation J, and the MD simulation which predicts an endo:exo ratio 
of 70:30 in aqueous solution is in reasonable agreement with Dobson’s experimental results. 
In the context of biological activity, it is thought that - lactamases preferentially bind to the exo 
envelope conformer J of penicillins. Through detailed MD simulations of penicillin G complexed 
with the class A TEM-1 -lactamase, Díaz et al. have shown that H-bonding interactions between the 
C3-carboxylate and Ser130, Ser235, and Arg244, are favoured with the equatorial conformer J and 
that a steric clash between the 2-methyl group and Ala237 is also avoided.263 Additional molecular 
modeling studies involving mechanisms of penicillin acylation in TEM-1 (class A)264,266,635 and P99 
(class C)636 -lactamases have also involved the exo envelope conformation J of the penicillins, but 
analogous studies with the class B and class D enzymes have yet to be reported.   
Recent crystallographic work, however, could be considered the strongest evidence that the exo 
envelope is the biologically active conformation. A non-covalent complex between the R61 
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transpeptidase and a peptidoglycan-mimetic penicillin has been trapped crystallographically199 and an 
X-ray crystal structure of benzylpenicillin bound to the Ser70Gly mutant of CTX-M-9 has been 
recently deposited in the PDB (Figure 36).637 These crystal structures show that the penicillin adopts 
the exo envelope conformation J in the active sites of the PBP and the -lactamase.   
2.8 Conformations of Cyclobutanone Derivatives and Hemiketal Formation 
Since the tendency for the cyclobutanones to undergo hydrate and hemiketal formation is central to 
their ability to function as -lactamase inhibitors, the strong evidence (discussed above) indicating 
that penicillins bind to PBPs and -lactamases in the exo envelope conformation brought to mind the 
following question: Does the conformation of the tetrahydrothiophene ring have a significant effect 
on the tendency of the cyclobutanones to undergo hydrate and hemiketal formation?  
Hemiketal formation with cyclobutanones was evaluated through simple NMR experiments in 
which the cyclobutanone of interest was dissolved in neat methanol-d4 (Table 5). As mentioned 
above, the dichlorocyclobutanones 65 and 84 (X = Cl) underwent hemiketal formation to a much 
greater extent than the dechlorinated ketones 110 and 111 (X = H). As expected, this pattern was also 
evident in the unsaturated system as hemiketal formation occurred to a greater extent with 118 (X = 
Cl) than with 126 (X = H).  
Exposure of the 3-alkoxy dichlorocyclobutanones 121–123 and 121–124 to methanol-d4 
revealed that the extent of hemiketal formation was highly dependent upon the steric environment 
surrounding the carbonyl group. Thus, hemiketal formation is highly favoured in cyclobutanones that 
prefer the exo envelope, 121–123 (98%), while hemiketal formation is less significant with 
cyclobutanones 121–124 (15–40%), which adopt the endo envelope. It is reasonable that the 
unsaturated esters 118 and 126 show larger proportions of hemiketal than 84 and 110, respectively, 
since the C3 methylene unit could impose additional steric congestion in the endo envelope. Steric 
hindrance of ketone hydration has been noted previously.605   
While it has been well established that nucleophilic attack on the carbonyl group is highly favoured 
from the exo face of bicyclo[3.2.0]heptan-6-ones, the reversible nature of hemiketal formation gave 
rise to a mixture of the ketone and each of the - and -hemiketals which often required weeks to  
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Table 5. Cyclobutanone Hemiketal Formation in Methanol-d4.
a   
 
Cyclobutanone 






    
65: R = H 2.7 : 1 88 
84: R = Et 2.7 : 1 91 
    
 
    
110: R = Et 1.8 : 1 19 
111: R = H 1.6 : 1 24 







    
118: X = Cl 1.8 : 1 96 
126: X = H 1.5 : 1 38 
    
 
121: Z = OMe 1.2 : 1 98 
122: Z = Oi-Pr 1.1 : 1 98 
123: Z = Ot-Bu 1.1 : 1 98 
    
 
121: Z = OMe 4.7 : 1 15 
122: Z = Oi-Pr 4.2 : 1 24 
123: Z = Ot-Bu 1.8 : 1 40 
124: Z = OAc 1.5 : 1 30 
      
a The extent of hemiketal formation was determined by 1H NMR 
experiments in neat CD3OD. 
b The / hemiketal ratio was 
determined when the system had reached equilibrium. 
equilibrate. Tabulation of the equilibrium ratios of -hemiketal/-hemiketal revealed that the relative 
stability of the - and -hemiketals is highly sensitive to steric hindrance in the same way that the 
extent of hemiketal formation was found to be. Namely, the cyclobutanone derivatives with the 
greatest steric bulk on the endo face of the bicycle have the highest /-hemiketal ratios. 
Interestingly, the coupling patterns in 1H NMR and the chemical shifts observed in the 13C NMR 
indicate that the -hemiketals of 3-alkoxy cyclobutanones 121–124 adopt the exo envelope 
conformation (Figure 37).  
In contrast to the fast hydrate formation observed with 65 (X = Cl) in D2O and the classical study 




Figure 37. Conformations of cyclobutanone hemiketals as indicated by 1H NMR and 13C NMR (R = 
Me, i-Pr, t-Bu). For tables of selected 1H and 13C NMR data for cyclobutanones and cyclobutanone 
hemiketals, see Appendix D.   
surprisingly slow given the high electrophilicity of the carbonyl carbon and required several hours to 
equilibrate (Appendix E).639 The results reported by the Wiberg group, which show that hemiketal 
formation with ketones is fast, were replicated in our laboratory under our conditions for 
cyclobutanone itself and were also reflected in the relatively fast hemiketal formation demonstrated 
by the dechlorinated cyclobutanones 110 and 111.  
Although the extent of hemiketal formation is greater for the 7,7-dichlorinated systems as 
compared with the non-chlorinated compounds, qualitative observations of relative rates of hemiketal 
formation suggest that the process is somewhat impeded by the halogen substituents. The 
approximate trend in relative rates of hemiketal formation is: 121–123 > 126  118  110 > 84 > 
123 > 122 > 121.  
Hemiketal formation must involve either protonation of the carbonyl oxygen or at least substantial 
H-bonding to the oxygen from the solvent to activate the carbonyl for nucleophilic attack at carbon. 
The chlorine atoms at C7 likely diminish electron density on the carbonyl oxygen atom making it less 
basic and less prone to protonation by an acid catalyst or to act as an H-bond acceptor. Furthermore, 
the chlorines likely offer a degree of steric hindrance to the solvation which might be required for 
lowering the activation energy for the addition step in hemiketal formation. 
2.9 Summary and Outlook  




Figure 38. Synthesis of 3-alkoxy, 3-alkoxy, and 3,4-unsaturated cyclobutanone analogues of -
lactams and the relationship between conformation and the extent of cyclobutanone hemiketal 
formation in methanol-d4.   
bicyclo[3.2.0]heptan-6-one-4-carboxylate skeleton and the results of preliminary biochemical assays 
with cyclobutanones 65 and 111 which encouraged the synthesis of other dichlorocyclobutanone 
analogues of -lactams. 3-Alkoxy derivatives were prepared through two complementary 
diastereoselective substitution reactions following a highly stereoselective chlorination of 84 with 
sulfuryl chloride (Figure 38). Cyclobutanone derivatives with 3 substituents favour an endo 
envelope conformation in solution, the solid state, and the gas phase, whereas those with 3 
substituents adopt an exo envelope conformation. Evidence from X-ray crystal structures and ab initio 
calculations suggests that an anomeric effect contributes to the large conformational preference of the 
tetrahydrothiophene ring that favours the 3-alkoxy substituent in an axial orientation. In addition, the 
conformation of the bicyclic system, which is determined by the stereochemistry of the 3-alkoxy 
substituent, has a dramatic effect on the ability of the cyclobutanone to undergo hemiketal formation 
in methanol-d4.  
If the extent of hemiketal formation in alcoholic solution can be used as an estimate of the relative 
stability of the tetrahedral adducts, then the results presented above (Table 5, Figure 38) indicate that 
3-alkoxy cyclobutanone derivatives should also form more stable hemiketal adducts than the 3-
epimers in the active sites of serine -lactamases. In addition, crystallographic and computational 
studies which indicate that penicillins bind to PBPs and -lactamases in the exo envelope 
conformation suggest that 3-alkoxy cyclobutanone derivatives, which strongly favour the exo 
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envelope conformation, would be better penicillin mimics than the 3-alkoxy analogues, which 
strongly favour the endo envelope conformation. The relatively rapid and complete hemiketal 
formation exhibited by the 3-alkoxy derivatives and the unsaturated cyclobutanone 118 are 
properties desirable for potential -lactamase inhibitors functioning by the mechanism described 
above and experiments designed to exploit these observations are presented in the following chapters 




Cyclobutanones Analogues of -Lactam Antibiotics: Inhibition of Serine- 
...and Metallo--Lactamases†,640  
3.1 A Modified Synthetic Route to the Free-Acid Form of the Cyclobutanones 
The relationship between the strong conformational preferences of 3-alkoxy-substituted 2-thia-
bicyclo[3.2.0]heptan-6-one-4-carboxylates and their tendency to undergo hemiketal formation led to 
the prediction that 3-alkoxy cyclobutanone derivatives should be better -lactamase inhibitors than 
the 3-alkoxy counterparts. In order to test this hypothesis in enzyme inhibition assays the carboxylic 
acid form of these derivatives was required. Not unexpectedly, however, the conditions used for the 
acid-catalyzed hydrolysis of other ethyl esters (6 M HCl/dioxane, 85 C) were found to be 
inappropriate for 3-alkoxy ethyl ester derivatives. Even 3 M HCl at room temperature led to the 
decomposition of the 3-alkoxy substrates, presumably through hydrolysis of the S,O-acetal 
functionality at C3. Since the sensitivity of the dichlorocyclobutanone ring to aqueous hydroxide had 
already been established other esters were considered for the protection of the C4-carboxylate (Figure 
39).   
 
Figure 39. Protecting group strategies considered for the C4-carboxylate of 3-alkoxy cyclobutanone 
derivatives.   
While the 3-alkoxy derivatives were unstable to concentrations of aqueous HCl required for ethyl 
ester hydrolysis, compounds such as 121 and 121 were fully stable in previous experiments with  
                                                     
 † Reproduced in part, with permission, from ref 640. Johnson, J. W.; Gretes, M.; Goodfellow, V. J.; 
Marrone, L.; Heynen, M. L.; Strynadka, N. C. J.; Dmitrienko, G. I. J. Am. Chem. Soc. 2010, 132, 
2558–2560. Copyright 2010 American Chemical Society.  
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0.1 M HCl in i-PrOH. Several protecting groups were considered potentially useful for the present 
application (methyl, t-butyl, allyl, benzyl, p-methoxybenzyl, p-nitrobenzyl, etc.) but the benzhydryl 
ester was chosen since deprotection typically involves TFA and because diphenyldiazomethane had 
already been prepared by other researchers in this laboratory.  
The esterification of 65 with diphenyldiazomethane in EtOAc cleanly afforded the benzhydryl ester 
149 in 98% yield (Scheme 27). While previous chlorinations at C3 employed SO2Cl2, the chlorination 
of 149 used N-chlorosuccinimide in order to avoid the production of HCl. Chlorinations with NCS, 
which selectively produced the -chloro isomer 150, were initially done in CH2Cl2 but were found 
to be faster in MeCN. While the succinimide byproduct could be removed with aqueous washes of 
150 in CH2Cl2, the washing process caused a certain amount of epimerization and elimination. As a 
result, the mixture of 150 and succinimide was typically used directly in the subsequent 
methanolysis without purification to generate the 3-methoxy substitution products 151 and 151 in 
a 3:1 ratio. The -chloro isomer 151 could be selectively crystallized from the mixture prior to the 
difficult separation of the diastereomers with flash chromatography. Treatment of each of the 3-
methoxy isomers with TFA (10% in CH2Cl2), followed by trituration with CH2Cl2/hexane, provided 
the free acids 152 and 152 without epimerization at C3.  
As with the ethyl esters, the conformational preferences of the new benzhydryl- and carboxylic acid 
derivatives were apparent by analysis of 1H NMR spectra and confirmed in some cases with single-
crystal X-ray structures. Namely, derivatives which lack functionality at C3 and derivatives with -
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methoxy substituents adopt the endo envelope conformation in which J3,4 and J4,5 are close to 0 Hz. 
The -methoxy epimers, on the other hand, favour the exo envelope conformation in which J3,4 = 4 
Hz and J4,5 = 6 Hz. One important consequence of the conformation of the five-membered ring is that 
the C4 carboxylate is oriented axially in the endo envelope and equatorially in the exo envelope.  
3.2 Synthesis of Cyclobutanone Analogues of Penems 
With the saturated cyclobutanone derivatives 65, 111, 152, and 152 in hand, the potential for 
unsaturated cyclobutanone analogues to act as inhibitors was also considered since such compounds 
could be considered as analogues of penems or carbapenems.  
The success of earlier elimination attempts (e.g. 119→118) supported the notion that the 
unsaturated acid 153 could be obtained by elimination of methanol from 152 or 152 under acidic 
conditions. While initial experiments involving Amberlyst 15, an acidic resin, effected elimination 
only slowly and resulted in partial decarboxylation, the unsaturated acid 153 was obtained cleanly by 
subjecting mixtures of 152 and 152 to 10% MsOH in CH2Cl2 at reflux for 2 hours (Scheme 28). 
This method provided enough material for X-ray crystallographic analysis and preliminary studies to 
evaluate the extent of hydrate formation in D2O, but this synthetic route to 153 was considered 
unfavourable since it consumed material (152 and 152) which could otherwise be used for 
biochemical and biological assays.  



































(93%, 3 steps)  
With a view to develop a more practical synthetic route toward 153, it was thought that the steps 
required for protection of the carboxylate as an ester and deprotection may be avoided if the readily 
available acid 65 could be used directly. Attempts to chlorinate 65 with SO2Cl2 directly were 
unsuccessful and indicated that some sort of modification of the carboxylate was necessary. As a 
rather unconventional solution to this problem, it was found that an acid chloride was an ideal 
protecting group for this purpose (Scheme 29). Thus, the saturated acid 65 was converted to the 
unsaturated acid 153 in three simple operations by treatment with SOCl2, SO2Cl2, and then 10% 
MsOH/CH2Cl2. Since the first two steps proceed in quantitative yield (by 
1H NMR) and the by-
products of SOCl2 and SO2Cl2 are volatile, no purification of the acid chloride intermediates 154 and 
155 was required and all three steps were done in a single flask. Isolation of the final product 
involved an aqueous workup and provided the crude unsaturated acid (95% pure by 1H NMR) in 
93% yield (one-gram scale) from acid 65.     
Scheme 30. Preparation of the Dechlorinated Unsaturated Cyclobutanone 156. 
 
Using the typical procedure for the dechlorination of cyclobutanones, acid 153 was heated with 
excess zinc dust in acetic acid. While this method was effective for the synthesis of other 
dechlorinated cyclobutanones (110, 111, 126), this method repeatedly provided only a very low yield 
(0–9%) of the desired cyclobutanone 156 (Scheme 30). Variations of the dechlorination (e.g. Zn in 
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AcOH at rt, or Zn in i-PrOH/AcOH 100:1) were also unsuccessful. In a different approach toward the 
dechlorinated acid 156, the direct hydrolysis of the ethyl ester 126 was attempted but the use of KOH 
(1 equiv) in THF or H2O resulted in a complex mixture of products. Since the failure of the alkaline 
hydrolysis was suspected to be a result of the ability of the cyclobutanone to participate in undesired 
enolate reactions, the ketone 126 was converted to the dimethyl ketal 157 using trimethyl 
orthoformate in acidic methanol. Protection of the ketone permitted the alkaline hydrolysis of the 
ethyl ester and KOH was used in D2O/methanol-d4 (2:1) so that the reaction could be followed by 
1H 
NMR. After 36 hours at room temperature, the desired product 158 was separated from small 
amounts of remaining unhydrolyzed ester by washing the alkaline aqueous phase with CH2Cl2. Acid-
catalyzed hydrolysis of the dimethyl ketal in TFA/acetone-d6/D2O (1:4:4) then furnished the 
dechlorinated acid 156 in 46% yield over three steps. TFA was used in favour of HCl because 
previous attempts to hydrolyze the unsaturated ester 119 with aqueous HCl led to extensive 
decomposition and, furthermore, HCl had been found to induce the ring-opening of cyclobutanone 
110 (Scheme 22).    
3.3 Inhibition of -Lactamases with Cyclobutanone Analogues of Penams and 
Penems 
While the synthetic studies described above were in progress, this laboratory acquired the expression 
systems for additional -lactamases as generous gifts from different researchers throughout the world. 
In addition to IMP-1 and OXA-10, which had already been given to this group by Prof. M. Galleni 
(U. Liège, Belgium) and Prof. S. Mobashery (U. Notre Dame), SPM-1 and OXA-45 were provided by 
Prof. J. Spencer and Prof. T. Walsh (U. Bristol, U.K.), and VIM-2, KPC-2, and GC1 were obtained 
from Prof. P. Nordmann (U. Paris), Prof. F. van den Akker (Case Western), and Prof. M. Nukaga 
(Josai International University, Japan), respectively.     
The KPCs (Klebsiella pneumoniae carbapenemases) are class A ESBLs that hydrolyze -lactams 
of all classes and are found on transferrable plasmids. KPC-producing strains have been isolated in 
New York, South America, Europe, China, and very recently in Canada.259,641,642 KPC-2 (Bush group 
2f) has been characterized structurally.643,644 IMP-1 is a class B1 metallo--lactamase which has a 
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wide spectrum of activity including all classes of -lactam except monobactams and is found in 
resistant strains of Serratia, Pseudomonas, Acinetobacter, Klebsiella, Citrobacter, Achromobacter, 
and Shigella.307,309,563 VIM-2 is a class B1 MBL that also has a broad spectrum of activity against 
penicillins, cephalosporins, and carbapenems.645 While VIM-2 is mainly observed in P. aeruginosa, it 
has spread more rapidly than the IMP family and, since it has been found in more than 37 countries 
across five continents, is now considered the global MBL.311,564 SPM-1, which was discovered from 
an isolate of P. aeruginosa in 2001,313 is the most important metallo--lactamase in Brazil564 and, 
unlike other class B1 MBLs, has very low affinity for the second zinc atom.344,345 GC1 is a group 1e 
class C enzyme from Enterobacter cloacae that owes its ESBL activity to a three amino acid insertion 
after Arg210 which gives additional conformational flexibility to the  loop and allows the enzyme 
to accommodate bulky oximino sidechains of third-generation cephalosporins.272,646,647 OXA-10 is a 
narrow-spectrum class D -lactamase (group 2d) that has been characterized by X-ray crystallography 
several times.291,293 OXA-45 is a class D enzyme with an extended-spectrum of activity (group 2de) 
which was discovered in a strain of P. aeruginosa from Texas that also expressed the metallo-enzyme 
VIM-7.648 Interestingly, OXA -lactamases employ a carbamylated lysine residue (Kcx70) as the 
general base in the turnover of -lactams.293  
With several cyclobutanone analogues of penams and penems in hand and several diverse -
lactamases available, the inhibition of class A, B, C, and D -lactamases could be studied (Table 6). 
Inhibition assays were conducted by Ms. Valerie Goodfellow and Dr. Laura Marrone with some 
assistance from Ms. Jun Wang.  
The cyclobutanone inhibitors found to be most potent against the serine -lactamases KPC-2, GC1, 
and OXA-10 were those which are hydrated to a larger extent in aqueous solution (Table 6). The 
dichlorocyclobutanones 65 and 153 undergo hydration to a much greater extent than their 
dechlorinated counterparts 111 and 156 and are also more effective as inhibitors of each serine -
lactamase. Among the dichlorocyclobutanones, steric hindrance of hydration is apparent as the 3-
methoxy derivative 152, which adopts the exo envelope, undergoes hydration to a greater extent 
than 65 and 152, which favour the endo envelope conformation and have greater steric bulk at C3 
(Figure 40). The corresponding observation that 152 is more potent than 65 and 152 against each 
enzyme is consistent with the hypothesis that each -lactamase binds more tightly the exo envelope  
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class D  
OXA-45e 
65 74   76 ± 8 >1000 >1000 >500 25 ± 3 268 ± 8 194 ± 28 
111 0   117 ± 13   235 ± 14 >1000  44 ± 3 1135 ± 33 689 ± 31 
152 >98   58 ± 2 122 ± 5 363 ± 9 524 ± 22    6.5 ± 1.4 156 ± 6 148 ± 21 
152 6   99 ± 5    38 ± 4   547 ± 19 392 ± 20 
153 93   26 ± 2   213 ± 21 >1000     4.5 ± 0.3   370 ± 15 47 ± 6 
156 <2 170 ± 2 >500   34 ± 3 >1000  
a IC50 values (M). Inhibition was assayed by monitoring nitrocefin hydrolysis. For assay conditions see ref 
640. b For a table of IC50 values corrected for the extent of hydration, see Appendix F. 
c Class A, C, and D 
enzymes are serine -lactamases and class B enzymes are metallo--lactamases. d The extent of cyclobutanone 
hydrate formation was determined by 1H NMR. Acetone-d6 was used as a cosolvent for solubility purposes. 
e 
Assays for the inhibition of KPC-2, IMP-1, VIM-2, GC-1, and OXA-10 used concentrations of nitrocefin close 
to Km. Concentrations of nitrocefin in SPM-1 and OXA-45 assays were >Km.  
 
Figure 40. Cyclobutanone hydration and steric interactions at C3.  
conformation than the endo envelope. In addition, the 3-methoxy derivative 152, which favours the 
endo envelope conformation by 5.0 kcal/mol, is a poorer inhibitor than 65, which favours the endo 
envelope by only 1.9 kcal/mol (Table 4). 
The unsaturated acid 153, in which the carboxylate is fixed in an equatorial orientation, was found 
to be comparable in potency to 152 with respect to the inhibition of GC1 and somewhat more potent 
than 152 against KPC-2. On the other hand, 152 and 65 were found to be more potent than 153 
with respect to OXA-10, suggesting that the relatively subtle difference in orientation of the C4 
carboxylate may be important for binding to the various serine -lactamases.  
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Preliminary data indicates that cyclobutanones are also moderate inhibitors of OXA-45. While 
minor differences in assay conditions prevent direct comparisons with other enzymes it appears that 
the overall trends in inhibition for OXA-45 are similar to those of the other serine -lactamases.  
Gratifyingly, the cyclobutanones also acted as moderate inhibitors of metallo--lactamases. As 
with the serine -lactamases, the inhibitors found to be most potent against IMP-1 were 152 and 
153. Since the unsaturated acid 153 was more effective than its dechlorinated analogue 156 against 
the serine enzymes and IMP-1, it was somewhat surprising to find that the dechlorinated acid 111 was 
more potent than compound 65 under these assay conditions. This exception to the general trend 
indicates that electron-withdrawing substituents like chlorines are not necessarily beneficial for the 
inhibition of all -lactamases. While the cyclobutanones were generally found to be less potent 
inhibitors of VIM-2 than IMP-1, the moderate inhibition exhibited by 152 is considered 
encouraging. In addition, preliminary assays indicate that the -methoxy derivative 152 is also a 
moderate inhibitor of SPM-1; however, the poor supply of this enzyme in this laboratory has 
prevented more detailed studies thus far.   
3.4 X-Ray Crystal Structure of a Cyclobutanone Bound to OXA-10 as a Serine 
Hemiketal 
In a collaborative effort with Prof. Natalie Strynadka and Dr. Michael Gretes at the University of 
British Columbia, structural insight into enzyme–inhibitor interactions was pursued by solving the X-
ray crystal structure of a complex of 152 with the class D -lactamase OXA-10 (Figure 41). The 
structure was obtained by soaking pre-formed crystals of OXA-10 with the inhibitor and was refined 
to 2.0 Å resolution.649 Consistent with previous observations (PDB: 1K54),293 two dimers of OXA-10 
are present in the asymmetric unit and the inhibitor is bound to only two of the four monomers 
(Figure 41A). It is interesting to note that the use of higher concentrations of inhibitor in early 
crystallization trials at UBC resulted in disruption of the crystal lattice. It is possible that this is a 
consequence of the binding of the inhibitor to chain D and displacement the loop of chain A (which 
includes Lys95) from the active site of chain D. Disruption of OXA-10 crystals has been observed 




Figure 41. X-ray structure of cyclobutanone 152 bound to OXA-10 as a serine hemiketal (PDB code: 
3LCE). (A) View of the asymmetric unit cell with two OXA-10 dimers. Cyclobutanone 152 is 
bound to chains A and B and a phosphate is observed in the active sites of chains C and D. (B) 
Interactions between OXA-10 active site residues and the bound inhibitor in chain A. (C) Stereoview 
of the active site of chain A with electron density. The continuous electron density from Ser67 to C6 
of the inhibitor is unambiguous support for the formation of a serine-bound hemiketal. (D) 
Stereoview of the chain A active site from an alternate perspective.  
state of OXA-10,297 is observed in all four monomers.  
The clear continuous electron density from the active site serine through to and including the 
tetrahedral carbon of the hemiketal linkage (Figure 41C) provides unambiguous support for the 
inhibition mechanism originally envisaged for such compounds (Figure 19). Recent studies with other 
serine-dependent hydrolytic enzymes suggest that such a hemiketal likely exists in the alkoxide form, 
stabilized by the functionality that defines the oxyanion hole.650,651,652 The structure also shows that  
the inhibitor adopts the exo envelope such that the C4 carboxylate has an equatorial orientation and 
the 3-methoxy group has an axial orientation.  
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The electron density associated with the chlorine atoms in the structure is relatively weak, possibly 
indicating that X-ray radiation had caused partial dechlorination of the inhibitor. X-ray radiation has 
been reported to cause cleavage of disulfides, decarboxylation of aspartate and glutamate residues, 
and cleavage of C–Br bonds.653 The cleavage of C–Cl bonds has also been described.654  
Another potential contributing factor that was considered for the weak electron density surrounding 
the chlorines involves disorder caused by a rapid conformational change of the inhibitor. Ab initio 
and DFT molecular modeling studies, which were undertaken to investigate this phenomenon, 
indicate that model hemiketals of 152, acid A and guanidinium salt B, can adopt two slightly 
different exo envelope conformations in which the chlorines show the greatest differences in position 
(Figure 42 and Figure 43). The low energy difference (0.1–0.3 kcal/mol) between the C4-puckered 
and S-puckered conformers and the low energy barrier (0.4–0.8 kcal/mol) for interconversion support 
this hypothesis. The possibility of an endo envelope-to-exo envelope conformational change in the 
active site of OXA-10 was discounted after the structures were superimposed. In addition, the large 
energy difference (3.5 kcal/mol) and barrier for interconversion (>4 kcal/mol) are inconsistent with 
the rapid conformational change required to account for the weak electron density associated with the 
chlorine atoms.  
Another curious aspect of the X-ray crystal structure is that close contacts are observed between the 
two chlorines of the inhibitor and amino acid residues of OXA-10. The contacts of 2.5 Å between the 
7-chloride and a methyl group of Val117 and 2.3 Å between the 7-chloride and the amide oxygen 
of Phe208 (Figure 41B) are much closer than contacts, 3.45 Å and 3.27 Å, calculated from the sum of 
the atomic van der Waals radii.625  
In an effort to find precedent for this sort of interaction, searches of the Cambridge structural 
database (CSD) and protein data bank (PDB) were conducted. In the CSD, a substructure search of 
the 2-chloropropane moiety returned 30 hits with ClO or ClC intermolecular contacts <3.0 Å but 
eight of these were disordered in some way. Of the remaining 22 structures, 18 showed ClO 
contacts655 and five showed ClC contacts.656 The structures with the shortest ClC contacts were 
CLMPMO,657 a trichloromethyl-substituted pyrimidone, and BCARPC,658,659 a tricyclic alkyl chloride 
(Figure 44). Coincidently, the structure with the shortest of the ClO contacts, NAFBUR, is a 


































































































Figure 42. Conformational analysis of model hemiketals A (left) and B (right). Structure optimizations 
and transition state calculations used Gaussian-03.623 Calculated energy differences are given in 
kcal/mol (na = not available, nd = not determined). 
 
Figure 43. Superimposition of two RHF-G31G(d)-optimized exo envelope conformations of hemiketal 
A and heavy atom displacements in the conformational change. Structure optimizations were done 
with Gaussian-03623 and the least-squares superimposition (RMSD = 0.78 Å) done in Sybyl.660   
shows a short ClC contact. 
A search of the PDB for enzyme ligands that contained “chloro” (but not chlorophyll or chloride) 
in the ligand name returned 714 hits. Inspection of each entry with the program RCSB PDB Ligand 
Explorer, which is available from the protein data bank, revealed that 280 structures contained a 
contact between a chlorine and a carbon, oxygen, nitrogen, or sulfur of less than 3.3 Å. Of these 
structures, 80 contained intermolecular contacts with chlorines of less than 3.0 Å and 17 entries 
showed contacts shorter than 2.7 Å.661,662,663 Aside from the structures that appeared to be disordered, 




Figure 44. X-ray crystal structures of small molecules in the Cambridge structural database (CSD) that 
have intermolecular close contacts between chlorines and carbons or oxygens.  
While most of these ligands were aryl- or heteroaryl chlorides, a dichloroacetamide (PDB: 1GRQ) 
and an alkyl chloride (PDB: 1XVF) were among those with the shortest contacts.  
It has been noted recently that close contacts between halogens (Cl, Br, I) and oxygens are present 
in more than 154 PDB structures. Lu et al.664 have studied this phenomenon computationally 
(ONIOM methods) in the context of halogen bonding and it is possible that halogen bonding plays a 
role in the present study.   
3.5 Molecular Models of -Lactamase Adducts with Cyclobutanones 
Computational models of enzyme–inhibitor complexes were constructed in order to gain further 
insight into specific active site interactions and provide support for the inhibition observed (Figure 
45). Cyclobutanone structures (obtained from optimizations in Gaussian-03)623 were manually docked 
into X-ray crystal structures of KPC-2 (PDB: 2OV5),643 IMP-1 (1JJE),665 and GC1 (1RGZ)666 using 
Sybyl660 and optimized using the MMFF94 force field.  
In complexes of cyclobutanones with serine -lactamases, pre-optimized cyclobutanone hemiketals 
were docked such that the hemiketal moiety was positioned suitably in the oxyanion hole and the C4-
carboxylate was able to interact appropriately with nearby Arg, Ser, or Thr residues. Although recent 
reports have concluded that tetrahedral adducts of an -ketoheterocycle and a peptidyl 
trifluoromethyl ketone are not protonated in the active sites of FAAH651 and elastase,652 the 

























































































































Figure 45. Structure-optimized models of cyclobutanones 153 (blue), 152 (red), and 65 (grey) bound 
as tetrahedral adducts to the class A, B, and C -lactamases KPC-2, IMP-1, and GC1. With the class 
D -lactamase OXA-10, the X-ray crystal structure of 152 bound to OXA-10 is shown (PDB: 
3LCE) and this structure was also used to generate a model of 153 with OXA-10.  
modeled as protonated species. Though not initially considered, it was found that the protonated 
hemiketal could act as a donor in a hydrogen bond with the backbone amide oxygen of the non-serine 
residue of the oxyanion hole (Thr237 in KPC-2, Ser321 in GC1, and Phe208 in OXA-10). 
Interestingly, the hemiketal of cyclobutanone 65 was initially docked in KPC-2 and GC1 in its 
favoured endo envelope conformation but the structure changed through the course of the 




Figure 46. Interactions of cyclobutanones with IMP-1 in modeled complexes of enzyme–inhibitor 
adducts.  
 
Figure 47. Conformations of enzyme-bound adducts of 153 (blue), 152 (red), and 65 (grey) extracted 
from modeled complexes with GC1.  
adopt the exo envelope conformation in order to avoid steric clashes within each active site (not 
shown). Changes with enzyme-bound hemiketals of 152 and 153 were more subtle with the 
inhibitors adopting one of two possible conformations (twisted forms) of the four-membered ring. As 
shown in Figure 42, the twist of the four-membered ring in inhibitors such as 152 causes a twist of 
the five-membered ring.   
Cyclobutanone hydrates were initially docked in the metallo--lactamase IMP-1 such that the 6-
oxygen would bridge the two zinc atoms in the position normally occupied by the nucleophilic 
hydroxide. In accord with speculations that Asn167 plays a role similar to that of the oxyanion hole of 
serine -lactamases, to polarize the -lactam carbonyl to facilitate hydrolysis (Section 1.4.6), the 
cyclobutanone hydrate was initially oriented to hydrogen bond with the amide sidechain of this 
residue; however, such a hydrogen bond was not observed in optimized complexes (Figure 46). It has 
also been suggested that the C3- and C4-carboxylates of carbapenems and cephalosporins coordinate 
to Zn2 during catalysis. While an attractive interaction was certainly observed in optimizations of the 
present study, coordination led to a large amount of strain such that the outputted structures displayed 
highly twisted rings and unreasonably skewed conformations. Reasonable conformations of adducts 
of 152 and 153, however, were obtained when cyclobutanone hydrates were initially docked such 
that the C4-carboxylate could not only form a salt bridge with Lys161 but also hydrogen bond with 
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the backbone amide of Asn167 and, very importantly, the water molecule that also hydrogen bonds to 
His139.  
In addition to the value that these models may have for the design of potentially more potent 
inhibitors, these computational studies provide support for the need for an equatorial carboxylate to 
interact appropriately with active-site residues and that cyclobutanones such as 65 and 152 must 
adopt their normally disfavoured exo envelope conformation in order to bind to each serine- and 
metallo--lactamase (Figure 47).  
3.6 Antimicrobial Assays with Cyclobutanones 
The recent acquisition of several -lactamase-producing carbapenem-resistant bacterial strains 
allowed our group to test the cyclobutanones for synergy with -lactams. These strains were collected 
as clinical isolates from Ontario and Calgary hospitals and were kindly provided by Prof. D. Pillai (U. 
Toronto) and by Prof. J. Pitout (U. Calgary), respectively. Microbiological assays were conducted in 
this laboratory by Valerie Goodfellow according to published procedures.667  
With the modest (micromolar) potency of the cyclobutanones against metallo--lactamases in 
biochemical assays, it was not surprising that cyclobutanones 65, 111, 152, and 153 were unable to 
enhance the potency of meropenem by greater than a factor of 2 (one 2-fold dilution) against VIM-2- 
and IMP-7-producing strains of P. aeruginosa at concentrations of up to 400 M. It was surprising, 
however, to discover that cyclobutanone 153 improved the MIC of meropenem by a factor of 4 
against MBL-producing strains of Chryseobacterium meningosepticum and Stenotrophomonas 
maltophilia at concentrations of 200 M and 100 M, respectively (Table 7). The MBLs expressed in 
these strains have not yet been identified but are thought to be BlaB668 and L1,368 respectively. The 
synergy observed with meropenem suggests that cyclobutanone 153 might have higher affinity for 
these enzymes than other MBLs and this encouraging possibility may be evaluated in future work.  
Although the carboxylic acid form of the inhibitors is required for favourable binding to -
lactamases, Cocuzza and Boswell reported in the mid-1980s that benzhydryl ester derivatives of 
cyclobutanones showed synergy with penicillin G against -lactamase-producing S. aureus.532,533 
Such benzhydryl esters presumably exhibited improved cell wall penetration and were converted to   
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Table 7. Antimicrobial Activity of Meropenem (MIC) in the Presence of Cyclobutanones Against MBL-Producing Carbapenem-Resistant Clinical 
Isolates.a,b  
 
ID clinical isolate enzyme  153 (g/mL) 65 (g/mL)  152 (g/mL) 111 (g/mL) 
    0 25 100 200 400 0 100 200 400  0 100 200 400 0 100 200 400 
24 P. aeruginosa C10 VIM-2  16   16 8 16  16 16  16 16 16 16 16 16   
25 P. aeruginosa C7 IMP-7  64   64 64 64  64 64  256 128 128 128 128 128   
26 P. aeruginosa IS 5563 MBL .  64 64 32 32  32  64           
32 C. meningosepticum IS 5824 MBL c  64 64 32 16  32  16           
34 S. maltophilia IS 6081 MBL d  64 32 16 16  32  64           
                      
ID clinical isolate enzyme  118 (g/mL) 149 (g/mL)  151 (g/mL)  
    0 25 100 200 400 0 100 200 400  0 100 200 400     
24 P.aeruginosa C10 VIM-2  16  16 16 16 16 16 16 16  16 16 16 16     
25 P.aeruginosa C7 IMP-7  256  128 128 128 256 256 128 256 e  256 256 256 256     
a The author gratefully acknowledges Ms. Valerie J. Goodfellow for the data contained in this Table.  b Underlined MIC values indicate enhancements in the 
potency of meropenem relative to control values. c The MBL of Chryseobacterium meningosepticum IS 5824 is likely BlaB. d The MBL of Stenotrophomonas 
maltophilia IS 6081 is likely L1. e Precipitation was observed.  
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the carboxylic acid form by esterases in vivo. In order to evaluate the possibility that esters of the 
present study might exhibit similar behaviour, cyclobutanones 118, 149, and 151 were also tested 
for synergy with meropenem and preliminary experiments indicate that ethyl ester 118 and 
benzhydryl ester 149 improved the potency of meropenem 2-fold against a strain of P. aeruginosa.  
3.7 Summary and Outlook 
Cyclobutanone analogues of penams and penems have been prepared and evaluated as inhibitors of 
class A, B, C, and D -lactamases. The cyclobutanone derivatives found to be most potent as 
inhibitors are those that are more extensively hydrated in aqueous solution. Inhibitors which favour 
conformations in which the C4 carboxylate is equatorial were found to be more potent than those in 
which the carboxylate is axial, and molecular modeling studies with enzyme–inhibitor complexes 
indicate that an equatorial carboxylate is required for binding to -lactamases. An X-ray crystal 
structure of the class D -lactamase OXA-10 complexed with a cyclobutanone confirms that a serine 
hemiketal is formed in the active site and that the inhibitor adopts the exo envelope. The unsaturated 
penem analogue 153 was also found to enhance the potency of meropenem against MBL-producing 
carbapenem-resistant strains of bacteria isolated from Canadian hospitals.   
-Lactamase inhibition has been studied for several decades and, despite much research effort, the 
goal of a universal inhibitor that is effective against all classes of -lactamase has remained elusive. 
The biochemical data described above demonstrate that cyclobutanones can indeed act as inhibitors of 
serine- and metallo--lactamases and these cyclobutanones represent the first type of reversible 
inhibitors to show moderate to low micromolar inhibition of all four classes of -lactamase. It is also 
worth noting that the inhibition demonstrated by the cyclobutanones in this study represents, to the 
knowledge of this author, the most successful application of cyclobutanones as inhibitors of serine- or 
cysteine-active enzymes.669 Although the activity of the compounds described herein is relatively 
modest, the breadth of activity and the synergy with meropenem in antimicrobial assays are 
particularly encouraging since it serves as a proof of principle for the concept that cyclobutanones 




Synthetic Studies Toward Other C3- and C7-Substituted    
Cyclobutanone Analogues of Penams and Penems 
4.1 Rationale for Modifications at C3 and C7  
The demonstration that cyclobutanones 152 and 153 can act as inhibitors of serine- and metallo--
lactamases and show synergy with meropenem against resistant bacteria is considered very 
encouraging. Improvement of the potency of the cyclobutanones requires increased affinity of such 
inhibitors for -lactamase active sites and might be achieved with additional hydrogen bonding 
interactions and favourable non-covalent contacts. As indicated by molecular modeling studies with 
enzyme–inhibitor complexes and by direct comparison with -lactam antibiotics (-lactamase 
substrates), the most appropriate sites for modification are at C3 and C7. 
 
Figure 48. C3-Alkoxy, -thioalkyl, and -alkyl cyclobutanone derivatives as potentially more potent 
analogues of inhibitors 152 and 153.  
In addition to 3-alkoxy cyclobutanone derivatives, 3-thioalkyl- and 3-alkyl derivatives are also 
considered worthy of exploration since carbapenems and mechanism-based inhibitors (e.g. 
tazobactam) possess thioalkyl- and alkyl sidechains at this position (Figure 48).  
Ab initio molecular orbital calculations indicate that the conformational preferences of 3-thioalkyl 
and 3-alkyl derivatives are much weaker than those of the corresponding 3-alkoxy derivatives (Table 
8). As noted in the previous chapter, the poorer inhibitory potency of the 3-methoxy derivative 
152, compared to its epimer 152, is thought to be a consequence of its large preference (5.0 
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Table 8. Calculated Conformational Preferences for Cyclobutanone Derivatives.a   
 
Cyclobutanone 





152: Z = OMe + 3.88 0 
159: Z = SMe + 0.74 0 
160: Z = Me 0 + 1.02 
152: Z = OMe 0 + 5.00 
159: Z = SMe 0 + 0.66 
160: Z = Me 0 + 0.12 
 
161: Z = OMe + 4.12 0 
162: Z = SMe + 1.42 0 
163: Z = Me 0 + 0.43 
 
161: Z = OMe 0 + 4.32 
162: Z = SMe 0 + 0.87 
163: Z = Me + 0.11 0 
a Structure optimizations (RHF/6-31G(d)) used Gaussian-
03623 and comparison of the relative energy of each 
conformer was done following zero-point energy corrections. 
kcal/mol) for the endo envelope conformation since the inhibitors must bind to the -lactamase in the 
exo envelope conformation. These computational studies therefore suggest that the weaker 
conformational preferences of the 3-thioalkyl and 3-alkyl derivatives might be beneficial for 
inhibition since the compounds could adopt the exo envelope conformation in the enzyme active site 
without a significant energetic penalty. As a result of these calculations, recent synthetic efforts have 
been focused more toward penam and penem analogues with thioalkyl- or alkyl sidechains at C3 than 
toward 3-alkoxy derivatives.    
In addition to the potential alterations at C3, modifications of the cyclobutanone analogues at C7 
have also been considered. Although the dichlorocyclobutanones described appear to be much better 




Figure 49. Penam-mimetic 7-acylamino- and carbapenem-mimetic 7-hydroxyalkyl sidechains which 
may improve the inhibitory potency of cyclobutanone derivatives toward -lactamases (X1 = H, OMe; 
X2 = H, F, Cl, OH; R2 = H, Me; Z = OR, SR, CH2R).  
as a dichlorocyclobutanone would be appropriate for clinical evaluation. It is well known that drug 
candidates which rely on an electrophilic functionality may be prone to inactivation by natural 
electrophile scavengers such as glutathione and might exhibit toxic side effects as a result of 
nonspecific covalent modification of biomolecules in the host. It should also be noted, however, that 
these complications do not necessarily indicate that all cyclobutanones are unsuitable for clinical use 
since numerous ketone-containing serine protease inhibitors, which also inhibit through the formation 
of serine hemiketals, have been pursued as drug candidates in clinical trials.670,671,672  
These issues indicate that cyclobutanones might be better suited for therapeutic use if the 
electrophilicity of the carbonyl was attenuated and if the stability of the inhibitors toward hydrolysis 
at neutral pH was improved. In addition, substitution of one or both of the chlorines at C7 for other 
functionalities could improve the affinity of the cyclobutanones for -lactamase active sites (Figure 
49). For example, the introduction of a penam-mimetic acylamino groups at C7 would provide an 
important hydrogen bonding interaction (Figure 36) and favourable non-covalent contacts that are 
important to the binding of potent (nanomolar) boronic acid-based inhibitors. Alternatively, 
carbapenem-mimetic hydroxymethyl or hydroxyethyl sidechains could be introduced as potential 
hydrogen bond donors in order to provide additional affinity for -lactamase active sites.  
The remainder of this chapter describes synthetic efforts made toward the stereoselective 
preparation of such C3- and C7-substituted cyclobutanone derivatives, with special focus on C3-
thioalkyl and C7-hydroxymethyl derivatives.     
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4.2 Substitution Reactions at C3 
Initial attempts to introduce sulfur-containing sidechains at C3 involved the treatment of the -chloro 
derivative 117 with thiols in MeCN. The desired substitution product was not observed, however, 
despite the success of similar conditions for the solvolysis of 117 in ROH/MeCN (Figure 27). The 
subsequent discovery that substitutions with alcohols could also be promoted by AgOTf (Table 3) 
encouraged the exploration of Lewis acid-promoted substitutions with thiols and SnCl4 proved to be a 
suitable reagent for this purpose (Scheme 31). Typically, SnCl4 was added slowly to a solution of 
117 and the thiol in CH2Cl2 provided the 3-SR and 3-SR substitution products (>3:1) with very 
low proportions of elimination and isomerization byproducts 118 and 117.673 As with the AgOTf-
promoted substitutions with alcohols, the SnCl4-promoted substitutions generated the inversion 
products in higher proportions than the retention products. 1H NMR spectra of the substitution 
products in CDCl3 indicate that the 3-SR derivatives adopt the exo envelope conformation and the 
3-SR derivatives favour the endo envelope conformation.  
Scheme 31. Substitutions at C3 with Thiols.  
 
With the hope that the S,S-acetal moiety at C3 would show greater stability to acidic conditions 
than the S,O-acetal functionality of 121–123, hydrolysis of the ethyl esters 164 and 165 was 
attempted with 6 M HCl in dioxane (Scheme 31). Unfortunately, the S,S-acetals were also found to be 
unstable to these conditions and it became clear that alternate protection of the C4-carboxylate would 
be necessary for the synthesis of the desired carboxylic acid derivatives.  
Given the reactivity of the 3-chloro derivative 117 toward solvolysis and substitution reactions 




Figure 50. Allylation of 117 with allyltrimethylsilane (Upper panel). Additional carbon-based 
nucleophiles that might be used in the synthesis of cyclobutanone inhibitors (Lower panel).  
toward allylation was also explored (Figure 50). In the first attempt to effect this transformation, 
which involved the slow addition of SnCl4 to a solution of 117 and allyltrimethylsilane, the 
substitution products 166 and 166 were generated cleanly and, as with other Lewis acid-promoted 
substitutions, the reaction was selective toward inversion. It is possible that other latent carbon 
nucleophiles could be used for substitutions at C3, including allenes,674 enolates, or imines, but such 
reactions have not yet been investigated.  
While the SnCl4-promoted substitutions provide efficient access to the 3-thioalkyl and 3-allyl 
derivatives from the -chloro derivative 117, a method selective for the 3 epimers was also 
desired. Some of the first attempts to generate 3-thioalkyl isomers were based on the concept that 
the conjugate addition of a thiol to the unsaturated ester 118 would occur preferentially from the exo 
face of the bicycle. Even weakly basic conditions, however, involving thioacetic acid and 
triethylamine at room temperature were found to be incompatible with 118 and decomposition of the 
starting material, presumably through ring-opening of the dichlorocyclobutanone ring, occurred 
quickly (Scheme 32). The conjugate addition of the thiol in the presence of a Lewis acid, which has 
some literature precedent,675 was considered to be an attractive alternative since the 
dichlorocyclobutanone ring was known to be very stable to acidic conditions and because the 
oxidation of the thiol nucleophile would be less problematic. In order to follow the reaction 
conveniently by NMR, the unsaturated ester 118 was combined with i-PrSH and SnCl4 in CDCl3. 
Although changes in 13C NMR chemical shifts had indicated that an interaction between the ethyl 
ester moiety and the Lewis acid was present ( = 0.9, 0.5, 0.5 for C3, OCH2, CO2Et, respectively), 
none of the desired conjugate addition product was observed after 13 hours. The use of TFA, as a 
Brønsted acid substitute for the Lewis acid, was also unsuccessful and no reaction was observed.  
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Scheme 32. Synthetic Efforts Toward 3-Allyl and 3-Thioalkyl Derivatives.  
















































































































While attempts to effect conjugate addition were being made, it was also considered that 3-
thioalkyl derivatives might be accessed through a Lewis acid-promoted substitution, which would be 
expected to favour inversion, from a 3-substituted derivative (e.g. 3-OAc, 3-Cl, or 3-Br). 
Perhaps the most obvious choice of 3-X derivative would be the 3-chloro epimer 117, but early 
attempts to prepare or isolate the 3-chloro derivative 117 in useful amounts were unsuccessful. 
While 117 was observed as a byproduct in many different reaction conditions involving polar 
solvent or acidic conditions (Lewis acids, Brønsted acids, flash chromatography), efforts to prepare 
the -chloride (e.g. BnNEt3Cl in MeCN; dry HCl in ether) generated mixtures of 117, 117, and the 
elimination byproduct 118.  
Since Lewis acid-promoted substitutions with acetoxy dihydrothiophenes are well-
precedented,618,676 the 3-acetoxy derivative 124 was also explored as a possible precursor to the 
desired 3-thioalkyl isomers. In contrast to the high-yielding reactions reported with other acetoxy 
dihydrothiophenes, BF3OEt2 and TiCl4 were not effective promoters in the present study and 
unreacted starting material 124 was isolated following attempted reactions with thiols and 
allyltrimethylsilane.   
With the apparently low reactivity of 124, attention had returned to the 3-halo derivatives and 
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brief attempts were made to produce the -bromo derivative 167 from 117. The -chloride 117 
was slow to react with Bu4NBr (TBAB) in acetone-d6 and, although the addition of ZnBr2 improved 
the rate of conversion, the reaction remained incomplete after 21 hours at room temperature and was 
comprised of a mixture of compounds (117:117:167:118  23:8:3:66).  
While the pursuit of the 3-bromo derivative 167 was abandoned because of its presumed poor 
stability, the concept that a Lewis acid could facilitate isomerization was applied to the 3-chloro 
derivatives. Thus, 117 was exposed to TiCl4 in CDCl3 and 1H NMR spectra revealed that the 
isomerization was relatively rapid since the 117/117 ratio had reached 15:85 within 4 minutes. The 
ratio was unchanged after 2 hours and the fact that this result was reproduced in a second experiment 
in CH2Cl2 suggests that the two isomers had reached equilibrium under these conditions. As an 
important benefit, the elimination product 118 was generated only when the mixture was subjected to 
an aqueous workup and this observation encouraged use of the equilibrium mixture directly in 
substitution reactions. In such an attempt, 117 was pretreated with TiCl4 for 30 minutes before the 
addition of p-Tol-SH and the substitution products 165 and 165 were isolated as a mixture (1:1) 
with no indication that elimination had occurred (Scheme 32). While the stereoselectivity of this 
method is clearly lower than that desired for the synthesis of the 3-SR derivatives, it does provide 
higher proportions of the 3-SR isomers than the SnCl4-promoted substitution method described 
above and can be considered a complementary approach.   
With methods available for substitutions at C3 with thiols, efforts were focused toward the 
application of these reactions in the synthesis of potential inhibitors. Although 2-propyl mercaptan 
and 4-methylbenzenethiol were considered useful for the development of the reactions described 
above, the isopropyl- and p-toluyl substituents are thought to be poor choices for sidechains of broad-
spectrum inhibitors. Instead, amine-containing acyclic and heterocyclic substituents (Figure 51) are 
considered more likely to provide favourable interactions within the active sites of a large number of 
-lactamases. Since molecular modeling studies have revealed that this region of the active site is 
highly variable among class A, B, C, and D -lactamases (and also within the same class), the design 
of such sidechains was based on similarity to carbapenem sidechains and the concept that hydrogen 




Figure 51. Installation of an imipenem-mimetic sidechain at C3 (Upper panel). Additional amine-
containing and carbapenem-mimetic sidechains that may provide favourable hydrogen bonding 
interactions and non-covalent contacts in the active sites of -lactamases (Lower panel).  
Scheme 33. Preparation of the Mercaptoproline Sidechain of Meropenem.  
 
One concern that had arisen from the design of the sidechains was whether the Lewis acid-
promoted substitution chemistry would be compatible with amine-containing nucleophiles. However, 
the reaction of 117 with 2-diethylaminoethanethiol, as its commercially available hydrochloride salt, 
proceeded smoothly to produce the substitution products (168/168  1:5) with only small amounts 
of 118 (Figure 51). The success of this reaction encouraged the preparation of more complex thiols 
for reactions with cyclobutanones and the substituent considered most interesting was the proline-
based sidechain of meropenem.   
The synthesis of the meropenem sidechain in this laboratory followed the concise route published 
by Merck researchers in 1996 (Scheme 33).677 Following the reaction of the amino acid (–)-trans-4-
hydroxy-L-proline with Boc2O under typical conditions,
678 the Boc-protected hydroxy acid 169 was 
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treated with diisopropylethylamine (Hünig’s base) and diphenylphosphinic chloride (1 equivalent) at 
–10 C and then with pyridine and methanesulfonyl chloride (1 equivalent) to generate 170 in situ. 
Sodium sulfide nonahydrate was allowed to react with 170 overnight to afford the [2.2.1] bicycle 171 
in 73% yield over 3 steps. As noted by Brands et al.,677 a variety of conditions can be used for the 
ring-opening of the cyclic thioester and Me2NHHCl was used with Et3N in MeCN in this laboratory 
rather than a solution of Me2NH in H2O/THF. Since the resulting thiol 172 is known to be sensitive to 
oxidation, the crude product was used directly in the attempted substitution reaction with 117 and 
SnCl4. The desired substitution products 173 and 173 were not observed, however, as the tert-butyl 
carbamate was found to be unstable to the reaction conditions. While the instability of the Boc group 
was not completely unexpected, it indicates that a different protecting group is required. It is thought 
that benzyl, p-nitrobenzyl, or allyl carbamates (as in 174 and 175), which have much greater stability 
to Lewis acids such as SnCl4 and TiCl4 and could be removed selectively without the use of strong 
base or strong acid, could be used as alternatives.   
Scheme 34. Attempted Allylation of 150 in the Presence of Weak Bases.  
 
As noted above, the S,S-acetal moiety was found to be unstable in 6 M HCl in attempts to 
hydrolyze the ethyl ester functionality (Scheme 31). While the use of benzhydryl esters proved to be 
successful for the synthesis of the 3-alkoxy derivatives (Chapter 3), such protection would not be 
appropriate for the synthesis of 3-thioalkyl and 3-alkyl derivatives since benzhydryl esters are known 
to have similar susceptibilities to Lewis acids and Brønsted acids as tert-butyl esters (Scheme 34).679 
An attempted SnCl4-promoted allylation of 150, in the presence of sterically hindered weak bases 
(to neutralize the HCl generated in the reaction), was unsuccessful and confirmed the suspicion that 
alternate protection of the C4-carboxylate is required for Lewis acid-promoted substitutions at C3.   
As a result of these investigations, it is thought that the C4-carboxylate of the cyclobutanone should 
be protected as a benzyl-, p-nitrobenzyl-, or allyl ester since such derivatives would exhibit sufficient 
stability to Lewis acids and low concentrations of HCl and deprotection could be achieved through a  
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Scheme 35. Revised Protecting Group Strategy for the Synthesis of 3-Thioalkyl and 3-Alkyl 
Cyclobutanone Derivatives.  
 
variety of methods that do not involve alkaline conditions or strong acid-catalyzed hydrolysis 
(Scheme 35).679 The PNB ester seems particularly attractive for future work since it has been used 
extensively as a protecting group for -lactam antibiotics, including sulfur-containing penams, 
penems, carbapenems, and oxapenems.   
4.3 C3-Substituted Cyclobutanone Analogues of Penems 
Although the discussion presented thus far has focused on the development of substitution reactions 
toward the synthesis of 3-thioalkyl and 3-thioaryl penam analogues, the synthesis of 3-thioalkyl 
analogues of penems and carbapenems has also been an important goal throughout this work. It is 
hoped that the synthetic scheme devised for the penam analogues might exhibit some versatility such 
that penem analogues could be generated by oxidation of the saturated precursors (Figure 52).  
 
Figure 52. General synthetic strategy for the synthesis of cyclobutanone analogues of penems and 
carbapenems from penam analogues.  
Some of the first attempts to produce unsaturated analogues involved the treatment of 117 and 
124 with SO2Cl2 (Scheme 36). Interestingly, the parent cyclobutanone 84 was found to react fairly 
rapidly with 1 equivalent of sulfuryl chloride to generate 117 in quantitative yield. Upon exposure  
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Scheme 36. Synthetic Studies Toward 3-Substituted Penem Analogues: Attempts to Oxidize 3-Alkoxy 











































































































































1175 : 1  
of 117 to excess SO2Cl2 (5 equivalents), in experiments aimed at generating the 3,3-dichloro 
species 179 or the unsaturated ester 180, 117 reacted slowly to produce a mixture of unidentified 
products with spectral characteristics inconsistent with those expected for 179 and 180. In related 
efforts, the -acetoxy derivative 124 and the 3-methoxy derivatives 121 (as mixtures of 121 and 
121) were found to be unreactive toward SO2Cl2, NCS, NBS, and DDQ in CH2Cl2 or MeCN. These 
results were somewhat unexpected since it was thought that the 3-alkoxy functionality could serve to 
stabilize the intermediate cation B; however, it seems that the electron-withdrawing properties of the 
C3 substituents of 117, 121, and 124 disfavour the formation of chlorosulfonium ion A.  
An attempt to oxidize the 3-thioaryl derivative 165 (4:1 dr) with SO2Cl2 failed to produce the 
desired unsaturated ester 181 and, unexpectedly, generated the 3-chloro derivatives 117 and 117. 
Although unintended, the substitution reaction indicates that oxidations may be possible with NCS, 
NBS, DDQ, or other reagents and more polar solvents and higher temperatures could be explored.  
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4.4 7-Monochloro- and 7-Hydroxymethyl Cyclobutanone Derivatives 
Although the dichlorocyclobutanones are generally much better inhibitors than their dechlorinated 
counterparts, dichlorocyclobutanones are susceptible to ring-opening by nucleophiles and have poor 
stability in aqueous solution at neutral pH. These undesirable properties indicated that modifications 
at C7 should be explored.    
With the high electrophilicity and reactivity of the dichlorocyclobutanones and the poorer 
inhibition of the dechlorinated cyclobutanones, the first C7-modified derivatives to be considered 
were monochlorocyclobutanones. In addition to the greater stability at neutral pH expected from 
monochlorocyclobutanones, -lactamase inhibition by a monochloro derivative was reported by 
Lowe and Swain. The 7-chloro-2-oxacyclobutanone 61 showed time-dependent inhibition of the 
class A enzymes R-TEM-2 and BcI.530,531  
Other modifications that have been considered for potential -lactamase inhibitors are the 7-
acylamino functionality of penams and cephems and the hydroxyalkyl group of carbapenems (Figure 
53). While both of these functional groups have the potential to improve inhibition through 
favourable hydrogen bonding interactions in -lactamase active sites, the carbapenem-mimetic  
 
Figure 53. Modifications at C7 that could potentially improve cyclobutanone stability and affinity for 
-lactamase active sites.  
 
Figure 54. Structure-optimized models of a 7-hydroxymethyl-7-chlorocyclobutanone derivative 
bound to the metallo--lactamase IMP-1 and the class D carbapenemase OXA-48.  
 
143 
Scheme 37. Unsuccessful Mono-Dechlorination Attempts.  
 
sidechain was considered especially interesting because of its potential to interact favourably with 
carbapenemases and its synthetic accessibility. In addition, molecular modeling studies with the 7-
hydroxymethyl derivative 182 indicate that the hydroxymethyl group could be used to interact 
specifically with the conserved zinc-coordinating aspartate residues in MBLs and conserved 
hydrolytic machinery in serine -lactamases (Figure 54). It is thought that the 7-chloride could be 
retained to improve the stability of the enzyme-bound hemiketal or hydrate and a hydroxymethyl 
group may be a better choice for the inhibition of -lactamases than a hydroxyethyl substituent 
because it may provide improved binding to a wider range of enzymes as a result of its flexibility.    
Efforts to prepare monocyclobutanones for inhibition studies were initiated in the early stages of 
the project but progress to this end has been made only recently. Initial efforts to effect the 
monodechlorination of cyclobutanone 84 with 1 equivalent of zinc dust in AcOH, at 70 C or at room 
temperature, resulted in mixtures of the starting material 84 with the di-dechlorinated product 110 and 
each of the monochloro derivatives 183 and 183 and chromatographic separation of each 
constituent was not achieved. Since hydrolysis of the ethyl ester in alkaline conditions would likely 
result in Favorskii ring-contraction588 and acid-catalyzed hydrolysis would cause epimerization, 
attempts were not made to convert the esters 183 into the acids 184. Instead, efforts were made to 
generate the acids 184 and/or 184 directly through the monodechlorination of acid 65. Not 
unexpectedly, a similar mixture of products 111, 184, and 184 was obtained and purification of the 
monochloro isomers was not possible by flash chromatography or through selective crystallizaton.  
It should be noted in passing that the fairly obvious approach to monochlorocyclobutanones 
involving the [2 + 2] cycloaddition of 83 with chloroketene was also unsuccessul despite considerable  
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Scheme 38. Mono-Dechlorinations Using Zinc with TMSCl.  
 
literature precedent for successful [2 + 2] cycloadditions with chloroketene. It is thought that the 
enolization of the cyclobutanone adduct is problematic since Lowe and Swain observed similar issues 
with phthalimidoketene.530,531   
After careful consideration, it was thought that monodechlorination could be achieved efficiently if 
bis-dechlorination were to be prevented by the formation of a silyl enol ether intermediate. Thus, the 
dichlorocyclobutanone 84 was combined with zinc dust and TMSCl in MeCN and heated to 40 C for 
4 hours before the reaction mixture was concentrated and subjected to an aqueous workup. It was 
satisfying to discover that the monochlorocyclobutanone 183 was produced fairly cleanly under 
these conditions (Scheme 38) and, while isomerization occurred upon exposure to aqueous HCl and 
during chromatography, the -chloro isomer 183 was not detected by 1H NMR of the crude reaction 
mixture. The major byproduct of the reaction was the bis-dechlorinated cyclobutanone 110 (ca. 30%) 
but additional experimentation revealed that the formation of 110 could be limited with the use of 
more strictly anhydrous conditions. The application of this method to the benzhydryl ester 149 
generated the monochloro acid 184 in approximately 25% yield (rather than the monochloro ester 
185) and achieved the monodechlorination and deprotection in one operation. Lower yields were 
obtained in subsequent experiments, however, and the relative proportions of the monochloro acid 
184 and ester 185 were also highly variable. The addition of anisole failed to improve the yield of 
184 and 185 and a reaction involving TMS-imidazole instead of TMSCl generated a complex 
mixture. An attempt to apply this method to the -methoxy derivative 151 was also unsuccessful.    
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Scheme 39. Hydroxymethylation of Cyclobutanone Derivatives at C7.  
 
With a method for monodechlorination available, synthetic studies toward 7-hydroxymethyl 
cyclobutanones were undertaken. In collaboration with Ms. Nootaree Niljianskul, an undergraduate 
researcher in this laboratory, the hydroxymethylation conditions first explored involved the treatment 
of 183 (as a mixture of 183 and 183) with paraformaldehyde and Et3N in MeCN at 70 C (Scheme 
39). This operationally simple protocol produced the hydroxymethyl diastereomers 187 and 186 in a 
>5:1 ratio, as indicated by 1H NMR of the crude product, and flash chromatography afforded the 
major isomer in 65% yield. Spectral data and NOE correlations support the conclusion that the major 
stereoisomer was the expected 7-hydroxymethyl derivative 187.  
Despite the realization that the hydroxymethyl derivative 186 could potentially undergo a variety of 
undesired base-induced reactions, including retro-aldol deformylation, Favorskii ring-contraction, and 
epoxidation, attempts were made to convert the ethyl ester 187 to the carboxylic acid 188 through 
alkaline hydrolysis. As anticipated, complex mixtures of products were observed upon exposure of 
187 to KOH (1–5 equiv) in MeOH/H2O or THF/H2O. Efforts to hydrolyze the ethyl esters were 
discontinued after the pleasing discovery that the hydroxymethyl derivative 188 could be prepared 
directly from the monochloro acids 184. The conditions used for the hydroxymethylation of the ethyl 
esters 183 were applied to a mixture of the acids 184 and 184 and the hydroxymethyl acid 188 was 
generated in modest yield. The C7-epimer of 188 was not detected by 1H NMR.  
Recent biochemical assays indicate that the hydroxymethyl acid 188 is a reasonable inhibitor of the 
recently acquired metallo--lactamase NDM-1 (IC50 = 55 M). This result should be considered only 
preliminary, however, since the sample of 188 tested was of questionable purity. More detailed 
inhibition studies with NDM-1 and other -lactamases are in progress.      
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65 74   76 ± 8 >1000 >1000 25 ± 3 268 ± 8 
111 0   117 ± 13   235 ± 14 >1000 44 ± 3 1135 ± 33 
184 nd c >500 260 >500 >500 >500 
a IC50 values (M). b For comparisons to C3-alkoxy derivatives and penem analogues, see 
Table 6. c nd = not determined.  
Preliminary biochemical assays with 184 indicate that the monochloro derivative is a poorer -
lactamase inhibitor than the dichloro acid 65 and the dechlorinated acid 111 (Table 9). These 
somewhat surprising results may be an indication that the interaction of the 7-Cl with residues in -
lactamase active sites are disfavourable and suggest that the -chloro isomer 184 may show greater 
affinity for these enzymes. Greater insight might also be gained with investigations of the tendency of 
184 and 184 to undergo hydrate formation and the extent to which isomerization occurrs under the 
assay conditions.  
4.5 Summary and Outlook 
Ab initio molecular orbital calculations, which indicated that C3-thioalkyl and C3-alkyl 
cyclobutanone derivatives have relatively weak preferences for endo or exo envelope conformations, 
encouraged synthetic studies toward such analogues since it is possible that conformational flexibility 
could improve affinity for -lactamase active sites. As an extension of the methodology developed for 
substitutions at C3 with alcohols, C3-thioalkyl and C3-alkyl analogues were prepared from 3-chloro 
derivatives through SnCl4- or TiCl4-promoted substitutions with thiols or allyltrimethylsilane. 
Substitutions were efficient with the ethyl ester derivatives but were unsuccessful with Lewis acid-
sensitive benzhydryl esters. As a result, alternate protection of the C4-carboxylate is required and 
further synthetic efforts toward C3-thioalkyl and C3-alkyl cyclobutanone analogues may involve the 
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use of benzyl-, para-nitrobenzyl-, or allyl esters as protective groups.    
In order to explore modifications at C7 which have the potential to improve inhibition and 
cyclobutanone stability, a method for the monodechlorination of dichlorocyclobutanones was 
developed. Although the 7-chloro cyclobutanone 184 showed poor inhibition relative to its 
dichloro and dechlorinated counterparts, the monochloro derivative served as a precursor for the 
synthesis of a 7-hydroxymethyl cyclobutanone 188 that was designed to interact with specific 
residues in the active sites of both serine- and metallo--lactamases. Preliminary biochemical data 
with cyclobutanone 188 is encouraging and additional 7-hydroxymethyl-7-chloro analogues should 
be prepared and evaluated for -lactamase inhibition and for synergy with -lactams against resistant 






5.1 General Synthetic Experimental Procedures 
Chemical shifts in 1H NMR and 13C NMR spectra are reported in parts per million (ppm) relative to 
tetramethylsilane (TMS), with calibration of the residual solvent peaks according to values reported 
by Gottlieb et al. (chloroform: H 7.26, C 77.0 (exception); acetone: H 2.05, C 29.84, 206.26; 
acetone in water: H 2.22, C 30.89, 215.94; acetonitrile: H 1.94, C 1.32, 118.26; methanol: H 3.31, 
C 49.00; DMSO: H 2.50, C 39.52, ).680 19F NMR chemical shifts are reported relative to CFCl3 ( 0) 
using a TFA external standard. 31P NMR chemical shifts are reported relative to H3PO4 ( 0) using an 
H3PO4 external standard. When peak multiplicities are given, the following abbreviations are used: s, 
singlet; d, doublet; t, triplet; q, quartet; sept., septet; dd, doublet of doublets; m, multiplet; br, broad; 
app., apparent; gem, geminal. 1H NMR spectra were acquired at 300 MHz and 500 MHz with a digital 
resolution (Brüker parameter: FIDRES) of 0.245 and 0.0993 Hz/point, respectively. The coupling 
constants reported herein therefore have uncertainties of 0.5 Hz and 0.2 Hz at 300 MHz and 500 
MHz, respectively. Assignments of protons and carbons relied on data from 2-dimensional NMR 
experiments including COSY, HMQC, and HMBC. Melting points (mp) are uncorrected. Reactions 
were carried out at room temperature (rt) if temperature is not specified. All reactions were done 
under an atmosphere of either nitrogen or argon, with the exception of selected reactions done in 
aqueous media. For the purification of compounds by flash chromatography, 230–400 mesh (40–63 
M) flash silica was used (Silicycle, Québec, QC). Figures of X-ray crystal structures were generated 
with Mercury.681  
5.2 General Molecular Modeling Procedures 
Ab initio calculations made use of GaussView682 and Gaussian-03.623 Determination of energy 
differences between conformations involved an optimization and frequency calculation followed by 
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addition of the zero-point energy correction for each conformation. All optimized structures were 
checked for zero imaginary frequencies and all transition states for one imaginary frequency. In 
addition, IRC calculations were done for HF/6-31G(d)-optimized transition states. All optimizations 
using Gaussian were done in the gas phase. 
The Sybyl 7.2 modeling package683 was used for least-squared superimpositions of small 
molecules, for docking of inhibitors to enzyme active sites, and for structural optimizations of 
enzyme–inhibitor complexes. Structural optimizations used the MMFF94 force field and included the 
inhibitor and monomers (amino acid residues and waters) within a 6 Å radius of the inhibitor.  
PyMOL was used to generate graphics of selected structures of small molecules and of enzyme–
inhibitor complexes.684  
5.3 Synthetic Procedures 
Triethyl Phosphonoacetate (103) 
 
As a modification of the procedure reported by Wolinsky and Erickson,591 ethyl bromoacetate (102) 
(35.02 g, 209.7 mmol) and triethyl phosphite (36.10 g, 217.2 mmol) were combined neat at rt. The 
mixture was slowly heated to 90 °C over 2 h593 and stirred at this temperature for an additional 22 h. 
The crude product was distilled under reduced pressure to afford phosphonate 103 as a colourless oil 
(46.09 g, 205.6 mmol, 98%). Bp: 89–90 °C/~0.1 mmHg. 1H NMR (300 MHz, CDCl3):  1.29 (t, J = 
7.1 Hz, 3H, CO2CH2CH3), 1.35 (t, J = 7.1 Hz, 6H, P(OCH2CH3)2), 2.97 (d, 
2JP,H = 21.6 Hz, 2H, 
PCH2), 4.18–4.22 (m, 6H, P(OCH2CH3)2 and CO2CH2CH3). 
13C NMR (75.5 MHz, CDCl3):  14.0, 
16.3 (d, 3JP,C = 6.2 Hz), 34.3 (d, 
1JP,C = 133.4 Hz), 61.5, 62.6 (d, 
2JP,C = 6.3 Hz), 165.8 (d, 
2JP,C = 6.0 
Hz). 31P NMR (121.5 MHz, CDCl3):  21.4. LRMS (EI) m/z (relative intensity): 224 (M+, 20), 197 
(100), 179 (85), 152 (50), 151 (55), 123 (65). 
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In a similar procedure to that described above, methyl bromoacetate (104) (50.04 g, 327.1 mmol) 
and triethyl phosphite (54.72 g, 329.3 mmol) were combined neat at rt. The mixture was slowly 
heated to 85 °C over 1.5 h593 and stirred at this temperature for an additional 12 h. The reaction 
mixture was cooled to rt before volatile material was removed under reduced pressure and the crude 
phosphonate 105 (estimated to be 97% pure by 1H NMR) was used in the next step without further 
purification. 1H NMR (300 MHz, CDCl3):  1.33 (t, J = 7.1 Hz, 6H, P(OCH2CH3)2), 2.95 (d, 2JP,H = 
21.6 Hz, 2H, PCH2), 3.73 (s, 3H, CO2CH3), 4.10–4.21 (m, 4H, P(OCH2CH3)2). 
















Following a published procedure,577 phosphonate 103 (46.09 g, 205.6 mmol) was added to a 
solution of paraformaldehyde (12.35 g, 411.3 mmol) and piperidine (2.05 mL, 20.6 mmol) in MeOH 
(500 mL) over 30 min at rt using a pressure-equalized dropping funnel. The suspension was heated to 
reflux for 24 h and the solvent was then removed under reduced pressure to give the primary 
alcohol.594 The crude oil was taken up in PhMe (500 mL), treated with TsOH·H2O (3.918 g, 20.60 
mmol), and the solution heated to reflux under a Dean–Stark trap.595 At 16 h the solution was 
concentrated and distilled under reduced pressure to give the vinyl phosphonate 93 as a clear, dull 
yellow oil (44.00 g, 186.3 mmol, 91% over 2 steps). Bp 98–100 °C/~0.2 mmHg. 1H NMR (300 MHz, 
CDCl3):  1.33 (m, 9H, P(OCH2CH3)2 and CO2CH2CH3), 4.08–4.25 (m, 4H, P(OCH2CH3)2), 4.29 (q, 
J = 7.2 Hz, 2H, CO2CH2CH3), 6.75 (dd, Jgem = 1.9 Hz, 
3JP,Hcis = 20.5 Hz, 1H, H3cis), 7.00 (dd, Jgem = 
1.9 Hz, 3JP,Htrans = 41.9 Hz, H3trans). 
13C NMR (75.5 MHz, CDCl3):  14.0, 16.3 (d, 3JP,C = 6.3 Hz), 
61.5, 62.7 (d, 2JP,C = 5.9 Hz), 133.2 (d, 
1JP,C = 186.2 Hz), 143.2 (d, 
3JP,C = 4.8 Hz), 163.8 (d, 
2JP,C = 
16.2 Hz). 31P NMR (121.5 MHz, CDCl3):  13.7. 
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Methyl-2-(diethoxyphosphoryl) Acrylate (94) 
 
Phosphonate 105 (25.90 g, 123.2 mmol) was added dropwise to a suspension of paraformaldehyde 
(7.398 g, 246.4 mmol) and piperidine (1.25 mL, 12.6 mmol) in MeOH (250 mL) at rt. The reaction 
mixture was slowly heated to reflux over 3 h and maintained at this temperature for an additional 12 h 
before the solvent was removed under reduced pressure to give the primary alcohol. The crude oil 
was taken up in PhMe (250 mL), treated with TsOH·H2O (2.405 g, 12.61 mmol), and the solution 
heated to reflux under a Dean–Stark trap.595 After 12 h at reflux the solution was concentrated and 
distilled under reduced pressure to give the vinyl phosphonate 94 as a clear, colourless oil (21.40 g, 
96.32 mmol, 78% over 2 steps). Bp 98–100 °C/~0.2 mmHg. 1H NMR (300 MHz, CDCl3):  1.34 (t, 
6H, P(OCH2CH3)2), 3.83 (s, 3H, CO2CH3), 4.13–4.21 (m, 4H, P(OCH2CH3)2), 6.74 (dd, Jgem = 1.9 Hz, 
3JP,Hcis = 20.5 Hz, 1H, H3cis), 6.99 (dd, Jgem = 1.9 Hz, 
3JP,Htrans = 41.9 Hz, H3trans).  
Ethyl 2,5-Dihydrothiophene-3-carboxylate (81)  
 
Similar to the procedures developed by McIntosh and Sieler for the synthesis of 
dihydrothiophenes,576,577 a solution of the vinyl phosphonate 93 (44.00 g, 186.29 mmol) in dry 
CH2Cl2 (100 mL) was added to a suspension of p-dithiane-2,5-diol (14.18 g, 93.17 mmol) and Et3N 
(26.4 mL, 188.64 mmol) in dry CH2Cl2 (200 mL) over 30 minutes using a pressure-equalized 
dropping funnel. The solution was stirred at reflux for 6 h before it was cooled to rt, acidified to pH 1 
with 5% HCl, and extracted with CH2Cl2 (3 × 100 mL). The organic phase was dried over Na2SO4 
and concentrated under reduced pressure. Caution: the dihydrothiophene product is somewhat 
volatile. Flash chromatography (20% EtOAc/hexane) gave dihydrothiophene 81 as a pale yellow oil 
(22.17 g, 140.12 mmol, 75%). 1H NMR (300 MHz, CDCl3):  1.30 (t, J = 7.2 Hz, 3H, CO2CH2CH3), 
3.92 (s, 4H, CH2SCH2), 4.22 (q, J = 7.2 Hz, 2H, CO2CH2CH3), 6.89 (brs, 1H, H4). 
13C NMR (75.5 
MHz, CDCl3):  14.2, 37.1, 38.9, 60.8, 135.7, 140.4, 163.9.  IR (film, cm–1): 2982, 2908, 1715, 1645, 
1334, 1263, 1211, 1079. LRMS (EI) m/z (relative intensity): 160 (M+2, 5), 158 (M+, 100), 129 (50), 
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113 (30), 85 (80), 84 (30).  












Similar to the procedures described above, a solution of vinyl phosphonate 94 (48.78 g, 208.6 
mmol) in dry CH2Cl2 (50 mL) was added slowly to a suspension of p-dithiane-2,5-diol (15.89 g, 
104.4 mmol) and Et3N (32.0 mL, 229 mmol) in dry CH2Cl2 (200 mL) over 30 minutes using a 
pressure-equalized dropping funnel. The solution was stirred at reflux for 21 h before it was cooled to 
rt, acidified to pH 1 with 5% HCl, and extracted with CH2Cl2 (2 × 200 mL). The organic phase was 
dried over Na2SO4, filtered through Celite, and concentrated under reduced pressure. Caution: the 
dihydrothiophene product is somewhat volatile. Flash chromatography (10% EtOAc/hexane) gave 
dihydrothiophene 95 as a pale yellow oil (21.94 g, 152.2 mmol, 73%). 1H NMR (300 MHz, CDCl3):  
3.75 (s, 3H, CO2CH3), 3.87–3.93 (brs, 4H, CH2SCH2), 6.85–6.93 (brs, 1H, H4).  
2,5-Dihydrothiophene-3-carboxylic Acid (82)  
 
Ethyl ester 81 (7.699 g, 48.66 mmol) was stirred in a solution of 25% aqueous NaOH (80 mL) at 70 
°C for 16 h. The reaction mixture was then cooled to rt before it was washed with CH2Cl2 (2 × 50 
mL). The aqueous phase was acidified with concentrated HCl, extracted with CH2Cl2 (3 × 200 mL), 
dried with Na2SO4, and concentrated in vacuo to give the title compound 82 as a light yellow powder 
(5.40 g, 41.49 mmol, 85%). An analytical sample was obtained by recrystallization from 
EtOAc/hexane. Mp 169–170 C (lit.580 mp 174–176 °C). 1H NMR (300 MHz, CDCl3):  3.94 (s, 4H, 
CH2SCH2), 7.03 (s, 1H, H4). 
13C NMR (75.5 MHz, CDCl3):  36.7, 39.1, 134.9, 143.7, 169.1. IR 
(film, cm–1): 3044, br 3200–2800, 1684, 1645, 1278. LRMS (EI) m/z (relative intensity): 130 (M+, 




Alternatively, the acid 82 could be obtained through hydrolysis of the methyl ester 95. The methyl 
ester 95 (21.94 g, 152.2 mmol) was stirred in a solution of 25% aqueous NaOH (50 mL) at 85 °C for 
2.5 h. The reaction mixture was then cooled to rt before it was washed with CH2Cl2 (100 mL). The 
aqueous phase was acidified with concd HCl and extracted with CH2Cl2 (4 × 200 mL), dried with 
Na2SO4, and concentrated in vacuo to give the title compound 82 as an off-white powder (18.47 g, 
141.8 mmol, 93%) with identical spectral characteristics as those reported above.  
Ethyl 2,3-Dihydrothiophene-3-carboxylate (83)  
 
To a stirring solution of conjugated acid 82 (992.7 mg, 7.626 mmol) and Et3N (2.302 g, 22.75 
mmol) in CH2Cl2 (20 mL) was added a solution of ethyl chloroformate (1.732 g, 15.96 mmol) in 
CH2Cl2 (15 mL) dropwise over 5 minutes.  The solution was stirred at rt for 24 h before it was 
washed with 5% HCl (50 mL), sat. NaHCO3 (50 mL), and brine (50 mL). The organic solvent was 
dried with Na2SO4 before it was removed under reduced pressure. Caution: The deconjugated ester 
product is somewhat volatile. The crude product was purified by flash chromatography (20% 
EtOAc/hexane) to give the deconjugated ester 83 (1.136 g, 7.177 mmol, 94%). 1H NMR (300 MHz, 
CDCl3):  1.29 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.40 (dd, J = 10.3 Hz, Jgem = 11.5 Hz, 1H, one of 
SCH2), 3.63 (dd, J = 8.2 Hz, Jgem = 11.5 Hz, 1H, one of SCH2), 3.92–3.95 (m, 1H, H3), 4.19 (q, J = 
7.1 Hz, 2H, CO2CH2CH3), 5.63 (dd, J4,3 = 2.8 Hz, J4,5 = 5.9 Hz, 1H, H4), 6.28 (dd, J5,3 = 2.4 Hz, J5,4 = 
5.9 Hz, 1H, H5). 
13C NMR (75.5 MHz, CDCl3):  14.2, 33.2, 52.9, 61.2, 120.2, 128.5, 172.0. IR (film, 
cm–1): 3072, 2982, 1732, 1645, 1575, 1188, 1048. LRMS (EI) m/z (relative intensity): 160 (M+2, 2), 




Ethyl 7,7-Dichloro-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylate (84)  
 
To a stirring solution of deconjugated ester 83 (5.986 g, 37.83 mmol) and Et3N (13.4 mL, 95.7 
mmol) in dry hexane (350 mL) was added a solution of dichloroacetyl chloride (9.10 mL, 94.6 mmol) 
in hexane (40 mL) over 3 h at rt using a motor-driven syringe pump. The reaction mixture was stirred 
for an additional 21 h before it was filtered through Celite. The filter cake was rinsed with hexane and 
the filtrate washed with 5% HCl (3 × 100 mL), sat. NaHCO3 (3 × 100 mL), and brine (100 mL). The 
organic phase was dried over Na2SO4 before the solvent was removed in vacuo. Flash 
chromatography (5% Et2O/hexane) afforded the cycloadduct 84 as a pale yellow oil which 
crystallized upon storage at 4 C (6.645 g, 24.69 mmol, 65%). Mp: 32–33 C. 1H NMR (300 MHz, 
CDCl3):  1.28 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.05 (dd, Jgem = 12.4 Hz, J3,4 = 5.8 Hz, 1H, H3), 
3.45 (d, Jgem = 12.4 Hz, 1H, H3), 3.66 (d, J4,3 = 5.8 Hz, 1H, H4), 4.20 (q, J = 7.1 Hz, 2H, 
CO2CH2CH3), 4.52 (d, J1,5 = 8.3 Hz, 1H, H1), 5.07 (d, J5,1 = 8.3 Hz, 1H, H5). 
13C NMR (75.5 MHz, 
CDCl3):  14.1, 35.6, 50.1, 58.9, 62.1, 67.4, 89.2, 169.8, 194.8. IR (film, cm–1): 2983, 1810, 1732, 
1445, 1370, 1331, 1213, 1025. LRMS (EI) m/z (relative intensity): 272 ([M(37Cl2)]
+, 7), 270 
([M(37Cl35Cl)]+, 35), 268 ([M(35Cl2)]
+, 50), 222 (15), 208 (45), 194 (40), 180 (20), 135 (40), 85 (100). 
HRMS (EI) m/z: 267.9728 calcd for C9H10
35Cl2O3S; 267.9726 obsd.  








Small amounts of the 4 epimer were isolated by chromatography from reactions in which Et3N 
was added to a solution of the dihydrothiophene with dichloroacetyl chloride. 109: 1H NMR (300 
MHz, CDCl3):  1.31 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.10 (B of ABX, Jgem = 12.0 Hz, J3,4 = 7.6 
Hz, H3), 3.14 (A of ABX, Jgem = 12.0 Hz, J3,4 = 10.5 Hz, H3), 3.28 (dt, J4,3 = 7.6 Hz, J4,3 = 10.5 
Hz, J4,5 = 7.6 Hz, H4), 4.23 (B of ABX3, JBA = 10.8 Hz, JBX = 7.2 Hz, one of CO2CH2CH3), 4.28 (A of 
ABX3, JAB = 10.8 Hz, JAX = 7.2 Hz, one of CO2CH2CH3), 4.45 (d, J1,5 = 8.4 Hz, H1), 4.81 (dd, J5,1 = 
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8.4 Hz, J5,4 = 7.6 Hz, H5). 
13C NMR (75.5 MHz, CDCl3):  14.0, 33.3, 51.4, 58.2, 61.8, 66.1, 89.7, 
168.3, 193.3. 
Ethyl 2-Thiabicyclo[3.2.0]heptan-6-one-4-carboxylate (110) 
 
To a stirring solution of dichlorocyclobutanone 84 (800.5 mg, 2.974 mmol) in glacial acetic acid 
(25 mL) was added zinc dust (972.1 mg, 14.87 mmol). The reaction mixture was stirred at 80 °C for 5 
h before it was cooled, diluted with EtOAc, and filtered to remove residual zinc. The solvents were 
removed under reduced pressure before the crude oil taken up in EtOAc (75 mL), washed with satd 
Na2CO3 (2 × 75 mL) and brine (2 × 75 mL), dried over Na2SO4, and concentrated in vacuo. The crude 
yellow product was purified by flash chromatography (10% EtOAc/hexane) to give the title 
compound 110 as a colourless oil (510.2 mg, 2.548 mmol, 86%). 1H NMR (300 MHz, CDCl3):  1.27 
(t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.98 (dt, J7,5 = 3.3 Hz, J7,1
 = 3.3 Hz, Jgem = 18.7 Hz, 1H, H7), 3.21 
(dd, Jgem
 = 12.2 Hz, J3,4 = 5.9 Hz, 1H, H3), 3.45 (d, Jgem = 12.2 Hz, 1H, H3), 3.57 (d, J4,3 = 5.9 Hz, 
1H, H4), 3.63 (ddd, Jgem = 18.7 Hz, J7,1 = 8.3 Hz, J7,5 = 3.6 Hz, 1H, H7), 4.12–4.21 (m, 3H, H1 and 
CO2CH2CH3), 4.63 (m, 1H, H5). 
13C NMR (75.5 MHz, CDCl3):  14.0, 35.3, 36.9, 50.0, 56.5, 61.5, 
71.5, 170.8, 208.4.  IR (film, cm–1): 2982, 1784, 1732, 1446, 1369, 1331, 1214, 1027. LRMS (EI) m/z 
(relative intensity): 200 (M+, 12), 158 (40), 99 (10), 85 (100). HRMS (EI) m/z: 200.0507 calcd for 
C9H12O3S; 200.0497 obsd. 
7,7-Dichloro-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylic Acid (65) 
 
Ethyl ester 84 (1.323 g, 4.916 mmol) was dissolved in dioxane (10 mL) and stirred with 6 M HCl 
(20 mL) at 80 °C for 6 h. The reaction mixture was cooled to rt, extracted with CH2Cl2 (3 × 20 mL), 
and dried with Na2SO4 before the solvent was removed in vacuo. The crude beige-coloured solid was 
recrystallized from PhMe to give dichlorocyclobutanone 65 (936.1 mg, 3.883 mmol, 79%) as light 
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yellow needles. Mp 160–161 °C. 1H NMR (300 MHz, acetone-d6):  3.06 (dd, Jgem = 12.4 Hz, J3,4 = 
5.9 Hz, 1H, H3), 3.50 (d, Jgem = 12.4 Hz, 1H, H3), 3.81 (d, J4,3 = 5.9 Hz, 1H, H4), 4.69 (d, J1,5 = 8.5 
Hz, 1H, H1), 5.14 (d, J5,1 = 8.5 Hz, 1H, H5). 
13C NMR (75.5 MHz, acetone-d6):  36.3, 50.7, 59.5, 
68.6, 90.2, 171.3, 196.0. IR (film, cm–1): br 3200–2600, 2951, 1810, 1700, 1453, 1417, 1262, 1190. 
LRMS (EI) m/z (relative intensity): 244 (M[(37Cl2)]
+, 5), 242 ([M(37Cl35Cl)]+, 27), 240 ([M(35Cl2)]
+, 
38), 222 (10), 194 (20), 180 (60), 141 (40), 130 (40), 85 (100). HRMS (EI) m/z: 239.9415 calcd for 
C7H6
35Cl2O3S; 239.9421 obsd. 
Ethyl 2-Thiabicyclo[3.2.0]heptan-6-one-4-carboxylic Acid (111) 
 
Zinc dust (293.4 mg, 4.486 mmol) was added to a stirring solution of dichlorocyclobutanone 65 
(212.1 mg, 0.8798 mmol) in glacial acetic acid (25 mL) at rt before it was heated to 80 C. An 
additional portion of zinc dust was added after 1.5 h (293.0 mg, 4.481 mmol) and the suspension was 
stirred for an additional 16 h before it was cooled to rt. The solution was diluted with EtOAc (100 
mL) and filtered through glass wool to remove residual solid before concentration under reduced 
pressure. The resulting oil was re-dissolved in EtOAc (50 mL) and washed with 10% HCl (2 × 50 
ml). The organic phase was then dried over Na2SO4 and the solvent removed under reduced pressure. 
Trituration with CH2Cl2/hexane provided the product 111 as a white solid (134.0 mg, 0.7782 mmol, 
88%). Mp 98–100 C. 1H NMR (300 MHz, acetone-d6):  2.85 (ddd, Jgem = 18.4 Hz, J7,1 = 3.2 Hz, 
J7,5 =
 3.2 Hz, 1H, H7), 3.22 (dd, Jgem = 12.1 Hz, J3,4 = 5.9 Hz, 1H, H3), 3.44 (d, Jgem = 12.1 Hz, 1H, 
H3), 3.56 (d, J4,3 = 5.9 Hz, 1H, H4),  3.70 (ddd, Jgem = 18.3 Hz, J7,1 = 8.2 Hz, J7,5 = 3.5 Hz, 1H, 
H7) 4.17 (ddd, J1,5 = 8 Hz, J1,7 = 8.2 Hz, J1,7 = 3.5 Hz, 1H, H1), 4.64 (m, 1H, H5). 
13C NMR (75.5 
MHz, acetone-d6):  35.6, 37.5, 50.3, 56.6, 72.3, 172.4, 208.4. IR (film, cm–1): br 3200–2600, 2933, 
1780, 1705, 1383, 1252. LRMS (EI) m/z (relative intensity): 174 ([M+2]+, 2.7), 173 ([M+1]+, 4.4), 




Ethyl 3,7,7-Trichloro-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylate (117)  
 
To a stirring solution of dichlorocyclobutanone 84 (1.005 g, 3.735 mmol) in dry CH2Cl2 (45 mL) at 
0 °C was added a solution of SO2Cl2 (1 M in CH2Cl2, 4.50 mL, 4.50 mmol). The solution was stirred 
at rt for 4 h before it was concentrated under reduced pressure to give 117 as a white crystalline 
solid (1.132 g, 3.729 mmol, 99.8%). Mp 84–87 °C. 1H NMR (300 MHz, CDCl3):  1.30 (t, J = 7.1 
Hz, 3H, CO2CH2CH3), 3.97 (dd, J4,3 = 4.8 Hz, J4,5 = 5.8 Hz, 1H, H4), 4.23 (B of ABX3, JAB = 10.8 Hz, 
JBX = 7.1 Hz, 1H, one of CO2CH2CH3), 4.26 (A of ABX3, JAB = 10.8 Hz, JAX = 7.1 Hz, 1H, one of 
CO2CH2CH3), 4.94 (d, J1,5 = 8.3 Hz, 1H, H1),  5.20 (dd, J5,1 = 8.3 Hz, J5,4 = 5.8 Hz, 1H, H5) 5.87 (d, 
J3,4 = 4.8 Hz, 1H, H3). 
13C NMR (75.5 MHz, CDCl3):  14.0, 59.8, 60.0, 62.5, 65.5, 74.1, 85.0, 
166.2, 192.0. IR (film, cm–1): 2985, 1815, 1740, 1372, 1266, 1236, 1212. LRMS (EI) m/z (relative 
intensity): 306 (M[(37Cl2
35Cl)]+, 1), 304 ([M(37Cl35Cl2)]
+, 2), 302 ([M(35Cl3)]
+, 2), 267 (10), 259 (15), 
207 (100), 169 (50), 131 (55), 99 (90). HRMS (EI) m/z: 301.9338 calcd for C9H9
35Cl3O4S; 301.9336 
obsd. 









The 3-chloro isomer 117 was observed as a by-product in most solvolysis reactions in alcohol, 
substitution reactions with AgOTf, and elimination attempts involving 117. Although 117 was, for 
the most part, unstable to chromatography, a small amount could be isolated in a nearly pure form 
(98%) from chromatography of the reaction mixture resulting from: 117 in t-BuOH  123 (major) 
+ 123 (minor) + 117 (minor) + 118 (minor). 117: 1H NMR (300 MHz, CDCl3):  1.31 (t, J = 7.1 
Hz, 3H, CO2CH2CH3), 4.08 (s, 1H, H4), 4.23 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.72 (d, J1,5 = 8.7 Hz, 
1H, H1), 5.15 (d, J5,1 = 8.7 Hz, 1H, H5), 6.14 (s, 1H, H3). 
13C NMR (125 MHz, CDCl3):  14.0, 61.4, 
62.3, 62.9, 65.9, 71.5, 89.7, 167.1, 192.7. 
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Ethyl 7,7-Dichloro-2-thiabicyclo[3.2.0]hept-3-ene-6-one-4-carboxylate (118)  
 
A solution of cyclobutanone 117 (105.0 mg, was 0.346 mmol) in CH2Cl2 (2 mL) was slowly 
added to a stirring solution of AgOTf (104.1 mg, 0.405 mmol) in refluxing CH2Cl2 (20 mL) dropwise 
over 10 minutes.  After 2 h at reflux, the solution was cooled to rt, diluted with CH2Cl2, filtered 
through Celite, and concentrated in vacuo. Purification by flash chromatography (10% EtOAc/ 
hexane) furnished the elimination product 118 as a colourless oil that solidified under reduced 
pressure (74.4 mg, 0.279 mmol, 81%). Mp 75–76 °C. 1H NMR (300 MHz, CDCl3):  1.31 (t, J = 7.1 
Hz, 3H, CO2CH2CH3), 4.21 (B of ABX3, JAB = 10.7 Hz, JBX = 7.1 Hz, 1H, one of CO2CH2CH3), 4.24 
(A of ABX3, JAB = 10.7 Hz, JAX = 7.1 Hz, 1H, one of CO2CH2CH3), 4.89 (d, J1,5 = 10.0 Hz, 1H, H1) 
5.43 (dd, J5,1 = 10.0 Hz, J5,3 = 1.7 Hz, 1H, H5), 7.43 (d, J3,5 = 1.7 Hz, 1H, H3). 
13C NMR (75.5 MHz, 
CDCl3):  14.2, 59.6, 61.2, 71.3, 93.8, 122.2, 144.4, 161.1, 187.4. IR (film, cm–1): 3075, 2984, 1812, 
1705, 1576, 1370, 1327, 1238, 1078. LRMS (EI) m/z (relative intensity): 268 ([M(37Cl35Cl)]+, 1.5), 
266 ([M(35Cl2)]
+, 2.0), 238 (20), 203 (100), 175 (40). HRMS (EI) m/z: 265.9571 calcd for 
C9H8
35Cl2O3S; 265.9572 obsd.  
 
The unsaturated ester 118 could also be prepared from 117 using MsOH. Methanesulfonic acid (2 
mL) was added to a solution of the -chloride 117 (304.5 mg, 1.003 mmol) in CH2Cl2 (18 mL) and 
the solution was heated to reflux for 2 h. The reaction was cooled to rt, diluted with CH2Cl2 (70 mL), 
and washed with satd NaHCO3 (2  50 mL) and brine (25 mL). The organic phase was dried over 
Na2SO4, concentrated under reduced pressure, and filtered through silica to provide the title 
compound 118 as a clear light yellow oil that solidified under vacuum (194.2 mg, 0.7269 mmol, 




Alternatively, the unsaturated ester 118 could be prepared from thiolactol 119. TsOHH2O (10.9 
mg, 0.057 mmol) was stirred in PhMe (40 mL) and heated at reflux under a Dean–Stark trap595 for 2 
h. (Note: incomplete conversion was observed if the TsOH was not predried). The thiolactol 119 
(83.7 mg, 0.294 mmol) was then added as a solution in PhMe (2 mL) and stirred at reflux for an 
additional 18 h. The solution was concentrated under reduced pressure and purified by flash 
chromatography (10% EtOAc/hexane) to give a colourless oil that crystallized under vacuum (73.8 
mg, 0.276 mmol, 94%).  
Ethyl 7,7-Dichloro-3-hydroxy-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylate (119)  
 
A solution of the trichlorocyclobutanone 117 (57.5 mg, 0.189 mmol) in MeCN (2 mL) was added 
slowly dropwise to a stirring solution of AgOTf (60.1 mg, 0.234 mmol) in MeCN (5 mL) and H2O (2 
mL). The mixture was stirred for 4 h at rt before it was concentrated under reduced pressure, diluted 
with CH2Cl2 (25 mL), and filtered through Celite. The resulting yellow oil was subjected to flash 
chromatography (10% EtOAc/hexane) which provided a colourless oil (48.6 mg, 0.170 mmol, 90%) 
that was determined to be an 88:6:6 mixture of the thiolactol 119, epimer 119, and an oxa-thia-
tricyclo-octane 119c, respectively. Thiolactol 119: 1H NMR (500 MHz, CDCl3):  1.26 (t, J = 7.1 
Hz, 3H, CO2CH2CH3), 2.7–2.9 (brs, 1H, OH), 3.83 (s, 1H, H4), 4.18 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 
4.67 (d, J1,5 = 8.5 Hz, 1H, H1) 5.05 (d, J5,1 = 8.5 Hz, 1H, H5), 5.98 (s, 1H, H3). 
13C NMR (125 MHz, 
CDCl3):   14.0, 59.3, 59.8, 62.3, 65.0, 86.0, 90.4, 167.9, 193.1. IR (film, cm–1): br 3600–3300, 2984, 
1815, 1732, 1246, 1213, 1024. LRMS (EI) m/z (relative intensity): 288 (M[(37Cl2)]
+, 0.4), 286 
([M(37Cl35Cl)]+, 5), 284 ([M(35Cl2)]
+, 8.0), 238 (15), 203 (50), 195 (75), 151 (85), 115 (100). HRMS 
(EI) m/z: 283.9677 calcd for C9H10
35Cl2O4S; 283.9681 obsd. Epimer 119: 1H NMR (500 MHz, 
CDCl3):  1.26 (3H, CO2CH2CH3), 2.7–2.9 (1H, OH), 3.70 (dd, J4,3 = 4.6 Hz, J4,5 = 4.8 Hz, 1H, H4), 
4.18 (2H, CO2CH2CH3), 4.79 (d, J1,5 = 8.4 Hz,  1H, H1) 5.08 (dd, J5,1 = 8.4 Hz, J5,4 = 4.8 Hz,  1H, H5), 
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5.84 (d, J3,4 = 4.6 Hz, 1H, H3). 
13C NMR (125 MHz, CDCl3):   14.0, 57.0, 58.7, 61.6, 65.7, 86.2, 
87.0, 166.8, 192.3.  Oxa-thia-tricyclo-octane 119c: 1H NMR (500 MHz, CDCl3):  1.26 (3H, 
CO2CH2CH3), 2.7–2.9 (1H, OH), 3.7 (m, 1H, H4), 3.97 (m, 1H, H5), 4.18 (m, 2H, CO2CH2CH3), 4.26 
(m, 1H, H1), 5.87 (m, 1H, H3). 
13C NMR (125 MHz, CDCl3):  14.0, 50.1, 55.2, 56.4, 62.3, 86.8, 
90.6, 105.7, 168.4. 
 
Alternatively, 119 could be obtained by hydrolysis of 117 without AgOTf. H2O (15 mL) was 
added to a solution of the 3-Cl cyclobutanone 117 (769.2 mg, 2.534 mmol) in MeCN (15 mL). 
After stirring at rt for 48 h, the solution was concentrated in vacuo to a yellow oil. Flash 
chromatography (10% EtOAc/hexane) afforded a colourless oil (543.2 mg, 1.905 mmol, 75%) with 
identical spectral properties to material prepared in ROH/MeCN: an 88:6:6 mixture of 119, 119, 
and 119c. 
Ethyl 7,7-Dichloro-3-methoxy-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylate (121)  
 
The 3-chlorocyclobutanone 117 (102.2 mg, 0.337 mmol) was dissolved in MeCN (5 mL) and 
stirred with MeOH (5 mL) at rt for 48 h. The solution was concentrated under reduced pressure to 
give a colourless oil that partially crystallized in vacuo. 1H NMR of the crude mixture showed a 
product distribution of 75:24:1 for 121:121:118, respectively. Flash chromatography (5% 
EtOAc/hexane) provided 121 (23.4 mg, 0.0782 mmol, 23%, 98% pure) and a 68:32 mixture of 121 
and 121 (50.3 mg, 0.168 mmol, 50%). 1H NMR (300 MHz, CDCl3):  1.27 (t, J = 7.1 Hz, 3H, 
CO2CH2CH3), 3.32 (s, 3H, OCH3), 3.75 (app. t, J4,3 = 4.5 Hz, J4,5 = 5.5 Hz, 1H, H4), 4.17 (B of 
ABX3, JAB = 10.8 Hz, JBX = 7.1 Hz, 1H, one of CO2CH2CH3), 4.26 (A of ABX3, JAB = 10.8 Hz, JAX = 
7.1 Hz, 1H, one of CO2CH2CH3), 4.66 (d, J1,5 = 8.1 Hz, 1H, H1), 5.17 (dd, J5,4 = 5.5 Hz, J5,1 = 8.1 Hz, 
1H, H5), 5.32 (d, J3,4 = 4.5 Hz, 1H, H3). 
13C NMR (75.5 MHz, CDCl3):  14.1, 56.7, 57.4, 58.7, 61.8, 
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66.4, 85.3, 97.4, 167.3, 193.4. IR (film, cm–1): 2986, 2930, 2831, 1813, 1739, 1464, 1335, 1265, 
1215, 1085, 1021. LRMS (EI) m/z (relative intensity): 302 (M[(37Cl2)]
+, 0.4), 300 ([M(37Cl35Cl)]+, 
1.5), 298 ([M(35Cl2)]
+, 2), 253 (20), 217 (10), 203 (20), 189 (20), 167 (60), 165 (100), 143 (50). 
HRMS (EI) m/z: 297.9833 calcd for C10H12
35Cl2O4S; 297.9827 obsd.  





















The 3-chlorocyclobutanone 117 (104.1 mg, 0.343 mmol) in CH2Cl2 (1 mL) was added dropwise 
over 10 minutes to a suspension of AgOTf (118.3 mg, 0.460 mmol), MeOH (75 L, 1.841 mmol), 
and 3 Å MS (1 g) in CH2Cl2 (8 mL) at 0 °C. The reaction mixture was allowed to warm to rt over 2 h 
and stirred for an additional 4 h at rt before dilution with CH2Cl2 and filtration through Celite. The 
filtrate was concentrated under reduced pressure and 1H NMR of the crude mixture showed a product 
distribution of 22:72:2:4 for 121:121:117:118, respectively. Flash chromatography (5% 
EtOAc/hexane) provided 121 (29.7 mg, 0.099 mmol, 29%) and a 38:62 mixture of 121:121 (32.0 
mg, 0.107 mmol, 31%). 1H NMR (300 MHz, CDCl3):  1.28 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.34 
(s, 3H, OCH3), 3.82 (s, 1H, H4), 4.19 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.59 (d, J1,5 = 8.6 Hz, 1H, H1) 
5.02 (d, J5,1 = 8.6 Hz, 1H, H5), 5.46 (s, 1H, H3). 
13C NMR (75.5 MHz, CDCl3):  14.0, 56.3, 57.9, 
59.4, 62.2, 64.9, 90.4, 95.2, 167.8, 192.7. IR (film, cm–1): 2984, 2934, 2829, 1817, 1734, 1370, 1313, 
1259, 1212, 1086. LRMS (EI) m/z (relative intensity): 302 (M[(37Cl2)]
+, 1), 300 ([M(37Cl35Cl)]+, 5), 
298 ([M(35Cl2)]
+, 8), 263 (30), 252 (20), 217 (40), 203 (100), 189 (90), 169 (55), 165 (55). HRMS 
(EI) m/z: 297.9833 calcd for C10H12
35Cl2O4S; 297.9836 obsd.  
Ethyl 7,7-Dichloro-3-isopropoxy-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylate (122)  
 
The 3-chlorocyclobutanone 117 (197.1 mg, 0.649 mmol) was dissolved in MeCN (8 mL) and 
stirred with i-PrOH (8 mL) at rt for 40 h. The reaction mixture was concentrated in vacuo and 1H 
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NMR of the crude mixture showed a product distribution of 46:20:16:18 for 122:122:117:118, 
with 85% conversion. Flash chromatography (5% EtOAc/hexane) provided 122 (9.7 mg, 0.030 
mmol, 4.6%) and a 77:23 mixture of 122:122  (121.7 mg, 0.372 mmol, 57%). 1H NMR (300 MHz, 
CDCl3):  1.08 (d, J = 6.1 Hz, 3H, one of CHCH3), 1.15 (d, J = 6.1 Hz, 3H, one of CHCH3), 1.28 (t, J 
= 7.1 Hz, 3H, CO2CH2CH3), 3.73 (dd, J4,3 = 4.5 Hz, J4,5 = 5.6 Hz, 1H, H4), 3.79 (sept., J = 6.1 Hz, 
1H, CHMe2), 4.18 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.69 (d, J1,5 = 8.1 Hz, 1H, H1), 5.20 (dd, J5,4 = 
5.6 Hz, J5,1 = 8.1 Hz, 1H, H5), 5.54 (d, J3,4 = 4.5 Hz, 1H, H3). 
13C NMR (75.5 MHz, CDCl3):  14.1, 
20.3, 22.8, 57.5, 58.7, 61.7, 66.7, 70.9, 85.2, 93.3, 167.3, 193.7. IR (film, cm–1): 2977, 2926, 1811, 
1739, 1467, 1371, 1239. LRMS (EI) m/z (relative intensity): 330 (M[(37Cl2)]
+, 3), 328 ([M(37Cl35Cl)]+, 
12), 326 ([M(35Cl2)]
+, 20), 291 (12), 281 (20), 267 (30), 224 (40), 195 (90), 157 (90), 129 (100), 101 
(80). HRMS (EI) m/z: 326.0146 calcd for C12H16
35Cl2O4S; 326.0152 obsd.  
Ethyl 7,7-Dichloro-3-isopropoxy-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylate (122)  
 
The 3-chlorocyclobutanone 117 (200.4 mg, 0.660 mmol) in CH2Cl2 (2 mL) was added dropwise 
over 10 minutes to a suspension of AgOTf (206.2 mg, 0.803 mmol), i-PrOH (265 L, 3.328 mmol), 
and 4 Å MS (1 g) in CH2Cl2 (8 mL) at 0 °C. The reaction mixture was allowed to warm to rt over 2 h 
and stirred for an additional 10 h at rt before dilution with CH2Cl2 and filtration through Celite. The 
filtrate was concentrated under reduced pressure and 1H NMR of the crude mixture showed a product 
distribution of 16:71:2:11 for 122:122:117:118, respectively. Flash chromatography (2.5% 
EtOAc/hexane) provided 122 (63.0 mg, 0.193 mmol, 29%) and a 1:3 mixture of 122:122 (48.5 
mg, 0.148 mmol, 22%). 1H NMR (300 MHz, CDCl3):  1.13 (d, J = 6.1 Hz, 6H, CH(CH3)2), 1.28 (t, J 
= 7.1 Hz, 3H, CO2CH2CH3), 3.75 (s, 1H, H4), 3.98 (sept., J = 6.1 Hz, 1H, CHMe2), 4.19 (q, J = 7.1 
Hz, 2H, CO2CH2CH3), 4.59 (d, J1,5 = 8.4 Hz, 1H, H1) 5.03 (d, J5,1 = 8.4 Hz, 1H, H5), 5.71 (s, 1H, H3). 
13C NMR (75.5 MHz, CDCl3):  14.1, 19.7, 22.4, 57.9, 59.5, 62.2, 65.3, 69.4, 90.1, 90.2, 168.2, 
192.3. IR (film, cm–1): 2977, 1818, 1734, 1374, 1258, 1211. LRMS (EI) m/z (relative intensity): 330 
(M[(37Cl2)]
+, 0.5), 328 ([M(37Cl,35Cl)]+, 2.0), 326 ([M(35Cl2)]
+, 3.5), 291 (20), 267 (15), 238 (25), 205 
(40), 203 (100), 175 (40). HRMS (EI) m/z: 326.0146 calcd for C12H16
35Cl2O4S; 326.0139 obsd.  
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Ethyl 3-tert-Butoxy-7,7-dichloro-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylate (123)  
 
Solid t-BuOH (8 g) was combined with the 3-chlorocyclobutanone 117 (216.9 mg, 0.7145 
mmol) at rt and the reaction mixture was slowly heated to 80 C (with stirring) over 30 minutes. After 
64 h at 80 C, the reaction mixture was concentrated under reduced pressure and 1H NMR of the 
crude mixture showed a product distribution of 37:26:28:9 for 123:123:118:119, respectively. 
Flash chromatography (5% EtOAc/hexane) provided 123 (10.8 mg, 0.0316 mmol, 4.4%, 98% pure) 
and a 58:42 mixture of 123:123  (135.1 mg, 0.396 mmol, 55%). 123: Mp 97–99 °C. 1H NMR 
(300 MHz, CDCl3):  1.21 (s, 9H, C(CH3)3), 1.29 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.70 (app. t, J4,3 
= 5.0 Hz, J4,5 = 5.2 Hz, 1H, H4), 4.09 (B of ABX3, JAB = 10.8 Hz, JBX = 7.1 Hz, 1H, one of 
CO2CH2CH3), 4.24 (A of ABX3, JAB = 10.8 Hz, JAX = 7.1 Hz, 1H, one of CO2CH2CH3), 4.78 (d, J1,5 = 
8.2 Hz, 1H, H1), 5.13 (dd, J5,1 = 8.2 Hz, J5,4 = 5.2 Hz, 1H, H5), 5.75 (d, J3β,4 = 5.0 Hz, 1H, H3β). 
13C 
NMR (75.5 MHz, CDCl3):  14.1, 27.9 (3C), 57.8, 58.8, 61.6, 66.6, 76.8, 85.9, 89.0, 167.5, 193.7.  IR 
(film, cm–1): 2983, 2946, 1808, 1739, 1469, 1370, 1235, 1210, 1179, 1060. LRMS (EI) m/z (relative 
intensity): 344 (M[(37Cl2)]
+, 0.2), 342 ([M(37Cl35Cl)]+, 1.5), 340 ([M(35Cl2)]
+, 2.0), 284 (10), 267 (10), 
238 (10), 203 (10), 57 (100). HRMS (EI) m/z: 340.0303 calcd for C13H18
35Cl2O4S; 340.0294 obsd.  





















The 3-chlorocyclobutanone 117 (201.5 mg, 0.664 mmol) in CH2Cl2 (2 mL) was added dropwise 
over 10 minutes to a suspension of AgOTf (206.0 mg, 0.802 mmol), t-BuOH (497.0 mg, 6.705 
mmol), and 4 Å MS (1 g) in CH2Cl2 (8 mL) at 0 °C. The reaction mixture was allowed to warm to rt 
over 2 h and stirred for an additional 6 h at rt before dilution with CH2Cl2 and filtration through 
Celite. The filtrate was concentrated under reduced pressure and 1H NMR of the crude mixture 
showed a product distribution of 5:42:30:22 for 123:123:117:118, respectively, with 92% 
conversion. Flash chromatography (5% EtOAc/hexane) provided 123 (21.3 mg, 0.0624 mmol, 
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9.4%) and a 86:14 mixture of 123:123  (65.1 mg, 0.191 mmol, 29%). 1H NMR (300 MHz, CDCl3): 
 1.23 (s, 9H, C(CH3)3), 1.28 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.61 (s, 1H, H4), 4.19 (q, J = 7.1 Hz, 
2H, CO2CH2CH3), 4.58 (d, J1,5 = 8.4 Hz, 1H, H1), 4.98 (d, J5,1 = 8.4 Hz, 1H, H5), 5.79 (s, 1H, H3). 
13C NMR (75.5 MHz, CDCl3):  14.1, 27.5 (3C), 59.6 (2C), 62.1, 65.3, 77.5, 86.6, 90.6, 168.2, 193.0. 
IR (film, cm–1): 2980, 2934, 1818, 1735, 1369, 1252, 1209, 1188, 1064, 1027. LRMS (EI) m/z 
(relative intensity): 344 (M[(37Cl2)]
+, 0.2), 342 ([M(37Cl,35Cl)]+, 1.2), 340 ([M(35Cl2)]
+, 1.6), 284 (10), 
238 (15), 203 (30), 57 (100). HRMS (EI) m/z: 340.0303 calcd for C13H18
35Cl2O4S; 340.0302 obsd.  



















The 3-chlorocyclobutanone 117 (53.3 mg, 0.176 mmol) was dissolved in AcOH (4 mL) at rt and 
stirred at 80 °C for 1 h. The solution was cooled, diluted with EtOAc (40 mL), and washed with H2O 
(3 × 40 mL), dried with Na2SO4, and concentrated under reduced pressure to give an amber oil. 
1H 
NMR of the crude mixture showed a product distribution of 3:52:43:2 for 124:124:117:118, 
respectively.685 Purification by flash chromatography (20% EtOAc/hexane) afforded the title 
compound as a dull yellow oil (40.2 mg, 0.123 mmol, 70%) that solidified under vacuum. 1H NMR 
(300 MHz, CDCl3):  1.29 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.02 (s, 3H, COCH3), 3.81 (s, 1H, H4), 
4.21 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.64 (d, J1,5 = 8.6 Hz, 1H, H1) 5.13 (d, J5,1 = 8.6 Hz, 1H, H5), 
6.55 (s, 1H, H3). 
13C NMR (75.5 MHz, CDCl3):  14.0, 20.7, 56.3, 59.6, 62.7, 65.6, 85.8, 90.1, 
167.2, 169.0, 192.9. IR (film, cm–1): 2999, 2956, 1813, 1747, 1740, 1369, 1213, 1022. LRMS (EI) 
m/z (relative intensity): 330 (M[(37Cl2)]
+, 0.4), 328 ([M(37Cl35Cl)]+, 1.5), 326 ([M(35Cl2)]
+, 2.0), 266 
(20), 224 (100), 220 (45), 203 (50), 195 (30). HRMS (EI) m/z: 325.9783 calcd for C11H12
35Cl2O5S; 
325.9786 obsd.  
The 3-acetoxy derivative 124 was not isolated by chromatography and could only be identified 
by three signals in the 1H NMR of the crude reaction mixture: 2.03 (s, 3H, COCH3), 3.84 (dd, H4), 























The 3-chlorocyclobutanone 117 (157.8 mg, 0.5198 mmol) was dissolved in 2,2,2-
trifluoroethanol (6 mL) and stirred at rt for 48 h. The solvent was removed under reduced pressure 
and 1H NMR of the crude mixture showed a product distribution of 125:125:118 of 5:76:19.686 
Flash chromatography (5% EtOAc/hexane) afforded 125 (122.1 mg, 0.3325 mmol, 64%) as a 
colourless oil. 1H NMR (300 MHz, CDCl3):  1.29 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.83 (B of ABF3, 
JBA = 12.4 Hz, JBF = 8.1 Hz, 1H, one of CO2CH2CF3), 3.93 (s, 1H, H4), 4.04 (A of ABF3, JAB = 12.4 
Hz, JAF = 8.9 Hz, 1H, one of CO2CH2CF3), 4.21 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.64 (d, J1,5 = 8.5 
Hz, 1H, H1), 5.08 (d, J5,1 = 8.4 Hz, 1H, H5), 5.76 (s, 1H, H3). 
13C NMR (75.5 MHz, CDCl3):  14.0, 
57.9, 59.7, 62.6, 65.1, 65.2 (q, 2JC,F = 35.0 Hz), 90.0, 94.2, 123.3 (q, 
1JC,F = 279.1 Hz), 167.2, 191.6. 
19F NMR (282.4 MHz, CDCl3):  –72.5. IR (film, cm–1): 2989, 1819, 738, 1371 1278, 1167, 1109. 
LRMS (EI) m/z (relative intensity): 370 (M[(37Cl2)]
+, 0.5), 368 ([M(37Cl35Cl)]+, 2.8), 366 ([M(35Cl2)]
+, 
3.8), 331 (6), 320 (15), 285 (10), 257 (35), 233 (100), 203 (40), 183 (25). HRMS (EI) m/z: 365.9707 
calcd for C11H11
35Cl2F3O4S; 365.9704 obsd.  
Ethyl 2-Thiabicyclo[3.2.0]hept-3-ene-6-one-4-carboxylate (126)  
 
Dichlorocyclobutanone 118 (171.3 mg, 0.641 mmol) was dissolved in AcOH (15 mL), combined 
with zinc dust (216.0 mg, 3.303 mmol), and stirred at 80 °C for 5 h. The reaction mixture was cooled 
to rt, diluted with EtOAc, and filtered through glass wool to remove residual zinc dust. The organic 
solution (75 mL) was washed with 10% HCl (2 × 75 mL) and brine (50 mL) before it was dried over 
Na2SO4 and concentrated. Flash chromatography (10% EtOAc/hexane) provided the dechlorinated 
cyclobutanone 126 as a colourless oil (106.5 mg, 0.537 mmol, 84%). 1H NMR (300 MHz, CDCl3):  
1.25 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.34 (ddd, Jgem = 18.7 Hz, J7,1 = 5.7 Hz, J7,5 = 3.3 Hz, 1H, 
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H7), 3.74 (ddd, Jgem = 18.7 Hz, J7,1 = 8.3 Hz, J7,5 = 5.1 Hz, 1H, H7), 4.11–4.22 (m, 3H, H1 and 
CO2CH2CH3), 5.05–5.14 (m, 1H, H5), 7.43 (s, 1H, H3). 
13C NMR (75.5 MHz, CDCl3):  14.2, 37.0, 
60.7 (2C), 76.0, 121.2, 143.2, 161.8, 200.0. IR (film, cm–1): 3069, 2983, 1790, 1700, 1567, 1370, 
1328, 1305, 1226. LRMS (EI) m/z (relative intensity): 200 ([M+2]+, 2), 199 ([M+1]+, 5), 198 ([M]+, 
40), 170 (10), 156 (40), 141 (40), 128 (60), 111 (100), 97 (25). HRMS (EI) m/z: 198.0351 calcd for 
C9H10O3S; 198.0349 obsd.  
Benzhydryl 7,7-Dichloro-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylate (149)  
 
A solution of diphenyldiazomethane687 (1.0 M in EtOAc, 5.0 mL) was added slowly to a stirring 
solution of acid 65 (1207 mg, 5.004 mmol) in EtOAc (20 mL) and stirred for 2 h at rt before the 
reaction was quenched with acetic acid (2 mL). After stirring for 30 min, the solution was diluted 
with EtOAc to 50 mL and washed with H2O (2 × 20 mL), sat. NaHCO3 (2 × 20 mL), and brine (20 
mL). The organic solution was dried over Na2SO4 and concentrated under reduced pressure to a 
yellow oil that partially crystallized under vacuum. Flash chromatography (10% EtOAc/hexane) 
provided the benzhydryl ester 149 as a white powder (2007 mg, 4.927 mmol, 98%). Mp 95–96 °C. 1H 
NMR (300 MHz, CDCl3):  3.09 (dd, Jgem = 12.4 Hz, J3,4 = 5.8 Hz, 1H, H3), 3.50 (d, Jgem = 12.4 Hz, 
1H, H3), 3.76 (d, J3,4 = 5.8 Hz, 1H, H4), 4.50 (d, J1,5 = 8.3 Hz, 1H, H1), 5.07 (d, J5,1 = 8.3 Hz, 1H, 
H5), 6.87 (s, 1H, CHPh2), 7.28–7.40 (m, 10H, ArH). 
13C NMR (75.5 MHz, CDCl3):  35.6, 50.3, 58.9, 
67.4, 78.7, 89.3, 126.9 (2C), 127.1 (2C), 128.3 (2C), 128.7 (2C), 139.2 (2C), 169.0, 194.6. IR (film, 
cm–1): 3064, 3031, 2933, 1808, 1738, 1495, 1454, 1207, 1177, 742, 699. LRMS (NH3 CI) m/z 
(relative intensity): 428 ([M(37Cl2) + NH4]
+, 1.0), 426 ([M(37Cl35Cl) + NH4]
+, 5.5), 424 ([M(35Cl2) + 
NH4]
+, 7.0), 167 (100).   
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Benzhydryl 7,7-Dichloro-3-methoxy-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylates (151 and 
151)  
 
N-Chlorosuccinimide (261.9 mg, 2.015 mmol) was added as a suspension in CH2Cl2 (5 mL) to a 
stirring solution of the benzhydryl ester 149 (722.1 mg, 1.773 mmol) in CH2Cl2 (20 mL). After 
stirring the solution at rt for 24 h, the solvent was removed under reduced pressure to provide a 
mixture of succinimide and the 3-chloro intermediate as a yellow oily solid. The 3-Cl epimer 150 
was not detected by 1H NMR. 150: 1H NMR (300 MHz, CDCl3):  4.08 (app. t, J4,3 = 4.7 Hz, J4,5 = 
5.9 Hz, 1H, H4), 4.93 (d, J1,5 = 8.3 Hz, 1H, H1), 5.18 (dd, J5,1 = 8.3 Hz, J5,4 = 5.9 Hz, 1H, H5), 5.94 (d, 
J3,4 = 4.7 Hz, 1H, H3), 6.91 (s, 1H, CHPh2), 7.28–7.40 (m, 10H, ArH). 
The intermediate mixture of 150 with succinimide was then dissolved in MeOH (25 mL) and 
stirred at rt for 24 h before concentration in vacuo. The mixture was then dissolved in CH2Cl2 (75 
mL) and washed with H2O (3 × 25 mL) and brine (25 mL) before the solution was dried over Na2SO4 
and concentrated under reduced pressure. The resulting viscous oil was then subjected to high 
vacuum for several hours for the removal of methanol. 1H NMR spectra of the crude mixture showed 
a product distribution of 77:23 for 151:151. Recrystallization from CH2Cl2/hexane provided a pure 
sample of 151 as white needles (195.1 mg, 0.446 mmol, 25%). The mother liquor was concentrated 
and subjected to flash chromatography (10% EtOAc/hexane) to provide the 3-methoxy derivative 
151 as a white solid (37.5 mg, 4.8%) and additional samples of 151/151 mixtures. 151: Mp 
161–163 °C. 1H NMR (300 MHz, CDCl3):  3.15 (s, 3H, OCH3), 3.91 (app. t, J4,3 = 4.6 Hz, J4,5 = 5.4 
Hz, H4), 4.66 (d, J1,5 = 8.2 Hz, H1),  5.21 (dd, J5,1 = 8.2 Hz, J5,4 = 5.4 Hz, H5), 5.39 (d, J3,4 = 4.6 Hz, 
H3), 6.97 (s, 1H, CHPh2), 7.30-7.41 (m, 10H, ArH). 
13C NMR (75.5 MHz, CDCl3):  56.3, 57.4, 
58.6, 66.3, 78.3, 85.2, 97.3, 127.1 (2C), 127.3 (2C), 128.1, 128.2, 128.4 (2C), 128.5 (2C), 139.1, 
139.4, 166.4, 193.1. IR (film, cm–1): 3067, 3033, 2957, 1813, 1744, 1450, 1430, 1285, 1234, 1180, 
1079, 944, 881. LRMS (NH3 CI) m/z (relative intensity): 458 ([M(
37Cl2) + NH4]
+, 10), 456 
([M(37Cl35Cl) + NH4]
+, 35), 454 ([M(35Cl2) + NH4]
+, 55), 420 (15), 184 (40), 167 (100). 151: Mp 
136–139 C. 1H NMR (300 MHz, CDCl3):  3.35 (s, 3H, OCH3), 3.93 (s, 1H, H4), 4.58 (d, J1,5 = 8.5 
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Hz, 1H, H1), 5.03 (d, J5,1 = 8.5 Hz, 1H, H5), 5.51 (s, 1H, H3), 6.86 (s, 1H, CHPh2), 7.26–7.39 (m, 
10H, ArH). 13C NMR (75.5 MHz, CDCl3):  56.3, 58.1, 59.4, 64.9, 78.9, 90.5, 95.0, 127.0 (2C), 127.1 
(2C), 128.3, 128.4, 128.7 (4C), 139.0 (2C), 167.0, 192.5. IR (film, cm–1): 3064, 3032, 2930, 2828, 
1816, 1741, 1600, 1496, 1454, 1304, 1256, 1207, 1176, 1085, 700. LRMS (NH3 CI) m/z (relative 
intensity): 458 ([M(37Cl2) + NH4]
+, 3), 456 ([M(37Cl35Cl) + NH4]
+, 15), 454 ([M(35Cl2) + NH4]
+, 20), 
184 (50), 167 (100).  
7,7-Dichloro-3-methoxy-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylic Acid (152)  
 
TFA (1.0 mL) was added dropwise to a solution of the 3-methoxy benzhydryl ester 151 (190.5 
mg, 0.436 mmol) and anisole (200 L, 1.84 mmol) in CH2Cl2 (10 mL). The solution was stirred for 2 
h at rt before the solvent was removed under reduced pressure. Trituration with hexane provided the 
acid 152 as a white solid (93.8 mg, 0.346 mmol, 79%). Mp 144–147 °C. 1H NMR (300 MHz, 
acetone-d6):  3.34 (s, 1H, OCH3), 3.84 (dd, J4,3 = 4.4 Hz, J4,5 = 6.0 Hz, 1H, H4), 4.77 (d, J1,5 = 8.4 
Hz, 1H, H1), 5.13 (dd, J5,1 = 8.4 Hz, J5,4 = 6.0 Hz, 1H, H5), 5.57 (d, J3,4 = 4.4 Hz, 1H, H3). 
13C NMR 
75.5 MHz, acetone-d6):  56.8, 58.3, 58.8, 67.7, 86.7, 98.5, 168.6, 194.7. IR (film, cm–1): br 3500–
2500, 2953, 2831, 1813, 1720, 1422, 1258, 1192, 1071. LRMS (EI) m/z (relative intensity): 274 
([M(37Cl2)]
+, 0.5), 272 ([M(37Cl35Cl)]+, 1.5), 270 ([M(35Cl2)]
+, 2.0), 165 (100), 143 (60), 115 (40), 83 
(80). HRMS (EI) m/z: 269.95203 calcd for C8H8
35Cl2O4S; 269.9530 obsd.  
7,7-Dichloro-3-methoxy-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylic Acid (152)  
 
TFA (1.0 mL) was added dropwise to a solution of the 3-methoxy benzhydryl ester 151 (95.7 
mg, 0.219 mmol) and anisole (100 L, 0.92 mmol) in CH2Cl2 (9 mL). The solution was stirred for 2 h 
at rt before the solvent was removed under reduced pressure. Trituration with hexane and 
recrystallization from CH2Cl2/hexane provided the acid 152 as a white solid (36.1 mg, 0.133 mmol, 
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61%). Mp 190 C (dec). 1H NMR (300 MHz, acetone-d6):  3.33 (s, 3H, OCH3), 3.90 (s, 1H, H4), 
4.78 (d, J1,5 = 8.6 Hz, 1H, H1), 5.12 (d, J5,1 = 8.6 Hz, 1H, H5), 5.61 (s, 1H, H3). 
13C NMR 75.5 MHz, 
acetone-d6):  56.4, 58.6, 60.0, 66.2, 91.5, 96.4, 169.4, 193.8. IR (film, cm–1): 2958, 1814, 1703, 
1430, 1286, 1234, 944, 828. LRMS (EI) m/z (relative intensity): 274 ([M(37Cl2)]
+, 2), 272 
([M(37Cl35Cl)]+, 2), 270 ([M(35Cl2)]
+, 3), 252 (20), 217 (50), 189 (100), 175 (95), 165 (55), 128 (35), 
83 (35). HRMS (EI) m/z: 269.9520 calcd for C8H8
35Cl2O4S; 269. 9512 obsd.   
7,7-Dichloro-2-thiabicyclo[3.2.0]hept-3-ene-6-one-4-carboxylic Acid (153)  
 
A mixture of the methoxy acids 151 and 151 (51.8 mg, 0.191 mmol, 10:1 dr) was stirred in a 
solution of 50% MsOH/CH2Cl2 (5 mL) at rt for 1 h. The solution was diluted with EtOAc (50 mL) 
and washed with H2O until the aqueous washes were no longer acidic (4 × 25 mL). The combined 
aqueous washes were back-extracted with EtOAc (2 × 25 mL) and CH2Cl2 (2 × 25 mL). The organic 
extracts were combined, dried over Na2SO4, and concentrated under reduced pressure to give the 
unsaturated acid 153 as an off-white solid (30.4 mg, 0.127 mmol, 67%). Mp 162–163 C. 1H NMR 
(300 MHz, acetone-d6):  5.23 (d, J1,5 = 10.0 Hz, 1H, H1), 5.62 (dd, J5,1 = 10.0 Hz, J5,3 = 1.8 Hz, 1H, 
H5), 7.68 (d, J3,5 = 1.8 Hz, 1H, H3). 
13C NMR 75.5 MHz, acetone-d6):  60.1, 72.8, 94.8, 123.3, 146.1, 
162.3, 189.5. IR (film, cm–1): br 3500–2300, 3066, 2925, 1807, 1700, br 1690–1630, 1558, 1446, 
1338, 1258. LRMS (EI) m/z (relative intensity): 240 ([M(37Cl35Cl)]+, 1.8), 238 ([M(35Cl2)]
+, 2.1), 210 




Alternatively, the unsaturated acid could be prepared in a one-pot three-step procedure from the 
acid 63 through the acid chloride 154. SOCl2 (4 mL, 55 mmol) was added to a solution of acid 65 
(1.475 g, 6.120 mmol) in CH2Cl2 (30 mL) and heated to reflux for 4 h. Concentration of the solution 
in vacuo provided the crude acid chloride 154 as a yellow oil that was used directly in the next step 
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without purification. 1H NMR (300 MHz, CDCl3):  3.13 (dd, Jgem = 13.1 Hz, J3,4 = 6.0 Hz, 1H, H3), 
3.54 (d, Jgem = 13.1 Hz, 1H, H3), 4.03 (d, J4,3 = 6.0 Hz, 1H, H4), 4.55 (d, J1,5 = 8.2 Hz, 1H, H1), 5.03 
(d, J5,1 = 8.2 Hz, 1H, H5). 
13C NMR (75.5 MHz, CDCl3):  35.4, 58.3, 60.3, 66.8, 89.1, 172.0, 192.9. 
IR (film, cm–1): 2965, 1809, 1780, 1443, 997, 927, 873. LRMS (EI) m/z (relative intensity): 264 
([M(37Cl3)]
+, 0.5), 262 ([M(37Cl2
35Cl)]+, 3), 260 ([M(37Cl35Cl2)]
+, 7), 258 ([M(35Cl3)]
+, 7), 225 (4), 223 
(6), 200 (15), 198 (15), 141 (30), 131 (30), 85 (100), 55 (40). HRMS (EI) m/z: 257.9076 calcd for 
C7H5
35Cl3O2S; 257.9080 obsd.  
SO2Cl2 (550 L, 6.85 mmol) was added dropwise over 2 min to a stirring solution of the crude acid 
chloride 154 in CH2Cl2 (25 mL). After 12 h at rt, the reaction mixture was concentrated under 
reduced pressure to give the 3-chloro acid chloride 155 as an off-white solid. 1H NMR (300 MHz, 
CDCl3):  4.37 (dd, J4,3 = 4.2 Hz, J4,5 = 5.2 Hz, 1H, H4), 4.99 (d, J1,5 = 8.1 Hz, 1H, H1), 5.13 (dd, J5,1 
= 8.1 Hz, J5,4 = 5.2 Hz, 1H, H5), 6.03 (d, J3,4 = 4.2 Hz, 1H, H3). 
13C NMR (75.5 MHz, CDCl3):  
60.0, 64.1, 69.4, 72.9, 84.7, 167.2, 190.5.  
MsOH (4 mL) was added to a solution of the crude acid chloride 155 in CH2Cl2 (36 mL) and the 
solution was heated to reflux for 3 h. The reaction mixture was cooled to rt, diluted with EtOAc (100 
mL), washed with H2O (4  75 mL) until the aqueous washes showed a pH of 4. The combined 
aqueous washes were back-extracted with EtOAc (2  100 mL) and the combined organic extracts 
were dried over Na2SO4 and concentrated in vacuo to give the unsaturated acid 153 as a beige solid 
(1.368 g, 5.722 mmol, 94% over 3 steps) which was estimated to be 95% pure by 1H NMR. 
Analytically pure material was obtained by recrystallization from CHCl3/hexane.     
2-Thiabicyclo[3.2.0]hept-3-ene-6-one-4-carboxylic Acid (156)  
 
Following a typical procedure for the dechlorination of cyclobutanones, zinc dust (82.1 mg, 1.26 
mmol) was added to a stirring solution of the dichlorocyclobutanone 153 (60.0 mg, 0.251 mmol) in 
AcOH (18 mL) at rt. The suspension was heated to 85 C for 12 h before the addition of another 
portion of zinc dust (78.0 mg, 1.20 mmol). After stirring for an additional 2 h, the reaction mixture 
was cooled to rt, diluted with EtOAc, and filtered for the removal of residual zinc, and the solution 
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was concentrated under reduced pressure. The resulting solid was suspended in EtOAc (75 mL) and 
washed with 10% HCl (2 × 50 mL). The organic phase was dried over Na2SO4 and concentrated in 
vacuo to give an off-white solid (20 mg). This material was soluble only in DMSO-d6 and 
1H NMR 
showed only a small amount of the dechlorinated acid 156 within a complex mixture. A small amount 
of 156 was obtained, however, from back-extraction of the combined aqueous HCl washes (100 mL) 
with EtOAc (50 mL) and CH2Cl2 (50 mL). These organic extracts were combined, dried over Na2SO4, 
and concentrated under reduced pressure to give the acid 156 as a white solid (3.9 mg, 0.023 mmol, 
9%). 1H NMR (300 MHz, acetone-d6):  3.30 (ddd, J7,1 = 5.4 Hz, J7,5 = 3.2 Hz, Jgem = 18.5 Hz, 1H, 
H7), 3.85 (ddd, J7,1 = 8.4 Hz, J7,5 = 4.9 Hz, Jgem = 18.5 Hz, 1H, H7), 4.39 (ddd, J1,7 = 8.4 Hz, J1,7 
= 5.4 Hz, J1,5 = 8.5 Hz, 1H, H1), 5.12–5.18 (m, 1H, H5), 7.59 (s, 1H, H3). 
13C NMR (75.5 MHz, 
acetone-d6):  38.1, 61.6, 77.0, 122.5, 144.6, 163.0, 201.1. LRMS (EI) m/z (relative intensity): 172 
([M +2]+, 2), 171 ([M + 1]+, 9), 170 (M+, 21), 141 (20), 128 (100), 111 (100), 97 (30). HRMS (EI) 
m/z: 170.0038 calcd for C7H6O3S; 170.0038 obsd.  
With the low yield of 156 using the dechlorination procedure described above, alternate methods 
for the synthesis of acid 156 were pursued. Attempts to effect dechlorination of 153 were also 
unsuccessful with zinc in AcOH at rt and with zinc in i-PrOH/AcOH 100:1. While the direct 
hydrolysis of ethyl ester 126 using KOH (1 equiv) in THF/H2O was also unsuccessful, hydrolysis of 
the ester could be accomplished through the dimethyl ketal 157.  
 
Acetyl chloride (100 L) was added to a stirring solution of trimethyl orthoformate (1 mL) and 
ketone 126 (17.3 mg, 0.087 mmol) in MeOH (16 mL). After stirring at rt for 4 h, the solvents were 
removed under reduced pressure to give the dimethyl ketal 157 as a yellow oil. 1H NMR (300 MHz, 
CDCl3):  1.28 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.49 (dd, J7,1 = 6.4 Hz, Jgem = 13.1 Hz, 1H, H7), 
2.72 (ddd, J7,1 = 8.3 Hz, J7,5 = 3.2 Hz, Jgem = 13.1 Hz, 1H, H7), 3.10 (s, 3H, one of OCH3), 3.32 (s, 
3H, one of OCH3), 3.97–4.04 (m, 1H, H1),  4.15 (B of ABX3, JAB = 10.8 Hz, JAX = 7.1 Hz, 1H, one of 
CO2CH2CH3), 4.23 (A of ABX3, JBA = 10.8 Hz, JBX = 7.1 Hz, 1H, one of CO2CH2CH3), 4.34–4.37 
(m, 1H, H5), 7.39 (s, 1H, H3). 
13C NMR (75.5 MHz, CDCl3):  14.3, 38.9, 45.2, 48.7, 49.4, 59.3, 60.2, 
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105.9, 126.0, 143.2, 163.3. 
The crude dimethyl ketal was used in the following step without further characterization or 
purification. A crystal of KOH (24.0 mg, 0.429 mmol) was added to a solution of ketal 157 in CD3OD 
(0.5 mL) and D2O (1.0 mL) and the progress of the reaction was followed by NMR. After 36 h at rt, 
the solution was concentrated in vacuo, diluted with H2O (25 mL), and washed with CH2Cl2 (25 mL). 
The aqueous phase (pH ~10) was then acidified with TFA (~1 mL) to pH 2 and extracted with 
CH2Cl2 (2 × 25 mL). The organic extracts were dried over Na2SO4 and concentrated under reduced 
pressure to provide the ketal acid 158 as a white solid. 1H NMR (300 MHz, acetone-d6):  2.42 (dd, 
J7,1 = 6.1 Hz, Jgem = 13.1 Hz, 1H, H7), 2.70 (ddd, J7,1 = 8.4 Hz, J7,5 = 2.9 Hz, Jgem = 13.1 Hz, 1H, 
H7), 3.06 (s, 3H, one of OCH3), 3.26 (s, 3H, one of OCH3), 4.04–4.10 (app. br q, 1H, H1), 4.33 (br d, 
J5,1 = 8 Hz, 1H, H5), 7.43 (s, 1H, H3). 
TFA (100 L) was added to an NMR tube containing a solution of the ketal 158 in acetone-d6 (400 
L) and D2O (400 L) and the progress of the hydrolysis was followed by NMR. After 16 h at rt the 
solution was diluted with H2O (40 mL) and extracted with CH2Cl2 (3 × 30 mL). The organic extracts 
were dried over Na2SO4 and concentrated under reduced pressure to provide ketone 156 as a white 
solid (6.9 mg, 0.041 mmol, 46% over 3 steps) with spectral data identical to that obtained using the 
dechlorination procedure above. 
Ethyl 7,7-Dichloro-3-(isopropylthio)-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylate (164)  
 
A solution of SnCl4 (200 L, 1.0 M in CH2Cl2) was added dropwise at rt to a solution of -chloro 
derivative 117 (51 mg, 0.17 mmol) and 2-propanethiol (50 L, 0.54 mmol) in CH2Cl2 (7 mL) and 
stirred for 16 h at rt. The reaction mixture was diluted with CH2Cl2 (75 mL), filtered through Celite, 
washed with H2O (20 mL), dried over Na2SO4, and concentrated in vacuo. The substitution products 
were not purified but used as a mixture in a failed attempt to effect hydrolysis of the ethyl ester. 
Compounds 164 and 164 were identified by 1H NMR of the crude mixture, however, which 
showed a product distribution of 15:83:2 for 164:164:118, respectively. 164: 1H NMR (300 MHz, 
CDCl3):  1.22–1.35 (m, 9H, CO2CH2CH3 + SCH(CH3)2), 3.06 (sept, J = 6.6 Hz, 1H, SCH(CH3)2), 
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3.75 (dd, J4,3 = 5.8 Hz, J4,5 = 2.1 Hz, 1H, H4), 4.21 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.70 (d, J1,5 = 
8.4 Hz, 1H, H1), 4.90 (d, J5,1 = 8.4 Hz, J5,4 = 2.1 Hz, 1H, H5), 4.67 (d, J3,4 = 5.8 Hz, 1H, H3). 164: 
1H NMR (300 MHz, CDCl3):  1.22–1.35 (m, 9H, CO2CH2CH3 + SCH(CH3)2), 3.13 (sept, J = 6.7 Hz, 
1H, SCH(CH3)2), 3.72 (s, 1H, H4), 4.21 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.60 (d, J1,5 = 8.6 Hz, 1H, 
H1), 4.98 (d, J5,1 = 8.6 Hz, 1H, H5), 5.10 (s, 1H, H3).   
Ethyl 7,7-Dichloro-3-(p-tolylthio)-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylate (165)  
 
A solution of the 3-chloride 117 (74.9 mg, 0.247 mmol) in CH2Cl2 (1 mL) was added dropwise 
at rt to a solution of 4-methylbenzenethiol (84.7 mg, 0.682 mmol) and SnCl4 (300 L, 1.0 M in 
CH2Cl2) in CH2Cl2 (8 mL). After 2 h of stirring at rt, the reaction mixture was diluted with CH2Cl2 
(50 mL), washed with H2O (40 mL) and satd NaHCO3 (30 mL), dried over Na2SO4, and concentrated 
under reduced pressure. 1H NMR spectra of the crude product showed a product distribution of 
32:>67:<1 for 165:165:118, respectively. Flash chromatography (10% EtOAc/Hex) provided the 
3-S-p-Tol isomer 165 (33.4 mg, 0.085 mmol, 35%) and additional fractions of 165/165 
mixtures. 165: 1H NMR (300 MHz, CDCl3):  1.33 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.36 (s, 3H, 
ArCH3), 3.85 (dd, J4,3 = 5.9 Hz, J4,5 = 3.1 Hz, 1H, H4), 4.24 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.57 
(d, J1,5 = 8.5 Hz, 1H, H1), 4.90 (d, J3,4 = 5.9 Hz, 1H, H3), 4.95 (dd, J5,4 = 3.1 Hz, J5,1 = 8.5 Hz, 1H, 
H5), 7.16 (d, J = 8.0 Hz, 2H, ArH), 7.40 (d, J = 8.0 Hz, 2H, ArH). 165: 1H NMR (300 MHz, CDCl3): 
 1.24 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.35 (s, 3H, ArCH3), 3.71 (s, 1H, H4), 4.13 (B of ABX3, JBA 
= 10.7 Hz, JBX = 7.1 Hz, 1H, one of CO2CH2CH3), 4.16 (A of ABX3, JAB = 10.7 Hz, JAX = 7.1 Hz, 
1H, one of CO2CH2CH3), 4.62 (d, J1,5 = 8.6 Hz, 1H, H1), 4.99 (d, J5,1 = 8.6 Hz, 1H, H5), 5.33 (s, 1H, 
H3), 7.17 (d, J = 8.0 Hz, 2H, ArH), 7.35 (d, J = 8.0 Hz, 2H, ArH). 
13C NMR (75.5 MHz, CDCl3):  
14.0, 21.2, 56.8, 60.8, 61.0, 62.4, 66.3, 89.8, 130.2 (2C), 130.5, 132.8 (2C), 139.0, 168.8, 193.9.  
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Ethyl 3-Allyl-7,7-dichloro-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylate (166)  
 
A solution of SnCl4 (560 L, 0.1 M in CH2Cl2) was added to a stirring solution of the 3-chloro 
derivative 117 (155 mg, 0.511 mmol) and allyltrimethylsilane (320 L, 2.70 mmol) in CH2Cl2 (6 
mL) and stirred for 1.5 h at rt. The solution was diluted with EtOAc (75 mL), washed with H2O (3  
25 mL) and brine (20 mL), dried over Na2SO4, and concentrated under reduced pressure. 
1H NMR 
spectra of the crude product showed a 166/166 ratio of >10:1 and flash chromatography (5% 
EtOAc/Hex) provided the 3-allyl product 166 (47 mg, 0.151 mmol, 30%) as a colourless oil and 
additional fractions of 166/166 mixtures. The 3-allyl isomer 166 was not purified with a single 
column but was identified in mixtures with 166 by 1H NMR. 166: 1H NMR (300 MHz, CDCl3):  
1.28 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.12–2.28 (m, 1H, B of ABX, one of CH2CH=CH2), 2.52–2.66 
(m, 1H, A of ABX, one of CH2CH=CH2), 3.55 (d, J = 3 Hz, 1H, H4), 3.62–3.73 (m, 1H, H3), 4.10–
4.35 (m, 2H, CO2CH2CH3), 4.61 (d, J1,5 = 8 Hz, 1H, H1), 4.80 (d, J5,1 = 8 Hz, 1H, H5), 5.07–5. 18 (m, 
2H, CH=CH2), 5.60–5.85 (m, 1H, CH=CH2). 166: 1H NMR (500 MHz, CDCl3):  1.28 (t, J = 7.1 
Hz, 3H, CO2CH2CH3), 2.33–2.43 (m, 2H CH2CH=CH2), 3.47 (dd, J4,5 = 2.0 Hz, J4,3 = 3.5 Hz, 1H, 
H4), 3.96 (dt, J3,4 = 3.5 Hz, J3,3 = 7.8 Hz, 1H, H3), 4.20 (B of ABX3, JBA = 10.9 Hz, JBX = 7.1 Hz, 
1H, one of CO2CH2CH3), 4.20 (A of ABX3, JAB = 10.9 Hz, JAX = 7.1 Hz, 1H, one of CO2CH2CH3), 
4.56 (d, J1,5 = 8.5 Hz, 1H, H1), 4.95 (dd, J5,1 = 8.5 Hz, J5,4 = 2.0 Hz, 1H, H5), 5.11–5.16 (m, 2H, 
CH=CH2), 5.67–5.77 (m, 1H, CH=CH2). 
13C NMR (125 MHz, CDCl3):  14.1, 41.4, 54.0, 55.6, 59.8, 
62.1, 68.0, 88.3, 118.5, 134.4, 170.5, 194.8.  
















Zinc dust (587 mg, 8.98 mmol) was added at rt to a solution of the dichlorocyclobutanone 84 
(1.209 g, 4.491 mmol) and TMSCl (1.71 mL, 13.47 mmol) in dry MeCN (80 mL). The suspension 
was heated to 40 C and stirred for an additional 8 h before the solvent was removed in vacuo. The 
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reaction mixture was then taken up in CH2Cl2, washed with H2O, dried over Na2SO4, and 
concentrated under reduced pressure. Flash chromatography (20% EtOAc/Hex) provided the 7-
chlorocyclobutanone 183 as a colourless oil (763 mg, 3.25 mmol, 72%) that was used in the 
following step without further purification. 1H NMR (300 MHz, CDCl3):  1.29 (t, J = 7.1 Hz, 3H, 
CO2CH2CH3), 3.03 (dd, Jgem = 12.3 Hz, J3,4 = 6.0 Hz, 1H, H3), 3.38 (d, Jgem = 12.3 Hz, 1H, H3), 
3.62 (d, J4,3 = 6.0 Hz, 1H, H4), 4.19 (1.29 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.47 (dd, J1,5 = 7.9 Hz, 
J1,7 = 8.1 Hz, 1H, H1), 4.69 (dd, J5,1 = 7.9 Hz, J5,7 = 3.4 Hz, 1H, H5), 5.19 (dd, J7,1 = 8.1 Hz, J7,5 = 
3.4 Hz, 1H, H7). 
Ethyl 7-Chloro-7-hydroxymethyl-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylate (187)  
 
Triethylamine (0.10 mL, 0.74 mmol) was added to a suspension of the 7-chlorocyclobutanone 
183 (115.7 mg, 0.493 mmol) and paraformaldehyde (44.4 mg, 1.48 mmol) in MeCN (20 mL) and 
heated to 70 C. After 6 h at this temperature, the solution was cooled to rt and the solvent removed 
under reduced pressure. The reaction mixture was dissolved in CH2Cl2 (20 mL), washed with 5% HCl 
(20 mL), brine (20 mL), dried over Na2SO4, and concentrated under reduced pressure. Flash 
chromatography (20% EtOAc/hexane) provided the title compound 187 as a dull yellow oil (85 mg, 
0.32 mmol, 65%). 1H NMR (300 MHz, CDCl3):  1.26 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.50–2.58 
(brs, 1H, OH), 3.02 (dd, Jgem = 12.4 Hz, J3,4 = 5.8 Hz, 1H, H3), 3.38 (d, Jgem = 12.4 Hz, 1H, H3), 
3.58 (d, J3,4 = 5.8 Hz, 1H, H4), 3.98 (B of AB, JAB = 11.7 Hz, one of CH2OH), 4.06 (A of AB, JAB = 
11.7 Hz, one of CH2OH), 4.17 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.35 (d, J1,5 = 8.4 Hz, 1H, H1), 4.69 
(d, J5,1 = 8.4 Hz, 1H, H5). 
13C NMR (75.5 MHz, CDCl3):  14.0, 35.7, 49.3, 50.5, 62.0, 65.6, 67.8, 
82.4, 170.6, 204.1. IR (film, cm–1): 3600–3200 (br), 2984, 1795, 1730, 1265, 1184, 910, 733. LRMS 
(EI) m/z (relative intensity): 266 (M[(37Cl)]+, 5), 264 ([M(35Cl)]+, 15), 246 (10), 218 (10), 173 (20), 
158 (25), 99 (20), 85 (100). HRMS (EI) m/z: 264.0223 calcd for C10H13
35ClO4S; 264.0226 obsd.  
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7-Chloro-7-hydroxymethyl-2-thiabicyclo[3.2.0]heptan-6-one-4-carboxylic Acid (188)  
 
Zinc dust (323 mg, 4.97 mmol) was added at rt to a stirring solution of the dichlorocyclobutanone 
149 (1003 mg, 2.46 mmol), TMSCl (935 L, 7.37 mmol), and PhOMe (800 L, 7.36 mmol) in dry 
MeCN (15 mL). The suspension was heated to 40 C and stirred for an additional 4 h before the 
solvent was removed under reduced pressure. The reaction mixture was then taken up in CH2Cl2 (50 
mL) and washed with 5% HCl (50 mL). The aqueous washes were back-extracted with CH2Cl2 (25 
mL) before the organic extracts were combined and extracted with satd NaHCO3 (2  20 mL). The 
aqueous extracts were then acidified with 6 M HCl (~4 mL) to pH 1–2 and extracted with CH2Cl2 (3 
 20 mL). The organic solution was dried over Na2SO4 and concentrated under reduced pressure to 
give a mixture of monochlorocyclobutanones 184 and 184 (87.2 mg, 0.423 mmol, 17%) that was 
used in the following reaction without additional purification or characterization. 184: 1H NMR 
(300 MHz, acetone-d6):  3.37 (dd, Jgem = 12.3 Hz, J3,4 = 6.2 Hz, 1H, H3), 3.55 (dd, Jgem = 12.3 Hz, 
J3,4 = 1.9 Hz, 1H, H3), 3.74 (dd, J4,3 = 1.9 Hz, J4,3 = 6.2 Hz, 1H, H4), 4.18 (dd, J1,5 = 8.2 Hz, J1,7 = 
3.5 Hz, 1H, H1), 4.85–4.95 (m, 2H, H5
 + H7). 184: 1H NMR (300 MHz, acetone-d6):  2.97 (dd, Jgem 
= 12.1 Hz, J3,4 = 6.0 Hz, 1H, H3), 3.36 (d, Jgem = 12.1 Hz, 1H, H3), 3.63 (d, J4,3 = 6.0 Hz, 1H, H4), 
4.55 (dd, J1,5 = 7.9 Hz, J1,7 = 8.0 Hz, 1H, H1), 4.77 (dd, J5,1 = 7.9 Hz, J5,7 = 3.3 Hz, 1H, H5), 5.54 
(dd, J7,1 = 8.0 Hz, J7,5 = 3.3 Hz, 1H, H7). LRMS (EI) m/z (relative intensity): 208 (M[(
37Cl)]+, 20), 
206 ([M(35Cl)]+, 50), 146 (20), 130 (40), 85 (100). HRMS (EI) m/z: 205.9804 calcd for C7H7O3
35ClS; 
205.9808 obsd. 
Triethylamine (110 L, 0.786 mmol) was added at rt to a suspension of the monochloro-
cyclobutanones 184 (40.7 mg, 0.197 mmol, 184:184  3:97) and paraformaldehyde (12 mg, 0.40 
mmol) in MeCN (15 mL) and H2O (0.4 mL). The suspension was heated to 50 C and stirred for 1.5 h 
before the reaction mixture was concentrated under reduced pressure. The crude mixture was taken up 
in CH2Cl2 (25 mL) and extracted with satd NaHCO3 (25 mL) before the aqueous extracts were 
acidified with 6 M HCl (~2 mL) to pH 2 and extracted with CH2Cl2 (2  40 mL). The organic solution 
was dried over Na2SO4 and concentrated under reduced pressure to provide hydroxymethylated 
 
177 
cyclobutanone derivative 188 as a white solid (23.8 mg, 0.101 mmol, 51%). 1H NMR (300 MHz, 
acetone-d6):  2.96 (dd, Jgem = 12.2 Hz, J3,4 = 5.8 Hz, 1H, H3), 3.42 (d, Jgem = 12.2 Hz, 1H, H3), 
3.63 (d, J4,3 = 5.8 Hz, 1H, H4), 3.96 (B of AB, JAB = 11.3 Hz, 1H, one of CH2OH), 4.04 (A of AB, 
JAB = 11.3 Hz, 1H, one of CH2OH), 4.47 (d, J1,5 = 8.4 Hz, 1H, H1), 4.71 (d, J5,1 = 8.4 Hz, 1H, H5). 
13C 
NMR (75.5 MHz, acetone-d6):  36.4, 50.2, 51.0, 66.0, 69.3, 83.2, 172.3, 205.5.  
5.4 Cyclobutanone Hydrate Formation688 


















The dichlorocyclobutanone 65 (32.5 mg, 0.135 mmol) was dissolved in acetone-d6 (0.2 mL) and 
combined with D2O (0.6 mL). 
1H NMR of the mixture within 5 minutes showed a ketone:hydrate 
ratio of 26:74 and this ratio did not change in the following 3 weeks. Ketone: 1H NMR (300 MHz, 
D2O):  3.08 (dd, Jgem = 12.6, J3,4 = 5.9, 1H, H3), 3.48 (d, Jgem = 12.6, 1H, H3), 3.85 (d, J4,3 = 5.9 
Hz, 1H, H4), 4.72 (d, J1,5 = 8.4 Hz, 1H, H1), 5.20 (d, J5,1 = 8.4 Hz, 1H, H5). 
13C NMR (75.5 MHz, 
D2O):  36.9, 51.3, 59.9, 69.0, 90.3, 174.7, 198.3. Hydrate: 1H NMR (300 MHz, D2O):  3.33 (d, Jgem 
= 11.5, 1H, H3), 3.49 (dd, Jgem = 11.5, J3,4 = 6.5, 1H, H3), 3.64 (d, J4,3 = 6.5 Hz, 1H, H4), 3.97 (d, 
J5,1 = 8.9 Hz, 1H, H5), 4.41 (d, J1,5 = 8.9 Hz, 1H, H1). 
13C NMR (75.5 MHz, D2O):  39.1, 49.7, 59.5, 
62.1, 96.6, 98.7, 177.0.  
Hydrate Formation with Cyclobutanone 111  
 
The dechlorinated cyclobutanone 111 (21.1 mg, 0.123 mmol) was dissolved in acetone-d6 (0.2 mL) 




even after 3 weeks in solution. Ketone: 1H NMR (500 MHz, D2O):  3.00 (ddd, J7,1 =3.4 Hz, J7,5 = 
3.3 Hz, Jgem = 19.1 Hz, 1H, H7), 3.27 (dd, Jgem = 12.5 Hz, J3,4 = 6.0 Hz, 1H, H3), 3.44 (d, Jgem = 12.5 
Hz, 1H, H3), 3.66 (d, J4,3 = 6.0 Hz, H4), 3.81 (ddd, J7,1 = 8.4 Hz, J7,5 = 4.0 Hz, Jgem = 19.1 Hz, 1H, 
H7), 4.27 (ddd, J1,5 = 8.0 Hz, J1,7 = 8.4 Hz, J1,7 = 3.4 Hz, 1H, H1), 4.66 (m, 1H, H5). 
13C NMR (125 
MHz, D2O):  36.3, 38.3, 51.3, 57.4, 72.6, 175.9, 214.8.  





















The 3-methoxy dichlorocyclobutanone 152 (23.9 mg, 0.088 mmol) was dissolved in acetone-d6 
(150 L) and combined with D2O (450 L). 1H NMR of the mixture within 5 minutes showed >98% 
as the signals corresponding to the ketone could not be identified. Hydrate: 1H NMR (500 MHz, 
D2O):  3.33 (s, 3H, OCH3), 3.75 (dd, J4,3 = 4.4 Hz, J4,5 = 9.5 Hz, 1H, H4), 3.83 (dd, J5,1 = 9.4 Hz, J5,4 
= 9.5 Hz, 1H, H5), 4.44 (d, J1,5 = 9.4 Hz, 1H, H1), 5.52 (d, J3,4 = 4.4 Hz, 1H, H3). 
13C NMR (125 
MHz, D2O):  56.4, 57.0, 57.4, 59.3, 95.3, 97.1, 97.9, 173.0.  





















The 3-methoxy dichlorocyclobutanone 152 (15 mg, 0.055 mmol) was dissolved in acetone-d6 
(150 L) before the addition of D2O (450 L), as done previously with 152 (see above). However, 
the addition of D2O induced a large amount of precipitation, and additional acetone-d6 (300 L) was 
required to dissolve most of the solid. Integration of the 1H NMR spectrum of the mixture within 10 
minutes indicated approximately 6.5% hydration of the ketone (ketone:hydrate = 93.5:6.5) and this 
ratio did not change over 24 h. Ketone: 1H NMR (500 MHz, D2O):  3.37 (s, 3H, OCH3), 3.91 (s, 1H, 
H4), 4.81 (d, J1,5 = 8.6 Hz, H1), 5.17 (d, J5,1 = 8.6 Hz, H5), 5.61 (s, 1H, H3). 
13C NMR (125 MHz, 
D2O):  57.2, 59.2, 60.3, 66.5, 91.5, 96.8, 171.9, 196.4. Hydrate: 1H NMR (500 MHz, D2O):  3.52 
(s, 3H, OCH3), 3.79 (br s, 1H, H4), 4.23 (dd, J5,1 = 9.6 Hz, J5,4 = 1.8 Hz, H5), 4.56 (d, J1,5 = 9.6 Hz, 
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H1), 5.75 (d, J3,4 = 1.2 Hz, H3). 
13C NMR (125 MHz, D2O):  56.9, 57.7, 61.0, 62.5, 98.5.689  


















The unsaturated dichlorocyclobutanone 153 (21.8 mg, 0.0912 mmol) was dissolved in acetone-d6 
(250 L) and combined with D2O (750 L). 1H NMR of the mixture within 5 minutes showed 93% 
hydration and the ketone:hydrate (93.3:6.7) ratio did not change over 12 h. Ketone: 1H NMR (500 
MHz, D2O):  5.21 (d, J5,1 = 10.1 Hz, 1H, H5), 5.56 (dd, J1,3 = 1.8 Hz, J1,5 = 10.1 Hz, 1H, H1), 7.73 (d, 
J3,1 = 1.8 Hz, 1H, H3). 
13C NMR (125 MHz, D2O):  60.5, 72.5, 94.7, 123.0, 149.0, 165.4, 192.4. 
Hydrate: 1H NMR (500 MHz, D2O):  4.45 (dd, J1,3 = 1.4 Hz, J1,5 = 10.1 Hz, 3H, H5), 4.88 (d, J1,5 = 
10.1 Hz, 1H, H1), 7.63 (d, J3,1 = 1.4 Hz, 1H, H3). 
13C NMR (125 MHz, D2O):  61.6, 62.7, 97.6, 
101.5, 126.6, 149.9, 166.9.  
Hydrate Formation with Cyclobutanone 156  
 
The unsaturated dichlorocyclobutanone 156 (6.2 mg, 0.041 mmol) was dissolved in acetone-d6 
(350 L) and combined with D2O (700 L). The cyclobutanone hydrate could not be detected by 1H 
NMR, even after 48 h in solution. Given the relatively poor solubility of 156 in this solvent mixture 
and the detection limit of 1H NMR in this experiment, we conclude that the extent of hydration is less 
than 2%. Ketone: 1H NMR (500 MHz, D2O):  3.42 (ddd, J7,1 = 8.7 Hz, J7,5 = 3.4 Hz, Jgem = 19.1 
Hz,1H, H7), 3.92 (ddd, J7,1 = 8.4 Hz, J7,5 = 5.3 Hz, Jgem = 19.1 Hz,1H, H7), 4.39–4.45 (m, 1H, H1), 
5.14–5.18 (m, 1H, H5), 7.71 (s, 1H, H3). 
13C NMR (125 MHz, D2O):  38.7, 61.6, 76.4, 122.0, 148.1, 
166.1, 206.9.  
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5.5 Cyclobutanone Hemiketal Formation 
General 
A neat sample of the cyclobutanone (typically 20–25 mg) was dissolved in neat methanol-d4 (1 g) 
with swirling. Between periodic NMR experiments, the solution remained in the NMR tube at 
ambient temperature. 1H NMR was done at 500 MHz, 13C NMR at 125 MHz, and protons were 
assigned based on COSY, HMQC, and HMBC experiments. 
Assignment of signals to protons of the  and  hemiketals was based on reasoning that 
nucleophilic attack by the alcohol on the carbonyl is kinetically much faster from the exo () face of 
the [3.2.0] bicycle, and would give the thermodynamically more stable -hemiketal. Peaks of the first 
hemiketal to form were therefore assigned to the -hemiketal and the peaks of the second hemiketal 
to form were assigned to the -hemiketal. As expected, the ratio of -hemiketal:-hemiketal was >1 
at equilibrium with all cyclobutanones tested. NOE and NOESY experiments were performed, but 
could not give an unambiguous assignment of any protons to either of the hemiketals. Ketone:: 
ratios were calculated using a weighted average of the integrated values of the most resolved peaks. 
In many experiments, quaternary carbons C6 and C7 could not be observed, and in some cases (in 
which the proportion of a compound was less than 5% of the mixture) none of the carbons could be 
observed. 
After equilibrium had been reached, the solvent was removed in vacuo to give the ketone in all 
cases. For several substrates the -hemiketal persisted, but removal of methanol could be facilitated 
by washing a solution of the compound in CH2Cl2 with water, followed by removal of the solvent 
under reduced pressure. With the carboxylic acids 65 and 111, hemiketal formation was also found to 
be fully reversible, but after two weeks or more in methanol-d4 a significant amount of esterification 
was observed (ca. 30% after two weeks by 1H NMR). 
Hemiketal Formation with Cyclobutanone 65  
 
The cyclobutanone 65 (20.6 mg, 0.085 mmol) was dissolved in methanol-d4 (1 g). 7 d were 
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required for the system to reach equilibrium and the ketone:: ratio was 12:65:24. Ketone: 1H NMR 
(500 MHz, CD3OD):  3.00 (dd, J3,4 = 5.9 Hz, Jgem = 12.3 Hz, 1H, H3), 3.42 (d, Jgem = 12.3 Hz, 1H, 
H3), 3.75 (d, J4,3 = 5.9 Hz, 1H, H4), 4.58 (d, J1,5 = 8.4 Hz, 1H, H1), 5.10 (d, J5,1 = 8.4 Hz, 1H, H5). 
13C NMR (125 MHz, CD3OD):  35.2, 50.0, 58.7, 67.7, 172.9, 195.1.690 -Hemiketal: 1H NMR (500 
MHz, CD3OD):  3.30 (m, 1H, H3), 3.47–3.55 (m, 2H, H3 and H4), 3.96 (d, J5,1 = 8.9 Hz, H5), 4.29 
(d, J1,5 = 8.9 Hz, H1). 
13C NMR (125 MHz, CD3OD):  37.3, 48.5, 55.4, 61.3, 93.9, 100.2, 174.2. -
Hemiketal: 1H NMR (500 MHz, CD3OD):  3.30–3.35 (m, 1H, H3), 3.4–3.5 (m, 2H, H3 and H4), 
3.89 (dd, J5,4 = 2.6 Hz, J5,1 = 9.2 Hz, 1H, H5), 4.27 (d, J1,5 = 9.2 Hz, 1H, H1).
 13C NMR (500 MHz, 
CD3OD):  37.6, 48.0, 58.6, 60.7, 94.9, 99.2, 174.3.  

































The cyclobutanone 84 (20.0 mg, 0.074 mmol) was dissolved in methanol-d4 (1 g). 12 d were 
required for the system to reach equilibrium and the ketone:: ratio was 9:67:25. Ketone: 1H NMR 
(500 MHz, CD3OD):  1.28 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.05 (dd, Jgem = 12.4 Hz, J3,4 = 5.8 Hz, 
1H, H3), 3.46 (d, Jgem = 12.4 Hz, 1H, H3), 3.78 (d, J3,4 = 5.8 Hz, 1H, H4), 4.17 (app. q, J = 7.1 Hz, 
2H, CO2CH2CH3), 4.64 (d, J1,5 = 8.4 Hz, 1H, H1), 5.16 (d, J5,1 = 8.4 Hz, 1H, H5). 
13C NMR (125 
MHz, CD3OD):  13.0, 35.1, 50.1, 58.7, 61.6, 67.5, 170.2, 195.1.690 -Hemiketal: 1H NMR (500 
MHz, CD3OD):  1.26 (m, 3H, CO2CH2CH3), 3.29 (d, Jgem = 10.8 Hz, 1H, H3), 3.50 (dd, Jgem = 10.8 
Hz, J3,4 = 6.6 Hz, 1H, H3), 3.54 (d, J4,3 = 6.6 Hz, 1H, H4), 3.96 (d, J5,1 = 8.9 Hz, 1H, H5), 4.10–4.15 
(m, 2H, CO2CH2CH3), 4.29 (d, J1,5 = 8.9 Hz, 1H, H1). 
13C NMR (500 MHz, CD3OD):  13.0, 37.3, 
48.5, 55.1, 60.7, 61.0, 93.9, 100.2, 174.2. -Hemiketal: 1H NMR (500 MHz, CD3OD):  1.26 (m, 3H, 
CO2CH2CH3), 3.29 (dd, Jgem = 11.5 Hz, J3,4 = 2.7 Hz, 1H, H3), 3.36 (dd, Jgem = 11.5 Hz, J3,4 = 6.7 
Hz, 1H, H3), 3.56 (app. dt, J4,3 = 2.7 Hz, J4,3 = 6.7 Hz, J4,5 = 2.7 Hz, 1H, H4), 3.88 (dd, J5,1 = 9.3 
Hz, J5,4 = 2.7 Hz, 1H, H5), 4.10–4.15 (m, 2H, CO2CH2CH3), 4.27 (d, J1,5 = 9.3 Hz, 1H, H1). 
13C NMR 
(125 MHz, CD3OD):  13.0, 37.6, 48.4, 55.1, 58.7, 60.0, 60.7, 95.5, 99.2, 172.5.  
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Hemiketal Formation with Cyclobutanone 110  
 
The cyclobutanone 110 (25.5 mg, 0.127 mmol) was dissolved in methanol-d4 (1 g). Equilibrium 
was reached in 7 d and the ketone:: ratio was 81:12:6.5. Ketone: 1H NMR (500 MHz, CD3OD):  
1.29 (t, 3H, CO2CH2CH3), 2.90 (app. dt, J7,5 = 3.3 Hz, J7,1
 = 3.3 Hz, Jgem = 18.5 Hz, 1H, H7), 3.23 
(dd, Jgem
 = 12.2 Hz, J3,4 = 6.0 Hz, 1H, H3), 3.42 (d, Jgem = 12.2 Hz, 1H, H3), 3.58 (d, J4,3 = 6.0 Hz, 
1H, H4), 3.70 (ddd, J7,1 = 8.3 Hz, J7,5 = 3.6 Hz, Jgem = 18.5 Hz, 1H, H7), 4.12–4.21 (m, 3H, H1 and 
CO2CH2CH3), 4.65 (app. ddd, J5,1 = 7.6 Hz, J5,7 = 3.6 Hz, J5,7 = 3.3 Hz, 1H, H5). 
13C NMR (125 
MHz, CD3OD):  13.0, 34.7, 36.8, 50.0, 55.9, 61.2, 71.5, 171.3, 208.7. -Hemiketal: 1H NMR (500 
MHz, CD3OD):  1.28 (t, 3H, CO2CH2CH3), 2.02 (dd, J7,1 = 4.3 Hz, Jgem = 13.5 Hz, 1H, H7), 2.83 
(ddd, J7,1 = 7.8 Hz, J7,5 = 3.6 Hz, Jgem = 13.5 Hz, 1H, H7), 3.37 (dd, Jgem = 11.4 Hz, J3,4 = 2.0 Hz, 
1H, H3), 3.43 (dd, Jgem
 = 11.4 Hz, J3,4 = 6 Hz, 1H, H3), 3.47 (dd, J4,3 = 6 Hz, J4,3 = 2.0 Hz, 1H, 
H4), 3.72–3.77 (m, 2H, H1 and H5), 4.15–4.19 (m, 2H, CO2CH2CH3). 
13C NMR (125 MHz, CD3OD): 
 13.1, 35.6, 38.0, 44.2, 49.0, 57.4, 60.7, 96.4, 173.1. -Hemiketal: 1H NMR (500 MHz, CD3OD):  
1.27 (t, 3H, CO2CH2CH3), 2.17 (dd, J7,1
 = 6.0 Hz, Jgem = 13.4 Hz, 1H, H7), 2.62 (ddd, J7,1 = 8.4 Hz, 
J7,5 = 3.0 Hz, Jgem = 13.4 Hz, 1H, H7), 3.31 (dd, Jgem
 = 11.9 Hz, J3,4 = 6.0 Hz, 1H, H3), 3.36 (dd, 
Jgem = 11.9 Hz, J3,4 = 2.4 Hz, 1H, H3),  3.50 (app. dt, J4,3 = 6.0 Hz, J4,3 = 2.4 Hz, J4,5 = 2 Hz, 1H, 
H4), 3.70–3.74 (m, 1H, H5), 3.80 (app. dt, J1,5
 = 8 Hz, J1,7
 = 8.4 Hz, J1,7
 = 6.0 Hz, 1H, H1), 4.15–4.19 
(m, 2H, CO2CH2CH3). 
13C NMR (125 MHz, CD3OD):  13.1, 35.5, 37.7, 43.7, 48.5, 59.9, 60.7, 95.8, 
173.2.  
Hemiketal Formation with Cyclobutanone 111  
 
The cyclobutanone 111 (18.3 mg, 0.1063 mmol) was dissolved in methanol-d4 (1 g). Less than 12 h 
were required for the system to reach equilibrium and the ketone:: ratio was 76:14.5:9.2. Ketone: 
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1H NMR (500 MHz, CD3OD):  2.89 (dt, J7,5 = 3.3 Hz, J7,1 = 3.4 Hz, Jgem = 18.5 Hz, 1H, H7), 3.22 
(dd, Jgem
 = 12.1 Hz, J3,4 = 6.1 Hz, 1H, H3), 3.44 (d, Jgem = 12.1 Hz, 1H, H3), 3.55 (d, J4,3 = 6.1 Hz, 
1H, H4), 3.69 (ddd, J7,1 = 8.3 Hz, J7,5 = 3.6 Hz, Jgem = 18.5 Hz, 1H, H7), 4.17 (ddd, J1,5 = 8.0 Hz, 
J1,7 = 8.3 Hz, J1,7 = 3.4 Hz, 1H, H1), 4.64 (app. dt, J5,1 = 8.0 Hz, J5,7 = 3.6 Hz, J5,7 = 3.3 Hz, 1H, 
H5).  
13C NMR (125 MHz, CD3OD):  34.8, 36.8, 50.0, 55.8, 71.7, 173.2, 209.1. -Hemiketal: 1H 
NMR (500 MHz, CD3OD):  2.02 (dd, J7,1 = 4.0 Hz, Jgem = 13.5 Hz, 1H, H7), 2.82 (ddd, J7,1 = 7.4 
Hz, J7,5 = 3.9 Hz, Jgem = 13.5 Hz, 1H, H7), 3.35–3.45 (m, 3H, H4 and H3 and H3), 3.73–3.76 (m, 
2H, H1 and H5). 
13C NMR (125 MHz, CD3OD):  35.6, 38.1, 44.2, 48.9, 57.5, 96.4, 175.1. -
Hemiketal: 1H NMR (500 MHz, CD3OD):  2.17 (dd, J7,1 = 6.0 Hz, Jgem = 13.3 Hz, 1H, H7), 2.62 
(ddd, J7,1 = 8.4 Hz, J7,5 = 3.0 Hz, Jgem = 13.3 Hz, 1H, H7), 3.30 (dd, Jgem
 = 11.7 Hz, J3,4 = 6.1 Hz, 
1H, H3), 3.41 (m, 1H, H3),  3.48 (app. dt, J4,3 = 6.1 Hz, J4,3 = 2 Hz, J4,5 = 2 Hz, 1H, H4), 3.72–3.76 
(m, 1H, H5), 3.81 (app. dt, J1,5
 = 8 Hz, J1,7
 = 8 Hz, J1,7
 = 6 Hz, 1H, H1). 
13C NMR (125 MHz, 
CD3OD):  34.8, 37.8, 43.7, 48.4, 60.0, 95.4, 175.2  
Hemiketal Formation with Cyclobutanone 121  
 
The 3-methoxycyclobutanone 121 (13.5 mg, 0.045 mmol) was dissolved in methanol-d4 (0.6 g). 
Equilibrium was reached within 7 d and the ketone:: ratio was 1.6:54:44. Ketone: 1H NMR (500 
MHz, CD3OD):  1.28 (t, 3H, CO2CH2CH3), 3.34 (s, 3H, OCH3), 3.84 (dd, J4,3 = 5.0 Hz, J4,5 = 5.7 
Hz, 1H, H4), 4.15–4.30 (m, 2H, CO2CH2CH3), 4.74 (d, J1,5 = 8.3 Hz, 1H, H1), 5.15 (dd, J5,1 = 8.3 Hz, 
J5,4 = 5.7 Hz, 1H, H5), 5.49 (d, J3,4 = 5.0 Hz, 1H, H3). -Hemiketal: 1H NMR (500 MHz, CD3OD): 
 1.28 (t, 3H, CO2CH2CH3), 3.27 (s, 3H, OCH3), 3.69 (dd, J4,3 = 4.4, J4,5 = 9.1, 1H, H4), 3.91 (dd, J5,1 
= 9.7, J5,4 = 9.1, 1H, H5), 4.15 (B of ABX3, JAB = 10.7 Hz, JBX = 7.1 Hz, 1H, one of CO2CH2CH3), 
4.23 (A of ABX3, JAB = 10.7 Hz, JAX = 7.1 Hz, 1H, one of CO2CH2CH3), 4.31 (d, J1,5 = 9.7, 1H, H1), 
5.39 (d, J3,4 = 4.4, 1H, H3). 
13C NMR (125 MHz, CDCl3):  13.1, 52.2, 55.1, 55.2, 58.9, 60.7, 93.1, 
96.9, 99.2, 169.1. -Hemiketal: 1H NMR (500 MHz, CD3OD):  1.27 (t, 3H, CO2CH2CH3), 3.25 (s, 
3H, OCH3), 3.63 (dd, J4,3 = 4.4, J4,5 = 10.5, 1H, H4), 3.79 (dd, J5,1 = 9.6, J5,4 = 10.5, 1H, H5), 4.15 (B 
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of ABX3, JAB = 10.7 Hz, JBX = 7.1 Hz, 1H, one of CO2CH2CH3), 4.23 (A of ABX3, JAB = 10.7 Hz, JAX 
= 7.1 Hz, 1H, one of CO2CH2CH3), 4.28 (d, J1,5 = 9.6, 1H, H1), 5.40 (d, J3,4 = 4.4, 1H, H3). 
13C 
NMR (125 MHz, CDCl3):  13.1, 55.1, 55.3, 55.9, 58.2, 60.8, 93.9, 97.0, 97.8, 169.0.  
Hemiketal Formation with Cyclobutanone 121  
 
The 3-methoxycyclobutanone 121 (18.0 mg, 0.060 mmol) was dissolved in methanol-d4 (1 g). 
Equilibrium was reached in 14 d and the ketone:: ratio was 85:12:2.6. Ketone: 1H NMR (500 
MHz, CDCl3):  1.30 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.34 (s, 3H, OCH3), 3.88 (s, 1H, H4), 4.20 (q, 
J = 7.1 Hz, 2H, CO2CH2CH3), 4.72 (d, J1,5 = 8.6 Hz, 1H, H1) 5.10 (d, J5,1 = 8.6 Hz, 1H, H5), 5.54 (s, 
1H, H3). 
13C NMR (125 MHz, CDCl3):  12.9, 55.1, 57.8, 59.1, 61.7, 65.0, 90.4, 95.4, 168.1, 192.7. 
-Hemiketal: 1H NMR (500 MHz, CD3OD):  1.30 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.49 (s, 3H, 
OCH3), 3.72 (app t., J4,3 = 1.5 Hz, J4,5 = 1.5 Hz, 1H, H4), 4.15 (dd, J5,1 = 9.7 Hz, J5,4 = 1.5 Hz, 1H, 
H5), 4.20 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.47 (d, J1,5 = 9.7 Hz, 1H, H1), 5.70 (d, J3,4 = 1.5 Hz, 1H, 
H3). 
13C NMR (125 MHz, CDCl3):  12.9, 55.5, 55.6, 57.6, 61.6 (2C), 97.2, 169.5.691 -Hemiketal: 
1H NMR (500 MHz, CD3OD):  1.30 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.40 (s, 3H, OCH3), 3.56 (dd, 
J5,1 = 9.7 Hz, J5,4 = 8.6 Hz, 1H, H5), 3.64 (dd, J4,3 = 7.0 Hz, J4,5 = 8.6 Hz, 1H, H4), 4.20 (q, J = 7.1 
Hz, 2H, CO2CH2CH3), 4.28 (d, J1,5 = 9.7 Hz, 1H, H1), 5.68 (d, J3,4 = 7.0 Hz, 1H, H3)  
Hemiketal Formation with Cyclobutanone 122  
 
The 3-isopropoxycyclobutanone 122 (8.9 mg, 0.027 mmol) was dissolved in methanol-d4 (0.4 
g). Equilibrium was reached within 7 d and the ketone:: ratio was 2:51:47 by the integration of 
peaks in the 500 MHz 1H NMR. Ketone: 1H NMR (500 MHz, CD3OD):  4.76 (d, J1,5 = 8.1 Hz, 1H, 




1H NMR (500 MHz, CD3OD):  1.09 (d, J = 6.1 Hz, 3H, one of CHCH3), 1.13 (d, J = 6.1 Hz, 3H, one 
of CHCH3), 1.28 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.68 (dd, J4,3 = 4.5 Hz, J4,5 = 8.9 Hz, 1H, H4), 
3.76 (sept., J = 6.1 Hz, 1H, CHMe2), 3.93 (app. t, J5,1 = 9.7 Hz, J5,4 = 8.9 Hz, 1H, H5), 4.17 (m, 2H, 
CO2CH2CH3), 4.34 (d, J1,5 = 9.7 Hz, 1H, H1), 5.64 (d, J3,4 = 4.5 Hz, 1H, H3). 
13C NMR (125 MHz, 
CD3OD):  13.2, 19.4, 21.8, 52.5, 55.2, 58.9, 60.7, 70.3, 92.8, 93.1, 99.3, 169.2. -Hemiketal: 1H 
NMR (500 MHz, CD3OD):  1.10 (d, J = 6.1 Hz, 3H, one of CHCH3), 1.12 (d, J = 6.1 Hz, 3H, one of 
CHCH3), 1.29 (m, 3H, CO2CH2CH3), 3.62 (dd, J4,3 = 4.5 Hz, J4,5 = 10.4 Hz, 1H, H4), 3.72 (sept., J = 
6.1 Hz, 1H, CHMe2), 3.81 (dd, J5,1 = 9.7 Hz, J5,4 = 10.4 Hz, 1H, H5), 4.15–4.19 (m, 2H, CO2CH2CH3), 
4.31 (d, J1,5 = 9.7 Hz, 1H, H1), 5.65 (d, J3,4 = 4.5 Hz, 1H, H3). 
13C NMR (125 MHz, CD3OD):  
13.2, 19.4, 21.7, 55.4, 56.2, 58.2, 60.7, 70.4, 92.9, 94.1, 97.9, 169.1.  
Hemiketal Formation with Cyclobutanone 122  
 
The 3-isopropoxycyclobutanone 122 (21.7 mg, 0.066 mmol) was dissolved in methanol-d4 (1 g). 
Equilibrium was reached in 14 d and the ketone:: ratio was 77:19:4. Ketone: 1H NMR (500 MHz, 
CD3OD):  1.13 (d, J = 6.1 Hz, 1H, one of CH(CH3)2), 1.15 (d, J = 6.1 Hz, 1H, one of CH(CH3)2), 
1.29 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.81 (s, 1H, H4), 4.00 (sept., J = 6.1 Hz, 1H, CHMe2), 4.20 (q, 
J = 7.1 Hz, 2H, CO2CH2CH3), 4.71 (d, J1,5 = 8.5 Hz, 1H, H1), 5.12 (d, J5,1 = 8.5 Hz, 1H, H5), 5.78 (s, 
1H, H3). 
13C NMR (125 MHz, CD3OD):  12.9, 18.6, 21.4, 57.9, 59.3, 61.7, 65.4, 69.2, 90.1, 90.4, 
168.3, 192.4. -Hemiketal: 1H NMR (500 MHz, CD3OD):  1.15 (d, J = 6.2 Hz, 3H, one of 
CH(CH3)2), 1.24 (d, J = 6.2 Hz, 3H, one of CH(CH3)2), 1.29 (t, 3H, J = 7.1 Hz, CO2CH2CH3), 3.65 
(dd, J4,3 = 1.5 Hz, J4,5 = 1.8 Hz, 1H, H4), 4.10 (sept., J = 6.2 Hz, 1H, CHMe2), 4.13 (dd, J5,1 = 9.6 Hz, 
J5,4 = 1.8 Hz, 1H, H5), 4.19 (q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.45 (d, J1,5 = 9.6 Hz, 1H, H1), 5.90 (d, 
J3,4 = 1.5 Hz, 1H, H3). 
13C NMR (125 MHz, CD3OD):  12.9, 18.9, 21.3, 55.8, 57.4, 61.5, 61.6, 
71.2, 92.5, 95.6, 100.8, 169.6. -Hemiketal: 1H NMR (500 MHz, CD3OD):  1.10 (d, J = 6.1 Hz, one 
of CH(CH3)2), 1.19 (d, J = 6.1 Hz, one of CH(CH3)2), 1.29 (m, 3H, CO2CH2CH3), 3.42 (app. t, J5,1 = 
9.7 Hz, J5,4 = 9.7 Hz, 1H, H5), 3.57 (dd, J4,3 = 9.6 Hz, J4,5 = 9.7 Hz, 1H, H4), 4.18 (m, 1H, H1), 4.2 
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(m, 2H, CO2CH2CH3), 5.68 (d, J3,4 = 9.6 Hz, 1H, H3).  
Hemiketal Formation with Cyclobutanone 123  
 
The 3-tert-butoxycyclobutanone 123 (10.8 mg, 0.031 mmol) was dissolved in methanol-d4 (0.5 
g). Equilibrium was reached within 7 d and the ketone:: ratio was 2.1:52:46. Ketone: 1H NMR 
(500 MHz, CD3OD):  1.25 (s, 9H, C(CH3)3), 1.30 (t, 3H, J = 7.1 Hz, CO2CH2CH3), 3.76 (dd, J4,3 = 
5.1 Hz, J4,5 = 5.7 Hz, 1H, H4), 4.05–4.25 (m, 2H, CO2CH2CH3), 4.51 (d, J1,5 = 8.3 Hz, 1H, H1), 5.13 
(dd, J5,1 = 8.3 Hz, J5,4 = 5.7 Hz, 1H, H5), 5.94 (d, J3,4 = 5.1 Hz, 1H, H3). -Hemiketal: 1H NMR 
(500 MHz, CD3OD):  1.21 (s, 9H, C(CH3)3), 1.30 (t, 3H, CO2CH2CH3), 3.60 (dd, J4,3 = 5.1 Hz, J4,5 
= 8.3 Hz, 1H, H4), 3.91 (dd, J5,1 = 9.6 Hz, J5,4 = 8.3 Hz, 1H, H5), 4.10 (B of ABX3, JAB = 10.8 Hz, JBX 
= 7.1 Hz, 1H, one of CO2CH2CH3), 4.22 (A of ABX3, JAB = 10.8 Hz, JAX = 7.1 Hz, 1H, one of 
CO2CH2CH3), 4.39 (d, J1,5 = 9.6 Hz, 1H, H1), 5.90 (d, J3,4 = 5.1 Hz, 1H, H3). 
13C NMR (125 MHz, 
CDCl3):  13.1, 26.9, 53.0, 55.5, 59.2, 60.7, 75.6, 88.5, 93.6, 99.4, 169.2. -Hemiketal: 1H NMR 
(500 MHz, CD3OD):  1.19 (s, 9H, C(CH3)3), 1.29 (t, 3H, J = 7.1 Hz, CO2CH2CH3), 3.61 (dd, J4,3 = 
5.3, J4,5 = 10.6 Hz, 1H, H4), 3.85 (dd, J5,1 = 9.6 Hz, J5,4 = 10.6 Hz, 1H, H5), 4.05 (B of ABX3, JAB = 
10.8 Hz, JBX = 7.1 Hz, 1H, one of CO2CH2CH3), 4.24 (A of ABX3, JAB = 10.8 Hz, JAX = 7.1 Hz, 1H, 
one of CO2CH2CH3), 4.36 (d, J1,5 = 9.6 Hz, 1H, H1), 5.85 (d, J3,4 = 5.3 Hz, 1H, H3). 
13C NMR (125 
MHz, CDCl3):  13.1, 26.9, 55.8, 56.6, 58.4, 60.8, 75.6, 88.8, 94.2, 98.1, 169.5.  
Hemiketal Formation with Cyclobutanone 123  
 
The 3-tert-butoxycyclobutanone 123 (20.6 mg, 0.060 mmol) was dissolved in methanol-d4 (1 g). 
Equilibrium was reached in 12 d and the ketone:: ratio was 60:26:14. Ketone: 1H NMR (500 MHz, 
CD3OD):  1.25 (s, C(CH3)3), 1.29 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.68 (s, 1H, H4), 4.20 (q, J = 7.1 
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Hz, 2H, CO2CH2CH3), 4.68 (d, J1,5 = 8.5 Hz, 1H, H1), 5.07 (d, J5,1 = 8.5 Hz, 1H, H5), 5.89 (s, 1H, 
H3). 
13C NMR (125 MHz, CD3OD):  13.1, 26.9, 59.5, 59.6, 61.6, 65.4, 76.9, 86.9, 90.5, 168.4, 
192.9. -Hemiketal: 1H NMR (500 MHz, CD3OD):  1.29 (3H, CO2CH2CH3), 1.32 (s, C(CH3)3), 
3.58 (dd, J4,3 = 3.6 Hz, J4,5 = 3.7 Hz, 1H, H4), 3.93 (dd, J5,1 = 9.6 Hz, J5,4 = 3.7 Hz, 1H, H5), 4.20 
(2H, CO2CH2CH3), 4.35 (d, J1,5 = 9.6 Hz, 1H, H1), 5.95 (d, J3,4 = 3.6 Hz, 1H, H3). 
13C NMR (125 
MHz, CD3OD):  13.1, 26.9, 55.8, 56.6, 60.9, 61.4, 77.6, 88.7, 95.2, 100.6, 170.3. -Hemiketal: 1H 
NMR (500 MHz, CD3OD):  1.19 (s, C(CH3)3), 1.29 (3H, CO2CH2CH3), 3.37 (dd, J5,1 = 9.8 Hz, J5,4 = 
10.3 Hz, 1H, H5), 3.53 (dd, J4,3 = 9.0 Hz, J4,5 = 10.3 Hz, 1H, H4), 4.16 (d, J1,5 = 9.8 Hz, 1H, H1), 4.20 
(2H, CO2CH2CH3), 5.79 (d, J3,4 = 9.0 Hz, 1H, H3). 
13C NMR (125 MHz, CD3OD):  13.1, 26.9, 
54.9, 55.0, 58.4, 61.0, 75.3, 90.3, 94.2, 98.4, 172.2.  



































The 3-acetoxycyclobutanone 124 (25.2 mg, 0.077 mmol) was dissolved in methanol-d4 (1 g). 
Equilibrium was reached in 14 d and the ketone:: ratio was 70:18:12 by the average integration of 
the most resolved peaks in the 1H NMR: H1 and H5 in this case. Ketone: 
1H NMR (500 MHz, 
CD3OD):  1.28 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 1.99 (s, 3H, COCH3), 3.99 (s, 1H, H4), 4.18 (app. 
q, J = 7.1 Hz, 2H, CO2CH2CH3), 4.76 (d, J1,5 = 8.6 Hz, 1H, H1), 5.21 (d, J5,1 = 8.6 Hz, 1H, H5), 6.52 
(s, 1H, H3). 
13C NMR (125 MHz, CD3OD):  13.0, 19.4, 56.2, 59.4, 62.1, 65.8, 85.9, 90.0, 167.5, 
169.1, 193.1. -Hemiketal: 1H NMR (500 MHz, CD3OD):  1.26 (t, 3H, CO2CH2CH3), 2.10 (s, 3H, 
COCH3), 3.79 (dd, J4,3 = 3.3 Hz, J4,5 = 4.1 Hz, 1H, H4), 3.86 (dd, J5,1 = 9.6 Hz, J5,4 = 4.1 Hz, 1H, H5), 
4.2 (m, 2H, CO2CH2CH3), 4.34 (d, J1,5 = 9.6 Hz, 1H, H1), 6.47 (d, J3,4 = 3.3 Hz, 1H, H3). 
13C NMR 
(125 MHz, CD3OD):  13.0, 19.2, 53.9, 56.3, 61.5, 61.9, 88.6, 167.5, 170.7.691 -Hemiketal: 1H 
NMR (500 MHz, CD3OD):  1.26 (m, 3H, CO2CH2CH3), 2.04 (s, 3H, COCH3), 3.62 (dd, J5,1 = 9.8 
Hz, J5,4 = 7.5 Hz, 1H, H5), 3.82 (dd, J4,3 = 5.6 Hz, J4,5 = 7.5 Hz, 1H, H4), 4.2 (m, 2H, CO2CH2CH3), 
4.31 (d, J1,5 = 9.8 Hz, 1H, H1), 6.51 (d, J3,4 = 5.6 Hz, 1H, H3). 
13C NMR (125 MHz, CD3OD):  
13.0, 19.2, 53.5, 58.5, 60.8, 61.5, 88.9, 167.5, 170.8.691  
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Hemiketal Formation with Cyclobutanone 118  
 
The cyclobutanone 118 (21.2 mg, 0.079 mmol) was dissolved in methanol-d4 (1 g). The system 
required 4 d to reach equilibrium and the ketone:: ratio was 4:62:34. Ketone: 1H NMR (500 MHz, 
CD3OD):  1.30 (t, 3H, J = 7.1 Hz, CO2CH2CH3), 4.20 (m, 2H, CO2CH2CH3), 5.13 (d, J1,5 = 10.0 Hz, 
1H, H1), 5.53 (dd, J5,1 = 10.0 Hz, J5,3 = 1.8 Hz, 1H, H5), 7.64 (d, J3,5 = 1.8 Hz, 1H, H3). -Hemiketal: 
1H NMR (500 MHz, CD3OD):  1.30 (t, 3H, CO2CH2CH3), 4.20 (m, 2H, CO2CH2CH3), 4.45 (dd, J5,1 
= 10.2 Hz, J5,3 = 1.1 Hz, 1H, H5), 4.80 (d, J1,5 = 10.2 Hz, 1H, H1), 7.50 (d, J3,5 = 1.1 Hz, 1H, H3). 
13C 
NMR (125 MHz, CD3OD):  13.1, 58.3, 60.2, 61.0, 95.1, 103.1, 125.3, 146.0, 162.9. -Hemiketal: 
1H NMR (500 MHz, CD3OD):  1.30 (t, 3H, CO2CH2CH3), 4.20 (m, 2H, CO2CH2CH3), 4.35 (dd, J5,1 
= 10.0 Hz, J5,3 = 1.5 Hz, 1H, H5), 4.72 (d, J1,5 = 10.0 Hz, 1H, H1), 7.43 (d, J3,5 = 1.5 Hz, 1H, H3). 
13C 
NMR (125 MHz, CD3OD):  13.1, 59.7, 60.2, 62.2 95.5, 102.6, 126.4, 145.0, 163.2  
Hemiketal Formation with Cyclobutanone 126  
 
The cyclobutanone 126 (25.6 mg, 0.129 mmol) was dissolved in methanol-d4 (1 g). 16 d were 
required for the system to reach equilibrium and the ketone:: ratio was 62:23:15. Ketone: 1H NMR 
(500 MHz, CD3OD):  1.31 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 3.33 (ddd, J7,1 = 5.7 Hz, J7,5 = 3.3 Hz, 
Jgem = 18.5 Hz, 1H, H7), 3.83 (ddd, J7,1 = 8.5 Hz, J7,5 = 5.2 Hz, Jgem = 18.5 Hz, 1H, H7), 4.18–4.24 
(m, 2H, CO2CH2CH3), 4.32 (app. dt, J1,5
 = 8.5 Hz, J1,7
 = 8.5 Hz, J1,7
 = 5.7 Hz, 1H, H1), 5.14 (dddd, 
J5,1 = 8.5 Hz, J5,3 = 1.7 Hz, J5,7 = 5.2 Hz, J5,7 = 3.3 Hz, 1H, H5), 7.62 (d, J3,5 = 1.7 Hz, H3). 
13C NMR 
(125 MHz, CD3OD):  13.2, 37.2, 60.3, 60.4, 75.6, 120.9, 144.2, 162.3, 201.0. -Hemiketal: 1H 
NMR (500 MHz, CD3OD):  1.30 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 2.40 (ddd, J7,1 = 6.5 Hz, J7,5 = 
1.2 Hz, Jgem = 13.1 Hz, 1H, H7), 2.91 (ddd, J7,1 = 8.4 Hz, J7,5 = 3.5 Hz, Jgem = 13.1 Hz, 1H, H7), 
3.99 (app. dt, J1,5
 = 8 Hz, J1,7
 = 8.4 Hz, J1,7
 = 6.5 Hz, 1H, H1), 4.18–4.24 (m, 2H, CO2CH2CH3), 
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4.20–4.24 (m, 1H, H5), 7.53 (s, 1H, H3). 
13C NMR (125 MHz, CD3OD):  13.2, 38.4, 47.2, 60.1, 
102.7, 125.8, 144.3, 163.9. -Hemiketal: 1H NMR (500 MHz, CD3OD):  1.26 (t, J = 7.1 Hz, 3H, 
CO2CH2CH3), 3.46 (ddd, J7,1 = 6.9 Hz, J7,5 = 1.2 Hz, Jgem = 12.8 Hz, 1H, H7), 2.73 (ddd, J7,1 = 8.2 
Hz, J7,5 = 3.6 Hz, Jgem = 12.8 Hz, 1H, H7), 4.05 (app. dt, J1,5
 = 8 Hz, J1,7
 = 8.2 Hz, J1,7
 = 6.9 Hz, 
1H, H1), 4.18–4.24 (m, 2H, CO2CH2CH3), 4.30 (m, 1H, H5), 7.46 (s, 1H, H3). 
13C NMR (125 MHz, 
CD3OD):  13.2, 38.6, 46.3, 60.0, 64.1, 102.2, 126.1, 143.6, 164.1  
Hemiketal Formation with Cyclobutanone 118 in Trifluoroethanol-d3.
693  
 
The dichlorocyclobutanone 118 (24.9 mg, 0.0932 mmol) was dissolved in trifluoroethanol-d3 (1 g). 
After 8 d in solution the ketone:: ratio was 96.6:2.4:1.0. Ketone: 1H NMR (500 MHz, 
CF3CD2OD):  1.29 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 4.20 (B of ABX3, JBX = 7.1 Hz, JBA = 10.6 Hz, 
2H, one of CO2CH2CH3), 4.22 (A of ABX3, JAX = 7.1 Hz, JAB = 10.6 Hz, 2H, one of CO2CH2CH3), 
4.91 (d, J1,5 = 10.0 Hz, 1H, H1), 5.37 (dd, J5,1 = 10.0 Hz, J5,3 = 1.8 Hz, 1H, H5), 7.52 (d, J3,5 = 1.8 Hz, 
1H, H3). 
13C NMR (125 MHz, CF3CD2OD):  14.4, 61.2, 63.7, 72.7, 95.3, 123.4, 148.2, 165.0, 192.0. 
-Hemiketal: 1H NMR (500 MHz, CF3CD2OD):  4.43 (dd, J5,1 = 10.2 Hz, J5,3 = 1.0 Hz, 1H, H5), 
4.76 (d, J1,5 = 10.2 Hz, 1H, H1).
694 -Hemiketal: 1H NMR (500 MHz, CF3CD2OD):  4.51 (d, J5,1 = 9 
Hz, 1H, H5), 4.76 (d, J1,5 = 9 Hz, 1H, H1).
694  
Hemiketal Formation with Cyclobutanone 118 in Isopropanol-d8.
695  
 
The dichlorocyclobutanone 118 (25.0 mg, 0.0936 mmol) was dissolved in isopropanol-d8 (0.8 mL). 
After 8 d in solution the ketone:: ratio was 63:33:3.8. Ketone: 1H NMR (500 MHz, (CD3)2CDOD): 
 1.29 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 4.17 (B of ABX3, JBX = 7.3 Hz, JBA = 10.8 Hz, 2H, one of 
CO2CH2CH3), 4.22 (A of ABX3, JAX = 7.1 Hz, JAB = 10.8 Hz, 2H, one of CO2CH2CH3), 5.13 (d, J1,5 = 
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10.1 Hz, 1H, H1), 5.54 (dd, J5,1 = 10.1 Hz, J5,3 = 1.8 Hz, 1H, H5), 7.58 (d, J3,5 = 1.8 Hz, 1H, H3). 
13C 
NMR (125 MHz, (CD3)2CDOD):  14.4, 60.0, 61.4, 72.2, 94.6, 122.7, 145.8, 161.7, 188.0. -
Hemiketal: 1H NMR (500 MHz, (CD3)2CDOD):  1.26 (t, J = 7.2 Hz, 3H, CO2CH2CH3), 4.12 (B of 
ABX3, JBX = 7.2 Hz, JBA = 10.9 Hz, 2H, one of CO2CH2CH3), 4.17 (A of ABX3, JAX = 7.2 Hz, JAB = 
10.9 Hz, 2H, one of CO2CH2CH3), 4.36 (d, J5,1 = 10.2 Hz, 1H, H5), 4.66 (d, J1,5 = 10.2 Hz, 1H, H1), 
7.37 (s, 1H, H3). 
13C NMR (125 MHz, (CD3)2CDOD):  14.4, 60.1, 60.8, 63.3, 97, 104, 126.6, 146.1, 
163.6. -Hemiketal: 1H NMR (500 MHz, (CD3)2CDOD):  1.26–1.28 (m, 3H, CO2CH2CH3), 4.15–
4.25 (m, 2H, CO2CH2CH3), 4.36 (d, J5,1 = 9.9 Hz, 1H, H5), 4.57 (d, J1,5 = 9.9 Hz, 1H, H1), 7.27 (s, 1H, 
H3).  
Hemiketal Formation with Cyclobutanone 118 in tert-Butanol-d10.
696  
 
The dichlorocyclobutanone 118 (34.2 mg, 0.128 mmol) was dissolved in liquid t-butanol-d10 (1 g, 
mp: 11 C). After 18 d in solution the ketone:: ratio was ≥94:4.7:≤0.9. Ketone: 1H NMR (300 
MHz, (CD3)3COD):  1.28 (t, J = 7.1 Hz, 3H, CO2CH2CH3), 4.16 (B of ABX3, JBX = 7.1 Hz, JBA = 
10.9 Hz, 2H, one of CO2CH2CH3), 4.22 (A of ABX3, JAX = 7.1 Hz, JAB = 10.9 Hz, 2H, one of 
CO2CH2CH3), 5.09 (d, J1,5 = 10.0 Hz, 1H, H1), 5.53 (d, J5,1 = 10.0 Hz, 1H, H5), 7.56 (s, 1H, H3). -
Hemiketal: 1H NMR (300 MHz, (CD3)3COD):  4.35 (d, J5,1 = 10.0 Hz, 1H, H5), 4.62 (d, J1,5 = 10.0 
Hz, 1H, H1), 7.33 (s, 1H, H3).












































































































































































































































































































































































































































































































































































a This table provides the structures of representative -lactams of each class and should not be considered to 
be a comprehensive list of all -lactam antibiotics. b Expanded-spectrum refers to antibiotic activity and not -












clav or tazo c
Characteristics 
Representative 
enzymes   
1 C Cephalosporins No Greater hydrolysis of 
cephalosporins than PenG; 
hydrolyze cephamycins 
E. coli AmpC, P99, 
ACT-1, CMY-2, FOX-
1, MIR-1 
1e C Cephalosporins No Increased hydrolysis of 




2a A Penicillins Yes Greater hydrolysis of PenG than 
cephalosporins 
PC1, BcI 
2b A Penicillins, early 
cephalosporins 
Yes Similar hydrolysis of PenG and 
cephalosporins 
TEM-1, TEM-2, SHV-1
2be A Extended-spectrum 
cephalosporins 
Yes Increased hydrolysis of oxi-
mino--lactams (cefotaxime, 
ceftazidime, ceftizxone, 
cefepime, aztreonam)  
TEM-3, TEM-26,  
SHV-2, CTX-M-15, 
K1,  PER-1, VEB-1 
2br A Penicillins No Resistance to clavulanic acid, 
sulbactam, and tazobactam 
TEM-30,  TEM-31, 
SHV-10 
2ber A Extended-spectrum 
cephalosporins, 
monobactams 
No Increased hydrolysis of 
oximino--lactams combined 
with resistance to clav/sul/tazo 
TEM-50  
2c A Carbenicillin Yes Increased hydrolysis of 
carbenicillin 
PSE-1, CARB-3 
2ce A Carbenicillin, 
cefepime 
Yes Increased hydrolysis of carbeni-
cillin, cefepime, and cefpirome 
RTG-4 
2d D Cloxacillin Variable Increased hydrolysis of 
cloxacillin or oxacillin 
OXA-1, OXA-2,   
OXA-10 
2de D Extended-spectrum 
cephalosporins 
Variable Hydrolyzes cloxacillin or oxa-
cillin and oximino--lactams 
OXA-11, OXA-15, 
OXA-18,d OXA-45 d 
2df D Carbapenems Variable Hydrolyzes cloxacillin or 
oxacillin and carbapenems 
OXA-23, OXA-40, 
OXA-48 
2e A Extended-spectrum 
cephalosporins 
Yes Hydrolyzes cephalosporins, 
Inhibited by clav but not 
aztreonam 
CepA 
2f A Carbapenems Variable Increased hydrolysis of 
carbapenems, oximino--
lactams, cephamycins 
KPC-2, IMI-1, SME-1, 
GES-2 to GES-15,  
NMC-1 
3a B (B1) Carbapenems No Broad-spectrum hydrolysis 
including carbapenems but not 
monobactams 
BcII, IMP-1, VIM-1, 
CcrA, IND-1 
 B (B3)    L1, GOB-1, FEZ-1 
3b B (B2) Carbapenems No Preferential hydrolysis of 
carbapenems 
CphA, Sfh-1 
a Adapted from refs 235–238, 697 and tables at www.lahey.org/studies. b See ref 231. c clav = clavulanic acid, 
tazo = tazobactam, sul = sulbactam, PenG = penicillin G = benzyl penicillin. d Classifications of OXA-18 and 




Known -Lactamase Inhibitors a 







A, (C), (D) 
- Beecham, 1976: X-ray crystal structure.443  
- Weak antibiotic activity (31–125 g/mL),119 but a potent inhibitor of 
penicillinases and cephalosporinases.398  
- Potent mechanism-based inhibitor of penicillinases such as TEMs and 
SHVs (class A) (IC50 values < 0.1 g/mL); ineffective against MBLs 
(class B); much less active against cephalosporinases (class C); 
variable efficacy against OXAs (class D).403,414     
- Herzberg, 1992: X-ray of complex with TEM-1 (class A) (1BLC).455 
- Sulton et al., 2006: Mechanistic studies of TEM-1 and SHV-
1inactivation.459   
- Blanchard, 2008: X-ray of complex with BlaC (class A) (3CG5).698  
- X-ray structure of clavulanate bound to a E166A mutant of SHV-1 
(2A49)699 and a double mutant (M69V, E166A) of SHV-1 (2H0T).700 




- Pfizer, 1978: Weak antibacterial activity but showed similar potency 
against penicillinases to that of clavulanate.446 
- Potent mechanism-based inhibitor of class A enzymes, but much less
effective against class C and class D enzymes. Ineffective against 
MBLs.414  
- Labia,460 Knowles,461–464 and Mobashery465 groups, 1981–1994: 
Mechanisms of inhibition of class A -lactamases.   
- Poor inhibitor of OXA-10 (class D).704  
- X-ray structures of sulbactam bound to the E166A mutant of SHV-1 
(2A3U)699 and the M69V E166A double mutant of SHV-1 (2H10).700 
- Mechanism in SHV-1: Raman studies by Carey.702  
- Akova, 2008: Review of sulbactam-containing -lactamase inhibitor 
combinations.703  
3 A 
- Cartwright, Coulson, 1979: irreversible inhibition of PC1 at pH 7.469  





- Aronoff, 1984: Synergy with Amoxicillin and Ampicillin and 
comparisons with clavulanate.475  
- Bush, 1993: Kinetic interactions of tazobactam with -lactamase 
from all major structural classes.449 
- Effective mechanism-based inhibitor vs TEM-1. 
- Poor activity against MBLs but some activity against CcrA. 
- IC50 value of 48 M vs AmpC (class C).  
- Poor inhibitor of OXA-10 (class D).704 
- X-ray structure of tazobactam bound to WT SHV-1 (1VM1),705 a 
S130G mutant of SHV-1 (1TDG),706 an E166A mutant of SHV-1 




- Loosemore and Pratt, 1978: Epimerization in solution and preparation 
of 6-bromopenicillanic acid.479  
- Pratt and Loosemore, 1978: Potent irreversible inhibition of BcI and 
enzyme of B. licheniformis by 6-BPA; less potent vs penicillinases 
of S. aureus and E. coli. Poor inhibition of BcII.250  
- Knott-Hunziker et al., 1979: 3H-labelled 6-BPA and labelling of 
Ser44 of BcI.251   
- Loosemore, Cohen, Pratt, 1980: Kinetics of inactivation of BcI.480   





- Pfizer, 1980: 6-Iodopenicillanic acid via SN2 reactions from 
penicillin-6-triflates.707  
- Daehne, 1980: Synthesis and purification of 6-halopenicillins.708  
- Sauvage (Liège), Pratt, JACS 2009: X-rays in the class A enzyme 
BS3 (2WK0) and R39 DD-transpeptidase (2WKE).483 
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- Roveri, 1993: Poor inhibition of BcI (mM IC50 values).
709   
- The 6-chloropenicillanic acid is less potent than the bromo- and 
iodo penicillinates.708   
8 A 
- Dmitrienko and Viswanatha groups, 1982–1985.470,471,472,473,474  
- Potent mechanism-based inhibitor of B. cereus 569/H, B. 
licheniformis 749/C, and E. coli R6K. But less effective against S. 
aureus PC1. 
9 (A) 
- Changov et al., 1999 (Bulgarian group): Synergy with Ampicillin 
against Gram-positives; poor synergy against Gram-negatives.710 










- Knowles, 1984: Designed to generate an ,-unsaturated acylenzyme 
upon ring-opening of -lactam.484  
11 
 
A, C, D 
- Hoffman–La Roche, 1982: Potent irreversible inhibitor of PC1, 
TEMs, SHV-1, OXAs, and chromosomal -lactamases (class C). 
More potent than clavulanate and sulbactam.485a  
- Hoffman–La Roche, 1982: Poor affinity for PBPs of E. coli. Synergy 
with piperacillin and ceftriaxone.485b   
- Hoffman–La Roche, 1983: Mechanism of inactivation of TEM-1.485c 
- Hoffman–La Roche, 1986 and 1992: Prodrug evaluations.485e,485g   
- Hoffman–La Roche, 1987: the geometrical isomer is less active.485f 
12 A - Bycroft, 1988: “Exhibit significant -lactamase inhibitory and 




- Wyeth patent 2002: Improves antimicrobial activity of piperacillin.712  
- Wyeth 2003: Mechanism-based inhibition similar to that of the 6-
alkylidene derivatives.496 
- IC50 values 0.1–13 M against TEM-1 (class A) and 0.02–66 M vs 
AmpC (class C).  
14 A, B, C - Wyeth group, 2000: Mid to sub-M activities reported against TEM-
1 (class A), CcrA (class B), and AmpC (class C).713   
15 A 
- Buynak, Bonomo, Carey, van den Akker, 2006: X-ray structure of a 
complex of SA2-13 with SHV-1 (class A) (2H5S).466  
- Rational design of an inhibitor that could form a long-lived trans-
enamine intermediate.  
16 A, C 
- Naeja Pharmaceuticals, 2005 (Edmonton, AB):  Low to sub-
micromolar IC50 values against TEM-1 (class A), CTX-1 (class A), 
and a class C enzyme.477   
17 A, C 
- Buynak, 2005: IC50 values of 34 M against TEM-1 (class A) and 28 
M against P99 (class C) for the carboxymethyl compound; better 
than sulbactam.714  
- IC50s for 3-methylidene analogues were >1 mM.  
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18 A, C, D 
- Pfizer, 1986: more potent than clavulanate against -lactamases from 
S. aureus and E. coli. Its reaction with methoxide provided insight 
into its likely mechanism of inhibition.486  



























- Buynak, 1999: Moderate inhibition of TEM-1 (class A), PC1 (class 
A), and P99 (class C). Mid-M to mid-nM IC50s.715  
- Buynak, 2004: More active against Bacillus anthracis class A Bla1 
(low to high nM) than class B Bla 2 (low M).716  
- Buynak, Bonomo, Carey, 2007: One analogue (SA-1-204) has a Ki
value of 42 nM against SHV-1 (class A) and 1 M against OXA-1 
(class D).494 Raman spectroscopy indicates that hey bind as Michaelis 
complexes. 
- Buynak, Bonomo, 2009: X-ray structure of a complex of LN-1-255 
(Ar = 2-pyridyl) in SHV-1 (3D4F).717 LN-I-255 has Ki values of 110 
and 100 nm against SHV-1 and SHV-2; Improves pipericillin potency 
vs SHV-producing E. coli.  
- Buynak, Bonomo, 2010: LN-I-255 has low to sub-micromolar Kis 
against class D enzymes: 0.70 (OXA-1), 8.0 (OXA-10), 1.4 (OXA-
14), 0.20 (OXA-17), 0.65 (OXA-24/40).718  
20 C 
- Buynak, 1993: The vinylidene PAS with R = t-Bu showed an IC50 of 
1 M vs P99, approximately equal in potency to clavulanate.488 
- Buynak, 1994: The cephem sulfone with R = t-Bu gave an IC50 of 
0.05 g/mL vs P99 and other derivatives sub-micromolar as well.489  
21 A, C 
- Buynak, 1995: 6-(Carboxymethylene)PAS showed potent, partially 
irreversible broad spectrum activity against class A and C enzymes.490
- IC50 values against TEM-2, P99, and E-2 (from E. cloacae) were 120 
nM, 45 nM, and 91 nM, respectively.  












- SynPhar Labs (Edmonton), 1996: IC50 of 0.2 and 0.7 M vs TEM 
(class A) and P99 (class C) and synergy with ampicillin against -




- Buynak patent 2000: Antibacterial Activity of -Lactamase-
Inhibiting Cephalosporins.719  
- Buynak, 2000: Potent IC50 values against TEM-1 (class A), PC1 
(class A), P99 (class C), and GC1 (class C).720  
- Buynak, 2000: Synthesis of alkylidene cephalosporins.721  
- Knox, 2001: X-ray structure of an alkylidene cephem sulfone in GC1 
(1GA0).722  
- Buynak, 2002: Potent IC50 values against TEM-1 (class A) and P99 
(class C): sub-micromolar to low nanomolar.723  
- Buynak patent for preparation, 2003.724  
- Buynak, 2001: Coupling reactions with 3-stannylated cephem 
sulfones.725  
24 A, C 
- Buynak, 2000: IC50 values: Low-M against TEM-1 (class A), high 
M vs PC1 (class A), nanomolar against P99 (class C).493  
- Buynak, Bonomo, 2010: ASR-II-292 has low-M Ki values against 
OXAs: 1.40 (OXA-1), 17 (OXA-10), 4.0 (OXA-14), 0.87 (OXA-17), 
2.4 (OXA-24/40).718  
25 A, B, C 
- Buynak patent 2003, BMCL 2004: Low M IC50 values against TEM-
1 (class A), L1 (class B), BcII (class B), and P99 (class C).556,726  
- Buynak, 2004: More active against Bacillus anthracis class B Bla2 
(low M) than class A Bla1 (high M).716  
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N-hydroxy cephalosporins oximino cephalosporins
B 
(A, C, D) 
- Pratt, Buynak, 2009: Intended for both serine- and metallo--
lactamases, but they are turned over by TEM-1 (class A), P99 (class 
C), and OXA-1 (class D).728 
- Low M IC50 values against class B MBLsVIM-2 and GIM-1 (2–270 
M).  
28  
- Sutton and Yu, patents 2009, 2010: Mechanism-based inhibitors 
designed to release a leaving group (e.g. epoxide ring-opening) and 












A, C, D 
- Beecham, 1989: Penem BRL 42715 lacks antibacterial activity but 
showed potent (0.001–0.01 g/mL) inhibition of TEM-1, SHV-1, K1, 
P99, OXA-1, PSE-4, and others; synergy with amoxicillin.497  
- SmithKline Beecham, 1994: BRL 42715 quickly inactivates class A 
(BcI, TEM-1 (Ki est. 6.3 nM), K1 (Ki est. 7.3 nM)) and the C enzyme 
P99.501  
- Mobashery, 1995: Kinetic studies with BRL 42715. Nanomolar Ki
values against TEM-1 (class A) and Q908R (class C).502  
- SmithKline Beecham and Frère groups, 1995: Kinetic studies with 
BRL 42715 and -lactamases and DD-peptidases. The penem inhibits 




- SynPhar Laboratories (Edmonton, AB), 1997: Synergy with 
piperacillin against Gram-positive and Gram-negative isolates was 





















A, B,  
C, D 
- Nukaga, 2003: X-ray structures of a penem bound to SHV-1 (class A) 
(1ONG) and GC1 (class C) (1ONH). IC50 values are 0.4, 9.0, and 6.2 
nm against TEM-1, SHV-1, and GC1, respectively.503  
- Wyeth, 2004: Low to high nM IC50s against TEM-1 (class A), Imi-1 
(class A), CcrA (class B), AmpC (class C), and OXA-1 (class 
D).506,508,509,510,511,512,731,732  
- Frère, 2005: X-ray of BRL-42715 bound to Enterobacter clocae
908R (class C) (1Y54).504  
- Bonomo, 2010: Wyeth’s Penem-1 shows synergy with piperacillin, 
aztreonam, cefotaxime, and cefepime against blaKPC-possessing K. 

































A, C, D 
- Cherry, 1978: The 2-ethyl derivative was a potent inhibitor (superior 
to clavulanate) but was inactive against intact bacteria and lacked 
chemical stability.734     
- Wild and Metzger (Bayer), 1993: Synthesis of various 6-substituted 
derivatives.735  
- Pfaendler et al., 1993: Synthesis and antibacterial activity of 
derivatives such as AM-114, which showed low MIC values (<2 
g/mL) vs S. aureus, B. fragilis, E. coli, and others.736   
- Aston University and Micron Research, UK. Amura, UK. 2003: AM-
112–AM-115 show low to high nanomolar activity against TEM-1, 
TEM-10, SHV-5 (class A enzymes), P99, S2, S+A (class C 
enzymes), OXA-1, and OXA-5 (class D enzymes).737   
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A, C, (D) 
- Carbapenems are generally poor substrates for class A and C 
enzymes. Some OXA- enzymes are susceptible, some are 
carbapenemases.  
- Mobashery, 1995: Mechanism of turnover of imipenem by TEM-1.429
- Mobashery, Samama 1998: X-ray structure of imipenem in TEM-1 
(1BT5).430  
- Shoichet, 2002: Imipenem inhibits class C enzymes. X-ray structure 
of a complex with AmpC (class C) (1LL5).432  
- Nukaga, Knox, Bonomo, 2008: Carbapenems are resistant to 
hydrolysis by SHV-1. X-ray of meropenem in SHV-1 (2ZD8) shows 
two conformations of meropenem.431   
- Blanchard, 2009: Carbapenems are poor/very slow substrates for 
BlaC (class A), allowing the determination of the X-ray structure a 
complex with meropenem (3DWZ).738  
- Queenan, 2010: Hydrolysis and inhibition profiles of -lactamases 






















- Banyu Tsukuba Research Institute (Japan), 1999: A series of 
carbapenems were screened for inhibition of IMP-1 (class B MBL).557
- J-110,441 had an IC50 of <0.1 M against IMP-1 and J-110,225 
showed an IC50 of 0.7 M; Ki of 0.18 M relative to imipenem. 
- Banyu, 2000: J-110,225 had better antibacterial activity than 
imipenem, and was hydrolyzed slower by CcrA, L1, and BcII.558 




- Glaxo, 1994: Antibacterial activity of GV104326.144 
- Wise, 1996: In vitro activity of GV104326.145  
- Tamura et al., 1998: In vivo antibacterial activities of sanfetrinem.146  
- Matagne, 2001: Kinetic study of the interaction of LK-156 and LK-
157 with class C -lactamases”.433  
- Lek Pharmaceuticals (Slovenia), 2002: Low M IC50s against TEM-
1(class A) and 908R (class C).434,739  
- Lek, 2007: Mid-nanomolar IC50s against TEM-1, SHV-1 (class A), 
and AmpC (class C).435  
- Lek, 2009: X-ray structure of LK-157 (R = Me, R1 = Me) and another 
trinem (R = n-Bu) in AmpC (2Q9M, 2Q9N).436  
- Lek patents 2009 (compounds with the hydroxyethyl sidechain).740  
36 
 




- Mobashery, 1995: 6-hydroxymethyl penicillin (1) inhibits TEM-1 
(class A) rapidly with a partition ratio (kcat/kinact) of 28; Ki = 48 M; 
kcat = 0.029 s
–1; Km = 24 M.437  
- The low rate of hydrolysis (kcat/Km = 1200 M
–1 s–1) makes it a very 
poor substrate for TEM-1; No conformational change associated with 
inhibition.  
- Mobashery, 1996: X-ray structure of 1 in TEM-1 (1TEM).438 
- Mobashery, 1998: Comparison of 1, 2, and 3 against TEM-1 and 
NMC-A (class A).439  
- Hydroxypropyl moiety is too big to fit in TEM-1 but this derivative 
(3) inactivates NMC-A with a Ki value of 390 M.  
- X-ray of the 6-hydroxypropyl derivative 3 in NMC-A (class A) 
(1BUL).   
- The 6-hydroxymethyl cmpd (1) has a Km of 70 M vs NMC-A.  
- Mobashery, 2000: 1, 1, 2, and 2 tested against OXA-10.286  
- Compounds 1 and 2 are substrates for OXA-10 but 1 and 2 are 
competitive inhibitors with Ki values of 1900 and 1200 M. 
- Mobashery, 2002:  X-ray structure of 6-hydroxypropyl (3) in 
OXA-10.440 The structure was first published in PNAS (1K54).293 
- 3 and 3 had Ki values of 300 and 240 M against OXA-10.  
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- Mobashery, 2001: Postulated that a bis(hydroxymethyl) derivative 
might be able to impair the approach of the hydrolytic water molecule 
(which approaches from different faces) in class A and class C -
lactamases.441  




- Wyeth 1999: Synthesis of several hydroxyethyl- and hydroxymethyl 
penicillins and PASs and evaluation against TEM-1 and AmpC.742  
- Most showed IC50 values in the mid-M range but the 6-
hydroxymethyl PAS was best with an IC50 of 8 nM against TEM-1 
and 1.2 M vs AmpC.  
- Also showed synergy with piperacillin vs -lactamase-producing E. 
coli and S. marcescens. 
- Wyeth 1999: 2-substituted derivatives of the hydroxymethyl 
























cephalosporins A, C 
- Fujisawa Pharma (Japan), 1989: Poor antibacterial activity alone but 
reasonable inhibitors of penicillinases and cephalosporinases.744  
41 C 
- Squibb, 1982: Discovery165 and interaction with -lactamases.514  
- Hydrolyzed slowly by TEMs (class A), but binds poorly and is active 
against class A-producing organisms. 
- Competitive, progressive inhibitor of C. freundii cephalosporinase 
(class C).167 
- Bind poorly to MBLs such as IMP-1 (class B). Not turned over.  
42 A 
- Miller, Mobashery, 1993,745 1995,746 1999,747 2000.748  
- Fast reaction with TEM-1 but activity is recovered.  
- X-rays in TEM-1 (not deposited in PDB).   


















- Naeja Pharmaceuticals, 1999: IC50 values of 2–10 nM against AmpC 
(class C); modest inhibition of TEMs (class A).749  
44 C 
- Page, Basilea Pharmaceutica 2010 : Modest inhibition of class C -
lactamases, poor inhibition of MBLs and class A enzymes, but good 
inhibition (sub-micromolar) of PBPs.750 




























- Hoffman–La Roche patent, 1992.752  
- Hoffman–La Roche, J. Med. Chem. 1998.516 
- Miller, 1997: Synthetic route.753  
- Livermore, 1997: Synergy of Ro48-1256 with -lactams against P. 
aeruginosa.517  
- Merck patent 2009:  IC50 of 1.2 M vs P99 (class C).  
- Merck, 2010: The (S)-azepine analogue 2 was better than Ro48-1256 
and was selected for preclinical development.518  
- IC50 for cmpd 2 against P. aeruginosa AmpC was 1.0 M.   
- X-ray structures of AmpC of P. aeruginosa (class C) with 2 (S)-
(2WZX) and (R)-azepine-bearing inhibitors (2WZZ).  
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- Merck patents, 2009: One compound showed an IC50 value of 465 
nM against AmpC (class C).754  
47 
 
A, C, D 
- Aventis Pharma patent, 2003: Synthesis of azabicycles.  
- Aventis Pharma, 2004: Nanomolar IC50s vs TEM-1 (8 nM) and P99 
(80 nM); Improved the antibacterial activity of ceftazidime against 
SHV- and AmpC producers.540   
- Livermore, Woodford, Novexel (France), 2008: NXL 104 improved 
the potency of cephalosporins against Enterobacteriaceae that 
produced CTX-M ESBLs, AmpC (class C), KPC (class A), SME 
(class A), and OXA-48 (class D).541  
- Novexel, 2009: Activity against KPC-2 and KPC-2-producing 
Enterobacteriaceae; IC50s of 170 nM and 35 nM after 5- and 30 min 
pre-incubations, respectively, against KPC-2.542  
- Bonomo, 2009: NXL104 effectively lowers MICs of -lactams 
against KPC-2-producing clinical isolates of K. pneumoniae.543  
- NXL104: Currently in clinical development; Displays broad-
spectrum inhibition against class A (TEM-, SHV-, and CTX-M-
types), and class C (CTX-M ESBLs), and some class D (OXA...). 
- Patents in 2009.755  
- But not effective with cephalosporins against MBL producers (IMP 
or VIM MBLs).  
48 
 
















- Cooper, 1994: Some analogues showed inhibition (>50%) of P99 at a 
fixed concentration of 200 M but poor inhibition of TEM-1.757  





- Buynak. JACS 1998: No activity against TEM-1 (class A) or P99 



























- Waley, 1978: Phenylboronic acid, m-aminobenzeneboronic acid, and 
boric acid as reversible inhibitors of BcI (class A).524  
- Waley, 1983: Inhibition of class C -lactamases by boronic acids.525  
- Jones group (UofT), 1994: Arylalkylboronic and arylboronic acids
with Ki values ranging between 13 and 3700 M against R-TEM-1.759
- Shoichet group, 1998: X-ray of m-aminophenylboronic acid (MAPB) 
bound to AmpC.760 Ki values for MAPB and MNPB (nitro) were 7.3 
and 1.2 M, respectively, vs AmpC. Inhibition is not time-dependent.
- Shoichet group, 1998: Benzo[b]thiophene-2-boronic acid was the 
most potent of several arylboronic acids tested with an IC50 of 27 nM 
against AmpC (class C).761  
- Shoichet, 1999: X-ray structure of benzo[b]thiophene-2-boronic acid 
bound to AmpC (1C3B).762    
- Shoichet group, 2002: Structure-based approach for binding site 
identification in AmpC (class C).763  
- X-ray structures of AmpC with 3-nitrophenylboronic acid (1KDS), 4-
carboxyphenylboronic acid (1KDW, 3BM6), 4-(carboxyvin2-yl)-
phenylboronic acid (1KE0), and 4,4′-biphenyldiboronic acid (1KE3).
- Shoichet, 2007: Complex of the di-N-formylmethyl derivative in 
AmpC (2I72).764 
- X-ray structures of benzo[b]thiophene-2-boronic acid with WT 
AmpC (1C3B) and the K67R mutant (3FKV).765    
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- Shoichet group 2001: X-ray structure of AmpC with a boronic acid 
lacking the carboxylic acid at the 4-position (1GA9). 
- Shoichet group and Italian group, 2010: IC50 values of high-M to 
low-M.766  
- X-ray structure of the compound shown in AmpC (3BM6); IC50 of 26 
nM.  
53 A 
- Jones group (UofT), 1995.767  
- The compounds shown are very potent against TEM-1 with Ki values 
of 5.9 and 13 nM. 
- X-ray structures of these boronic acids in TEM-1 by the Strynadka 




- Shoichet group, 2001: Several acylglycineboronic acid analogues of 
-lactams with low to sub-micromolar Ki values against TEM-1 and 
AmpC.770  
- The analogue of ceftazidime has Ki values of 0.39 and 0.020 M 
against TEM-1 and AmpC, respectively. 
- X-ray structures of AmpC with the cloxacillin analogue (1FSY) and 
the cephalothin analogue (1FSW). 
- Synergy observed with amoxicillin and cefotaxime against resistant 
strains of E. cloacae and S. aereus.   
- Bonomo, van den Akker, 2011: X-ray structures of boronic acids with 
the sidechains of cefoperazone and ceftazidime bound to SHV-1 




- Shoichet, Biochemistry 2003: X-ray of carboxy (1PI5) and non-
carboxy (1PI4) cmpds in N289A mutant of AmpC.772  
- Shoichet, JACS 2003: X-ray structures of same compounds in WT 
AmpC (class C) (1MXO, 1MY8).773  
- Shoichet, JACS 2006: Ultrahigh resolution X-ray structure of the non-
carboxy cmpd in the N289A mutant of AmpC (2FFY – a higher 
resolution structure of 1PI4).281  
- Shoichet patent 2007.774  
- Shiochet 2008: X-ray of a carboxyvinyl derivative in AmpC (2RCX); 
Ki values for non-carboxy, carboxy, and carboxyvinyl compounds 
against AmpC: 35 nM, 1 nM, and 1 nM.775   
56 A, C 
- Burns, Jackson, patents 2009 (Protez Pharma).776  
- Burns, patent 2010 (Novartis).777  
57 
 
A, C, D 
- Merck Rahway, 2010: DSABA gave IC50 values of 1.1, 0.57, 1.2, 
0.62, and 5.6 M against TEM-1, SHV-5 (class A enzymes), AmpC, 
P99 (class C), and OXA-40 (class D).778  
58 C 
- Shoichet, 2010: Sulfonamides compared with carboxamides vs 
AmpC (class C). No simple correlations observed due to differences 
in geometry and polarity.779  
- One compound showed a Ki value of 25 nM.   
59 A, C 
- Anacor, Naeja Pharmaceutials, 2011. Low micromolar to low 
nanomolar Ki values against CTX-M-9a, TEM-1, P99, and CMY-2.
780
60 A, C, D 
- Pratt, 2008: Vanadates are better inhibitors than the boronates.781 
- Low M IC50 values against TEM-2 (class A), P99 (class C), and 
OXA-1 (class D). 
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61 A, C, D 
- Merck, Methylgene Patents 2006, 2007, and 2008.782  
- IC50 of 0.6 M vs TEM-1 (class A).  
- Also inhibitors of AmpC enzymes from P. aeruginosa and A. 
baumannii (class C), and OXA-40 (class D).  
62 A, C 
- Pratt, Science 1989: Rapid inactivation of P99 and very slow 
reactivation.526  
- Pratt, 1992: Mechanism of P99 inhibition.783   
- Pratt, 1994: Thermodynamic and kinetic data with PC1 confirms that 
phosphonates act as transition state analogues.784  
- Pratt and Herzberg, 1993: X-ray in PC1, the class A -lactamase from 
S. aureus (1BLH).785 
- Pratt, Knox, 1994: X-ray structure in P99 (1BLS).786  
















- Nukaga, Pratt, Knox, 2004: X-rays of the transition state analogue 
shown in class C -lactamase from Citrobacter freundii (1RGY) and 
in class C ESBL GC1 (1RGZ).666  
- Silvaggi, Pratt, Kelly, 2003: Similar phosphonates have been used as 
transition state analogues with R61 transpeptidase (1MPL).788  
64 C 
- SmithKline Beecham 1994: Analogues of dipeptides mostly showed 
IC50s greater than 100 M against TEM-1, P99, PC1, SHV-5, OXA-
1, and PSE-4, but acyclic compounds showed IC50s in the 10ʹs of M 
against P99 (only).789  
65 (A, C), D 
- Pratt, JOC 2006: Ketophosph(on)ates were modest inhibitors of P99 
(class C), OXA-1, and OXA-10 with Ki values of 70–1590 M.790  
- Pratt, 2008: Intramolecular cooperativity between hydrophobic sites 
of OXA-1.791   
66 A, C 
- Pratt, JACS 1998: Acyl phosph(on)ates react -lactamases P99 and 
TEM-1 to form phosphoryl enzymes which can hydrolyze or react 




- Pratt, 1998: Salicyloyl phosphate inhibits TEM-1 (class A), P99 
(class C), and R61 transpeptidase.793  
- Pratt, 1998792 and 2001: Additional studies revealed subtle differences 
between cyclic and acylic acyl phosphates.794  
- Silvaggi, Pratt, Kelly, 2004: X-ray structures in R61 transpeptidase 




- Pratt, 2005: Potent inhibitors of OXA-1: Ki values from 200 nM 
down to <1 nM.796  
- Pratt, 2005: These compounds are less potent vs OXA-10.797   





- Pratt, 2006: Tested against TEM-1, PC1 (class A), P99 (class C), and 
DD-peptidases R61, R39, and PBP3, but no inhibition of these 
enzymes was observed. Some derivatives were substrates, but most 
were not.799  
70 C 
- Pratt and Shoichet, 2007: X-ray of cross-linked AmpC (2P9V).800 
- Pratt, 2008: Irreversible inhibitors of P99 (class C).801  
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71 A, C 
- Pratt, 2001: Concludes that specific electrophilic ketones are, at best, 


















- Adlington, Baldwin, Schofield groups, 1996: Some TFMKs showed 
low M Ki values against the MBL from X. maltophilia (e.g. 1.5 and 
3.0 M).538 
- TFMKs and alcohols showed low M Ki values against the MBL 
from A. hydrophilia (e.g. 6, 11, 44 M);  All TFMKs and alcohols 
had high M Ki values against the MBLs from B. cereus and P. 
aeruginosa.  
- Synthesis, 1997802 and 1998.803  
73 C 
- Merck Rahway group, 2010 (as a small part of a paper about boronic 
acids).778   
- No IC50s given; only % inhibition of AmpC (class C) at 2 M.  
74 B 
- Concha et al., 2000: X-ray structures of IMP-1 alone (1DDK) and 
with the mercaptocarboxylate inhibitor (1DD6).384  
- This mercaptocarboxylate inhibits IMP-1, B. fragilis, and L1 enzymes 
with IC50 values between 100 and 500 nM.  
75 B 
- Yamaguchi et al., 2007: X-ray of the thiol in VIM-2 (2YZ3).804  
- This mercaptocarboxylate has Ki values of 220 nM and 1660 nM 




- García-Sáez, 2003: X-ray of D-captopril in the dizinc MBL BlaB 
from C. meningosepticum (1M2X).668 
- Ki approx. 70–100 M against BlaB.   
- Schofield, 2008: X-ray of D-captopril in CphA (2QDS).805 Very 




- Page, 2001.806  
- Ki values against BcII range between 3.0 M and 515 M.  
- Inhibition is reversible and competitive.  
78 B 
- Crowder and Geysen, 2006.807  
- Homo-cysteinyl peptides more potent than cysteinyl peptides against 
L1.  
- Several compounds with low nanomolar Ki values against L1 




- Payne et al., SmithKline Beecham, 1997.808  
- IC50 values 2–186 M  against L1, 0.5–30 against CphA, and 38–650 
against BcII. IC50s were >1000 M against CfiA (B. fragilis). 
- Irreversible inhibition of BcII via mechanism-based delivery of 
mercaptoacetic acid and formation of a disulfide bond with the active 
site Cys; One compound showed uncompetitive inhibition of CphA 
but irreversible inhibition of L1.  
- Payne, 1997: With mercaptophenylacetic acid thioesters, potent IC50
values against L1 (as low as <1.95 M); competitive inhibitors of 
BcII but not as potent (Ki of 185 M for one compound).809  
80 B 
- Merck Rahway, 1999.810,811  
- Several compounds were very potent against IMP-1 (IC50s as low as 
0.4 nM) but few had activity against CcrA (lowest IC50 was 180 M). 
- The parent thiols themselves were potent (20–300 nM) but less potent 
than thioesters.  
- Reversible inhibition of IMP-1.    
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- Schofield, Galleni, Frère, 2001: The (R) isomer has a Ki value of 0.09 
M vs BcII and the (S)- isomer has a Ki value of 1.28 M.812  
- Other simple thiols were also screened against BcII with Ki values 
between 0.21 M and 346 M.  
- Broad-spectrum MBL inhibition was demonstrated with racemic 
thiomandelic acid with the following Ki values: 0.34 (BcII), 0.80 
(CfiA), 0.081 (L1), 0.029 (IMP-1), 0.059 (IMP-2), 0.23 (VIM-1), 
0.56 (BlaB), 0.27 (FEZ-1), 144 (CphA).   
































- Dmitrienko, 2003.552  
- Classical, slow-binding inhibitors of IMP-1 (pH dependent) with low 
M IC50 values. Differences observed between negatively charged 
thiols and neutral ones.  
- Two compounds were similarly potent against BcII (IC50s of 30 and 
25 M), but were poorer inhibitors of CcrA (IC50s of 950 and 170 
M). 
83 B 
- Goto, 1997: Screened simple thiols against IMP-1 which showed low 
M IC50 values.814  
- Goto, 2004: Arylalkyl thiols and dansyl thiols screened against IMP-1 



















- Kurosaki, 2005: X-ray in IMP-1 (1VGN).817  
- Irreversible inhibitor of IMP-1 via thiol coordination with zinc atoms 
and subsequent aminolysis of the aryl ester by Lys224.  
86 B 
- Schofield 2008: Thiols which have low to sub-micromolar Ki values 
against MBLs of all three classes: B1 (IMP-1, BcII), B2 (CphA), B3 
(L1, FEZ-1).805  
- The valine derivative drawn had Ki values of 0.063, 0.32, 3.6, and 
0.082 M against IMP-1, BcII, CphA, and L1, respectively.  









- Galleni, Schofield, 2007: Screened pyridine carboxylates for 
inhibition of MBLs.818  
- Little inhibition of MBLs except for  2-picolinic acid  and the 2,4-
isomer with CphA (Ki values of 5.7 and 4.5 M, respectively, relative 
to imipenem hydrolysis). (pH dependent inhibition).  
- X-ray structure of pyridine-2,4-dicarboxylate in CphA (2GKL). The 
pyridine nitrogen and 2-carboxylate coordinate to the zinc atom.   
88 B 
- Hodder and Fokin at Scripps, 2009819 and 2010.820  
- Libraries of triazoles from Click chemistry.  
- Inhibit VIM-2 only; no inhibition of IMP-1, TEM-1, or AmpC. 
- Enhance the antimicrobial activity of imipenem against VIM-2-
producing E. coli at low concentrations of inhibitor (10, 20 M).  
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- Dmitrienko, 2002.554  











- Dmitrienko group, patent 2010.555  
- Low micromolar IC50 values against IMP-1, VIM-2, OXA-10, and 




- Toney et al., Merck Rahway, 2001.665  
- Screened the Merck chemical collection and found some of these 
compounds to have IC50s of 2.7, 3.7, 9, and 13 nM against IMP-1.  
- X-ray of two of these compounds in IMP-1 (1JJE, 1JJT).  
- Later, in 2005, one of these compounds was reported to enhance the 
activity of meropenem against a carbapenem-resistant MBL-
producing strain of E. coli.821 
92 B 
- Olsen et al., 2006: “New leads” for MBL inhibitors from structure-
based pharmacophore design.822  
- IC50s against BcII from 7 to 100 M (for the compounds shown) and 













- Japanese group: Patents 2007.823  
- Patent 2008.824 Preparation. Compound with R1 = i-Pr, R2 = c-Hex 
had IC50s of 0.19 and 0.16 M against IMP-1 and VIM-2. 
- Patent 2009.825 Combination with ceftriaxone is effective against 
MBL-producing P. aeruginosa.   











IC50 = 0.97 M
B 
- Japanese group. Patent 2008.827 Bioorg Med Chem Lett., 2009.828  
- High M IC50s down to sub-M against IMP-1 (class B). 
- Increase the potency of biapenem against IMP-1-producing 













- Toney et al., Merck, 1988: Inhibition of the di-zinc MBL from 
Bacteriodes fragilis.829  
- X-ray of L-159,061 in the B. fragilis MBL (1A8T). 
- X-ray of MES (buffer molecule) bound to this same MBL (1A7T). 
- Toney et al., 1999: A series of biphenyl tetrazoles were not as potent 
against the B. fragilis MBL as L-159,061 (low to high M IC50s), 
only a few had IC50s <200 M against IMP-1, and most had high 
(100–800 M) IC50s against DHP-1.830  
96 B 
- Schofield group, 2007.831  
- Selectively inhibit FEZ-1 with surprisingly little inhibition of IMP-1, 
BcII, CphA, and L1.  
- Very modest inhibitors of FEZ-1 as well, except for the 
benzophenone derivative shown (Ki of 6.1 M). Several others with 
IC50 values around 100 M. 
97 B 
- Payne, GSK 2002: Screening of natural products for activity against 
BcII led to a small set of tricyclic natural products which had activity 
against IMP-1 and CfiA as well (low micromolar Ki values). But little 
inhibition of the MBL L1 and of serine -lactamases.832  
- Improve activity of meropenem against MBL-producing strains of B. 
fragilis and S. maltophilia, but not P. aeruginosa.  












- Page group, 1996: The carboxy derivative is not an inhibitor of any of 
the -lactamases tested.833  
- Page, 2003: Rates of inactivation of P99 (class C) given for the N-










OHcitrate isocitrate  
A, C 
- Marchand-Brynaert, 2008: The amino derivative inhibit BS3 (class A 
enzyme from Bacillus licheniformis) and TEM-1 (class A) with IC50s 
of 250 M and 150 M, respectively – modest, but more potent than 
citrate and isocitrate.834 
- X-ray of aminocitrate in BS3 (3B3X); X-ray of isocitrate in BS3 
(1W7F, to be published); X-ray of citrate in the class C enzyme 
CMY-2 (1ZC2, to be published).  





















- Simm, Walsh, Bennett, 2005.835  
- Competitive inhibition of the di-zinc form of BcII (Ki = 230 M), but 
not the mono-zinc form (Ki >900 M). 
- No inhibition of the ImiS, the mono-zinc MBL from Aeromonas 
veronii (Ki >900 M); Partial non-competitive inhibition of L1 from 
S. maltophilia (Ki = 2.5 M).   
- Models suggest that the sulfate could coordinate to the zincs.  
101 C 
- Shoichet, 2002: Non--lactam inhibitors of AmpC and X-ray 
structure with 1 (1L2S).836   
- Shoichet 2005: Several analogues with low micromolar Ki values and 
X-ray structures of AmpC with 10 (1XGJ) and 11 (1XGI).837  
- Shoichet, 2006: Deconstructing fragment-based inhibitor discovery: 
X-ray structures of AmpC with fragments 2-carboxythiophene 
(2HDQ), 4-amino-3-hydroxybenzoic acid (2HDR), 4-
methanesulfonylaminobenzoic acid (2HDS), 2-acetamidothiophene-
3-carboxylic acid (2HDU).838   
102 A,(C) 
- Shoichet, 2009: Fragment-based inhibitor discovery: These 2 
compounds showed Ki values of 21 and 12 M against CTX-M (class 
A) and 2.8 mM vs AmpC (class C).839  






















5: R = 4-COMe




















- Shoichet, 2009: Docking for fragment inhibitors of AmpC.277  
- Docked >137,000 fragments, 48 of the highest ranked structures were 
purchased and tested. 23 had Ki values from 0.7 to 9.2 mM. 
- X-ray structures were determined for 8 complexes with AmpC: 1
(3GSG), 3 (3GR2), 5 (3GQZ), 8 (3GVB), 12 (3GRJ), 20 (3GTC), 21
(3GV9); 22 was done previously (2HDU).   
104 A? 
- Indian group, 2010:  Extracts from the plant Holoptelea integrifolia
inhibited a 30 kD enzyme (probably a -lactamase) isolated from 
amoxicillin-resistant S. aureus.840  
- No IC50 or Ki values given.   
- Naphthoquinone was identified by GCMS and IR only.  
105 
 
A -  Jaramillo et al., 2009: “Kmʹ 407 M” for the best inhibitor.841   
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- Shoichet and Italian groups, 2008: Analysis of hits from HTS and 
docking screens.842  
- Of the 1274 hits from a library of 70,563 compounds, 95% were 
found to be detergent-sensitive. Of the 70 remaining compounds, 25 
were -lactams (covalent-acting), 12 were promiscuous covalent 
inhibitors, and the last 33 were aggregators or irreproducible. Thus, 
the library produced 0 compounds that were specific reversible 
inhibitors (desired).     
- Analogues of a phthalimide hit improved Kis to 8 M.  
- X-ray structures of AmpC with an oxadiazole covalently bound 
(2PU4) and with phthalimides non-covalently bound (2PU2, 2R9W, 




- Miyamura, Ochiai, 1974: A macromolecular -lactamase inhibitor 
(M-540) from a species of Streptomyces (see ref 396 and refs 
therein).    
- Strynadka, Nature 1994: Structure and kinetic characterization.843  
- Gretes, Strynadka, 2009: X-ray crystal structures of BLIP alone 
(3GMU), BLIP-I alone (3GMV), BLIP-I with TEM-1 (3GMW), BLP 
alone (3GMX), and a selenomethionine BLP (3GMY).844  
- Both BLIP (-lactamase inhibitory protein) and BLP (BLIP-like-
protein) have nanomolar affinities for TEM-1.  
- Wang et al., 2009.845  
- Bonomo, Handel groups, 2009: KPC-2 with BLIP (3E2L, 3E2K).846  
108 single-stranded DNA B 
- Kim et al., 2009: Nanomolar Ki values against B. cereus 5/B/6 
MBL.847  
- Rapid, reversible, non-competitive inhibition.   
109 B 
- Vella et al., 2011: Fragment-based screening for MBL inhibitors.848  




- Hoffman La Roche, 1983: Antibacterial and -lactamase inhibiting 
properties.849  
- Roche, 1988: Interactions with PBPs.850 
- Roche, 1988: Antibacterial activity.851  
 CYCLOBUTANONES   
C1  
- Gordon, Pluščec, and Ondetti. Tetrahedron Lett. 1981.528  
- Compounds 2, 4, 11, and 13 were also tested for inhibition of R61 
transpeptidase and R-TEM -lactamase and “did not exhibit 
significant reversible or irreversible enzyme inhibition.”  




- Meth-Cohn, Reason, and Roberts. Chem. Commun. 1982.529  
- The authors describe only the synthesis of these compounds in the 
paper and write that “It is hoped that -lactamase inhibitory activity 




- Lowe and Swain. Chem. Commun. 1983 and Perkin Trans. 1
1985.530,531  
- “The mixture of epimeric ketones 1 and 12 showed inhibition of 
Streptomyces R61 D,D-carboxypeptidase only at 260 g/mL and no 
significant activity against a range of bacteria at 128 g/mL. The 
chloroketone 6 and the epimeric mixture of ketones 1 and 12, 
however, showed time-dependent inhibition of E. coli R-TEM and B. 
cereus I -lactamases which may be associated with the slow 
formation of a tetrahedral adduct between the inhibitor and the 
enzyme.”  
- Lowe and Swain. In Recent Advances in the Chemistry of -Lactams, 
1985.  
- No antibacterial activity was observed at a maximum concentration of 
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128 mg/L.  
- The mixture of 1 and 27 did show weak inhibition of Streptomyces
R61 D,D -carboxypeptidase with 50% inhibition at 260 mg/L (MW = 
289.28; IC50 = 900 M).  
- The mixture of 1 and 27 and 2 each showed slow, time-dependent 
inhibition of E. coli RTEM-2 -lactamase and -lactamase type I 




















10: Z = SOPh
11: Z = SO2Ph  
 
- Cocuzza and Boswell (Du Pont). Tetrahedron Lett. 1985.532  
- Synthesis of a cyclobutanone analogue of N-acetylthienamycin.  
- Derivatives with electron-withdrawing groups at C3 were able to 
acylate benzylamine.  
- “While no cyclobutanone carboxylic acids (such as 22) of the present 
study demonstrated any antibacterial activity, we were pleased that 
sulfoxide and sulfone benzhydryl esters (such as 10, 11, 19, and 20) 
were active against Gram-positive bacteria (with typical MICs of 25–
50 g/mL vs S. aureus). Moreover, several sulfide, sulfone, and 
sulfone esters demonstrated anti--lactamase activity [as deduced 
























R = H, CHPh2
A 
- Boswell and Cocuzza. US Patent 1985; Chem. Abstr. 1985.533  
- Synthetic and biological procedures are given with the tables of 
synergy data below.   
- None of the free acids showed synergy but many of the benzhydryl 





- Lange, Savard, Viswanatha, Dmitrienko. Tetrahedron Lett. 1985: 
Synthesis of the 7,7-dichloro-2-thiabicyclo[3.2.0]heptan-6-one-4-
carboxylate system described but no biochemical data given in the 
paper.534  
- No significant inhibition of TEM-1 or BcI was observed (unpublished 
results, Dmitrienko and Viswanatha groups).    
- Kelly, Knox, Moews, Hite, Bartolone, and Zhao. J. Biol. Chem. 1985: 
Reported weak competitive inhibition of R61 transpeptidase (Ki = 1 
mM); 4 Å resolution X-ray structure of a complex with R61 D-alanyl 
carboxypeptidas-transpeptidase.535 (Synthesis of this compound was 
done by Tomczuk).537  
C8  
- Johnson, Evanoff, Savard, Lange, Ramadhar, Assoud, Taylor, 
Dmitrienko. J. Org. Chem. 2008.568  
- Synthetic studies, conformational properties, and study of hydration 




- Johnson, Gretes, Goodfellow, Marrone, Heynen, Strynadka, 
Dmitrienko. J. Am. Chem. Soc. 2010.640   
- Low-micromolar IC50s against KPC-2 (aESBL) and GC1 (cESBL).  
- Mid-micromolar IC50s against IMP-1 (MBL) and OXA-10 (class D). 
- Dichlorocyclobutanones are better inhibitors of serine enzymes than 
the dechlorinated compounds, but 2 was reasonable against IMP-1.  
- Compounds that favour the carboxylate in an equatorial orientation 
are better inhibitors that those with axial carboxylates.  
- X-ray structure of 4 bound to OXA-10 (3LCE).  
- The unsaturated acid 5 enhanced the antimicrobial activity of 





Selected Spectral Data for Cyclobutanone Derivatives 
Selected 1H NMR, 13C NMR, and IR Data for Cyclobutanones.a  
 
 X COR  H1   H3   H3   H4   H5  IR ketone IR COR
   65b Cl CO2H 4.77 3.37 2.88 3.75 5.14 1810 1700 
154 Cl COCl 4.55 3.54 3.13 4.03 5.02 1809 1780
84 Cl CO2Et 4.52 3.45 3.05 3.66 5.07 1810 1732
149 Cl CO2CHPh2 4.50 3.50 3.09 3.76 5.07 1808 1738
110 H CO2Et 4.15 3.45 3.21 3.57 4.64 1784 1732
  111b H CO2H 4.17 3.44 3.19 3.55 4.64 1780 1705 
 
 X COR  C1  C3  C4  C5  C6  C7  COR 
 65b Cl CO2H 59.5 36.3 50.7 68.6 196.0 90.2 171.3 
154 Cl COCl 58.3 35.4 60.3 66.8 192.9 89.1 172.0
84 Cl CO2Et 58.9 35.6 50.1 67.4 194.8 89.2 169.8
149 Cl CO2CHPh2 58.9 35.6 50.3 67.4 194.6 89.3 169.0
110 H CO2Et 36.9 35.3 50.0 71.5 208.4 56.5 170.8










 X COR  H1  H3   H5  IR ketone IR COR 
118 Cl CO2Et 4.89 7.43 5.43 1812 1704 
 153b Cl CO2H 5.23 7.68 5.62 1807 1700 
126 H CO2Et 4.15 7.43 5.15 1790 1700 
156 H CO2H 4.39 7.59 5.15 nd nd 
 
 X COR  C1  C3  C4  C5  C6  C7  COR 
118 Cl CO2Et 59.6 144.4 122.1 71.3 187.4 93.7 161.1 
 153b  Cl CO2H 60.1 146.1 123.3 72.8 189.5 94.8 162.3
126 H CO2Et 37.0 143.2 121.2 76.0 200.0 60.7 161.8
156 H CO2H 38.1 144.6 122.5 77.0 201.1 61.6 163.0 
 
                                                     
 (a) NMR spectra were acquired in CDCl3 except where indicated. 




 -Z COR  H1   H3   H4   H5  IR ketone IR COR
117 Cl CO2Et 4.95 5.88 3.97 5.21 1815 1740 
150 Cl CO2CHPh2 4.93 5.94 4.08 5.18 nd nd
155 Cl COCl 4.99 6.03 4.37 5.13 nd nd
 119c OH CO2Et 4.79 5.83 3.71 5.09 na na
121 OMe CO2Et 4.66 5.32 3.75 5.17 1813 1739
151 OMe CO2CHPh2 4.66 5.39 3.91 5.21 1813 1744
 152b OMe CO2H 4.77 5.57 3.84 5.13 1813 1720
122 Oi-Pr CO2Et 4.69 5.54 3.73 5.20 1811 1739
123 Ot-Bu CO2Et 4.78 5.76 3.70 5.12 1808 1739
164 S-i-Pr CO2Et 4.70 4.67 3.75 4.90 nd nd
165 S-p-Tol CO2Et 4.57 4.90 3.85 4.95 nd nd
166 Allyl CO2Et 4.61 4.70 3.56 4.82 nd nd 
 -Z COR  H1   H3   H4   H5  IR ketone IR COR
117 Cl CO2Et 4.72 6.14 4.08 5.15 nd nd 
119 OH CO2Et 4.67 5.98 3.83 5.05 1815 1732
121 OMe CO2Et 4.60 5.46 3.82 5.02 1817 1734
151 OMe CO2CHPh2 4.58 5.51 3.93 5.03 1816 1741
  152b OMe CO2H 4.78 5.61 3.90 5.12 1814 1703
122 Oi-Pr CO2Et 4.59 5.71 3.76 5.03 1818 1734
123 Ot-Bu CO2Et 4.58 5.79 3.61 4.98 1818 1735
124 OAc CO2Et 4.62 6.51 3.79 5.10 1813 1740-7
125 OTFE CO2Et 4.64 5.76 3.93 5.08 1819 1738
164 S-i-Pr CO2Et 4.60 5.10 3.72 4.98 nd nd
165 S-p-Tol CO2Et 4.62 5.33 3.71 4.99 nd nd
166 Allyl CO2Et 4.56 3.95 3.47 4.95 nd nd 
 
 -Z COR  C1  C3  C4  C5  C6  C7  COR 
117 Cl CO2Et 60.0 74.1 59.8 65.5 192.0 85.0 166.2 
150 Cl CO2CHPh2 59.8 73.7 60.1 65.5 191.9 85.1 165.4
155 Cl COCl 60.0 72.9 69.4 64.1 190.5 84.7 167.2
 119c OH CO2Et 58.7 87.0 57.0 65.7 192.3 86.2 166.8
121 OMe CO2Et 58.7 97.4 57.4 66.4 193.4 85.3 167.3
151 OMe CO2CHPh2 58.6 97.3 57.4 66.3 193.1 85.2 166.4
 152b OMe CO2H 58.8 98.5 58.2 67.7 194.7 86.7 168.6
122 Oi-Pr CO2Et 58.7 93.4 57.6 66.7 193.7 85.3 167.3
123 Ot-Bu CO2Et 58.8 89.0 57.9 66.6 193.7 85.9 167.5 
 -Z COR  C1  C3  C4  C5  C6  C7  COR 
117 Cl CO2Et 61.4 71.5 62.3 65.9 192.7 89.7 167.1 
119 OH CO2Et 59.8 86.0 59.3 65.0 193.1 90.4 167.9
121 OMe CO2Et 59.4 95.2 57.9 64.9 192.7 90.4 167.8
151 OMe CO2CHPh2 59.4 95.0 58.1 64.9 192.5 90.5 167.0
  152b OMe CO2H 60.0 96.4 58.6 66.2 193.8 91.5 169.4
122 Oi-Pr CO2Et 59.5 90.1 57.9 65.3 192.3 90.2 168.2
123 Ot-Bu CO2Et 59.6 86.6 59.6 65.3 193.0 90.6 168.2
124 OAc CO2Et 59.6 85.8 56.3 65.6 192.9 90.1 167.2
125 OTFE CO2Et 59.7 94.2 57.9 65.1 191.6 90.0 167.2




 X7 X7 COR  H1  H3   H3  H4  H5 
 65b Cl Cl CO2H 4.77 3.37 2.88 3.75 5.14 
84 Cl Cl CO2Et 4.52 3.45 3.05 3.66 5.07
110 H H CO2Et 4.15 3.45 3.21 3.57 4.64
 111b H H CO2H 4.17 3.44 3.19 3.55 4.64
 183c Cl H CO2Et 4.09 3.50 3.20 3.61 4.94
    184b,c Cl H CO2H 4.18 3.55 3.37 3.74 4.9
183 H Cl CO2Et 4.46 3.36 3.01 3.60 4.68
  184b H Cl CO2H 4.57 3.38 2.97 3.65 4.79
  185d H Cl CO2CHPh2 4.46 3.38 2.98 3.74 4.73
187 CH2OH Cl CO2Et 4.35 3.38 3.02 3.58 4.69
 188b CH2OH Cl CO2H 4.48 3.41 2.96 3.64 4.70 
c,d 
                                                     
 (c) This compound was observed by NMR only, and was not isolated.  
 (d) CD3CN was the solvent used for NMR.  
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ketone Z  H1  H3β  H4  H5  C1  C3  C4  C5  C6  C7 
121 OMe 4.31 5.39 3.69 3.91 58.9 96.9 55.2 52.2 99.2 93.1 
122 Oi-Pr 4.34 5.64 3.68 3.93 58.9 92.8 55.2 52.5 99.3 93.1


















ketone Z  H1  H3β  H4  H5  C1  C3  C4  C5  C6  C7 
121 OMe 4.28 5.40 3.63 3.79 58.2 97.0 55.3 55.9 97.8 93.9 
122 Oi-Pr 4.31 5.65 3.62 3.81 58.2 92.9 55.4 56.2 97.9 94.1
123 Ot-Bu 4.36 5.85 3.62 3.85 58.4 88.8 55.8 56.6 98.1 94.2 
 
ketone Z  H1  H3α  H4  H5  C1  C3  C4  C5  C6  C7 
121 OMe 4.47 5.70 3.72 4.15 61.6 97.2 55.6 57.6 - - 
122 Oi-Pr 4.45 5.90 3.65 4.13 61.5 92.5 55.8 57.4 100.8 95.6 
123 Ot-Bu 4.35 5.95 3.58 3.93 60.9 88.7 56.6 55.8 100.6 95.2 

















ketone Z  H1  H3α  H4  H5  C1  C3  C4  C5  C6  C7 
121 OMe 4.28 5.68 3.64 3.56 - - - - - - 
122 Oi-Pr 4.18 5.68 3.57 3.42 - - - - - -
123 Ot-Bu 4.16 5.79 3.53 3.37 58.4 90.3 54.9 55.0 98.4 94.2
124 OAc 4.31 6.45 3.82 3.62 58.5 88.9 53.5 60.8 - - 
 
                                                     
 (e) NMR spectra were acquired in methanol-d4 (




Hemiketal Formation with Cyclobutanones in Methanol-d4 
f,g 
  
time     
(h) 
 















0  1.00 0.00 0.00  100 0.0 0.0 0.0 
0.17  1.00 0.43 0.00  69.9 30.1 0.0 30.1 
1.08  0.29 1.00 0.05  21.6 74.6 3.7 78.4 
25  0.18 1.00 0.16  13.4 74.6 11.9 86.6 
167  0.18 1.00 0.35  11.8 65.4 22.9 88.2 
284  0.18 1.00 0.37  11.6 64.5 23.9 88.4 
312  0.18 1.00 0.38  11.5 64.1 24.4 88.5 
  
time     
(h) 
 















0  1.00 0.00 0.00  100 0.0 0.0 0.0 
0.83  1.00 2.55 0.00  28.2 71.8 0.0 71.8 
14  0.11 1.00 0.06  9.4 85.5 5.1 90.6 
194  0.13 1.00 0.31  9.0 69.4 21.5 91.0 
284  0.13 1.00 0.37  8.7 66.7 24.7 91.3 
 
                                                     
 (f) 1H NMR spectra were acquired at 500 MHz as overlapping peaks in the 300 MHz spectra made 
integrations unreliable.  
 (g) The data tabulated in this Appendix is also presented graphically in the supporting information for 
reference 568.   
 (h) The values listed for ketones, -hemiketals, and -hemiketals are integrations that were used for 




time     
(h) 
 















0  1.00 0.00 0.00  100 0.0 0.0 0.0 
0.25  1.00 0.20 0.00  83.3 16.7 0.0 16.7 
16  1.00 0.18 0.03  82.6 14.9 2.5 17.4 
112  1.00 0.16 0.07  81.3 13.0 5.7 18.7 
142  1.00 0.16 0.09  80.0 12.8 7.2 20.0 
163  1.00 0.16 0.09  80.0 12.8 7.2 20.0 
324  1.00 0.16 0.09  80.3 12.9 6.8 19.7 
  
time     
(h) 
 















0  1.00 0.00 0.00  100 0.0 0.0 0.0 
13  1.00 0.20 0.12  75.8 15.2 9.1 24.2 
25  1.00 0.20 0.12  75.8 15.2 9.1 24.2 
46  1.00 0.20 0.12  75.8 15.2 9.1 24.2 
192  1.00 0.20 0.12  75.8 15.2 9.1 24.2 
  
time     
(h) 
 















0  1.00 0.00 0.00  100 0.0 0.0 0.0 
0.08  0.25 1.00 0.04  19.4 77.5 3.1 80.6 
0.17  0.06 1.00 0.04  5.5 90.9 3.6 94.5 
0.50  0.04 1.00 0.05  3.2 92.2 4.6 96.8 
2.4  0.03 0.96 0.08  2.8 89.7 7.5 97.2 
23  0.03 0.81 0.25  2.8 74.3 22.9 97.2 
163  0.03 1.00 0.82  1.6 54.1 44.3 98.4 




time     
(h) 
 















0  1.00 0.00 0.00  100 0.0 0.0 0.0 
0.17  1.00 0.00 0.00  100 0.0 0.0 0.0 
3.0  1.00 0.03 0.00  97.1 2.9 0.0 2.9 
18  1.00 0.09 0.00  91.7 8.3 0.0 8.3 
168  1.00 0.13 0.03  86.2 11.2 2.6 13.8 
408  0.98 0.14 0.03  85.2 12.2 2.6 14.8 
  
time     
(h) 
 















0  1.00 0.00 0.00  100 0.0 0.0 0.0 
1.0  0.05 0.96 0.07  4.6 88.9 6.5 95.4 
3.0  0.04 0.93 0.10  3.7 86.9 9.3 96.3 
18  0.04 0.80 0.25  3.7 73.4 22.9 96.3 
144  0.03 0.55 0.50  2.8 50.9 46.3 97.2 
168  0.025 0.55 0.50  2.3 51.2 46.5 97.7 
180  0.025 0.55 0.50  2.3 51.2 46.5 97.7 
  
time     
(h) 
 















0  1.00 0.00 0.00  100 0.0 0.0 0.0 
0.50  1.00 0.00 0.00  100 0.0 0.0 0.0 
7.0  1.00 0.07 0.00  93.5 6.5 0.0 6.5 
24  1.00 0.18 0.00  84.7 15.3 0.0 15.3 
42  0.99 0.23 0.01  80.5 18.7 0.8 19.5 
168  0.96 0.23 0.03  78.7 18.9 2.5 21.3 
192  0.95 0.24 0.03  77.9 19.7 2.5 22.1 




time     
(h) 
 















0  1.00 0.00 0.00  100 0.0 0.0 0.0 
0.33  0.06 1.00 0.06  5.4 89.3 5.4 94.6 
0.50  0.04 1.00 0.06  3.6 90.9 5.5 96.4 
1.5  0.04 1.00 0.07  3.6 90.1 6.3 96.4 
23  0.04 1.00 0.32  2.9 73.5 23.5 97.1 
168  0.04 1.00 0.87  2.1 52.4 45.5 97.9 
288  0.04 1.00 0.87  2.1 52.4 45.5 97.9 
  
time     
(h) 
 















0  1.00 0.00 0.00  100 0.0 0.0 0.0 
0.17  1.00 0.02 0.00  98.0 2.0 0.0 2.0 
1.0  1.00 0.05 0.00  95.2 4.8 0.0 4.8 
2.0  1.00 0.09 0.01  90.9 8.2 0.9 9.1 
24  1.00 0.41 0.12  65.4 26.8 7.8 34.6 
168  1.00 0.41 0.23  61.0 25.0 14.0 39.0 



































time     
(h) 
 















0  1.00 0.00 0.00  100 0.0 0.0 0.0 
1.0  0.96 0.07 0.00  93.2 6.8 0.0 6.8 
7.0  0.87 0.18 0.02  81.3 16.8 1.9 18.7 
119  0.98 0.22 0.14  73.1 16.4 10.4 26.9 




time     
(h) 
 















0  1.00 0.00 0.00  100 0.0 0.0 0.0 
2.5  0.05 1.00 0.13  4.2 84.7 11.0 95.8 
18  0.05 1.00 0.30  3.7 74.1 22.2 96.3 
92  0.06 1.00 0.52  3.8 63.3 32.9 96.2 
144  0.06 1.00 0.55  3.7 62.1 34.2 96.3 
  
time     
(h) 
 















0  1.00 0.00 0.00  100 0.0 0.0 0.0 
1.0  1.00 0.33 0.00  75.2 24.8 0.0 24.8 
2.8  1.00 0.34 0.00  74.6 25.4 0.0 25.4 
17  1.00 0.33 0.03  73.5 24.3 2.2 26.5 
162  1.00 0.35 0.16  66.2 23.2 10.6 33.8 












 KPC-2 (class A)  IMP-1 (class B)  GC1 (class C)  OXA-10 (class D)
 obsd (corrd)c  obsd (corrd)  obsd (corrd)  obsd (corrd) 
65 74  76 (20)  >1000 (>260)  25 (6.5)  268 (70) 
111 0  117 (117)  235 (235)  44 (44)  1135 (1135) 
152 >98  58 (<1.2)  122 (<2.4)  6.5 (<0.13)  156 (<3.1) 
152 6  99 (93)  ndd nae  38 (36)  547 (514) 
153 93  26 (1.8)  213 (15)  4.5 (0.32)  370 (26) 
156 <2  170 (>167)  >500 (>490)  34 (>33)  >1000 (>980) 
a IC50 values (M). Inhibition was assayed by monitoring nitrocefin hydrolysis. b Acetone-d6 was used as a 





Tables of Crystallographic Data 
Crystal Data and Structure Refinement for Cyclobutanone 65.852  
 
 Empirical formula C7H6Cl2O3S 
 Formula weight 241.09 
 Temperature 180(2) K 
 Wavelength 0.71073 Å 
 Crystal system Triclinic 
 Space group P-1 
 Unit cell dimensions a = 6.0993(3) Å, b = 8.1188(4) Å, c = 10.5373(5) Å 
   = 73.8750(10)°,  = 77.5700(10)°,  = 71.4820(10)° 
 Volume, Z 470.67(4) Å3, 2 
 Density (calculated) 1.701 
 Absorption coefficient 0.879 mm–1 
 F(000) 244 
 Crystal size 0.44 mm × 0.30 mm × 0.15 mm 
  range for data collection 2.03 to 29.99 
 Limiting indices –8  h  8, –11  k  11, –14  l  14 
 Reflections collected 5854 
 Independent reflections 2745 (Rint = 0.0341) 
 Completeness to  = 29.99 99.6 % 
 Absorption correction Integration 
 Max. and min. transmission 0.888 and 0.671 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 2745 / 0 / 123 
 Goodness-of-fit on F2 1.062 
 Final R indices [I>2(I)] R1 = 0.0299, wR2 = 0.0784 
 R indices (all data) R1 = 0.0325, wR2 = 0.0800 
 Extinction coefficient 0.070(6) 




Crystal Data and Structure Refinement for Cyclobutanone 84. 
 
 Empirical formula C9H10Cl2O3S 
 Formula weight 269.13 
 Temperature 200(2) K 
 Wavelength 0.71073 Å 
 Crystal system Triclinic 
 Space group P-1 
 Unit cell dimensions a = 10.845(4) Å, b = 11.266(4) Å, c = 12.189(4) Å 
   = 107.842(4)°,  = 103.885(4)°,  = 113.162(4)° 
 Volume, Z 1187.6(7) Å3, 4 
 Density (calculated) 1.505   
 Absorption coefficient 0.706 mm–1 
 F(000) 552 
 Crystal size 0.46 mm × 0.40 mm × 0.02 mm 
  range for data collection 3.35 to 28.00 
 Limiting indices –14 ≤ h ≤ 14, –14 ≤ k ≤ 14, –16 ≤ l ≤ 16 
 Reflections collected 14463 
 Independent reflections 5699 (Rint = 0.0259) 
 Completeness to  = 28.00 99.5% 
 Absorption correction Empirical 
 Max. and min. transmission 0.9860 and 0.7373 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 5699 / 6 / 277 
 Goodness-of-fit on F2 1.250 
 Final R indices [I>2(I)] R1 = 0.0377, wR2 = 0.0772 
 R indices (all data) R1 = 0.0495, wR2 = 0.0826 




Atomic Coordinates ( 104) and Equivalent Isotropic Displacement Parameters (Å2  103) for 84.a,b 
 x/a y/b z/c Ueq 
C(1A) 5983(2) 9628(2) 7031(2) 29(1) 
S(2A) 4757(1) 7787(1) 5861(1) 37(1) 
C(3A) 3712(2) 7420(2) 6973(2) 37(1) 
C(4A) 4853(2) 8269(2) 8165(2) 32(1) 
C(5A) 5908(2) 9751(2) 8327(2) 31(1) 
C(6A) 5250(2) 10719(2) 8295(2) 33(1) 
C(7A) 5444(2) 10735(2) 7081(2) 30(1) 
C(8A) 5686(2) 7514(2) 8457(2) 35(1) 
O(9A) 6994(2) 8031(2) 8864(2) 48(1) 
O(11A) 4750(2) 6177(2) 8198(2) 54(1) 
C(12A) 5361(3) 5276(3) 8377(3) 68(1) 
C(13A) 4220(4) 3834(4) 7844(5) 76(1) 
C(13C) 4375(14) 4048(13) 6898(16) 76(1) 
Cl(1A) 6876(1) 12451(1) 7424(1) 44(1) 
Cl(2A) 3817(1) 10208(1) 5840(1) 38(1) 
O(16A) 4720(2) 11226(2) 8906(2) 50(1) 
C(1B) 1266(2) 1768(2) 3153(2) 34(1) 
S(2B) 1143(1) 798(1) 4079(1) 43(1) 
C(3B) –798(2) –480(2) 3097(2) 38(1) 
C(4B) –996(2) –730(2) 1744(2) 31(1) 
C(5B) –57(2) 746(2) 1825(2) 31(1) 
C(6B) –663(2) 1763(2) 2108(2) 35(1) 
C(7B) 703(2) 2866(2) 3374(2) 39(1) 
C(8B) –549(2) –1798(2) 1137(2) 32(1) 
O(9B) 294(2) –1595(2) 645(2) 45(1) 
O(11B) –1259(2) –3023(2) 1211(2) 42(1) 
C(12B) –965(3) –4170(2) 652(2) 46(1) 
C(13B) –1525(4) –5252(3) 1106(4) 87(1) 
Cl(1B) 291(1) 3333(1) 4702(1) 58(1) 
Cl(2B) 1817(1) 4446(1) 3282(1) 69(1) 
O(16B) –1771(2) 1731(2) 1612(2) 49(1) 
a Two crystallographically different molecules of cyclobutanone 84 are present in the unit cell. 
Atoms are labeled with either A or B to differentiate the two molecules. b Atoms C13A and C13C 
are disordered with 75% and 25% occupancy, respectively. 
Bond Lengths (Å) for Cyclobutanone 84. 
 Length [Å]   Length [Å] 
C(1A)–C(7A) 1.564(3) C(6A)–C(7A) 1.548(3) 
C(1A)–C(5A) 1.568(3)  C(7A)–Cl(2A) 1.7603(19) 
C(1A)–S(2A) 1.792(2)  C(7A)–Cl(1A) 1.776(2) 
S(2A)–C(3A) 1.813(2)  C(8A)–O(9A) 1.197(2) 
C(3A)–C(4A) 1.529(3)  C(8A)–O(11A) 1.323(3) 
C(4A)–C(8A) 1.517(3)  O(11A)–C(12A) 1.453(3) 
C(4A)–C(5A) 1.524(3)  C(12A)–C(13A) 1.407(4) 
C(5A)–C(6A) 1.525(3)  C(12A)–C(13C) 1.640(16) 
C(6A)–O(16A) 1.189(2)    
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Bond Lengths (Å) for Cyclobutanone 84 (continued). 
 Length [Å]   Length [Å] 
C(1B)–C(7B) 1.563(3) C(6B)–O(16B) 1.190(2) 
C(1B)–C(5B) 1.565(3)  C(6B)–C(7B) 1.549(3) 
C(1B)–S(2B) 1.788(2)  C(7B)–Cl(1B) 1.763(2) 
S(2B)–C(3B) 1.813(2)  C(7B)–Cl(2B) 1.771(2) 
C(3B)–C(4B) 1.531(3)  C(8B)–O(9B) 1.196(2) 
C(4B)–C(8B) 1.521(3)  C(8B)–O(11B) 1.334(2) 
C(4B)–C(5B) 1.526(3)  O(11B)–C(12B) 1.458(3) 
C(5B)–C(6B) 1.524(3)  C(12B)–C(13B) 1.466(4) 
 
Bond Angles () for Cyclobutanone 84. 
 Angle []   Angle [] 
C(7A)–C(1A)–C(5A) 89.88(14) C(7B)–C(1B)–C(5B) 89.97(15)
C(7A)–C(1A)–S(2A) 118.02(13)  C(7B)–C(1B)–S(2B) 118.36(15) 
C(5A)–C(1A)–S(2A) 108.40(13)  C(5B)–C(1B)–S(2B) 107.91(13) 
C(1A)–S(2A)–C(3A) 92.10(10)  C(1B)–S(2B)–C(3B) 92.70(10) 
C(4A)–C(3A)–S(2A) 105.15(14)  C(4B)–C(3B)–S(2B) 105.68(13) 
C(8A)–C(4A)–C(5A) 110.24(16)  C(8B)–C(4B)–C(5B) 111.03(16) 
C(8A)–C(4A)–C(3A) 111.20(17)  C(8B)–C(4B)–C(3B) 112.43(16) 
C(5A)–C(4A)–C(3A) 106.72(15)  C(5B)–C(4B)–C(3B) 106.41(16) 
C(4A)–C(5A)–C(6A) 114.76(16)  C(4B)–C(5B)–C(6B) 114.46(16) 
C(4A)–C(5A)–C(1A) 109.64(16)  C(4B)–C(5B)–C(1B) 110.79(16) 
C(6A)–C(5A)–C(1A) 89.15(14)  C(6B)–C(5B)–C(1B) 89.20(15) 
O(16A)–C(6A)–C(5A) 135.39(19)  O(16B)–C(6B)–C(5B) 135.4(2) 
O(16A)–C(6A)–C(7A) 132.44(19)  O(16B)–C(6B)–C(7B) 132.4(2) 
C(5A)–C(6A)–C(7A) 92.08(15)  C(5B)–C(6B)–C(7B) 92.03(15) 
C(6A)–C(7A)–C(1A) 88.46(14)  C(6B)–C(7B)–C(1B) 88.39(15) 
C(6A)–C(7A)–Cl(2A) 113.93(14)  C(6B)–C(7B)–Cl(1B) 114.36(15) 
C(1A)–C(7A)–Cl(2A) 118.90(14)  C(1B)–C(7B)–Cl(1B) 118.46(15) 
C(6A)–C(7A)–Cl(1A) 110.80(13)  C(6B)–C(7B)–Cl(2B) 111.26(15) 
C(1A)–C(7A)–Cl(1A) 112.28(13)  C(1B)–C(7B)–Cl(2B) 112.86(15) 
Cl(2A)–C(7A)–Cl(1A) 110.67(10)  Cl(2B)–C(7B)–Cl(1B) 109.97(12) 
O(9A)–C(8A)–O(11A) 124.08(19)  O(9B)–C(8B)–O(11B) 124.26(19) 
O(9A)–C(8A)–C(4A) 125.93(19)  O(9B)–C(8B)–C(4B) 125.78(18) 
O(11A)–C(8A)–C(4A) 109.99(18)  O(11B)–C(8B)–C(4B) 109.95(16) 
C(8A)–O(11A)–C(12A) 117.28(19)  C(8B)–O(11B)–C(12B) 116.70(16) 
C(13A)–C(12A)–O(11A) 109.8(3)  C(13B)–C(12B)–O(11B) 108.3(2) 
C(13A)–C(12A)–C(13C) 49.1(5)    





Crystal Data and Structure Refinement for Cyclobutanone 109. 
 
 Empirical formula C9H10Cl2O3S 
 Formula weight 269.13 
 Temperature 296(2) K 
 Wavelength 0.71073 Å 
 Crystal system Triclinic 
 Space group P-1 
 Unit cell dimensions a = 5.316(12) Å, b = 14.52(3) Å, c = 14.90(3) Å 
   = 84.58(4)°,  = 89.84(4)°,  = 88.88(4)° 
 Volume, Z 1145(4) Å3, 4 
 Density (calculated) 1.562   
 Absorption coefficient 0.732 mm–1 
 F(000) 552 
 Crystal size 0.40 mm × 0.10 mm × 0.04 mm 
  range for data collection 2.97 to 25.00 
 Limiting indices –6 ≤ h ≤ 6, –17 ≤ k ≤ 17, –11 ≤ l ≤ 17 
 Reflections collected 5769 
 Independent reflections 3859 (Rint = 0.0168) 
 Completeness to  = 25.00 95.4% 
 Max. and min. transmission 0.9713 and 0.7583 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 3859 / 0 / 272 
 Goodness-of-fit on F2 1.131 
 Final R indices [I>2(I)] R1 = 0.0586, wR2 = 0.0864 
 R indices (all data) R1 = 0.0783, wR2 = 0.0930 
 Extinction coefficient 0.0006(3) 




Atomic Coordinates ( 104) and Equivalent Isotropic Displacement Parameters (Å2  103) for 109.a 
 x/a y/b z/c Ueq 
C(1A) 4985(7) 46(3) 1477(3) 47(1) 
S(2A) 6062(2) 1012(1) 728(1) 63(1) 
C(3A) 8007(8) 1452(3) 1560(3) 58(1) 
C(4A) 6617(7) 1247(3) 2425(3) 48(1) 
C(5A) 5569(7) 267(3) 2440(3) 46(1) 
C(6A) 7504(8) –504(3) 2499(3) 54(1) 
C(7A) 6662(7) –837(3) 1621(3) 49(1) 
Cl(8A) 8974(2) –981(1) 841(1) 68(1) 
Cl(9A) 4908(2) –1859(1) 1862(1) 72(1) 
O(8A) 9191(6) –706(2) 2990(2) 87(1) 
C(11A) 8165(9) 1361(3) 3245(3) 57(1) 
O(12A) 10335(6) 1527(3) 3227(3) 85(1) 
O(13A) 6792(6) 1280(3) 3958(2) 79(1) 
C(14A) 7969(11) 1400(5) 4813(4) 102(2) 
C(15A) 6082(12) 1391(5) 5472(4) 114(2) 
C(1B) –8(7) 4955(3) 3526(3) 46(1) 
S(2B) 1063(2) 3987(1) 4271(1) 64(1) 
C(3B) 2998(8) 3547(3) 3450(3) 59(1) 
C(4B) 1609(7) 3747(3) 2573(3) 49(1) 
C(5B) 577(7) 4739(3) 2562(3) 45(1) 
C(6B) 2516(8) 5497(3) 2494(3) 53(1) 
C(7B) 1656(7) 5832(3) 3374(3) 50(1) 
Cl(8B) –93(2) 6859(1) 3138(1) 72(1) 
Cl(9B) 3976(2) 5984(1) 4159(1) 68(1) 
O(8B) 4195(6) 5705(2) 2015(2) 85(1) 
C(11B) 3169(9) 3630(3) 1768(3) 58(1) 
O(12B) 5338(6) 3474(3) 1771(3) 86(1) 
O(13B) 1793(6) 3719(3) 1040(2) 80(1) 
C(14B) 2962(11) 3593(5) 198(4) 103(2) 
C(15B) 1080(13) 3617(5) –475(4) 118(2) 
a Two crystallographically different molecules of cyclobutanone 109 are present in the unit cell. 
Atoms are labeled with either A or B to differentiate the two molecules.  
Bond Lengths (Å) for Cyclobutanone 109. 
 Length [Å]   Length [Å] 
C(1A)–C(7A) 1.545(6) C(6A)–O(8A) 1.173(5) 
C(1A)–C(5A) 1.534(6)  C(6A)–C(7A) 1.510(6) 
C(1A)–S(2A) 1.809(5)  C(7A)–Cl(8A) 1.712(5) 
S(2A)–C(3A) 1.787(5)  C(7A)–Cl(9A) 1.775(5) 
C(3A)–C(4A) 1.492(6)  C(11A)–O(12A) 1.183(5) 
C(4A)–C(11A) 1.499(6)  C(11A)–O(13A) 1.284(6) 
C(4A)–C(5A) 1.537(6)  O(13A)–C(14A) 1.448(6) 
C(5A)–C(6A) 1.502(6)  C(14A)–C(15A) 1.402(8) 
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Bond Lengths (Å) for Cyclobutanone 109 (continued). 
 Length [Å]   Length [Å] 
C(1B)–C(7B) 1.563(6) C(6B)–O(8B) 1.168(5) 
C(1B)–C(5B) 1.529(6)  C(6B)–C(7B) 1.507(6) 
C(1B)–S(2B) 1.793(5)  C(7B)–Cl(8B) 1.749(5) 
S(2B)–C(3B) 1.755(5)  C(7B)–Cl(9B) 1.733(5) 
C(3B)–C(4B) 1.503(6)  C(11B)–O(12B) 1.171(5) 
C(4B)–C(11B) 1.478(6)  C(11B)–O(13B) 1.305(6) 
C(4B)–C(5B) 1.530(6)  O(13B)–C(14B) 1.425(6) 
C(5B)–C(6B) 1.519(6)  C(14B)–C(15B) 1.416(8) 
 
Bond Angles () for Cyclobutanone 109. 
 Angle []   Angle [] 
C(7A)–C(1A)–C(5A) 89.8(3) C(7B)–C(1B)–C(5B) 89.2(3) 
C(7A)–C(1A)–S(2A) 119.0(3)  C(7B)–C(1B)–S(2B) 119.5(3) 
C(5A)–C(1A)–S(2A) 106.8(3)  C(5B)–C(1B)–S(2B) 107.7(3) 
C(1A)–S(2A)–C(3A) 94.2(2)  C(1B)–S(2B)–C(3B) 93.3(2) 
C(4A)–C(3A)–S(2A) 104.6(3)  C(4B)–C(3B)–S(2B) 105.7(3) 
C(11A)–C(4A)–C(5A) 111.8(3)  C(11B)–C(4B)–C(5B) 111.1(3) 
C(11A)–C(4A)–C(3A) 113.6(4)  C(11B)–C(4B)–C(3B) 113.9(4) 
C(5A)–C(4A)–C(3A) 108.1(3)  C(5B)–C(4B)–C(3B) 106.3(3) 
C(4A)–C(5A)–C(6A) 115.4(4)  C(4B)–C(5B)–C(6B) 116.1(3) 
C(4A)–C(5A)–C(1A) 109.9(3)  C(4B)–C(5B)–C(1B) 109.4(3) 
C(6A)–C(5A)–C(1A) 88.5(3)  C(6B)–C(5B)–C(1B) 89.2(3) 
O(8A)–C(6A)–C(5A) 133.4(4)  O(8B)–C(6B)–C(5B) 135.7(4) 
O(8A)–C(6A)–C(7A) 133.7(4)  O(8B)–C(6B)–C(7B) 132.2(4) 
C(5A)–C(6A)–C(7A) 92.4(3)  C(5B)–C(6B)–C(7B) 91.7(3) 
C(6A)–C(7A)–C(1A) 87.8(3)  C(6B)–C(7B)–C(1B) 88.4(3) 
C(6A)–C(7A)–Cl(8A) 116.1(3)  C(6B)–C(7B)–Cl(8B) 108.4(3) 
C(1A)–C(7A)–Cl(8A) 117.3(3)  C(1B)–C(7B)–Cl(8B) 113.3(3) 
C(6A)–C(7A)–Cl(9A) 108.6(3)  C(6B)–C(7B)–Cl(9B) 116.6(3) 
C(1A)–C(7A)–Cl(9A) 113.0(3)  C(1B)–C(7B)–Cl(9B) 118.2(3) 
Cl(8A)–C(7A)–Cl(9A) 111.7(2)  Cl(8B)–C(7B)–Cl(9B) 110.2(3) 
O(12A)–C(11A)–O(13A) 125.2(5)  O(12B)–C(11B)–O(13B) 123.9(4) 
O(12A)–C(11A)–C(4A) 124.2(5)  O(12B)–C(11B)–C(4B) 125.4(5) 
O(13A)–C(11A)–C(4A) 110.6(4)  O(13B)–C(11B)–C(4B) 110.7(4) 
C(11A)–O(13A)–C(14A) 118.1(4)  C(11B)–O(13B)–C(14B) 118.7(4) 




Crystal Data and Structure Refinement for Cyclobutanone 111.852 
 
 Empirical formula C7H8O3S 
 Formula weight 172.20 
 Temperature 180(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group C2/c 
 Unit cell dimensions a = 24.0534(13) Å, b = 6.8583(4) Å, c = 19.0432(10) Å
   = 102.8310(10)° 
 Volume, Z 3063.0(3) Å3, 16 
 Density (calculated) 1.494 
 Absorption coefficient 0.373 mm–1 
 F(000) 1440 
 Crystal size 0.37 mm × 0.30 mm × 0.20 mm 
  range for data collection 1.74 to 30.00 
 Limiting indices –32  h  33, –9  k  9, –26  l  26 
 Reflections collected 12193 
 Independent reflections 4468 (Rint = 0.0168) 
 Completeness to  = 30.00 99.8 % 
 Absorption correction None 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 4468 / 0 / 208 
 Goodness-of-fit on F2 1.074 
 Final R indices [I>2(I)] R1 = 0.0405, wR2 = 0.1111 
 R indices (all data) R1 = 0.0435, wR2 = 0.1135 
 Extinction coefficient 0.0031(4) 




Crystal Data and Structure Refinement for Cyclobutanone 115a. 
 
 Empirical formula C7H9Cl2O4S ½ H2O 
 Formula weight 268.10 
 Temperature 295(2) K 
 Wavelength 0.71073 Å 
 Crystal system Triclinic 
 Space group P-1 
 Unit cell dimensions a = 5.5833(4) Å, b = 13.6105(9) Å, c = 14.7211(9) Å 
   = 96.940(1)°,  = 95.644(1)°,  = 95.335(1)° 
 Volume, Z 1098.85(13) Å3, 4 
 Density (calculated) 1.621   
 Absorption coefficient 0.772 mm–1 
 F(000) 548 
 Crystal size 0.40 mm × 0.29 mm × 0.13 mm 
  range for data collection 1.52 to 30.01 
 Limiting indices –7 ≤ h ≤ 7, –19 ≤ k ≤ 19, –20 ≤ l ≤ 20 
 Reflections collected 13507 
 Independent reflections 6349 (Rint = 0.0327) 
 Completeness to 2 = 30.01 99.1% 
 Max. and min. transmission 0.909 and 0.774 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 6349 / 0 / 271 
 Goodness-of-fit on F2 1.987 
 Final R indices [I>2(I)] R1 = 0.0608, wR2 = 0.1592 
 R indices (all data) R1 = 0.0675, wR2 = 0.1611 




Atomic Coordinates ( 104) and Equivalent Isotropic Displacement Parameters (Å2  103) for 115a. 
 x/a y/b z/c Ueq 
S(1) 825(1) 2180(1) 768(1) 36(1) 
C(2) 3135(6) 1817(2) 1565(2) 49(1) 
C(3) 4827(5) 2745(2) 2002(2) 32(1) 
C(4) 3301(4) 3623(2) 1975(2) 27(1) 
C(5) 4728(5) 4633(2) 2220(2) 31(1) 
C(6) 2933(4) 3949(2) 283(2) 31(1) 
C(7) 1731(4) 3503(2) 1043(1) 26(1) 
C(8) 5749(5) 2628(2) 2984(2) 35(1) 
O(9) 8029(4) 2522(2) 3108(1) 55(1) 
O(10) 4416(4) 2629(2) 3590(2) 67(1) 
O(11) 6918(4) 4725(1) 2463(2) 49(1) 
O(12) 3467(4) 5365(1) 2414(2) 55(1) 
Cl(13) 886(1) 3909(1) –723(1) 42(1) 
Cl(14) 5489(1) 3374(1) –39(1) 53(1) 
S(15) 9938(2) –235(1) 6660(1) 49(1) 
C(16) 7752(5) 384(2) 6005(2) 43(1) 
C(17) 8412(4) 1524(2) 6241(2) 30(1) 
C(18) 11080(4) 1685(2) 6604(2) 27(1) 
C(19) 12080(4) 2731(2) 7023(2) 29(1) 
C(20) 11162(5) 1141(2) 8251(2) 32(1) 
C(21) 11630(5) 898(2) 7249(2) 31(1) 
C(22) 7816(5) 1983(2) 5368(2) 34(1) 
O(23) 9344(4) 2239(2) 4882(1) 43(1) 
O(24) 5528(4) 2039(2) 5193(2) 65(1) 
O(25) 14193(4) 2859(1) 7397(1) 44(1) 
O(26) 10696(4) 3418(1) 6949(1) 45(1) 
Cl(27) 12183(2) 192(1) 8882(1) 56(1) 
Cl(28) 8103(1) 1248(1) 8400(1) 55(1) 
O(29) 1290(60) 4933(17) 4653(11) 310(20) 
O(30) 6040(100) 5130(14) 4833(11) 380(30) 
a Two crystallographically different molecules of cyclobutanone 115a are present in the unit cell. 
O29 and O30 represent disordered water molecules.  
Bond Lengths (Å) for Cyclobutanone 115a. 
 Length [Å]   Length [Å] 
S(1)–C(2) 1.802(3) C(5)–O(11) 1.230(3) 
S(1)–C(7) 1.809(2)  C(5)–O(12) 1.281(3) 
C(2)–C(3) 1.537(4)  C(6)–C(7) 1.519(3) 
C(3)–C(8) 1.518(3)  C(6)–Cl(13) 1.772(2) 
C(3)–C(4) 1.533(3)  C(6)–Cl(14) 1.767(3) 
C(4)–C(5) 1.508(3)  C(8)–O(9) 1.292(3) 
C(4)–C(7) 1.537(3)  C(8)–O(10) 1.217(3) 
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Bond Lengths (Å) for Cyclobutanone 115a (continued). 
 Length [Å]   Length [Å] 
S(15)–C(16) 1.813(3) C(19)–O(25) 1.240(3) 
S(15)–C(21) 1.807(2)  C(19)–O(26) 1.275(3) 
C(16)–C(17) 1.549(3)  C(20)–C(21) 1.525(3) 
C(17)–C(22) 1.518(3)  C(20)–Cl(27) 1.783(2) 
C(17)–C(18) 1.519(3)  C(20)–C(28) 1.760(3) 
C(18)–C(19) 1.513(3)  C(22)–O(23) 1.214(3) 
C(18)–C(21) 1.546(3)  C(22)–O(24) 1.290(3) 
 
Bond Angles () for Cyclobutanone 115a. 
 Angle []   Angle [] 
C(2)–S(1)–C(7) 95.21(11) C(21)–S(15)–C(16) 95.31(11)
C(3)–C(2)–S(1) 109.15(17)  C(17)–C(16)–S(15) 108.49(17) 
C(8)–C(3)–C(4) 111.2(2)  C(22)–C(17)–C(18) 113.7(2) 
C(8)–C(3)–C(2) 109.9(2)  C(22)–C(17)–C(16) 107.3(2) 
C(4)–C(3)–C(2) 105.9(2)  C(18)–C(17)–C(16) 106.6(2) 
C(5)–C(4)–C(3) 114.5(2)  C(19)–C(18)–C(17) 116.8(2) 
C(5)–C(4)–C(7) 113.45(18)  C(19)–C(18)–C(21) 112.82(18) 
C(3)–C(4)–C(7) 109.02(18)  C(17)–C(18)–C(21) 108.88(19) 
O(11)–C(5)–O(12) 124.2(2)  O(25)–C(19)–O(26) 124.9(2) 
O(11)–C(5)–C(4) 121.6(2)  O(25)–C(19)–C(18) 117.7(2) 
O(12)–C(5)–C(4) 114.2(2)  O(26)–C(19)–C(18) 117.4(2) 
C(7)–C(6)–Cl(14) 114.15(17)  C(21)–C(20)–Cl(28) 114.02(17) 
C(7)–C(6)–Cl(13) 111.75(17)  C(21)–C(20)–Cl(27) 108.89(17) 
Cl(13)–C(6)–Cl(14) 107.70(13)  Cl(28)–C(20)–Cl(27) 108.72(14) 
C(6)–C(7)–C(4) 114.80(19)  C(20)–C(21)–C(18) 116.80(19) 
C(6)–C(7)–S(1) 113.17(16)  C(21)–C(21)–S(15) 114.08(17) 
C(4)–C(7)–S(1) 105.24(14)  C(18)–C(21)–S(15) 103.84(15) 
O(10)–C(8)–O(9) 123.9(2)  O(23)–C(22)–O(24) 124.5(2) 
O(10)–C(8)–C(3) 121.8(2)  O(23)–C(22)–C(17) 123.2(2) 





Crystal Data and Structure Refinement for Cyclobutanone 117.852 
 
 Empirical formula C9H9Cl3O3S 
 Formula weight 303.59 
 Temperature 295(2) K 
 Wavelength 0.71073 Å 
 Crystal system Triclinic 
 Space group P-1 
 Unit cell dimensions a = 6.4915(15) Å, b = 9.542(2) Å, c = 11.396(3) Å 
   = 102.655(5)°,  = 103.497(5)°,  = 103.414(5)° 
 Volume, Z 639.2(3) Å3, 2 
 Density (calculated) 1.577 
 Absorption coefficient 0.868 mm–1 
 F(000) 308 
 Crystal size 0.40 mm × 0.38 mm × 0.20 mm 
  range for data collection 1.92 to 30.00 
 Limiting indices –9  h  9, –13 < k  13, –16  l  16 
 Reflections collected 7767 
 Independent reflections 3711 (Rint = 0.0367) 
 Completeness to  = 30.00 99.5 % 
 Absorption correction Integration 
 Max. and min. transmission 0.869  and 0.737 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 3711 / 0 / 147 
 Goodness-of-fit on F2 1.378 
 Final R indices [I>2(I)] R1 = 0.0494, wR2 = 0.0990 
 R indices (all data) R1 = 0.0601, wR2 = 0.1020 
 Extinction coefficient 0.090(5) 




Crystal Data and Structure Refinement for Cyclobutanone 123.852  
 
 Empirical formula C13H18Cl2O4S 
 Formula weight 341.25 
 Temperature 100(2) K 
 Wavelength 0.71073 Å 
 Crystal system Triclinic 
 Space group P-1 
 Unit cell dimensions a = 6.3646(6) Å, b = 10.6579(10) Å, c = 11.9831(11) Å
   = 92.940(2)°,  = 104.377(2)°,  = 101.967(2)° 
 Volume, Z 765.74(12) Å3, 2 
 Density (calculated) 1.480 
 Absorption coefficient 0.569 mm–1 
 F(000) 356 
 Crystal size 0.38 mm × 0.23 mm × 0.08 mm 
  range for data collection 3.38 to 30.08 
 Limiting indices –8  h  8, –15  k  15, –16  l  16 
 Reflections collected 10709 
 Independent reflections 4302 (Rint = 0.0134) 
 Completeness to  = 30.08 96.2 % 
 Absorption correction Empirical 
 Max. and min. transmission 0.9559 and 0.8128 
 Refinement method Fullmatrix leastsquares on F2 
 Data / restraints / parameters 4302 / 0 / 185 
 Goodness-of-fit on F2 1.182 
 Final R indices [I>2(I)] R1 = 0.0227, wR2 = 0.00653 
 R indices (all data) R1 = 0.0238, wR2 = 0.0739 

































 Empirical formula C11H12Cl2O5S 
 Formula weight 327.18 
 Temperature 295(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21/c 
 Unit cell dimensions a = 6.6343(6) Å, b = 20.9581(17) Å, c = 10.6260(9) Å 
   = 102.039(2)° 
 Volume, Z 1445.0(2) Å3, 4 
 Density (calculated) 1.504 
 Absorption coefficient 0.605 mm–1 
 F(000) 672 
 Crystal size 0.50 mm × 0.13 mm × 0.13 mm 
  range for data collection 1.94 to 30.00 
 Limiting indices –9  h  8, –29  k  24, –14  l  14 
 Reflections collected 11763 
 Independent reflections 4208 (Rint = 0.0323) 
 Completeness to  = 30.00 99.9 % 
 Absorption correction Integration 
 Max. and min. transmission 0.944  and 0.814 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 4208 / 0 / 175 
 Goodness-of-fit on F2 1.039 
 Final R indices [I>2(I)] R1 = 0.0467, wR2 = 0.1153 
 R indices (all data) R1 = 0.0606, wR2 = 0.1224 
 Extinction coefficient 0.0071(15) 




Crystal Data and Structure Refinement for Cyclobutanone 149. 
 
 Empirical formula C20H16Cl2O3S 
 Formula weight 407.29 
 Temperature 200(2) K 
 Wavelength 0.71073 Å 
 Crystal system Triclinic 
 Space group P-1 
 Unit cell dimensions a = 5.4269(11) Å, b = 11.291(2) Å, c = 16.198(3) Å 
   = 97.757(3)°,  = 93.275(3) 
 Volume, Z 954.1(3) Å3, 2 
 Density (calculated) 1.418 
 Absorption coefficient 0.466 mm–1 
 F(000) 420 
 Crystal size 0.30 mm × 0.20 mm × 0.10 mm 
  range for data collection 3.55 to 26.00 
 Limiting indices –6  h  6, –13  k  12, –19  l  18 
 Reflections collected 5248 
 Independent reflections 3552 (Rint = 0.0398) 
 Completeness to  = 26.00 94.5 % 
 Absorption correction Empirical 
 Max. and min. transmission 0.9548  and 0.8727 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 3552 / 0 / 236 
 Goodness-of-fit on F2 1.074 
 Final R indices [I>2(I)] R1 = 0.0681, wR2 = 0.1008 
 R indices (all data) R1 = 0.1109, wR2 = 0.1214 
 Extinction coefficient 0.0068(10) 




Atomic Coordinates ( 104) and Equivalent Isotropic Displacement Parameters (Å2  103) for 149.  
 x/a y/b z/c Ueq 
C(1) 3468(8) 7645(4) 789(3) 31(1) 
S(2) 2611(3) 6143(1) 119(1) 44(1) 
C(3) 166(8) 6652(4) –547(3) 32(1) 
C(4) 1144(7) 7921(4) –606(3) 24(1) 
C(5) 2361(7) 8588(4) 288(3) 25(1) 
C(6) 564(8) 8886(4) 933(3) 30(1) 
C(7) 1879(8) 8115(4) 1512(3) 32(1) 
O(8) –1274(6) 9417(3) 967(2) 41(1) 
Cl(9) –31(2) 7075(1) 1850(1) 52(1) 
Cl(10) 3745(3) 9135(1) 2402(1) 58(1) 
C(11) 3008(8) 7860(4) –1226(3) 28(1) 
O(12) 5116(5) 8338(3) –1068(2) 36(1) 
O(13) 2002(5) 7165(3) –1999(2) 40(1) 
C(14) 3600(8) 6926(4) –2669(3) 37(1) 
C(15) 2969(9) 5612(5) –3124(3) 38(1) 
C(16) 4478(12) 4741(6) –2959(4) 65(2) 
C(17) 3893(14) 3512(6) –3359(5) 78(2) 
C(18) 1770(13) 3144(5) –3920(4) 61(2) 
C(19) 236(12) 3991(6) –4092(4) 74(2) 
C(20) 839(11) 5217(5) –3694(4) 68(2) 
C(21) 3154(8) 7797(4) –3247(3) 39(1) 
C(22) 1390(9) 8629(5) –3175(3) 46(1) 
C(23) 1100(10) 9407(5) –3725(4) 52(2) 
C(24) 2504(10) 9331(5) –4378(4) 54(2) 
C(25) 4264(11) 8491(5) –4464(4) 57(2) 
C(26) 4609(10) 7727(5) –3907(3) 49(1) 
Bond Lengths (Å) for Cyclobutanone 149. 
 Length [Å]   Length [Å] 
C(1)–C(7) 1.563(6) C(14)–C(15) 1.497(6) 
C(1)–C(5) 1.576(6)  C(14)–C(21) 1.512(7) 
C(1)–S(2) 1.792(5)  C(15)–C(16) 1.364(7) 
S(2)–C(3) 1.799(5)  C(16)–C(17) 1.390(8) 
C(3)–C(4) 1.527(5)  C(17)–C(18) 1.349(9) 
C(4)–C(11) 1.513(5)  C(18)–C(19) 1.354(8) 
C(4)–C(5) 1.514(6)  C(19)–C(20) 1.389(7) 
C(5)–C(6) 1.520(6)  C(20)–C(15) 1.362(7) 
C(6)–C(7) 1.551(6)  C(21)–C(22) 1.377(7) 
C(6)–O(8) 1.194(5)  C(22)–C(23) 1.386(7) 
C(7)–Cl(9) 1.749(4)  C(23)–C(24) 1.375(7) 
C(7)–Cl(10) 1.776(5)  C(24)–C(25) 1.383(8) 
C(11)–O(12) 1.206(5)  C(25)–C(26) 1.384(7) 
C(11)–O(13) 1.343(5)  C(26)–C(21) 1.404(6) 
O(13)–C(14) 1.467(5)    
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Bond Angles () for Cyclobutanone 149. 
 Angle []   Angle [] 
C(7)–C(1)–S(2) 118.0(3) O(12)–C(11)–O(13) 123.4(4) 
C(5)–C(1)–S(2) 107.8(3)  C(11)–O(13)–C(14) 118.0(3) 
C(1)–S(2)–C(3) 93.0(2)  O(13)–C(14)–C(15) 105.8(3) 
S(2)–C(3)–C(4) 105.5(3)  O(13)–C(14)–C(21) 109.7(4) 
C(3)–C(4)–C(5) 106.8(3)  C(15)–C(14)–C(21) 113.6(4) 
C(4)–C(5)–C(6) 114.7(3)  C(20)–C(15)–C(16) 116.7(5) 
C(5)–C(6)–C(7) 92.1(3)  C(20)–C(15)–C(14) 122.3(5) 
C(4)–C(5)–C(1) 109.7(3)  C(14)–C(15)–C(16) 121.0(5) 
C(6)–C(5)–C(1) 88.9(3)  C(15)–C(16)–C(17) 121.9(6) 
C(6)–C(7)–C(1) 88.3(3)  C(16)–C(17)–C(18) 120.4(6) 
C(7)–C(1)–C(5) 89.5(3)  C(17)–C(18)–C(19) 118.9(6) 
C(5)–C(6)–O(8) 135.2(4)  C(18)–C(19)–C(20) 120.5(6) 
C(7)–C(6)–O(8) 132.5(4)  C(19)–C(20)–C(15) 121.8(6) 
C(6)–C(7)–Cl(9) 116.9(3)  C(22)–C(21)–C(26) 118.6(5) 
C(6)–C(7)–Cl(10) 107.9(3)  C(14)–C(21)–C(26) 117.3(5) 
C(1)–C(7)–Cl(9) 119.8(3)  C(14)–C(21)–C(22) 124.2(4) 
C(1)–C(7)–Cl(10) 110.8(3)  C(21)–C(22)–C(23) 120.9(5) 
Cl(9)–C(7)–Cl(10) 111.0(3)  C(22)–C(23)–C(24) 120.6(6) 
C(3)–C(4)–C(11) 111.9(3)  C(23)–C(24)–C(25) 119.1(5) 
C(5)–C(4)–C(11) 110.3(3)  C(24)–C(25)–C(26) 120.9(5) 
C(4)–C(11)–O(12) 126.4(4)  C(25)–C(26)–C(21) 119.9(5) 




Crystal Data and Structure Refinement for Cyclobutanone 151.853 
 
 Empirical formula C21H18Cl2O4S 
 Formula weight 437.31 
 Temperature 200(2) K 
 Wavelength 0.71073 Å 
 Crystal system Triclinic 
 Space group P-1 
 Unit cell dimensions a = 9.6137(19) Å, b = 9.816(2) Å, c = 12.382(3) Å 
   = 72.737(4)°,  = 67.724(3)°,  = 70.553(4)° 
 Volume, Z 999.9(3) Å3, 2 
 Density (calculated) 1.453 g/cm3 
 Absorption coefficient 0.454 mm–1 
 F(000) 452 
 Crystal size 0.38 mm × 0.35 mm × 0.20 mm 
  range for data collection 2.82 to 29.99 
 Limiting indices –11 h  13, –11 k  13, –17  l  17 
 Reflections collected 10634 
 Independent reflections 5728 (Rint = 0.0208) 
 Completeness to  = 29.99 98.0 % 
 Max. and min. transmission 0.9146 and 0.8463 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 5728 / 0 / 253 
 Goodness-of-fit on F2 1.243 
 Final R indices [I>2(I)] R1 = 0.0361, wR2 = 0.0881 
 R indices (all data) R1 = 0.0393, wR2 = 0.0900 




Crystal Data and Structure Refinement for Cyclobutanone 152.853 
 
 Empirical formula C21H18Cl2O4S 
 Formula weight 437.31 
 Temperature 200(2) K 
 Wavelength 0.71073 Å 
 Crystal system Triclinic 
 Space group P-1 
 Unit cell dimensions a = 9.6137(19) Å, b = 9.816(2) Å, c = 12.382(3) Å 
   = 72.737(4)°,  = 67.724(3)°,  = 70.553(4)° 
 Volume, Z 999.9(3) Å3, 2 
 Density (calculated) 1.453 g/cm3 
 Absorption coefficient 0.454 mm–1 
 F(000) 452 
 Crystal size 0.38 mm × 0.35 mm × 0.20 mm 
  range for data collection 2.82 to 29.99 
 Limiting indices –11 h  13, –11 k  13, –17  l  17 
 Reflections collected 10634 
 Independent reflections 5728 (Rint = 0.0208) 
 Completeness to  = 29.99 98.0 % 
 Max. and min. transmission 0.9146 and 0.8463 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 5728 / 0 / 253 
 Goodness-of-fit on F2 1.243 
 Final R indices [I>2(I)] R1 = 0.0361, wR2 = 0.0881 
 R indices (all data) R1 = 0.0393, wR2 = 0.0900 




























 Empirical formula C8H8Cl2O4S 
 Formula weight 271.10 
 Temperature 200(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21/c 
 Unit cell dimensions a = 12.0074(17) Å, b = 9.2141(13) Å, c = 10.8132(16) 
Å   = 90°,  = 112.413(2)°,  = 90° 
 Volume, Z 1106.0(3) Å3, 4 
 Density (calculated) 1.628 g/cm3 
 Absorption coefficient 0.765 mm–1 
 F(000) 552 
 Crystal size 0.28 mm × 0.10 mm × 0.02 mm 
  range for data collection 2.87 to 30.00 
 Limiting indices –16  h  15, –12  k  12, –15  l  15 
 Reflections collected 11393 
 Unique reflections 3193 (Rint = 0.0370) 
 Completeness to  = 30.00 99.6 % 
 Absorption correction Empirical 
 Max. and min. transmission 0.9849  and 0.8143 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 3193 / 0 / 141 
 Goodness-of-fit on F2 1.165 
 Final R indices [I>2(I)] R1 = 0.0414, wR2 = 0.0736 
 R indices (all data) R1 = 0.0621, wR2 = 0.0819 
























 Empirical formula C7H4Cl2O3S 
 Formula weight 239.06 
 Temperature 200(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21/c 
 Unit cell dimensions a = 7.464(3) Å, b = 10.568(4) Å, c = 11.510(4) Å 
   = 101.187(5)  
 Volume, Z 890.6(6) Å3, 4 
 Density (calculated) 1.783 g/cm3 
 Absorption coefficient 0.929 mm–1 
 F(000) 480 
 Crystal size 0.32 mm × 0.28 mm × 0.15 mm 
  range for data collection 3.39 to 27.99 
 Limiting indices –9  h  9, –13  k  13, –14  l  15 
 Reflections collected 7845 
 Unique reflections 2100 (Rint = 0.0284) 
 Completeness to  = 27.99 97.7 % 
 Max. and min. transmission 0.8732  and 0.7553 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 2100 / 0 / 123 
 Goodness-of-fit on F2 1.319 
 Final R indices [I>2(I)] R1 = 0.0316, wR2 = 0.0982 
 R indices (all data) R1 = 0.0352, wR2 = 0.1012 
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